CHAPTER 9 Therapeutic Agents - Avian...
102
Editors’ Disclaimer: Every attempt has been made to ensure accurate citation of dosages and references. However, the reader must assume ultimate responsibility for the use of any medica- tion. Indications and usage listed are as per the refer- ence(s) cited, and may not bear pharmacodynamic data verifying efficacy or safety. Dosages that vary significantly (by a factor of 50x or greater) from other empirical or pharmacokinetic stud- ies may be omitted from the table, but may be found in the references. No claims to efficacy or safety are intended or implied. See abbreviations key at the end. 9 Therapeutic Agents KEATH L. MARX, DVM CHAPTER
Transcript of CHAPTER 9 Therapeutic Agents - Avian...
Editors’ Disclaimer:
Every attempt has been made to ensure accurate citation
of dosages and references. However, the reader must
assume ultimate responsibility for the use of any medica-
tion. Indications and usage listed are as per the refer-
ence(s) cited, and may not bear pharmacodynamic data
verifying efficacy or safety.
Dosages that vary significantly (by a factor of 50x or
greater) from other empirical or pharmacokinetic stud-
ies may be omitted from the table, but may be found in
the references.
No claims to efficacy or safety are intended or implied.
See abbreviations key at the end.
9
TherapeuticAgentsKKEEAATTHH LL.. MMAARRXX,, DDVVMM
CHAPTER
Cl inica l Avian Medic ine - Volume I242
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Acep
rom
azin
e M
ale
ate
A
vian
0.
5-1
IM
Q
D
E
53, 7
04
Add k
etam
ine
Ace
pro
maz
ine
Mal
eate
C
asso
war
y, D
oub
le-w
attl
ed
0.63
IM
P
RN
G
44
7 A
dd e
torp
hin
e
Ace
pro
maz
ine
Mal
eate
H
awk
2.0
N
L
PR
N
D
1401
A
dd k
etam
ine
Ace
pro
maz
ine
Mal
eate
O
stri
ch
0.16
-0.1
9 IM
P
RN
B
44
7 A
dd e
torp
hin
e
Ace
pro
maz
ine
Mal
eate
O
stri
ch
25 M
G T
D
NL
P
RN
D
14
01
Add e
torp
hin
e +
xyl
azin
e
Ace
pro
maz
ine
Mal
eate
O
wl
2.0
NL
P
RN
D
14
01
Add k
etam
ine
Ace
pro
maz
ine
Mal
eate
R
apto
r 2.
2
IM
PR
N
E
1386
A
dd k
etam
ine
Ace
pro
maz
ine
Mal
eate
R
atit
e 0.
25-0
.5
IM
PR
N
G
418
Ace
pro
maz
ine
Mal
eate
R
atit
e 0.
1-0.
2 IV
P
RN
G
41
8
Acety
lcyst
ein
e
Am
azo
n, R
ed L
ore
d
22 m
g/m
l N
ebuliz
e Q
D
G
700
10%
co
nce
ntr
atio
n
Acti
vate
d C
harc
oal
Avi
an
52 P
O
On
ce
E
1526
G
ive
afte
r fi
rst
do
se o
f fl
uid
s fo
r o
iled b
irds
Act
ivat
ed C
har
coal
A
vian
2-
8 g/
kg
PO
N
L
E
1554
, 174
5
Act
ivat
ed C
har
coal
Psi
ttac
ine
2-8
g/kg
PO
PR
NE
1240
Ab
sorb
inge
sted
to
xin
s
Act
ivat
ed C
har
coal
Rap
tor
2-10
g/kg
PO
PR
NE
1400
An
tidia
rrh
eal,
abso
rbs
toxi
ns
Acyclo
vir
Avi
an1
g/L
wat
erD
rin
kN
LA
435
Acy
clo
vir
Avi
an
400
mg/
kg f
oo
d
Fee
d
On
ce
A
435
Acy
clo
vir
Avi
an
80
PO
T
ID
E
1470
, 147
3 F
or
her
pes
viru
s, (
also
ref
# 1
560,
165
0)
Acy
clo
vir
Avi
an
25
IM
NL
G
43
5
Acy
clo
vir
Avi
an
40
IM
TID
G
13
06
Fo
r P
ach
eco
's d
isea
se
Acy
clo
vir
Avi
an
80
PO
T
ID
G
1306
F
or
Pac
hec
o's
dis
ease
Acy
clo
vir
Avi
an
330
G
avag
e B
ID
G
1352
Acy
clo
vir
Avi
an
0.4
g/L
D
rin
k Q
D
G
1352
Acy
clo
vir
Ch
icke
n
10
IM
QD
B
43
5
Acy
clo
vir
Mac
aw
80
PO
T
ID
A
435
Acy
clo
vir
Par
akee
t, Q
uak
er
40
IM
TID
A
10
60
Acy
clo
vir
Par
akee
t, Q
uak
er1
g/L
fee
dF
eed
QD
A10
60C
han
ge f
eed B
ID
Acy
clo
vir
Psi
ttac
ine
0.4
g/L
wat
erD
rin
kN
LE
763
Acy
clo
vir
Psi
ttac
ine
80
PO
T
ID
E
1365
F
or
Pac
hec
o's
vir
us
Acy
clo
vir
Rap
tor
(Per
egri
ne
falc
on
) 80
PO
T
ID
G
Acy
clo
vir
Rap
tor
333
P
O
BID
G
94
Ju
ven
ile d
osa
ge
Alb
en
dazo
le
Avi
an
100
PO
O
nce
E
15
26
Fo
r n
emat
odes
an
d C
apilla
ria
Alb
endaz
ole
A
vian
50
PO
Q
D
E
1526
F
or
nem
ato
des
an
d C
apilla
ria
Alb
endaz
ole
B
ird, A
quat
ic
100
P
O
On
ce
E
1503
F
or
nem
ato
des
an
d C
apilla
ria
Alb
endaz
ole
B
ird, A
quat
ic 5
0 P
O
QD
E
15
03 F
or
nem
ato
des
an
d C
apilla
ria
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 243
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Alb
endaz
ole
C
ran
e 20
PO
Q
W
E
1361
F
or
trem
ato
des
Alb
endaz
ole
E
mu
10
NL
N
L
G
1471
F
or
fasc
iolia
sis
Alb
endaz
ole
P
engu
in
50
PO
Q
D
E
1478
F
or
nem
ato
des
an
d f
luke
s
Alb
endaz
ole
P
engu
in
100
PO
O
nce
E
14
78
Fo
r n
emat
odes
an
d f
luke
s
Alb
endaz
ole
R
atit
e 0.
264
P
O
BID
E
12
40
Rep
eat
in 2
wee
ks, a
nti
pro
tozo
al
Alf
axalo
ne +
Alf
ad
olo
ne
Avi
an
10-3
6 I
M-I
V-S
C
PR
N
E
704
Alf
axal
on
e +
Alf
ado
lon
e A
vian
5-
10
IV
PR
N
E
1181
Sh
ort
dura
tio
n, m
ay b
e ap
nea
Alf
axal
on
e +
Alf
ado
lon
e A
vian
36
IM-I
P
PR
N
E
1181
Sh
ort
dura
tio
n
Alf
axal
on
e +
Alf
ado
lon
e B
uzz
ard (
Augu
r, L
izza
rd)
10
IV
PR
N
B
1610
Alf
axal
on
e +
Alf
ado
lon
e C
hic
ken
10
IV
PR
N
B
1610
Alf
axal
on
e +
Alf
ado
lon
e C
ran
e 4-
8
IV
PR
N
E
1240
M
ay c
ause
tra
nsi
ent
apn
ea, s
urg
ical
an
esth
esia
fo
r 8
to 1
0 m
in
Alf
axal
on
e +
Alf
ado
lon
e E
agle
(A
fric
an F
ish
, Haw
k, T
awn
y)
and F
alco
ns
10
IV
PR
N
B
1610
Alf
axal
on
e +
Alf
ado
lon
e F
lam
ingo
4-
8
IV
PR
N
E
1240
Alf
axal
on
e +
Alf
ado
lon
e G
osh
awk,
Afr
ican
10
IV
PR
N
B
1610
Alf
axal
on
e +
Alf
ado
lon
eO
wl,
Gre
at-h
orn
ed6-
12IV
PR
NB
1174
Alf
axal
on
e +
Alf
ado
lon
eP
elic
an5.
4IV
PR
NG
595
Alf
axal
on
e +
Alf
ado
lon
eP
igeo
n5-
7IM
-IV
PR
NG
232
Alf
axal
on
e +
Alf
ado
lon
eP
sitt
acin
e5-
10IM
-IV
PR
NE
1240
Alf
axal
on
e +
Alf
ado
lon
eR
apto
r10
IVP
RN
B15
68F
or
wild
inju
red r
apto
rs a
nes
thes
ia in
duct
ion
All
op
uri
no
lA
vian
10-1
5IM
, PO
QD
G58
, 704
Allo
puri
no
lB
udge
riga
r0.
33 g
/L
Dri
nk
NL
G11
1
Allo
puri
no
lB
udge
riga
r0.
67 g
/L
Dri
nk
NL
E76
3F
or
gout
Allo
puri
no
lP
sitt
acin
e10
PO
QD
B10
35F
or
hyp
eruri
cem
ia
Allo
puri
no
lP
sitt
acin
e0.
33 g
/L
Dri
nk
NL
E12
40T
o t
reat
go
ut
Allo
puri
no
lP
sitt
acin
e10
-30
PO
BID
E17
56
Alo
e V
era
Avi
an16
ml/
LD
rin
kQ
DG
1682
Alo
e V
era
Avi
an30
ml/
LD
rin
kQ
DG
111
Am
an
tad
ine H
Cl
Avi
an0.
001
g/L
Dri
nk
NL
E16
50F
or
ort
ho
myx
ovi
ruse
s
Am
anta
din
e H
Cl
Avi
an25
PO
NL
E16
50F
or
ort
ho
myx
ovi
ruse
s
Am
anta
din
e H
Cl
Po
ult
ry2
PO
NL
G43
5
Am
anta
din
e H
Cl
Turk
ey10
PO
QD
G43
5
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I244
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Am
ikacin
Su
lfate
Am
azo
n, B
lue-
fro
nte
d10
-15
IMB
ID-T
IDA
697
Am
ikac
in S
ulf
ate
Am
azo
n, O
ran
ge-w
inge
d13
-20
IM/IV
BID
A73
6
Am
ikac
in S
ulf
ate
Avi
an10
-15
IM-I
V-S
CB
ID-T
IDA
1473
, 111
Am
ikac
in S
ulf
ate
Bir
d, A
quat
ic18
-20
IMB
IDE
1478
, 155
9
Am
ikac
in S
ulf
ate
Ch
icke
n20
IMT
IDA
1058
Fo
r h
ens
Am
ikac
in S
ulf
ate
Co
ckat
iel
15-2
0IM
BID
-TID
A32
, 697
, 879
Am
ikac
in S
ulf
ate
Co
ckat
oo
, Go
ffin
15-2
0IM
BID
-TID
A69
7
Am
ikac
in S
ulf
ate
Cra
ne
10IM
-SC
BID
E62
9
Am
ikac
in S
ulf
ate
Fo
wl,
Do
mes
tic
10-2
0IM
QD
-TID
A16
31F
or
salm
on
ello
sis
Am
ikac
in S
ulf
ate
Gull
15IM
BID
E13
57
Am
ikac
in S
ulf
ate
Ost
rich
7.6
IMT
IDA
747
Am
ikac
in S
ulf
ate
Par
rot,
Gre
y10
-20
IMB
ID-T
IDA
112,
692
Am
ikac
in S
ulf
ate
Pen
guin
, Afr
ican
15IM
BID
G13
53M
on
ito
r h
ydra
tio
n
Am
ikac
in S
ulf
ate
Pig
eon
15-2
0IM
-IV
BID
G59
0
Am
ikac
in S
ulf
ate
Psi
ttac
ine
15-4
0IM
QD
-BID
E56
5
Am
ikac
in S
ulf
ate
Rap
tor
15-2
0IM
QD
G13
14
Am
ikac
in S
ulf
ate
Rat
ite
7.6-
11IM
BID
G13
08
Am
ikac
in S
ulf
ate
Sto
rk, S
addle
-bill
ed10
IMB
IDG
1645
Am
ino
loid
Rap
tor
0.25
-0.7
5IM
q2w
E11
1In
duce
mo
ltin
g
Am
ino
nit
roth
iazo
leR
apto
r20
-40
PO
NL
E14
63F
or
tric
ho
mo
nia
sis
Am
ino
pen
tam
ide S
ulf
ate
Avi
an0.
05IM
-SC
BID
E11
1, 1
240.
147
3C
on
tro
l vo
mit
ion
Am
ino
ph
yll
ine
Avi
an
0.5
Neb
uliz
e B
ID-T
ID
G
1199
A
dd a
cety
lcys
tein
e, antibiotic, 5
ml N
aCl
Am
ino
ph
yllin
eA
vian
10IV
-PO
q3h
E11
51
Am
ino
pro
mazin
eA
vian
6.75
IMN
LF
1209
Am
ino
thia
zo
leP
igeo
n5
ml/
LD
rin
kQ
DE
1240
Am
itri
pty
lin
e H
Cl
Psi
ttac
ine
1-5
PO
B-Q
IDD
1446
, 111
, 124
0F
or
beh
avio
ral f
eath
er p
icki
ng
Am
mo
nia
So
luti
on
Avi
an10
ml/
LT
op
ical
PR
NG
111
Add a
loe
vera
+ 4
dro
ps
sulf
on
ate
det
erge
nt,
con
tro
l ski
n p
ruri
tis
Am
ob
arb
ital
So
diu
mA
nse
rifo
rmes
2P
OP
RN
G4
Soak
fo
od in
so
luti
on
Am
ob
arb
ital
So
diu
mD
uck
, Mal
lard
3.6
g/L
fee
dF
eed
On
ceG
1398
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 245
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Am
oxic
illi
nA
vian
150-
175
PO
QD
-BID
E11
1
Am
oxi
cilli
nA
vian
250
IMQ
DE
704
Lo
ng-
last
ing
pre
par
atio
n
Am
oxi
cilli
nA
vian
0.2-
0.4
g/L
Dri
nk
QD
E70
4So
ft f
eed
Am
oxi
cilli
nA
vian
167
PO
QD
-BID
E74
1
Am
oxi
cilli
nA
vian
150
IM-P
ON
LE
924
Bro
ad s
pec
trum
Am
oxi
cilli
nA
vian
100
PO
BID
E14
31
Am
oxi
cilli
nA
vian
150-
175
PO
QD
-BID
E14
73
Am
oxi
cilli
nA
vian
100-
150
SCQ
DE
1526
Bro
ad s
pec
trum
Am
oxi
cilli
nA
vian
100-
150
IMN
LG
1618
Fo
r o
pen
fra
cture
s
Am
oxi
cilli
nB
ust
ard
100
IM-S
CB
IDE
1240
Am
oxi
cilli
nC
anar
y0.
3 g/
LD
rin
kN
LA
1139
Am
oxi
cilli
nC
anar
y0.
5 g/
kg f
eed
Fee
dO
nce
A11
39
Am
oxi
cilli
nC
hic
ken
16P
OQ
DB
1006
Am
oxi
cilli
nC
urr
awo
ng,
Pie
d25
-50
PO
BID
G16
09P
ost
-surg
ical
Am
oxi
cilli
nD
uck
20D
rin
kQ
DC
705
Am
oxi
cilli
nF
alco
n10
0P
aren
tera
lq2d
G11
28
Am
oxi
cilli
nG
allif
orm
es0.
17 g
/L
Dri
nk
QD
E70
4
Am
oxi
cilli
nG
osh
awk
10P
OB
IDG
127
Pre
cede
wit
h t
icar
cilli
n
Am
oxi
cilli
nG
ull
100
PO
QD
-BID
E13
57
Am
oxi
cilli
nP
engu
in, A
fric
an20
0P
OT
IDG
1353
Am
oxi
cilli
nP
igeo
n20
-90
PO
QD
-BID
A49
3U
se c
apsu
les
Am
oxi
cilli
nP
igeo
n10
0P
OQ
D-B
IDA
565
Gra
m n
egat
ive
bac
teri
a
Am
oxi
cilli
nP
igeo
n50
IMQ
D-B
IDA
565
Gra
m p
osi
tive
bac
teri
a
Am
oxi
cilli
nP
igeo
n18
-91
PO
QD
-BID
A73
3U
se h
igh
do
sage
fo
r E
nte
rob
acte
riac
eae
Am
oxi
cilli
nP
igeo
n1.
5 g/
LD
rin
kN
LA
800
Fo
r Str
epto
cocc
us b
ovis
Am
oxi
cilli
nP
igeo
n15
0IV
-PO
NL
A80
0F
or
Str
epto
cocc
us b
ovis
Am
oxi
cilli
nP
igeo
n0.
2 g/
LD
rin
kN
LA
993
Am
oxi
cilli
nP
igeo
n75
-100
PO
BID
A10
66
Am
oxi
cilli
nP
igeo
n20
Dri
nk
QD
C70
4
Am
oxi
cilli
nP
igeo
n25
-50
PO
QD
G47
Am
oxi
cilli
nP
oult
ry15
-20
Dri
nk
QD
C70
5
Am
oxi
cilli
nP
oult
ry55
-110
PO
BID
-TID
G58
5
Am
oxi
cilli
nP
sitt
acin
e15
0-17
5P
OQ
D-B
IDE
565
Am
oxi
cilli
nP
sitt
acin
e25
0IM
QD
E11
40
Am
oxi
cilli
nP
sitt
acin
e10
0SC
NL
G16
13
Am
oxi
cilli
nR
apto
r15
0IM
-PO
BID
E14
00B
acte
rial
infe
ctio
ns
Am
oxi
cilli
nR
apto
r50
IMB
IDE
1612
Am
oxi
cilli
nR
atit
e15
-22
PO
BID
G13
08
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I246
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Am
oxic
illi
n +
Tylo
sin
Avi
an10
g/L
Dri
nk
QD
E14
92F
or
flo
ck t
reat
men
t o
f b
acte
rial
an
d
myc
op
lasm
al in
fect
ion
s
Am
oxi
cilli
n +
Tyl
osi
nA
vian
3000
PO
QD
E14
92
Am
oxi
cilli
n +
Tyl
osi
nA
vian
10 g
/L
Dri
nk
QD
E16
50
Am
oxi
cilli
n +
Tyl
osi
nA
vian
3000
PO
QD
E16
50
Am
oxic
illi
n D
ep
ot
Bust
ard
100-
250
IM-S
Cq3-
7dA
1127
, 124
0
Am
oxi
cilli
n D
epo
tP
igeo
n15
0IM
q2d
A49
3L
on
g-la
stin
g fo
rmula
tio
n
Am
oxi
cilli
n D
epo
tP
igeo
n15
0-20
0SC
QD
A99
1L
on
g-la
stin
g o
il b
ased
susp
.
Am
oxic
illi
n S
od
ium
+
Cla
vu
lan
ate
Po
tass
ium
Am
azo
n P
arro
t12
5N
LT
IDA
1491
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Avi
an12
5P
OQ
IDE
704
Do
sage
bas
ed o
n a
mo
xici
llin
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Avi
an10
0P
O, I
MB
IDE
1431
Use
ful i
n y
oun
g b
irds
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Avi
an50
IMB
ID-Q
IDE
1470
Fo
r b
acte
rial
infe
ctio
n w
ith
live
r dis
ease
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Avi
an15
0-17
5IM
-PO
BID
E14
74F
or
neo
nat
al s
epti
cem
ia
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Bir
d, A
quat
ic12
5-15
0IM
, PO
BID
E14
78P
re-
and p
ost
-op
erat
ive
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Can
ary
125
Gav
age
BID
G11
39F
or
GI
infe
ctio
n
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Ch
icke
n0.
5 g/
LD
rin
kN
LA
801
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Haw
k, R
ed-t
aile
d50
PO
BID
G16
26P
ost
-op
erat
ive
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Ow
l, G
reat
-ho
rned
125
PO
BID
G17
3
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Pas
seri
ne
200
NL
TID
G14
89F
or
fro
stb
ite
asso
ciat
ed s
kin
infe
ctio
n
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Pig
eon
125
Gav
age
BID
B75
1F
or
loca
lized
gut
infe
ctio
n
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Psi
ttac
ine
100
PO
BID
D14
46F
or
stap
hyl
oco
ccal
der
mat
itis
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Rap
tor
150
PO
, IM
BID
E14
00, 1
433
Can
be
nep
hro
toxi
c
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Rap
tor
125
PO
BID
G23
4
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 247
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Am
oxi
cilli
n S
odiu
m +
Cla
vula
nat
e P
ota
ssiu
m
Rat
ite
11-1
5IV
-PO
TID
G13
08
Am
ph
ote
ricin
BA
maz
on
, Yel
low
-nap
ed50
-75
mg
TD
ITQ
DG
740
Am
ph
ote
rici
n B
Avi
an1
ITT
IDE
625
Add f
lucy
tosi
ne
+ I
V a
mp
ho
teri
cin
B,
asp
ergi
llosi
s th
erap
y
Am
ph
ote
rici
n B
A
vian
1.
5 IV
T
ID
E
625,
674
S
ee a
bo
ve
Am
ph
ote
rici
n B
Avi
an10
0P
OB
IDE
1492
Fo
r m
acro
rhab
do
sis
(fo
rmer
ly m
egab
acte
ria
or
avia
n g
astr
ic y
east
)
Am
ph
ote
rici
n B
Avi
an0.
83gL
Neb
uliz
eB
IDE
1526
Fo
r as
per
gillo
sis
ther
apy.
Must
use
ste
rile
wat
er -
NaC
l in
acti
vate
s A
mp
ho
teri
cin
Am
ph
ote
rici
n B
Avi
an1
IPQ
DG
861
Am
ph
ote
rici
n B
Bir
d, A
quat
ic10
0-20
0P
OT
ID-Q
IDE
1503
Fo
r G
I ca
ndid
iasi
s
Am
ph
ote
rici
n B
Bir
d, A
quat
ic1.
5IV
-SC
QD
E15
03F
or
asp
ergi
llosi
s th
erap
y
Am
ph
ote
rici
n B
Budge
riga
r10
9P
OB
IDB
589
Fo
r m
acro
rhab
do
sis
(fo
rmer
ly m
egab
acte
ria
or
avia
n g
astr
ic y
east
)
Am
ph
ote
rici
n B
Cra
ne
0.33
-0.6
7 g/
LN
ebuliz
eT
IDG
1361
Am
ph
ote
rici
n B
Gull
1IT
BID
E13
57
Am
ph
ote
rici
n B
Gull
1.5
IVT
IDE
1357
Am
ph
ote
rici
n B
Psi
ttac
ine
1.5
IVB
ID-T
IDE
111,
745
Am
ph
ote
rici
n B
Psi
ttac
ine
1IT
BID
-TID
E11
1, 7
41, 1
309
Am
ph
ote
rici
n B
Rap
tor
1.5
IVT
IDB
1178
Add I
T a
mp
ho
teri
cin
B +
flu
cyto
sin
e +
rifa
mp
in f
or
asp
ergi
llosi
s
Am
pic
illi
nA
maz
on
Par
rot
150-
200
PO
BID
-TID
A56
7M
ay g
ive
com
bin
atio
n o
f b
oth
ora
l an
d
par
ente
ral
Am
pic
illin
An
seri
form
es10
0IM
q4h
E13
18, 1
358
Am
pic
illin
Avi
an0.
25g/
kgF
eed
QD
E74
1
Am
pic
illin
Avi
an1.
041
g/L
Dri
nk
QD
E74
1
Am
pic
illin
Can
ary
1-2
g/L
Dri
nk
QD
G49
Am
pic
illin
Can
ary
2-3
g/kg
fo
od
Fee
dQ
DG
49In
so
ft f
oo
d
Am
pic
illin
Cra
ne
15-2
0IM
-SC
BID
A59
6
Am
pic
illin
Cra
ne,
Gre
ater
San
d H
ill20
IMB
IDA
847
Am
pic
illin
Em
u20
IMB
IDA
847
Am
pic
illin
Fal
con
100
IM-P
OB
IDE
1027
Am
pic
illin
P
arro
t, B
lue-
nap
ed
150-
200
PO
BID
-TID
A56
7M
ay g
ive
com
bin
atio
n o
f b
oth
ora
l an
d
par
ente
ral
Am
pic
illin
Pig
eon
25-1
20P
OQ
D-B
IDA
493
Use
cap
sule
s
Am
pic
illin
Pig
eon
100
IMq2d
A49
3L
on
g-la
stin
g fo
rmula
tio
n
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I248
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Am
pic
illin
Po
ult
ry55
-110
Par
ente
ral
BID
-TID
G58
5
Am
pic
illin
Psi
ttac
ine
100
IMq4h
E11
1
Am
pic
illin
Psi
ttac
ine
100-
200
PO
QID
E12
40P
oo
rly
abso
rbed
Am
pic
illin
Rap
tor
100-
250
IMN
LE
1463
Am
pic
illi
n S
od
ium
Am
azo
n P
arro
t50
-100
IMq4-
8hA
567
May
giv
e co
mb
inat
ion
of
bo
th o
ral a
nd
par
ente
ral
Am
pic
illin
So
diu
mP
igeo
n15
0IM
QD
-BID
A49
3
Am
pic
illin
So
diu
mP
igeo
n77
3IM
QD
-BID
A73
3F
or
Ent
erob
acte
riac
eae
Am
pic
illin
So
diu
mP
igeo
n15
5IM
QD
-BID
A73
3
Am
pic
illin
So
diu
mR
atit
e0.
1 -
0.2
g/L
Dri
nk
NL
G41
8C
lost
ridia
l tre
atm
ent
Am
pro
liu
mA
vian
0.04
8-0.
096g
/L
Dri
nk
QD
E11
1
Am
pro
lium
A
vian
0.
08 g
/L
D
rin
k Q
D
E
1492
C
occ
idio
stat
ic, o
verd
ose
rev
erse
d b
y
adm
inis
trat
ion
of
vita
min
B c
om
ple
x
Am
pro
lium
Ch
icke
n40
-250
mg/
kg f
oo
dF
eed
QD
E56
4N
o s
laugh
ter
wit
hdra
wal
Am
pro
lium
Cra
ne
0.06
g/L
Dri
nk
QD
E13
61F
or
cocc
idio
sis
Am
pro
lium
Pig
eon
0.2
g/L
Dri
nk
QD
G23
2
Am
pro
lium
Po
ult
ry1.
25 c
c/L
Dri
nk
QD
G58
5U
se 2
0% p
ow
der
fo
rmula
tio
n
Am
pro
lium
Psi
ttac
ine
0.25
g/L
Dri
nk
QD
E13
65F
or
sarc
ocy
sto
sis
Ap
ram
ycin
Ch
icke
n0.
5 g/
LD
rin
kQ
DB
881
Fo
r co
libac
illo
sis
Are
co
lin
e H
yd
rob
rom
ide
Pel
ican
, Bro
wn
1-1.
6P
OQ
HB
1089
Giv
e th
iab
endaz
ole
pre
vio
us
day
Ars
an
ilic
Acid
Po
ult
ry0.
1 g/
kg f
oo
dF
eed
QD
E56
4N
utr
itio
nal
use
, 5-d
ay s
laugh
ter
wit
hdra
wal
Asc
orb
ic A
cid
A
vian
20
-40
IM
QD
-QW
E
14
73
Asc
orb
ic A
cid
Avi
an20
-50
IM-P
ON
LE
924
Fo
r vi
ral i
nfe
ctio
n, l
iver
dis
ease
, str
ess
Asc
orb
ic A
cid
Avi
an20
-40
IMQ
D-Q
WE
1473
Asc
orb
ic A
cid
Ost
rich
20-5
0 m
g T
DIM
q2d
G40
1F
or
chic
ks
Asc
orb
ic A
cid
Rap
tor
250
PO
QD
E13
59A
nti
oxi
dan
t th
erap
y, a
dm
inis
ter
duri
ng
lead
chel
atio
n t
her
apy
Asp
ara
gin
ase
Avi
an0.
4 K
IU/kg
IMQ
WE
1470
Asp
arag
inas
eO
wl,
Gre
at-h
orn
ed1.
7 K
IU/kg
SCO
nce
F12
5
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 249
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Asp
irin
Am
azo
n, R
ed L
ore
d0.
5-1
PO
QD
-BID
G17
56A
dd f
atty
aci
d o
meg
a 6:
om
ega
3 <
6:1
rat
io,
use
un
til r
enal
his
tolo
gy n
orm
aliz
es f
or
ren
al
dis
ease
Asp
irin
Am
azo
n, Y
ello
w-n
aped
0.5-
1P
OB
IDG
1033
Asp
irin
Avi
an5
PO
TID
-QID
D15
33
Asp
irin
Avi
an1.
2 g/
LD
rin
kQ
DE
1650
Asp
irin
Avi
an5
PO
TID
G13
41, 1
671
Asp
irin
Psi
ttac
ine
0.5-
1P
OQ
D-B
IDE
1756
Asp
irin
Sto
rk, S
addle
-bill
ed1
PO
QD
G16
45
Ast
rag
alu
s A
vian
1
0 dro
ps/
kg P
O
TID
E
12
05
Ch
ron
ic G
I p
rob
lem
s an
d in
fect
ion
s
Ast
raga
lus
Avi
an33
-66
dro
ps/
kgP
OQ
DE
1435
Imm
un
e st
imula
nt
Ati
pam
ezo
le
Ati
pam
ezo
leA
nse
rifo
rmes
0.25
IVP
RN
D15
03A
dd f
lum
azen
il to
rev
erse
ket
amin
e +
med
eto
mid
ine
+ m
idaz
ola
m
Ati
pam
ezo
leA
vian
0.25
-0.3
8IM
PR
NE
1181
Rev
erse
ket
amin
e +
xyl
azin
e o
r ke
tam
ine
+
med
eto
mid
ine
Ati
pam
ezo
leD
uck
, Mal
lard
0.25
mg
TD
IVP
RN
B76
4A
dd f
lum
azen
il
Ati
pam
ezo
leP
igeo
n0.
5IM
PR
NB
1588
Rev
erse
med
eto
mid
ine
Ati
pam
ezo
leP
sitt
acin
e0.
25-0
.38
IMP
RN
E12
40R
ever
se x
ylaz
ine
or
med
eto
mid
ine
Atr
op
ine
An
seri
form
es0.
1IM
-IV
q3-
4hD
1150
Fo
r an
tich
olin
este
rase
po
iso
nin
g
Atr
op
ine
Avi
an0.
04-0
.1IM
-SC
On
ceG
1309
Pre
anes
thet
ic
Atr
op
ine
Avi
an0.
1-0.
2IM
-SC
q4h
E11
51F
or
cho
liner
gic
toxi
n
Atr
op
ine
Avi
an0.
2-0.
5IV
q3-
4hE
1554
Fo
r an
tich
olin
este
rase
to
xici
ty
Atr
op
ine
Avi
an0.
01-0
.02
Par
ente
ral
q3-
4hE
1650
Fo
r o
rgan
op
ho
sph
ate
toxi
city
Atr
op
ine
Avi
an0.
1-0.
2IM
-SC
PR
NG
1309
Fo
r o
rgan
op
ho
sph
ate
po
iso
nin
g
Atr
op
ine
Can
ary
0.2
Par
ente
ral
q4h
G17
14F
or
con
vuls
ion
s p
oss
ibly
cau
sed b
y
org
ano
ph
osp
hat
e to
xici
ty
Atr
op
ine
Pig
eon
0.27
IM-I
Vq4-
8hG
590
Atr
op
ine
Psi
ttac
ine
0.05
IM-S
CQ
HE
1240
Fo
r ac
etyl
cho
lines
tera
se p
ois
on
ing
Atr
op
ine
Psi
ttac
ine
0.5
IM-S
CN
LE
1688
Atr
op
ine
Rap
tor
0.5
IM-I
VP
RN
G61
[May
th
icke
n s
ecre
tio
ns
and in
crea
se r
isk
of
airw
ay o
bst
ruct
ion
- K
LM
]
Atr
op
ine
Rap
tor
0.1
IM-I
Vq3-
4hE
1240
, 140
0F
or
acet
ylch
olin
este
rase
po
iso
nin
g
Atr
op
ine
Rap
tor
0.02
-0.0
5IM
-IV
PR
NE
1359
Fo
r o
rgan
op
ho
sph
ate
toxi
city
Azam
eth
iph
os
Po
ult
ry5-
20 g
/L
To
pic
alN
LE
1479
Ap
ply
to
an
imal
fac
iliti
es, i
nse
ct s
pra
y
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I250
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Azap
ero
ne
Ost
rich
4-6
IMP
RN
B52
2A
dd m
eto
mid
ate,
ch
ick
do
sage
Aza
per
on
eO
stri
ch3.
3-6.
6IM
PR
NG
283
Add m
eto
mid
ate
Aza
per
on
eR
atit
e0.
5-2
IMO
nce
G12
26A
dd k
etam
ine
+ d
iaze
pam
aft
er 1
0 to
15
min
ute
s, s
edat
ion
Azit
hro
mycin
Avi
an50
-80
PO
QD
G70
2F
or
chla
myd
op
hilo
sis
Azi
thro
myc
inA
vian
43P
OQ
DG
1154
Add e
tham
buto
l + r
ifab
uti
n f
or
myc
ob
acte
rio
sis
Azi
thro
myc
inF
alco
n40
PO
QW
F11
57F
or
chla
myd
op
hilo
sis
Bach
flo
wer
Avi
an1
dro
pD
rin
kQ
IDG
912
Fo
r ca
lmin
g ef
fect
, als
o a
pp
ly t
op
ical
ly a
s
spra
y
Bac
h f
low
er
Avi
an
45-7
5 dro
ps/
L
PO
Q
ID
G
912
S
ee a
bo
ve
Bacit
racin
Po
ult
ry11
0-22
0 m
g/kg
fee
dF
eed
QD
E56
4N
utr
itio
nal
use
, no
sla
ugh
ter
wit
hdra
wal
Bac
itra
cin
Rat
ite
0.4
g/L
Dri
nk
NL
G41
8C
lost
ridia
l th
erap
y
Bam
berm
ycin
Ch
icke
n3.
3 m
g/kg
fee
dF
eed
On
ceB
400
Bam
ber
myc
inO
stri
ch0.
07 m
g/kg
fee
dF
eed
On
ceC
283
Gro
wth
pro
mo
tan
t
Bari
um
Su
lfate
Avi
an50
ml/
kgP
ON
LE
1151
G.I
. pro
tect
ant
and a
nti
infl
amm
ato
ry
Bar
ium
Sulf
ate
Avi
an10
-20
ml/
kgP
ON
LE
1482
Mix
50:
50 w
ith
han
d-f
eedin
g fo
rmula
fo
r G
I
con
tras
t ra
ds
Ben
zyl
Ben
zo
ate
Pig
eon
25%
so
luti
on
To
pic
alP
RN
E70
4A
pp
ly t
o le
sio
n
Ben
zyl B
enzo
ate
Rap
tor
10%
so
luti
on
To
pic
alQ
DE
1612
Fo
r K
nem
idoc
opte
s
Beta
meth
aso
ne
Avi
an0.
1IM
NL
D, E
,
G
201,
153
3, 1
573
Bet
amet
has
on
eB
ird, A
quat
ic0.
1IM
NL
E15
03
Bet
amet
has
on
eP
igeo
n1
IMO
nce
E70
4A
nap
hyl
axis
Bio
tin
Rap
tor
0.02
5P
OQ
DE
1068
Duri
ng
regr
ow
th o
f cl
aw
Bio
tin
Rap
tor
0.05
PO
QD
E12
40A
id in
bea
k an
d c
law
gro
wth
Bis
mu
th S
ub
sali
cyla
teA
vian
35P
OB
IDE
1240
May
hel
p r
emo
ve in
gest
ed t
oxi
ns
Bis
muth
Sub
salic
ylat
eA
vian
35-8
8P
OO
nce
E15
26E
nte
ric
coat
ing
for
oile
d b
irds
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 251
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Bre
wers
yeast
An
seri
form
es75
g/kg
fee
dF
eed
QD
E13
58F
or
nia
cin
def
icie
ncy
wit
h le
g def
orm
itie
s,
wea
knes
s, p
oo
r gr
ow
th
Bro
mh
exin
e H
Cl
Avi
an3-
6IM
NL
E70
4, 1
434
Bro
mh
exin
e H
Cl
Avi
an1.
5IM
QD
-BID
E15
26, 1
617
Liq
uef
y re
spir
ato
ry m
ucu
s
Bro
mh
exin
e H
Cl
Rap
tor
1.5
IMQ
DE
1612
Muco
lyti
c
Bu
nam
idin
e H
Cl
Rap
tor
25P
ON
LE
1463
An
thel
min
tic
Bu
piv
acain
e H
Cl
Par
rot,
Gre
y2
IMP
RN
A13
39M
ain
tain
pla
sma
con
cen
trat
ion
fo
r le
ss t
han
2
ho
urs
Bu
pre
no
rph
ine H
Cl
Avi
an0.
01-0
.05
IM-I
V-S
CB
IDE
1167
Bup
ren
orp
hin
e H
Cl
Pig
eon
0.5
IMq5h
B16
56
Bu
torp
han
ol
Tart
rate
Am
azo
n, H
isp
anio
lan
1-3
IMN
LA
1339
Buto
rph
ano
l Tar
trat
eC
ock
ato
o1
NL
PR
NB
1678
Iso
flura
ne
spar
ing
Buto
rph
ano
l Tar
trat
eP
arro
t, G
rey
1-2
IMN
LA
1339
Pla
sma
leve
ls m
ain
tain
ed le
ss t
han
2 h
ours
at
2 m
g/kg
Buto
rph
ano
l Tar
trat
eP
arro
t, G
rey
1IM
NL
B58
6, 1
339
Buto
rph
ano
l Tar
trat
eP
igeo
n4
IMq3h
B16
56
Buto
rph
ano
l Tar
trat
eP
sitt
acin
e3-
4IV
-PO
NL
E11
1, 1
249
Buto
rph
ano
l Tar
trat
eP
sitt
acin
e3-
4IV
-PO
TID
E12
40A
lso
an
alge
sic
Buto
rph
ano
l Tar
trat
eR
apto
r2-
4IM
-SC
QD
E13
59
Buto
rph
ano
l Tar
trat
eR
hea
0.7
IMP
RN
G16
28A
dd k
etam
ine
+ m
edet
om
idin
e
Buto
rph
ano
l Tar
trat
eT
ouca
n, T
oco
2IM
On
ceG
1379
Po
st-s
urg
ical
pai
n
Calc
itri
ol
Avi
an0.
0000
25 (
0.02
5ug/
kg)
Gav
age
QD
G11
83A
dd c
alci
um
so
urc
e to
gav
age
for
hyp
oca
lcae
mia
Calc
ium
Bo
rog
luco
nate
Avi
an20
0IM
-IV
QD
E14
31U
sed d
uri
ng
egg
layi
ng
pro
ble
ms,
oft
en w
ith
oxy
toci
n
Cal
cium
Bo
rogl
uco
nat
eA
vian
100-
500
IM-S
CN
LE
1434
Fo
r eg
g b
indin
g an
d h
ypo
calc
emic
tet
any
Cal
cium
Bo
rogl
uco
nat
eG
osh
awk
300
IVN
LG
234
Cal
cium
Bo
rogl
uco
nat
eP
igeo
n10
0-50
0IM
-SC
NL
E14
32F
or
egg
bin
din
g an
d h
ypo
calc
emic
tet
any
Cal
cium
Bo
rogl
uco
nat
eP
sitt
acin
e10
0-20
0IM
-IV
NL
E12
40
Cal
cium
Bo
rogl
uco
nat
eR
apto
r10
0-50
0IV
-SC
On
ceE
1240
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I252
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Cal
cium
Bo
rogl
uco
nat
eR
apto
r10
-50
IV-S
CO
nce
E14
00F
or
egg
bin
din
g o
r h
ypo
calc
aem
ia, g
ive
IV
slo
wly
Calc
ium
Carb
on
ate
Rap
tor
10 g
/kg
fo
od
Fee
dO
nce
D16
12F
or
ost
eodys
tro
ph
y
Calc
ium
Glu
bio
nate
Avi
an0.
44 g
/L
Dri
nk
NL
E14
92F
or
egg
bin
din
g an
d c
alci
um
def
icie
nci
es
Cal
cium
Glu
bio
nat
eA
vian
150
PO
BID
G54
Calc
ium
Glu
bio
nate
+
Calc
ium
Lacto
bio
nate
Avi
an36
3P
OQ
DE
1617
Calc
ium
Glu
co
nate
Avi
an10
0-30
0IM
-SC
NL
E14
80A
dd p
hyt
on
adio
ne
for
ble
edin
g sy
ndro
me
Cal
cium
Glu
con
ate
Avi
an5-
10IM
-SC
BID
E14
73
Cal
cium
Glu
con
ate
Avi
an50
-100
IVN
LE
1473
Slo
wly
to
eff
ect
Cal
cium
Glu
con
ate
Avi
an5-
10IM
NL
E14
74
Cal
cium
Glu
con
ate
Avi
an50
-100
IVN
LE
1474
Giv
e sl
ow
ly, f
ollo
w w
ith
oxy
toci
n o
r
din
op
rost
on
e fo
r eg
g b
indin
g, m
ay a
dd
vita
min
E +
sel
eniu
m
Cal
cium
Glu
con
ate
Avi
an10
0-30
0SC
NL
E14
81
Calc
ium
Gly
cero
ph
osp
hate
+
Calc
ium
Lacta
te
Avi
an5-
10IM
-SC
NL
E15
70F
or
egg
bin
din
g
Cal
cium
Gly
cero
ph
osp
hat
e
+ C
alci
um
Lac
tate
Avi
an0.
5-1
IMQ
WG
54
Cal
cium
Gly
cero
ph
osp
hat
e
+ C
alci
um
Lac
tate
Lo
ry, R
ed7
IMN
LG
1621
Add o
xyto
cin
fo
r eg
g b
indin
g
Cal
cium
Gly
cero
ph
osp
hat
e
+ C
alci
um
Lac
tate
Par
rot,
Gre
y5-
10IM
-SC
BID
G88
Acu
te t
her
apy
Cam
ben
dazo
leA
vian
60-1
00P
OQ
DG
57A
void
duri
ng
bre
edin
g se
aso
n
Cam
ben
daz
ole
Pig
eon
75P
OQ
DE
1051
Fo
r as
cari
ds
and c
apill
aria
Cap
ryli
c A
cid
Avi
an27
0P
ON
LE
111
Adju
nct
to
asp
ergi
llosi
s th
erap
y
Carb
ary
lA
vian
N/A
To
pic
alN
LE
111
5% m
ixtu
re, p
ow
der
fo
rmula
tio
n
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 253
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Car
bar
ylA
vian
N/A
To
pic
alN
LE
1240
5% m
ixtu
re, l
igh
tly
dust
fea
ther
s fo
r
ecto
par
asit
es
Carb
en
icil
lin
Dis
od
ium
Avi
an15
0IM
-PO
NL
E92
4G
ram
neg
ativ
e, P
seud
omon
as
Car
ben
icill
in D
iso
diu
mA
vian
100
IMT
IDG
55
Car
ben
icill
in D
iso
diu
mA
vian
100-
200
IMB
IDG
861
Fre
eze
smal
l po
rtio
ns
indef
init
ely
Car
ben
icill
in D
iso
diu
mC
ran
e10
0IM
-IV
BID
-TID
E62
9, 1
361
Car
ben
icill
in D
iso
diu
mO
wl,
Gre
at-h
orn
ed15
0P
OB
IDG
173
Car
ben
icill
in D
iso
diu
mP
igeo
n10
0IM
BID
-TID
G26
0
Car
ben
icill
in D
iso
diu
mP
sitt
acin
e10
0-20
0IM
TID
-QID
E56
5
Car
ben
icill
in D
iso
diu
mP
sitt
acin
e10
0IM
BID
E76
3
Car
ben
icill
in D
iso
diu
mR
apto
r10
0-20
0IM
TID
E12
40
Car
ben
icill
in D
iso
diu
mR
apto
r10
0IT
QD
E12
40F
or
Gra
m n
egat
ive
bac
teri
a, s
yner
gist
ic
w/am
ino
glyc
osi
des
Car
ben
icill
in D
iso
diu
mR
apto
r10
0-20
0IM
TID
E14
00
Carb
on
Dio
xid
e G
as
Avi
anN
/A
IHN
LE
1564
Euth
anas
ia
Carb
op
lati
n
Am
azo
n, Y
ello
w-n
aped
125
mg/
m3
I
V
q2-
3w
G
1033
D
ilute
wit
h 5
% d
extr
ose
Car
bo
pla
tin
B
udge
riga
r 5
IV
QM
G
12
59
Dilu
te 1
:10
wit
h s
teri
le w
ater
Carb
oxym
eth
ylc
ell
ulo
se
So
diu
m
Avi
an0.
1% s
olu
tio
nD
rin
kQ
DG
1457
Add a
mp
ho
teri
cin
B, m
ix f
resh
dai
ly, a
llow
to
stan
d o
vern
igh
t, d
isso
lve
dru
g in
th
e A
M
Carf
en
tan
il C
itra
teO
stri
ch3
mg
TD
IMP
RN
B52
1A
dd x
ylaz
ine
Car
fen
tan
il C
itra
teO
stri
ch0.
024
NL
PR
NG
465
Carn
idazo
leA
vian
33P
OO
nce
E15
26F
or
tric
ho
mo
nia
sis,
no
fo
od/w
ater
nig
ht
bef
ore
tre
atm
ent
plu
s n
o w
ater
2 t
o 3
ho
urs
afte
r tr
eatm
ent
Car
nid
azo
leA
vian
20-3
0P
OO
nce
E15
54F
or
tric
ho
mo
nia
sis
and g
iard
iasi
s
Car
nid
azo
leB
ird, A
quat
ic33
PO
On
ceE
1503
Car
nid
azo
leB
ust
ard
20-2
5P
OO
nce
E12
40
Car
nid
azo
leD
ove
30P
ON
LG
61
Car
nid
azo
leF
alco
n25
PO
On
ceB
1420
Fo
r T
tich
om
on
iasi
s, le
ss e
ffec
tive
th
an
mult
iday
dim
etri
daz
ole
Car
nid
azo
leF
inch
20-3
0P
OO
nce
E15
72
Car
nid
azo
leP
igeo
n20
-30
PO
On
ceD
1221
Fo
r tr
ich
om
on
iasi
s
Car
nid
azo
leP
igeo
n20
0P
OO
nce
E11
1, 1
473
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I254
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Car
nid
azo
leP
igeo
n12
.5-2
5P
OO
nce
E12
40U
se lo
wer
do
sage
fo
r ju
ven
iles
Car
nid
azo
leP
igeo
n20
-30
PO
QW
-q2w
E13
64
Car
nid
azo
leP
sitt
acin
e20
-30
PO
On
ceE
1240
Fo
r tr
ich
om
on
iasi
s, h
exam
itia
sis,
his
tom
on
iasi
s, u
se lo
wer
do
sage
fo
r ju
ven
iles
Car
nid
azo
leR
apto
r30
PO
QD
G61
Carp
rofe
nA
maz
on
, Ora
nge
-win
ged
4IM
BID
G13
77P
ost
-surg
ical
Car
pro
fen
An
seri
form
es4
SCQ
DE
1190
Car
pro
fen
An
seri
form
es5-
10IM
NL
G13
45
Car
pro
fen
Avi
an1-
2IM
-PO
BID
D15
33
Car
pro
fen
Avi
an4
IM-I
V-P
ON
LE
1167
Car
pro
fen
Avi
an5-
10IM
QD
E14
31P
re-o
per
ativ
e p
ain
kille
r
Car
pro
fen
Bir
d, A
quat
ic1-
2IM
-PO
BID
E15
03
Car
pro
fen
Pig
eon
5-10
IMN
LG
1345
Car
pro
fen
Psi
ttac
ine
2-10
IM-I
V-S
CQ
DE
1240
Po
st-s
urg
ical
pai
n
Car
pro
fen
Rap
tor
1-2
IM-I
V-P
OB
IDD
1400
Car
pro
fen
Rap
tor
2-10
IM-I
V-S
CQ
DE
1240
Po
st-s
urg
ical
pai
n
Cefa
dro
xil
Pig
eon
100
PO
BID
G26
0
Cefa
zo
lin
So
diu
mC
ran
e25
-30
IM-I
VT
IDE
629
Cef
azo
lin S
odiu
mP
oult
ry11
-55
NL
BID
-TID
G58
5
Cef
azo
lin S
odiu
mR
apto
r10
0IM
On
ceE
1359
Per
iop
erat
ive,
use
am
oxi
cilli
n/cl
avula
nat
e
po
st-o
per
ativ
e
Cefo
taxim
e S
od
ium
Am
azo
n P
arro
t75
-100
IMq4-
8hA
697
Cef
ota
xim
e So
diu
mA
maz
on
, Blu
e-fr
on
ted
100
IMT
IDA
748
Cef
ota
xim
e So
diu
mA
vian
75-1
00IM
-IV
TID
-QID
A14
73
Cef
ota
xim
e So
diu
mB
ird, A
quat
ic10
0IM
TID
-QID
E14
78F
or
ho
ck jo
int
pre
ssure
so
re in
fect
ion
s
Cef
ota
xim
e So
diu
mC
ran
e50
-100
IM-S
CT
IDE
629
Cef
ota
xim
e So
diu
mH
awk,
Red
-tai
led
100
IMN
LG
1626
Intr
a-o
per
ativ
e
Cef
ota
xim
e So
diu
mP
igeo
n10
0IM
BID
-TID
G26
0
Cef
ota
xim
e So
diu
mP
sitt
acin
e50
-100
IMT
IDE
565
Cef
ota
xim
e So
diu
mP
sitt
acin
e50
-100
SCT
IDE
632
Neo
nat
e do
sage
Cef
ota
xim
e So
diu
mP
sitt
acin
e10
0IM
BID
E76
3F
roze
n r
eco
nst
itute
d d
rugs
last
s 12
wee
ks in
free
zer,
10
day
s in
ref
rige
rato
r
Cef
ota
xim
e So
diu
mR
apto
r10
0IM
-IV
On
ceE
1359
Per
iop
erat
ive,
use
am
oxi
cilli
n/cl
avula
nat
e
po
st-o
per
ativ
e
Cef
ota
xim
e So
diu
mR
atit
e25
IMT
IDG
1308
Fo
r yo
un
g b
irds
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 255
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ceft
azid
ime
Psi
ttac
ine
75-2
00IM
-IV
BID
-QID
E17
56F
or
bac
teri
al n
eph
riti
s
Ceft
iofu
r S
od
ium
Am
azo
n, O
ran
ge-w
inge
d10
IMB
ID-T
IDA
788
Cef
tio
fur
Sodiu
mA
vian
50-1
00IM
QID
E12
40
Cef
tio
fur
Sodiu
mC
hic
ken
0.16
mg
TD
IMQ
DA
788
Cef
tio
fur
Sodiu
mC
ock
atie
l10
IMq4h
A78
8
Cef
tio
fur
Sodiu
mP
sitt
acin
e10
0IM
TID
E17
56F
or
bac
teri
al n
eph
riti
s
Cef
tio
fur
Sodiu
mR
atit
e10
-20
IMB
IDG
1308
Ceft
riaxo
ne S
od
ium
Am
azo
n P
arro
t75
-100
IMq4-
8hA
697
Cef
tria
xon
e So
diu
mA
vian
75-1
00IM
-IV
TID
-QID
E11
1
Cele
co
xib
Avi
an (
Mac
aw)
10P
OQ
DG
1750
Fo
r p
rove
ntr
icula
r dila
tati
on
dis
ease
sym
pto
ms
Cep
hale
xin
Avi
an35
-50
PO
q4-
6hE
111
Cep
hal
exin
Avi
an40
-100
IM-P
OT
ID-Q
IDE
1240
Fo
r E
. col
i an
d P
rote
us
Cep
hal
exin
Avi
an35
-50
PO
q4-
6hE
1473
Cep
hal
exin
Avi
an35
-50
PO
QID
E14
92
Cep
hal
exin
Bir
d, A
quat
ic35
-50
PO
QID
E15
03
Cep
hal
exin
Bust
ard
40-1
00IM
-PO
TID
-QID
E12
40F
or
E. c
oli
and P
rote
us
Cep
hal
exin
Cra
ne
35-5
0P
OQ
IDA
596
Cep
hal
exin
Cra
ne
100
IMQ
IDA
697
Cep
hal
exin
Cra
ne
100
PO
q4-
6hE
111
Cep
hal
exin
Cra
ne
35-5
0P
OQ
IDA
457,
847
Cep
hal
exin
Duck
35-5
0P
Oq2-
3hA
457
Cep
hal
exin
Duck
100
IMB
ID-T
IDA
697
Cep
hal
exin
Duck
35-5
0P
OQ
IDA
847
Cep
hal
exin
Em
u35
-50
PO
QID
A41
8, 4
57, 8
47
Cep
hal
exin
Em
u10
0IM
QID
A69
7
Cep
hal
exin
Pig
eon
35-5
0P
OQ
IDA
847
Cep
hal
exin
Pig
eon
100
PO
BID
-TID
G26
0
Cep
hal
exin
Po
ult
ry55
-110
NL
BID
G58
5
Cep
hal
exin
Psi
ttac
ine
35-5
0P
OQ
IDE
763
Cep
hal
exin
Psi
ttac
ine
100
PO
TID
G69
7
Cep
hal
exin
Quai
l10
0IM
BID
-TID
A69
7
Cep
hal
exin
Quai
l, B
ob
wh
ite
35-5
0P
Oq2-
3hA
457
Cep
hal
exin
Quai
l, Ja
pan
ese
35-5
0P
OQ
IDA
847
Cep
hal
exin
Rap
tor
40-1
00IM
-PO
TID
-QID
E12
40
Cep
hal
exin
Rap
tor
50-1
00IM
-PO
TID
E14
00
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I256
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Cep
hal
exin
Rap
tor
50P
OQ
IDG
234
Cep
hal
exin
Rat
ite
15-2
2P
OT
IDG
1308
Cep
halo
thin
So
diu
mA
vian
100
IM-I
VQ
IDA
1473
Cep
hal
oth
in S
odiu
mA
vian
100
IM-I
VQ
IDE
111
Cep
hal
oth
in S
odiu
mA
vian
100
IMq2-
6hE
565
Cep
hal
oth
in S
odiu
mA
vian
100
IMQ
IDE
741
No
gas
tro
inte
stin
al a
bso
rpti
on
Cep
hal
oth
in S
odiu
mR
atit
e30
-40
IM-I
VQ
IDG
1308
Cep
hra
din
eA
vian
35-5
0P
Oq4-
6hE
111,
147
3
Cep
hra
din
eC
ran
e10
0P
Oq4-
6hE
111
Cep
hra
din
eE
mu, p
igeo
n10
0P
Oq4-
6hE
1473
Ch
ito
san
Avi
an<
50
To
pic
alq3d
-q2w
B16
33R
inse
an
d a
pp
ly s
par
ingl
y to
wo
un
d s
urf
ace
or
pac
k su
pp
ura
tin
g w
oun
d, p
rom
ote
wo
un
d
hea
ling
Ch
lora
l H
yd
rate
Avi
an (
budge
riga
r, c
anar
y, c
hic
ken
,
cro
w, c
ran
e)
106.
5IM
PR
NB
1084
Add m
agn
esiu
m s
ulf
ate
+ p
ento
bar
bit
al
sodiu
m, r
educe
do
se 1
5 to
20%
in d
ebili
tate
d
bir
ds
Ch
lora
l Hyd
rate
Eag
le, G
old
en80
.9IM
PR
NB
1086
Ch
lora
l Hyd
rate
Fal
con
, Pra
irie
64IM
PR
NB
1086
Ch
lora
l Hyd
rate
G
ull
(Cal
ifo
rnia
, Lau
ghin
g,
Her
rin
g)
106.
5IM
PR
NB
1084
Ch
lora
l Hyd
rate
H
awk
(Mar
sh, R
ed-t
aile
d,
Swai
nso
n's
)
64-6
8IM
PR
NB
1086
Ch
lora
l Hyd
rate
O
wl,
Saw
-wh
et
106.
5 IM
P
RN
B
10
84
Ch
lora
l Hyd
rate
Pea
Fo
wl,
ph
easa
nt
106.
5IM
PR
NB
1084
Ch
lora
l Hyd
rate
Pig
eon
, sp
arro
w, t
ouca
net
106.
5IM
PR
NB
1084
Ch
lora
l Hyd
rate
Rai
l, W
oo
d10
6.5
IMP
RN
B10
84
Ch
lora
lose
An
seri
form
es0.
4-0.
48g/
L b
ait
Fee
dO
nce
G12
30A
dd d
iaze
pam
fo
r an
esth
esia
Ch
lora
lose
Bir
d, S
eed-e
ater
2 g/
kg g
rain
Fee
dO
nce
E4
Ch
lora
lose
Bla
ckb
ird, R
ed-w
inge
d0.
02-0
.025
mg
TD
Fee
dO
nce
G12
30A
dd s
eco
bar
bit
al
Ch
lora
lose
Cra
ne
1.54
-1.7
9 g/
L c
orn
Fee
dO
nce
G13
61
Ch
lora
lose
Duck
0.4-
0.5
g/L
bai
tF
eed
On
ceG
1386
Add d
iaze
pam
Ch
lora
lose
Duck
, Mal
lard
15F
eed
On
ceB
1095
Ch
lora
lose
Duck
, Mal
lard
40P
OP
RN
D14
01
Ch
lora
lose
Turk
ey8
g/L
co
rnF
eed
On
ceE
1386
Sedat
ion
in 4
0-60
min
, 9%
mo
rtal
ity
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 257
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ch
lora
mp
hen
ico
lA
vian
50-1
00P
OQ
DE
704
Ch
lora
mp
hen
ico
lA
vian
200
mg
Neb
uliz
eT
DE
704
Dilu
te in
15
ml 0
.9%
sal
ine
solu
tio
n
Ch
lora
mp
hen
ico
lA
vian
50-1
00P
aren
tera
lQ
DE
704
Ch
lora
mp
hen
ico
lB
udge
riga
r50
IMB
IDA
394
Ch
lora
mp
hen
ico
lC
anar
y0.
1-0.
15 g
/L
Fee
dQ
DE
695
In s
oft
fo
od
Ch
lora
mp
hen
ico
lC
hic
ken
50IM
BID
A39
4
Ch
lora
mp
hen
ico
l C
on
ure
(N
anday
, Sun
)
50
IM
QID
A
39
4
Ch
lora
mp
hen
ico
lC
ran
e10
0SC
TID
A59
6
Ch
lora
mp
hen
ico
lD
uck
, Ch
ines
e10
0IM
-IV
QID
A50
8
Ch
lora
mp
hen
ico
lD
uck
, Ch
ines
e25
IM-I
Vq3h
A50
8
Ch
lora
mp
hen
ico
lD
uck
, Ch
ines
e24
0IM
-IV
TID
A50
8
Ch
lora
mp
hen
ico
lD
uck
, Musc
ovy
50IM
BID
A39
4
Ch
lora
mp
hen
ico
lE
agle
50IM
QD
A39
4
Ch
lora
mp
hen
ico
lG
oo
se, E
gyp
tian
50IM
BID
A39
4
Ch
lora
mp
hen
ico
lH
awk
50IM
BID
A39
4
Ch
lora
mp
hen
ico
lM
acaw
50IM
QID
A39
4
Ch
lora
mp
hen
ico
lO
stri
ch10
IMB
IDG
401
Do
ub
le d
osa
ge f
or
bir
ds
bel
ow
5 k
g
Ch
lora
mp
hen
ico
lO
wl,
Bar
red
50IM
BID
A39
4
Ch
lora
mp
hen
ico
lP
ea F
ow
l50
IMQ
DA
394
Ch
lora
mp
hen
ico
lP
igeo
n95
PO
QID
E11
1W
ith
gri
t in
die
t
Ch
lora
mp
hen
ico
lP
igeo
n50
PO
TID
E70
4
Ch
lora
mp
hen
ico
lP
igeo
n30
PO
QID
E14
73W
ith
out
grit
in d
iet
Ch
lora
mp
hen
ico
lP
igeo
n80
IMB
IDE
1650
Fo
r sa
lmo
nel
losi
s
Ch
lora
mp
hen
ico
lP
sitt
acin
e50
IM-I
VT
ID-Q
IDE
111
Ch
lora
mp
hen
ico
lR
apto
r50
IMT
IDE
1240
Ch
lora
mp
hen
ico
lR
atit
e35
-50
IM-I
V-P
O-
SC
TID
G13
08N
ot
for
foo
d a
nim
als
Ch
lora
mp
hen
ico
l
Palm
itate
Avi
an80
-100
Gav
age
BID
E74
1
Ch
lora
mp
hen
ico
l Pal
mit
ate
Avi
an50
PO
TID
G55
Ch
lora
mp
hen
ico
l Pal
mit
ate
Avi
an15
0-20
0P
OT
ID-Q
IDG
739
Fo
r la
rge
bir
ds
Ch
lora
mp
hen
ico
l Pal
mit
ate
Psi
ttac
ine
100
PO
BID
-QID
E74
1
Ch
lora
mp
hen
ico
l Pal
mit
ate
Turk
ey50
PO
QID
E74
1
Ch
lord
iazep
oxid
e H
Cl
Co
wb
ird, q
uai
l15
0 g/
kg f
oo
dF
eed
On
ceB
1094
An
esth
esia
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I258
DR
UG
NA
ME
S
PE
CIE
S
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ch
lorh
exid
ine G
luco
nate
Avi
an2.
5 m
l/L
of
2%
solu
tio
n/L
Dri
nk
NL
E74
1F
or
can
did
iasi
s o
r an
tim
icro
bia
l pro
ph
ylax
is
Ch
lorh
exid
ine
Glu
con
ate
Avi
an2.
5-7.
5 m
l of
2%
solu
tio
n/L
Dri
nk
NL
E12
40P
reve
nt
or
trea
t m
ild in
test
inal
can
did
iasi
s
Ch
lorh
exid
ine
Glu
con
ate
Avi
an0.
5% s
olu
tio
nF
lush
NL
E12
40W
oun
d f
lush
Ch
lorh
exid
ine
Glu
con
ate
Avi
an0.
005
g/L
Dri
nk
QD
E14
92F
or
can
did
iasi
s
Ch
loro
qu
ine
Avi
an0.
4 g/
LD
rin
kQ
DE
1180
Fo
r b
loo
d p
aras
ites
Ch
loro
quin
eA
vian
10P
OT
IDG
57U
sual
ly in
co
mb
inat
ion
wit
h p
rim
aquin
e
Ch
loro
quin
eA
vian
10P
OQ
DG
61A
dd p
rim
aquin
e p
ho
sph
ate
Ch
loro
quin
eF
alco
n10
PO
On
ceB
1177
Add p
rim
aquin
e, f
ollo
w 1
st d
ose
wit
h 5
mg/
kg a
t h
ours
6,1
8 an
d 2
4
Ch
loro
quin
eP
asse
rin
e, S
mal
l2.
1 g/
LD
rin
kN
LE
1187
Th
erap
euti
c b
ut
no
t cu
rati
ve f
or
Pla
smod
ium
Ch
loro
quin
eP
engu
in5
PO
QID
E11
1, 1
240
Lo
adin
g do
sage
10
mg/
kg
Ch
loro
quin
eP
engu
in, A
fric
an5
PO
QD
B26
2
Ch
loro
quin
eR
apto
r5
NL
NL
D16
12
Ch
loro
quin
eR
apto
r25
IMQ
DE
1400
Pla
smod
ium
an
d L
euco
cyto
zoon
Ch
loro
quin
eR
apto
r10
PO
QD
G61
, 94
Add p
rim
aquin
e p
ho
sph
ate
Ch
lorp
rom
azin
eA
vian
0.01
25 g
/L
Dri
nk
NL
E14
92, 1
650
Fo
r fe
ath
er p
icki
ng
and a
nxi
ety
Ch
lort
etr
acycli
ne H
Cl
Am
azo
n, B
lue-
fro
nte
d2.
5 g/
kg c
orn
Fee
dQ
DA
230
Fo
r th
erap
y le
ss t
han
2 w
eeks
dura
tio
n
Ch
lort
etra
cycl
ine
HC
lA
maz
on
, Gre
en-c
hee
ked
2.5
- 5.
0 g/
kg f
oo
dF
eed
On
ceB
1062
Fo
r C
hlam
ydop
hila
Ch
lort
etra
cycl
ine
HC
lA
maz
on
s5
g/kg
fo
od
Fee
dQ
DB
1079
Fo
r C
hlam
ydop
hila
Ch
lort
etra
cycl
ine
HC
lA
vian
1 g/
LD
rin
kQ
DE
704
Pro
ph
ylac
tic
do
sage
Ch
lort
etra
cycl
ine
HC
lA
vian
5 g/
LD
rin
kQ
DE
704
Th
erap
euti
c do
sage
Ch
lort
etra
cycl
ine
HC
lA
vian
100
PO
QID
E70
4
Ch
lort
etra
cycl
ine
HC
lA
vian
0.5
g/L
Dri
nk
QD
E74
1F
or
chla
myd
op
hilo
sis
init
ial t
her
apy
Ch
lort
etra
cycl
ine
HC
lA
vian
100
IM-P
ON
LE
924
Ch
lort
etra
cycl
ine
HC
lA
vian
34IV
NL
F12
09
Ch
lort
etra
cycl
ine
HC
lB
udge
riga
r5
g/kg
see
dF
eed
QD
A73
1H
ulle
d m
edic
ated
mill
et
Ch
lort
etra
cycl
ine
HC
lB
udge
riga
r50
0 m
g/kg
fo
od
Fee
dQ
DE
565
An
tich
lam
ydo
ph
ilial
Ch
lort
etra
cycl
ine
HC
lC
anar
y1.
5 g/
kg f
oo
dF
eed
QD
E69
5
Ch
lort
etra
cycl
ine
HC
lC
hic
ken
2.5
g/L
Dri
nk
NL
A80
2A
dd c
hlo
rtet
racy
clin
e fe
ed a
lso
Ch
lort
etra
cycl
ine
HC
l C
hic
ken
2.
5 g/
kg f
oo
d F
eed
On
ce
A
802
Add c
hlo
rtet
racy
clin
e dri
nki
ng
wat
er a
lso
Ch
lort
etra
cycl
ine
HC
lC
hic
ken
20-6
0P
ON
LC
705
Ch
lort
etra
cycl
ine
HC
lC
hic
ken
220
mg/
kg f
oo
dF
eed
QD
E56
4N
o s
laugh
ter
wit
hdra
wal
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 259
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ch
lort
etra
cycl
ine
HC
lC
ock
atie
l2.
4 g/
kg f
oo
dF
eed
QD
A73
8H
ulle
d m
illet
+ o
ats
for
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
l C
ock
ato
o, G
Sulf
ur-
cres
ted
4.4
g/kg
fo
od
Fee
d
QD
B
10
79
Fo
r ch
lam
ydo
ph
ilosi
s
Ch
lort
etra
cycl
ine
HC
l C
on
ure
(M
aro
on
-bel
lied, N
anday
) 2.
4 g/
kg f
oo
d
Fee
d
QD
A
73
8 H
ulle
d m
illet
+ o
ats
for
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
lF
inch
1 -
1.5
g/L
Dri
nk
QD
E15
72
Ch
lort
etra
cycl
ine
HC
lF
inch
1.5
g/kg
fo
od
Fee
dQ
DE
1572
Ch
lort
etra
cycl
ine
HC
lG
allif
orm
es30
Dri
nk
QD
E70
4
Ch
lort
etra
cycl
ine
HC
l L
ori
keet
0.
5 g/
kg f
ruit
F
eed
QD
A
10
77
Fo
r ch
lam
ydo
ph
ilosi
s
Ch
lort
etra
cycl
ine
HC
l L
ori
keet
0.
5 g/
L li
quid
fo
od
Fee
d
On
ce
A
1077
F
or
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
l L
ory
(O
rnat
e, p
urp
le-n
aped
)
0.5g
/kg
liquid
fo
od
Fee
d
On
ce
A
1077
F
or
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
l L
ove
bir
d, A
bys
sin
ian
2.
4 g/
kg f
oo
d
Fee
d
QD
A
73
8
Ch
lort
etra
cycl
ine
HC
lM
acaw
, Buff
on
's10
-15
g/kg
Fee
dO
nce
A78
1
Ch
lort
etra
cycl
ine
HC
l P
arak
eet
(Bo
urk
e's,
red
-fro
nt,
rin
g-
nec
ked)
2.4
g/kg
fo
od
Fee
dQ
DA
738
Hulle
d m
illet
+ o
ats
for
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
lP
asse
rin
e1.
5 g/
kg s
oft
fo
od
Fee
dQ
DE
1437
Add d
rug
to d
rin
k at
th
e sa
me
tim
e, u
se f
or
30 d
ays
for
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
l P
asse
rin
e 1.
0 -
1.5
g/L
D
rin
k Q
D
E
1437
A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e, u
se f
or
30 d
ays
for
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
lP
igeo
n40
-50
PO
B-T
IDA
565
Wit
ho
ut
grit
in d
iet
Ch
lort
etra
cycl
ine
HC
lP
igeo
n10
0IM
QD
G23
2
Ch
lort
etra
cycl
ine
HC
lP
igeo
n50
PO
TID
-QID
G26
0W
ith
or
wit
ho
ut
tylo
sin
Ch
lort
etra
cycl
ine
HC
lP
igeo
n0.
5 g/
LD
rin
kQ
DG
590
Ch
ange
dai
ly
Ch
lort
etra
cycl
ine
HC
lP
oult
ry0.
106-
0.26
4 g/
LF
eed
QD
C56
4P
rop
hyl
acti
c
Ch
lort
etra
cycl
ine
HC
lP
oult
ry11
0-55
0 m
g/kg
fee
dF
eed
QD
C56
4
Ch
lort
etra
cycl
ine
HC
lP
sitt
acin
e2.
5-10
g/kg
fo
od
Fee
dQ
DA
693
Do
sage
bas
ed o
n w
eigh
t o
f fo
od
Ch
lort
etra
cycl
ine
HC
lR
apto
r33
PO
TID
E16
12F
or
chla
myd
op
hilo
sis
Ch
lort
etra
cycl
ine
HC
lR
atit
e15
-20
PO
TID
G13
08
Ch
lort
etra
cycl
ine
HC
lT
urk
ey2.
5 g/
LD
rin
kN
LA
802
Add c
hlo
rtet
racy
clin
e fe
ed a
lso
Ch
lort
etra
cycl
ine
HC
lT
urk
ey10
-30
PO
NL
C70
5
Ch
oli
ne
Avi
an50
0-13
00F
eed
QD
E14
70F
or
hep
atic
lip
ido
sis
Ch
rom
ium
Pic
oli
nate
Avi
an10
dro
ps/
kgP
OQ
DE
1435
Sto
ck s
olu
tio
n 1
pill
per
30
ml l
actu
lose
fo
r
dia
bet
es
Ch
rom
ium
Pic
olin
ate
Avi
an0.
1P
OB
IDE
1205
Cim
eti
din
eP
engu
in, A
fric
an35
PO
QD
G12
8
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I260
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Cip
rofl
oxacin
HC
lA
vian
80P
OQ
DD
1470
, 157
1A
dd e
tham
buto
l + r
ifam
pin
fo
r liv
er
myc
ob
acte
rio
sis
Cip
rofl
oxa
cin
HC
lA
vian
20P
OB
IDD
1571
Add c
lofa
zim
ine
+ c
yclo
seri
ne
+ e
tham
buto
l
for
avia
n m
yco
bac
teri
osi
s
Cip
rofl
oxa
cin
HC
lA
vian
10-1
5P
OB
IDG
1319
Cip
rofl
oxa
cin
HC
lC
anar
y20
PO
BID
G48
Cip
rofl
oxa
cin
HC
lC
hic
ken
5P
ON
LA
797
Cip
rofl
oxa
cin
HC
lC
ock
atie
l30
PO
BID
G44
Cip
rofl
oxa
cin
HC
lG
ull
20P
OQ
DE
1357
Cip
rofl
oxa
cin
HC
lH
awk,
Red
-tai
led
50P
OB
IDA
168
Cip
rofl
oxa
cin
HC
lO
stri
ch20
NL
BID
E62
8F
or
ovi
duct
infe
ctio
n
Cip
rofl
oxa
cin
HC
lP
igeo
n0.
25 g
/L
Dri
nk
QD
G59
0C
han
ge d
aily
Cip
rofl
oxa
cin
HC
lP
igeo
n5-
20P
OB
IDG
590
Cip
rofl
oxa
cin
HC
lP
sitt
acin
e20
-40
PO
BID
E11
1
Cip
rofl
oxa
cin
HC
lT
ouca
n, T
oco
10P
OB
IDG
1379
Cis
ap
rid
eA
vian
0.5-
1P
OT
IDE
1151
To
imp
rove
G
I m
oti
lity
Cis
apri
de
Psi
ttac
ine
1N
LB
IDG
1263
Fo
r ile
us
Cis
apri
de
Rap
tor
0.25
PO
TID
E14
00In
crea
se g
ut
mo
tilit
y
Cis
pla
tin
Mac
aw, B
lue
and G
old
0.3
mg/
cm3
P
aren
tera
l Q
W
G
1369
In
tral
esio
nal
-fib
rosa
rco
ma
Cit
ric A
cid
Avi
an0.
5 g/
LD
rin
kQ
DE
704
Add o
xyte
trac
yclin
e
Cit
ric
Aci
dP
asse
rin
e, S
mal
l1.
0 g/
LD
rin
kN
LE
1187
Cla
no
bu
tin
Psi
ttac
ine
0.2
PO
QD
G17
22L
iver
sup
po
rt
Cla
rith
rom
ycin
Avi
an85
PO
QD
G11
54A
dd e
tham
buto
l + r
ifab
uti
n, d
ose
allo
met
rica
lly f
or
myc
ob
acte
rio
sis
Cla
zu
ril
An
seri
form
es5-
10P
Oq3d
D11
50F
or
cocc
idio
sis
Cla
zuri
lP
igeo
n5-
10P
OQ
DG
57R
epea
t af
ter
2 day
s
Cla
zuri
lP
igeo
n6.
5P
OO
nce
G10
9
Cla
zuri
lP
igeo
n5
PO
NL
G10
9
Cla
zuri
lP
oult
ry5-
10P
OQ
DG
57R
epea
t af
ter
2 day
s
Cla
zuri
lP
sitt
acin
e7
PO
QD
E12
40W
ait
2 day
s th
en r
epea
t fo
r co
ccid
iosi
s
Cla
zuri
lR
apto
r5-
10P
Oq3d
E12
40F
or
cocc
idio
sis
Cli
nd
am
ycin
HC
lA
vian
100
PO
QD
D12
21F
or
clo
stri
dio
sis
Clin
dam
ycin
HC
lA
vian
150
PO
QD
E14
31F
or
ost
eom
yelit
is
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 261
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Clin
dam
ycin
HC
lE
agle
, Lit
tle
40P
OB
IDG
1568
Fo
r p
ost
-op
erat
ive
ort
ho
ped
ic s
urg
ery
Clin
dam
ycin
HC
lG
osh
awk,
Bro
wn
40P
OB
IDG
1568
Clin
dam
ycin
HC
lG
ull
100-
150
PO
QD
E13
57
Clin
dam
ycin
HC
lO
wl,
Bar
n40
PO
BID
G15
68
Clin
dam
ycin
HC
lO
wl,
Gre
at-h
orn
ed12
.5P
OB
IDG
173
Add e
nro
flo
xaci
n
Clin
dam
ycin
HC
lP
igeo
n10
0P
OQ
DA
1473
Clin
dam
ycin
HC
lP
igeo
n10
0P
OQ
DE
111
Clin
dam
ycin
HC
lP
sitt
acin
e10
0P
OQ
DE
1240
Fo
r o
steo
mye
litis
an
d t
endo
n s
hea
th
infe
ctio
ns
Clin
dam
ycin
HC
lP
sitt
acin
e50
NL
BID
F11
70U
sed t
o t
reat
an
aero
bic
ost
eom
yelit
is
Clin
dam
ycin
HC
lP
sitt
acin
e25
NL
TID
F11
70
Clin
dam
ycin
HC
lR
apto
r30
-40
PO
BID
B15
68
Clo
fazim
ine
Avi
an6
PO
QD
D14
70A
dd e
tham
buto
l + r
ifam
pin
fo
r liv
er
myc
ob
acte
rio
sis
Clo
fazi
min
eA
vian
1.5
PO
QD
D15
71
Clo
fazi
min
eP
sitt
acin
e1.
5P
OQ
DE
1240
Fo
r m
yco
bac
teri
osi
s
Clo
fazi
min
eR
apto
r1-
5P
OQ
DE
1240
, 115
4
Clo
mip
ram
ine H
Cl
Avi
an0.
5-1
NL
QD
-BID
D14
75C
on
tro
l of
self
-muti
lati
on
, mix
ed r
esult
s
Clo
mip
ram
ine
HC
lC
ock
ato
o3
PO
BID
G12
78C
loac
al p
rola
pse
Clo
mip
ram
ine
HC
lP
sitt
acin
e0.
5-1
PO
BID
B43
Clo
mip
ram
ine
HC
lP
sitt
acin
e0.
5-1
PO
QD
-BID
E11
1G
radual
ly in
crea
se d
ose
ove
r 4
to 5
day
s
Clo
pid
ol
Ch
icke
n12
5-25
0 m
g/kg
fo
od
Fee
dQ
DE
564
5-day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Clo
pid
ol
Po
ult
ry0.
25 g
/kg
fo
od
Fee
dQ
DC
564
Pro
ph
ylac
tic
Clo
rsu
lon
An
seri
form
es20
PO
q2w
D11
50F
or
cest
odes
an
d n
emat
odes
Clo
rsulo
nA
vian
20P
Oq2w
G81
8F
or
tap
ewo
rms
Clo
rsulo
nP
sitt
acin
e20
PO
q2w
E11
1
Clo
rsulo
nR
apto
r20
PO
q2w
E12
40F
or
trem
ato
des
an
d c
esto
des
Clo
trim
azo
leC
ran
e10
g/L
Neb
uliz
eT
IDE
1361
An
tifu
nga
l
Clo
trim
azo
leR
apto
r70
-100
g/L
Neb
uliz
eB
IDE
1359
Clo
xacil
lin
So
diu
mA
vian
100-
200
IMQ
DE
565
Clo
xaci
llin
So
diu
mA
vian
250
PO
BID
E12
34F
or
bum
ble
foo
t
Clo
xaci
llin
So
diu
mA
vian
100
PO
QD
E14
70
Clo
xaci
llin
So
diu
mR
apto
r25
0P
OB
IDE
1240
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I262
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Clo
xaci
llin
So
diu
mR
apto
r10
0-25
0IM
NL
E14
63F
or
bac
teri
al in
fect
ion
s
Co
en
zym
e Q
10A
vian
1P
OQ
D-B
IDE
1205
, 143
5F
or
hea
rt, g
eria
tric
, dia
bet
ic, i
mm
un
e
def
icie
nt
bir
ds
Co
lch
icin
eA
vian
0.04
PO
QD
D14
70F
or
hep
atic
fib
rosi
s
Co
lch
icin
eM
acaw
0.01
PO
BID
G45
Co
lch
icin
eP
sitt
acin
e0.
2P
OB
IDE
111,
147
3
Co
lch
icin
eP
sitt
acin
e0.
04P
OQ
D-B
IDE
1756
Co
rtic
otr
op
inA
vian
16 I
U T
DIM
On
ceB
88, 5
32
Cro
tam
ito
nP
sitt
acin
e10
%T
op
ical
NL
E12
40F
or
knem
ido
cop
tic
mit
es
Cu
pri
c S
ulf
ate
Avi
an51
% p
ow
der
To
pic
alP
RN
E12
40F
or
ulc
erat
ive
der
mat
itis
Cup
ric
Sulf
ate
Ost
rich
0.5
g/L
Dri
nk
QD
G12
54, 2
83F
or
can
did
iasi
s, u
se a
cidif
ied c
op
per
sulf
ate
Cup
ric
Sulf
ate
Psi
ttac
ine
1:20
00 d
iluti
on
T
op
ical
q2w
D
14
46
Fo
r der
mat
om
yco
sis
Cyan
oco
bala
min
Avi
an0.
25-0
.5IM
QW
E11
1
Cyclo
ph
osp
ham
ide
**C
hec
k cu
rren
t lit
erat
ure
pri
or
to u
se
Cyc
lop
ho
sph
amid
eO
wl,
Gre
at-h
orn
ed25
PO
On
ceF
125
Max
imum
do
sage
list
ed
Cyc
lop
ho
sph
amid
eP
sitt
acin
e20
0 m
g/m
2
IO
Q
W
E
1470
L
ymp
ho
sarc
om
a
Cyclo
seri
ne
Avi
an5
PO
BID
D15
71A
dd c
ipro
flo
xaci
n o
r en
rofl
oxa
cin
+
clo
fazi
min
e +
eth
amb
uto
l fo
r av
ian
myc
ob
acte
rio
sis
Cyc
lose
rin
eR
apto
r5
PO
BID
E12
40, 1
154
Cyclo
spo
rin
eD
uck
, Pek
in60
IVQ
DA
835
Cyc
losp
ori
ne
Duck
, Pek
in10
IVT
ID-Q
IDA
835
Cyp
erm
eth
rin
Pig
eon
0.05
% s
olu
tio
nT
op
ical
QD
E70
4A
pp
ly a
s sp
ray
Cyp
erm
eth
rin
Psi
ttac
ine
2.0%
so
luti
on
NL
NL
E12
40Sp
ray
pre
mis
es f
or
Der
man
yssu
s, a
void
co
nta
ct
wit
h s
kin
Cyp
erm
eth
rin
Rap
tor
2% s
olu
tio
nN
LN
LE
1240
Dan
ofl
oxacin
Mesy
late
Ch
icke
n0.
05 g
/L
Dri
nk
NL
A83
7F
or
Myc
opla
sma
galli
sept
icum
Dan
ofl
oxa
cin
Mes
ylat
eC
hic
ken
5P
OQ
DB
893,
990
Fo
r co
lisep
tice
mia
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 263
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Deco
qu
inate
Ch
icke
n30
mg/
kg f
oo
dF
eed
QD
E56
4N
o s
laugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Dec
oquin
ate
Ph
easa
nt,
Rin
g-n
ecke
d0.
03 g
/kg
fo
od
Fee
dQ
DB
895
Fo
r co
ccid
iosi
s
Defe
rip
ron
eT
ouca
n50
PO
BID
G12
80F
or
iro
n s
tora
ge d
isea
se, z
inc
sup
ple
men
tati
on
may
be
requir
ed
Defe
roxam
ine M
esy
late
Avi
an10
0SC
QD
D14
70T
o r
educe
live
r ir
on
leve
ls
Def
ero
xam
ine
Mes
ylat
eA
vian
20P
OO
nce
G87
Co
nti
nue
IM q
4h a
s n
eeded
Def
ero
xam
ine
Mes
ylat
eM
ynah
40IM
QD
G34
0R
epea
t qo
w f
or
seri
es o
f 10
tre
atm
ents
Def
ero
xam
ine
Mes
ylat
eT
ouca
n10
0SC
QD
G12
80F
or
iro
n s
tora
ge d
isea
se
Def
ero
xam
ine
Mes
ylat
eT
ouca
n1.
28 m
g/kc
alIM
QD
E11
80Ir
on
ch
elat
ion
Delm
ad
ino
ne A
ceta
teA
vian
1IM
NL
E14
34
Del
mad
ino
ne
Ace
tate
Pig
eon
6.67
IMN
LE
1432
Deto
mid
ine H
Cl
Avi
an0.
3IM
NL
G13
20
Det
om
idin
e H
Cl
Ch
icke
n0.
3IM
PR
NE
1573
Sedat
ion
Det
om
idin
e H
Cl
Ost
rich
0.3
IMP
RN
E15
73Se
dat
ion
Dexam
eth
aso
ne
Avi
an1-
2IM
NL
D15
33
Dex
amet
has
on
eA
vian
2-4
IMQ
DE
1431
Use
sp
arin
gly
Dex
amet
has
on
eA
vian
N/A
To
pic
alN
LE
1151
Add d
imet
hyl
sulf
oxi
de
for
clo
acal
or
ute
rin
e
pro
lap
se
Dex
amet
has
on
eC
ran
e, S
arus
0.5
IVO
nce
G10
87
Dex
amet
has
on
eF
alco
n2
IM-I
VO
nce
E10
27F
or
sho
ck, t
raum
a, t
oxi
c co
ndit
ion
s
Dex
amet
has
on
eH
ero
n, G
reat
Blu
e0.
5IV
On
ceG
1087
Dex
amet
has
on
eP
igeo
n0.
15-1
.5IM
-IV
BID
E14
32
Dex
amet
has
on
eP
igeo
n0.
3-3
IM-I
VB
IDE
1432
Fo
r sh
ock
Dex
amet
has
on
eP
sitt
acin
e2-
4IM
QD
-BID
E12
40
Dex
amet
has
on
eP
sitt
acin
e4
IM-S
CN
LG
632
Neo
nat
e do
sage
, sh
ock
or
sep
sis
Dex
amet
has
on
eR
apto
r2-
4IM
QD
E14
33U
se w
ith
gre
at c
are
Dex
amet
has
on
eR
apto
r0.
3-3
IMq2d
E12
40L
on
g-la
stin
g fo
rmula
tio
n, r
educe
infl
amm
ato
ry r
esp
on
se a
nd s
ho
ck
Dexam
eth
aso
ne S
od
ium
Ph
osp
hate
Am
azo
n, Y
ello
w-n
aped
1IM
q3-
7dG
1033
Dex
amet
has
on
e So
diu
m
Ph
osp
hat
e
An
seri
form
es2
IMQ
DE
1240
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I264
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Dex
amet
has
on
e So
diu
m
Ph
osp
hat
e
Avi
an2
IM-I
VO
nce
E11
51
Dex
amet
has
on
e So
diu
m
Ph
osp
hat
e
Bust
ard
2IM
QD
E12
40
Dex
amet
has
on
e So
diu
m
Ph
osp
hat
e
Psi
ttac
ine
2-4
IM-I
VN
LE
1688
Dex
amet
has
on
e So
diu
m
Ph
osp
hat
e
Rap
tor
2IM
QD
E12
40
Dextr
ose
Avi
anN
/A
To
pic
alP
RN
E11
51F
or
flush
ing
wo
un
ds
Dex
tro
seA
vian
50IV
-PO
-SC
NL
E12
40Is
oto
nic
fo
r h
ypo
glyc
emia
an
d d
ehyd
rati
on
,
IV s
low
ly
Dex
tro
seA
vian
50-1
00IV
NL
E11
1G
ive
slo
wly
Dex
tro
seA
vian
50IV
-PO
-SC
NL
E12
40
Dex
tro
seA
vian
50-1
00IV
NL
E14
73G
ive
slo
wly
Dex
tro
seA
vian
1IV
NL
G13
11F
or
hyp
ogl
ycem
ia, 5
0% s
olu
tio
n, m
ay b
e
del
eted
Dex
tro
seP
sitt
acin
e2
ml/
kgIV
NL
G63
2N
eon
ate
do
sage
, use
50%
so
luti
on
, slo
w
bo
lus
Dex
tro
seR
apto
r50
0-10
00IV
On
ceE
1400
Giv
e sl
ow
ly f
or
hyp
ogl
ycem
ia
Dia
triz
oate
Meg
lum
ine
Budge
riga
r 0.
2 m
l TD
IP
N
L
G
95
Go
iter
th
erap
y
Dia
triz
oate
Meg
lum
ine +
Dia
triz
oate
So
diu
m
Am
azo
n, D
oub
le Y
ello
w-h
ead
400
IVO
nce
D17
56F
or
IV e
xcre
tory
uro
grap
hy
Dia
zep
am
An
seri
form
es1
NL
PR
ND
1403
Add k
etam
ine
Dia
zep
amA
nse
rifo
rmes
1.2-
1.6
g/L
bai
tF
eed
On
ceG
1230
Add c
hlo
ralo
se
Dia
zep
amA
nse
rifo
rmes
0.5-
1IM
-IV
BID
-TID
E12
40C
on
tro
l sei
zure
s
Dia
zep
amA
vian
0.5-
1IM
NL
E11
20, 1
492
Fo
r se
izure
s re
late
d t
o le
ad t
oxi
cose
s
Dia
zep
amB
ird, A
quat
ic0.
6IM
-IV
PR
NE
1503
Dia
zep
amB
ird, A
quat
ic0.
5-1
IM-I
VP
RN
E15
59F
or
lead
po
iso
nin
g to
co
ntr
ol c
on
vuls
ion
s
Dia
zep
amC
ran
e0.
5-1
NL
PR
NE
1189
Fo
r tr
anquili
zati
on
4 t
o 6
ho
urs
Dia
zep
amC
ran
e0.
2-0.
5N
LP
RN
E11
89A
dd k
etam
ine
for
anes
thes
ia
Dia
zep
amD
uck
1.3-
1.7
g/kg
bai
tF
eed
On
ceG
1386
Add c
hlo
ralo
se
Dia
zep
amE
mu
0.6
IVP
RN
G28
3A
dd p
ento
bar
bit
al a
fter
1 h
our
Dia
zep
amE
mu
5IV
NL
E4
Sedat
ion
Dia
zep
amF
alco
n1.
2IV
PR
ND
1401
Add k
etam
ine
Dia
zep
amH
awk,
Ro
ugh
-leg
ged
1-1.
5IV
PR
NG
1092
Co
mb
ine
wit
h k
etam
ine
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 265
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Dia
zep
amK
estr
el2.
2IV
PR
ND
1401
Add k
etam
ine
Dia
zep
amO
stri
ch1
IVP
RN
D14
01Sm
oo
th a
nes
thes
ia r
eco
very
Dia
zep
amO
stri
ch5
PO
PR
NE
4St
andin
g se
dat
ion
Dia
zep
amO
stri
ch1-
2IV
PR
NG
481
Giv
e ju
st p
rio
r to
rec
ove
ry f
rom
tile
tam
ine/
zola
zep
am
Dia
zep
amO
wl
1IV
PR
ND
1401
Add k
etam
ine
Dia
zep
amP
asse
rin
e0.
5P
ON
LE
1439
An
xio
lyti
c an
d h
yper
ph
agic
fo
r w
ild f
ract
ious
spec
ies
Dia
zep
amP
igeo
n2.
5IM
PR
NE
1432
Add k
etam
ine,
20
to 3
0 m
inute
s dee
p
sedat
ion
Dia
zep
amP
igeo
n0.
5-1
IM-I
VP
RN
G59
0A
dd k
etam
ine
Dia
zep
amP
sitt
acin
e2.
5-4
PO
PR
NE
1473
Dia
zep
amP
sitt
acin
e0.
5-1
IM-I
O-I
VP
RN
E16
88
Dia
zep
amP
sitt
acin
e1-
1.5
IM-I
VP
RN
G82
4
Dia
zep
amR
apto
r1
IMP
RN
D14
01A
dd k
etam
ine
Dia
zep
amR
apto
r1-
1.5
IVP
RN
D15
33A
dd k
etam
ine
Dia
zep
amR
atit
e1
NL
PR
ND
1403
Add k
etam
ine
Dia
zep
amR
atit
e0.
1IM
PR
NE
4A
dd k
etam
ine
Dia
zep
amR
atit
e0.
2-0.
3IV
PR
NE
243
Add k
etam
ine
Dia
zep
amR
atit
e0.
3IV
PR
NG
418
Tra
nquili
zati
on
par
ticu
larl
y duri
ng
anes
thes
ia
reco
very
Dia
zep
amR
hea
5IV
NL
E4
Sedat
ion
Dia
zep
amSw
an1.
3-1.
7 g/
kg b
ait
Fee
dO
nce
G13
86A
dd c
hlo
ralo
se
Dib
uty
ltin
Dil
au
rate
Ch
icke
n20
0 m
g/kg
fo
od
Fee
dQ
DE
564
10 d
ay s
laugh
ter
wit
hdra
wal
Dib
uty
ltin
Dila
ura
teP
oult
ry37
4 m
g/kg
fo
od
Fee
dQ
DC
564
Dic
hlo
rop
hen
Pig
eon
100
mg/
TD
PO
q10
dG
232
Dic
hlo
rvo
sA
vian
N/A
IHQ
DE
704
Imp
regn
ated
str
ip, 3
0 m
³ m
inim
um
Dic
hlo
rvo
s St
rip
Kak
arik
iN
/A
IHQ
DG
1609
Fo
r K
nem
idoc
opte
s
Dic
lazu
ril
Ch
icke
n0.
5-1.
0 m
g/kg
fo
od
Fee
dQ
DG
564
Dic
lazu
ril
Cro
w10
PO
QD
D14
38D
ose
on
day
s 0,
1, 2
, 4, 6
, 8 a
nd 1
0 fo
r
toxo
pla
smo
sis
Dic
lazu
ril
Par
trid
ge, E
uro
pea
n g
rey
0.36
6F
eed
QD
B89
1F
or
Eim
eria
Dic
lazu
ril
Pas
seri
ne
10P
OQ
DG
1334
Giv
e o
n d
ays
0, 1
, 2, 4
, 6, 8
an
d 1
0
Dic
lazu
ril
Ph
easa
nt,
Rin
g-n
ecke
d0.
369
Fee
dQ
DB
891
Fo
r E
imer
ia
Dic
lazu
ril
Quai
l, Ja
pan
ese
0.29
-0.5
6F
eed
QD
B89
1
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I266
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Dic
lofe
nac S
od
ium
Pig
eon
12.5
mg/
TD
PO
NL
E12
40F
or
arth
riti
s
Die
thylc
arb
am
azin
e
Cit
rate
Rap
tor
50P
ON
LE
1463
An
thel
min
tic
Die
thyls
tilb
est
rol
Avi
an0.
025-
0.07
5IM
NL
E11
1
Die
thyl
stilb
estr
ol
Avi
an0.
1-0.
3IM
NL
E14
73
Dig
oxin
Am
azo
n, Y
ello
w-n
aped
0.02
PO
BID
G10
33
Dig
oxi
nA
vian
0.02
NL
NL
D14
70
Dig
oxi
nA
vian
0.01
PO
QD
-BID
E11
52
Dig
oxi
nA
vian
0.02
-0.0
5P
OQ
D-B
IDE
1152
Dig
oxi
nA
vian
0.00
33 g
/L
Dri
nk
QD
G13
23C
han
ge d
aily
Dig
oxi
nB
udge
riga
r0.
02P
OQ
DA
882
Dig
oxi
n
Spar
row
0.
02 P
O
QD
A
88
2
Dim
erc
ap
rol
Avi
an
2.5
IM
q4h
E
11
20, 1
236
Co
nti
nue
BID
fo
r 10
day
s (o
r lo
nge
r if
nee
ded
) fo
r le
ad t
oxi
cose
s
Dim
erca
pro
lA
vian
25-3
5P
OQ
D-q
2dE
1240
, 147
3G
ive
5 day
s p
er w
eek
for
lead
to
xico
sis
Dim
eth
yl
Su
lfo
xid
eA
vian
Dim
eth
yl S
ulf
oxi
de
Avi
an5
ml
Neb
uliz
eN
LE
704
Add t
ylo
sin
+ 1
0 m
l 0.9
% s
alin
e so
luti
on
Dim
eth
yl S
ulf
oxi
de
Avi
an10
ml/
LN
ebuliz
eT
ID-Q
IDE
1650
Add a
pp
rop
riat
e an
tim
icro
bia
l, ad
jun
ct t
o
par
ente
ral t
her
apy
for
air
sacc
ulit
is
Dim
eth
yl S
ulf
oxi
de
Avi
anO
intm
ent
To
pic
alN
LE
1650
Fo
r p
rola
pse
d p
hal
lus
Dim
eth
yl S
ulf
oxi
de
Avi
an1
ml/
kg 5
0 %
so
luti
on
PO
NL
G17
17A
lso
ap
ply
to
pic
ally
Dim
eth
yl S
ulf
oxi
de
Avi
an20
IMB
ID-T
IDG
861
Fo
r h
eavy
met
al p
ois
on
ing
Dim
eth
yl S
ulf
oxi
de
Ch
icke
nM
ix 5
0:50
To
pic
alN
LB
1342
Add b
up
ivac
ain
e, p
rep
are
50:5
0 so
luti
on
Dim
eth
yl S
ulf
oxi
de
Rap
tor
N/A
To
pic
alN
LE
1240
Red
uce
sw
ellin
g, v
ehic
le t
o c
arry
dru
gs
thro
ugh
ski
n p
arti
cula
rly
on
legs
Dim
eth
ylg
lycin
eA
vian
5P
OT
IDE
1205
Bra
in d
iso
rder
s
Dim
eth
ylgl
ycin
e A
vian
2-
4 P
O
QD
-BID
E
14
35
Imm
un
e an
d e
ner
gy b
oo
ster
Dim
etr
idazo
leA
vian
50P
OQ
DE
704
Dim
etri
daz
ole
A
vian
1.
25lm
llpo
wder
/LlllllllllD
rin
k N
L
E
741
Fo
r tr
ich
om
on
iasi
s, g
iard
iasi
s an
d
his
tom
on
iasi
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 267
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Dim
etri
daz
ole
Avi
an50
PO
NL
E92
4F
or
pro
tozo
a
Dim
etri
daz
ole
Avi
an30
Gav
age
On
ceE
1650
Fo
r tr
ich
om
on
iasi
s, g
iard
iasi
s an
d
his
tom
on
iasi
s
Dim
etri
daz
ole
Fin
ch0.
1 g/
LD
rin
kQ
DG
1334
Fo
r co
chlo
som
iasi
s
Dim
etri
daz
ole
Lo
rike
et0.
1 g/
LD
rin
kQ
DE
1479
Dim
etri
daz
ole
Pig
eon
0.4
g/L
Dri
nk
NL
A79
1
Dim
etri
daz
ole
Pig
eon
50P
OQ
WE
1432
Dim
etri
daz
ole
Pig
eon
20P
OQ
DG
232
Dim
etri
daz
ole
Po
ult
ry50
0 m
g/kg
fo
od
Fee
dQ
DC
564
Pro
ph
ylac
tic
Dim
etri
daz
ole
Po
ult
ry0.
5-1.
0 g/
LD
rin
kQ
DG
585
Dim
etri
daz
ole
Rap
tor
125
PO
NL
D16
12F
or
tric
ho
mo
nia
sis
Dim
etri
daz
ole
Rap
tor
100
PO
NL
E14
63F
or
tric
ho
mo
nia
sis
Din
ito
lmid
eC
hic
ken
40-1
87 m
g/kg
fo
od
Fee
dQ
DE
564
No
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Din
op
rost
Tro
meth
am
ine
(Pro
stag
lan
din
F-2
a)
An
seri
form
es0.
02-0
.1IM
-To
pic
alO
nce
D11
50A
pp
ly t
o c
loac
al m
uco
sa t
op
ical
ly, e
gg
bin
din
g
Din
op
rost
Tro
met
ham
ine
An
seri
form
es0.
02-0
.1IM
On
ceE
1240
Fo
r eg
g b
indin
g
Din
op
rost
Tro
met
ham
ine
Avi
an0.
02-0
.1IM
On
ceE
1473
Als
o in
trac
loac
al
Din
op
rost
Tro
met
ham
ine
Ost
rich
5 m
g T
DP
aren
tera
lO
nce
G12
24F
or
case
ous
salp
ingi
tis,
add a
pp
rop
riat
e
anti
mic
rob
ials
fo
r 1
wee
k
Din
op
rost
Tro
met
ham
ine
Psi
ttac
ine
0.02
-0.1
Ven
tO
nce
E12
40A
pp
ly t
o c
loac
al m
uco
sa f
or
egg
bin
din
g
Din
op
rost
Tro
met
ham
ine
Psi
ttac
ine
0.02
-0.1
IMO
nce
E12
40F
or
egg
bin
din
g
Din
op
rost
Tro
met
ham
ine
Rap
tor
0.02
-0.1
Ven
tO
nce
E12
40
Din
op
rost
on
e
(Pro
stag
lan
din
E)
Avi
an0.
2V
ent
NL
E14
74P
rece
de
wit
h c
alci
um
glu
con
ate
for
egg
bin
din
g, a
pp
ly in
to c
loac
a, m
ay a
dd v
itam
in E
+ s
elen
ium
Din
op
rost
on
eC
ock
atie
l0.
02V
ent
On
ceG
1699
Fo
r eg
g b
indin
g
Dip
hen
hyd
ram
ine H
Cl
Avi
an2
ION
LE
1470
Giv
e b
efo
re a
spar
agin
ase
and d
oxo
rub
icin
to
min
imiz
e an
aph
ylax
is
Dip
hen
hyd
ram
ine
HC
lA
vian
4IM
TID
E15
54F
or
anti
cho
lines
tera
se t
oxi
city
Dip
hen
hyd
ram
ine
HC
lA
vian
2-4
PO
BID
D14
75C
on
tro
l of
self
-muti
lati
on
Dip
hen
hyd
ram
ine
HC
lA
vian
2-4
NL
BID
E14
77F
or
feat
her
, sutu
re a
nd b
andag
e p
icki
ng
Dip
hen
hyd
ram
ine
HC
lP
sitt
acin
e2-
4P
OB
IDE
1473
Dip
hen
hyd
ram
ine
HC
lR
apto
r4
IMT
IDG
50
Dip
ren
orp
hin
eC
asso
war
y, D
oub
le-w
attl
ed2
mg/
mg
eto
rph
ine
NL
PR
ND
1401
Eto
rph
ine
anta
gon
ist
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I268
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Dip
ren
orp
hin
eO
stri
ch0.
05-0
.06
IVP
RN
B44
7O
pio
id a
nta
gon
ist
Dip
ren
orp
hin
eO
stri
ch4.
5-24
mg
TD
IMP
RN
G48
1R
ever
se e
torp
hin
e
Do
cu
sate
So
diu
mP
sitt
acin
e0.
3 g/
LD
rin
kN
LE
763
To
aid
in e
xpel
ling
lead
or
pre
ven
t
con
stip
atio
n f
ollo
win
g cl
oac
al s
urg
ery
Do
xap
ram
HC
lA
nse
rifo
rmes
10IV
On
ceD
1150
Stim
ula
nt
Do
xap
ram
HC
lA
vian
5-10
IM-I
VO
nce
E11
1, 1
473
Do
xap
ram
HC
lA
vian
5IM
-IO
-IV
NL
E24
3
Do
xap
ram
HC
lA
vian
6IV
NL
G49
6
Do
xap
ram
HC
lA
vian
20IM
-IO
-IV
NL
E11
83A
lso
dro
p o
nto
to
ngu
e fo
r ca
rdia
c ar
rest
Do
xap
ram
HC
lF
alco
n10
IM-I
VO
nce
E10
27
Do
xap
ram
HC
lO
stri
ch0.
5-1.
5IV
PR
NG
522
Do
xap
ram
HC
lP
sitt
acin
e20
IM-I
O-I
VN
LE
1688
Do
xap
ram
HC
lR
apto
r10
IM-I
VO
nce
E12
40
Do
xap
ram
HC
lR
apto
r5-
20IT
-IV
On
ceE
1359
Fo
r an
esth
etic
em
erge
nci
es
Do
xep
in H
Cl
Avi
an0.
5-1
PO
BID
E11
1C
on
tro
l fea
ther
pic
kin
g
Do
xep
in H
Cl
Avi
an0.
5P
OB
IDE
704
Or
add t
o d
rin
kin
g w
ater
Do
xo
rub
icin
**C
hec
k cu
rren
t lit
erat
ure
pri
or
to u
se
Do
xoru
bic
inA
vian
30 m
g/m
2IO
q3w
E14
70G
ive
30 m
g/m
² o
f b
ody
surf
ace
for
lym
ph
osa
rco
ma
Do
xycycli
ne
Am
azo
n P
arro
t1
g/kg
fo
od
Fee
dQ
DA
693
Do
xycycli
ne** R
efe
ren
ces
foll
ow
ed
by *
* a
re b
ase
d
on
th
e l
on
g a
cti
ng
form
ula
)
Avi
an10
0IM
QW
A55
Euro
pea
n f
orm
ula
tio
n.
Fo
r
chla
myd
op
hilo
sis,
may
be
spac
ed 5
to
7 d
ays
for
firs
t 4
wee
ks
Do
xycy
clin
eA
maz
on
Par
rot
40-5
0P
OQ
D-B
IDE
111
Do
xycy
clin
e**
Am
azo
n P
arro
t 10
0IM
q5d
-QW
A23
0F
or
chla
myd
op
hilo
sis
Do
xycy
clin
e**
Am
azo
n50
IMq4-
5dB
1062
Do
xycy
clin
eA
nse
rifo
rmes
0.24
g/kg
fo
od
Fee
dQ
DD
1150
Do
xycy
clin
eA
nse
rifo
rmes
50P
OB
IDD
1150
Fo
r ch
lam
ydo
ph
ilosi
s
Do
xycy
clin
e**
Avi
an10
0IM
q10
dB
583
Do
xycy
clin
eA
vian
15D
rin
kQ
DC
705
Do
xycy
clin
e**
Avi
an75
-100
IM-S
Cq5d
-QW
E56
5A
nti
chla
myd
op
hili
al
Do
xycy
clin
e**
Avi
an75
-100
IMq5d
E70
3F
or
chla
myd
op
hilo
sis,
may
be
spac
ed 5
to
7
day
s fo
r fi
rst
4 w
eeks
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 269
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Do
xycy
clin
eB
ird, A
quat
ic25
-50
PO
QD
E15
03B
road
sp
ectr
um
, fo
od f
or
resp
irat
ory
infe
ctio
ns,
tre
at f
or
45 d
ays
for
chla
myd
op
hila
Do
xycy
clin
e B
ird, A
quat
ic
10 g
/L
D
rin
k Q
D
E
1503
S
ee a
bo
ve
Do
xycy
clin
e**
Bir
d, A
quat
ic
75-1
00
IM
QW
E
15
03 S
ee a
bo
ve
Do
xycy
clin
e**
Bust
ard, H
oub
ara
100
IM
QW
A
12
40 S
ee a
bo
ve
Do
xycy
clin
eB
ust
ard, H
oub
ara
22-4
4IV
On
ceA
1240
Co
nti
nue
ther
apy
wit
h I
M o
r P
O d
osa
ge f
or
seve
re c
hla
myd
op
hilo
sis
Do
xycy
clin
eC
hic
ken
20P
OQ
DA
762
Do
xycy
clin
eC
hic
ken
0.1
g/L
Dri
nk
NL
A80
3
Do
xycy
clin
eC
hic
ken
10D
rin
kQ
DB
1009
Fo
r fo
wl c
ho
lera
Do
xycy
clin
eC
ock
atie
l0.
83 g
/L
Dri
nk
QD
A16
38F
or
chla
myd
op
hilo
sis
Do
xycy
clin
eC
ock
atie
l0.
5 g/
kg s
eed
Fee
dQ
DA
1638
Fo
r ch
lam
ydo
ph
ilosi
s, m
ay c
ause
to
xico
sis
Do
xycy
clin
eC
ock
atie
l1
g/kg
mas
hF
eed
QD
A16
38F
or
chla
myd
op
hilo
sis
Do
xycy
clin
e**
Co
ckat
iel
100
IMq10
dA
1638
Fo
r ch
lam
ydo
ph
ilosi
s, m
ay n
ot
mai
nta
in
adeq
uat
e dru
g p
lasm
a le
vels
Do
xycy
clin
e C
ock
atie
l 40
-50
PO
Q
D
E
111,
703
F
or
chla
myd
op
hilo
sis
Do
xycy
clin
eC
ock
ato
o1
g/kg
fo
od
Fee
dQ
DA
693
Do
xycy
clin
eC
ock
ato
o, G
off
in25
PO
BID
A69
7
Do
xycy
clin
eC
ock
ato
o, G
off
in0.
4 g/
LD
rin
kN
LA
749
Do
xycy
clin
eC
ock
ato
o, G
off
in1
g/kg
mas
hF
eed
QD
A16
39
Do
xycy
clin
eM
acaw
25P
OB
IDA
697
Do
xycy
clin
eM
acaw
, Blu
e an
d G
old
1 g/
kg c
orn
mas
hF
eed
QD
A73
0E
ach
bir
d f
ed 1
00 g
mas
h
Do
xycy
clin
eO
stri
ch10
NL
BID
E62
8O
viduct
al in
fect
ion
th
erap
y
Do
xycy
clin
eP
arro
t, G
rey
25P
OB
IDA
697
Do
xycy
clin
eP
arro
t, G
rey
0.4
g/L
Dri
nk
NL
A74
9
Do
xycy
clin
eP
arro
t, G
rey
1 g/
kg f
oo
dF
eed
QD
A16
39
Do
xycy
clin
eP
asse
rin
e0.
25 g
/L
Dri
nk
QD
E14
37A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e, u
se f
or
30 d
ays
for
chla
myd
op
hilo
sis
Do
xycy
clin
eP
asse
rin
e1
g/kg
fo
od
Fee
dQ
DE
1437
Add d
rug
to d
rin
k at
th
e sa
me
tim
e, u
se f
or
30 d
ays
for
chla
myd
op
hilo
sis
Do
xycy
clin
eP
engu
in10
NL
QD
G13
53F
or
bab
esio
sis
Do
xycy
clin
eP
engu
in, A
fric
an20
PO
BID
G13
53
Do
xycy
clin
e **
Pig
eon
75IM
On
ceA
379
Do
xycy
clin
e**
Pig
eon
75-1
00IM
-SC
q5d
-QW
A56
5
Do
xycy
clin
eP
igeo
n25
PO
BID
A56
5W
ith
gri
t in
die
t
Do
xycy
clin
eP
igeo
n15
Dri
nk
QD
C70
4
Do
xycy
clin
eP
oult
ry0.
05 g
/L
Dri
nk
QD
C56
4
Do
xycy
clin
eP
oult
ry0.
25-0
.5 g
/L
Dri
nk
QD
G58
5A
dd t
ylo
sin
, an
tim
yco
pla
smal
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I270
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Do
xycy
clin
eP
sitt
acin
e25
-50
IVN
LE
111
Do
xycy
clin
e**
Psi
ttac
ine
100
IMQ
WE
632
Neo
nat
e do
sage
Do
xycy
clin
eP
sitt
acin
e50
PO
QD
E63
2N
eon
ate
do
sage
Do
xycy
clin
e **
Psi
ttac
ine
20IV
On
ceE
632
Neo
nat
e do
sage
Do
xycy
clin
eR
apto
r50
IMN
LB
1568
Do
xycy
clin
eR
apto
r25
PO
BID
G94
Juve
nile
do
sage
Do
xycy
clin
eR
atit
e2-
3.5
PO
BID
G13
08F
or
chla
myd
op
hilo
sis
Do
xycy
clin
e H
ycla
teA
vian
0.4
g/L
Dri
nk
QD
A70
3F
or
chla
myd
op
hilo
sis
Do
xycy
clin
e H
ycla
teA
vian
200-
400
mg/
kg f
oo
dF
eed
QD
E56
5A
nti
chla
myd
op
hili
al
Do
xycy
clin
e H
ycla
teC
ock
atie
l0.
2-0.
4 g/
LD
rin
kQ
DA
703
Fo
r ch
lam
ydo
ph
ilosi
s
Do
xycy
clin
e H
ycla
teC
ock
ato
o, G
off
in0.
8 g/
LD
rin
kQ
DA
703
Do
xycy
clin
e H
ycla
teP
arro
t, G
rey
0.8
g/L
Dri
nk
QD
A70
3
Do
xycy
clin
e H
ycla
teP
igeo
n55
PO
BID
G47
Ed
eta
te C
alc
ium
Dis
od
ium
An
seri
form
es10
-40
IM-I
VB
IDD
1150
Fo
r le
ad p
ois
on
ing
Edet
ate
Cal
cium
Dis
odiu
mA
vian
30-5
0IM
-IV
QID
D12
21F
or
lead
or
zin
c to
xico
sis,
may
use
in
con
jun
ctio
n w
ith
pen
icill
amin
e
Edet
ate
Cal
cium
Dis
odiu
mA
vian
20-4
0IM
-IV
BID
D14
70T
o r
educe
live
r le
ad a
nd z
inc
Edet
ate
Cal
cium
Dis
odiu
mA
vian
20-4
0IM
BID
-TID
E11
1
Edet
ate
Cal
cium
Dis
odiu
mB
ird, A
quat
ic35
IMB
IDD
1478
Giv
e 3
to 4
day
s p
er w
eek
for
lead
po
iso
nin
g
Edet
ate
Cal
cium
Dis
odiu
mC
ran
e, S
and H
ill35
IMB
IDB
1088
Rep
eat
4 day
s la
ter
for
lead
po
iso
nin
g
Edet
ate
Cal
cium
Dis
odiu
mL
ory
, Ch
atte
rin
g30
SCB
IDG
42
Edet
ate
Cal
cium
Dis
odiu
mM
acaw
35IM
BID
G40
Edet
ate
Cal
cium
Dis
odiu
mP
igeo
n30
IMB
IDG
590
Edet
ate
Cal
cium
Dis
odiu
mP
sitt
acin
e10
-40
IVB
IDE
1240
Lea
d a
nd h
eavy
met
al p
ois
on
ing
Edet
ate
Cal
cium
Dis
odiu
mR
apto
r35
-50
NL
BID
E11
88F
or
lead
to
xici
ty
Edet
ate
Cal
cium
Dis
odiu
mR
apto
r10
-40
IM-I
VB
IDE
1240
Lea
d a
nd h
eavy
met
al p
ois
on
ing
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 271
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
En
ilco
nazo
leA
vian
2 g/
L N
aCl
To
pic
alN
LE
924
Fo
r sk
in m
yco
sis
En
ilco
naz
ole
Psi
ttac
ine
2 g/
L N
aCl
Neb
uliz
eB
IDG
1034
Dilu
te 1
00 m
g/m
l 1:5
0 in
no
rmal
sal
ine
En
ilco
naz
ole
Psi
ttac
ine
0.1-
1% s
olu
tio
nIT
NL
E12
40
En
ilco
naz
ole
Rap
tor
5IT
QD
E12
40D
ilute
1:1
0
En
ilco
naz
ole
Rap
tor
0.2%
so
luti
on
To
pic
alB
IDE
1240
En
ilco
naz
ole
Rat
ite
10%
so
luti
on
Flu
shN
LG
1224
Fo
r m
yco
tic
der
mat
osi
s
En
rofl
oxacin
Am
azo
n P
arro
t7.
5-15
IM-P
OQ
D-B
IDA
1473
En
rofl
oxa
cin
Am
azo
n15
IMQ
DA
749
En
rofl
oxa
cin
Am
azo
n, B
lue-
fro
nte
d0.
5 m
g/kg
fo
od
Fee
dO
nce
A85
8F
or
chla
myd
op
hila
En
rofl
oxa
cin
Am
azo
n, R
ed L
ore
d10
IMB
IDG
700
2.5%
co
nce
ntr
atio
n
En
rofl
oxa
cin
An
seri
form
es10
-15
IM-P
OB
IDD
1150
, 135
8
En
rofl
oxa
cin
Ara
cari
, Bla
ck-n
ecke
d10
PO
BID
G13
67P
re-s
urg
ical
En
rofl
oxa
cin
Avi
an5-
15IM
-PO
-SC
QD
-BID
A91
6
En
rofl
oxa
cin
Avi
an30
PO
NL
E14
92F
or
Myc
opla
sma,
Chl
amyd
ophi
la
En
rofl
oxa
cin
Avi
an10
g/L
Neb
uliz
eT
ID-Q
IDE
1650
Add d
imet
hyl
sulf
oxi
de,
adju
nct
to
par
ente
ral
ther
apy
for
air
sacc
ulit
is
En
rofl
oxa
cin
Avi
an0.
25-1
g/kg
fo
od
Fee
dQ
DF
916
En
rofl
oxa
cin
A
vian
0.
05-0
.5 g
/L
D
rin
k N
L
F
916
En
rofl
oxa
cin
Avi
an15
PO
QD
G58
0A
dd e
tham
buto
l + r
ifam
pin
,
anti
myc
ob
acte
rial
En
rofl
oxa
cin
Bir
d, A
quat
ic30
IMB
IDE
1478
Po
st-t
raum
a in
fect
ion
s
En
rofl
oxa
cin
Budge
riga
r30
Fee
dO
nce
A92
0F
or
chla
myd
op
hilo
sis
En
rofl
oxa
cin
Bust
ard, H
oub
ara
15-3
0IM
-IV
-PO
BID
A79
0
En
rofl
oxa
cin
Ch
icke
n10
Dri
nk
NL
A81
1
En
rofl
oxa
cin
Duck
, Musc
ovy
15D
rin
kQ
DB
842
Puls
e do
se f
or
4 h
ours
eac
h d
ay
En
rofl
oxa
cin
Duck
, Pek
in10
Dri
nk
QD
A85
4F
or
Pas
teur
ella
an
d c
olif
orm
s
En
rofl
oxa
cin
Gull
10IM
BID
E13
57
En
rofl
oxa
cin
Haw
k, R
ed-t
aile
d5
IVQ
DA
978
En
rofl
oxa
cin
Ho
rnb
ill, G
reat
10-2
0P
OB
IDG
1587
En
rofl
oxa
cin
Lo
ry, R
ed15
PO
BID
G16
21
En
rofl
oxa
cin
Ost
rich
PO
TID
G41
8
En
rofl
oxa
cin
Ow
l, G
reat
-ho
rned
5IM
-PO
BID
G17
3A
dd c
lindam
ycin
or
cep
hal
oth
in
En
rofl
oxa
cin
Par
rot,
Gre
y0.
5 g/
LD
rin
kQ
DA
921
Fo
r sa
lmo
nel
losi
s
En
rofl
oxa
cin
Par
rot,
Gre
y0.
5 g/
kg f
oo
dF
eed
On
ceA
921
Hig
her
blo
od le
vels
in n
eon
ates
En
rofl
oxa
cin
Pen
guin
, Ro
ckh
op
per
9P
OQ
DG
1646
En
rofl
oxa
cin
Ph
easa
nt
20IM
-PO
NL
G67
8
En
rofl
oxa
cin
Ph
easa
nt,
Ch
ines
e R
ingn
eck
7.5
IMQ
DG
1296
Co
nti
nue
ther
apy
ora
lly
En
rofl
oxa
cin
Pig
eon
15IM
-SC
QD
A17
9
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I272
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
En
rofl
oxa
cin
Pig
eon
10P
OQ
DA
179
En
rofl
oxa
cin
Pig
eon
5-10
IM-I
V-P
O-
SC
QD
-BID
A86
6
En
rofl
oxa
cin
Pig
eon
10-2
0IM
-PO
-SC
QD
-BID
A91
9
En
rofl
oxa
cin
Pig
eon
5D
rin
kQ
DA
919
En
rofl
oxa
cin
Pig
eon
5P
OB
IDA
1473
En
rofl
oxa
cin
Po
ult
ry15
NL
BID
G58
5
En
rofl
oxa
cin
Psi
ttac
ine
2.5-
20P
OQ
DA
179
En
rofl
oxa
cin
Psi
ttac
ine
11-1
7.5
Dri
nk
NL
B75
0
En
rofl
oxa
cin
Psi
ttac
ine
10-2
0IM
NL
E63
2N
eon
ate
do
sage
, may
cau
se jo
int
def
ects
En
rofl
oxa
cin
Rap
tor
15IM
-PO
BID
E12
40B
road
sp
ectr
um
incl
udin
g P
seud
omon
as,
Kle
bsie
lla, M
ycop
lasm
a
En
rofl
oxa
cin
Rat
ite
1.5-
2.5
PO
-SC
BID
G13
08F
or
Gra
m n
egat
ive
infe
ctio
ns
Ep
inep
hri
ne
Avi
an0.
1IO
-IP
-IT
-IV
NL
E14
73
Ep
oeti
n A
lfa
Avi
an0.
1SC
q2-
3dE
1151
Fo
r an
emia
Erg
on
ovin
e M
ale
ate
Avi
an0.
06IM
On
ceE
111,
147
3, 1
650
Wit
h o
r w
ith
out
calc
ium
glu
con
ate
for
egg
bin
din
g
Ery
thro
mycin
Avi
an0.
125
g/L
Dri
nk
NL
E11
1
Ery
thro
myc
inA
vian
25IM
QD
E56
5
Ery
thro
myc
inA
vian
100
PO
NL
E70
4
Ery
thro
myc
inA
vian
200
mg/
kgF
eed
QD
E70
4So
ft f
oo
d
Ery
thro
myc
inA
vian
10-2
0 g/
LN
ebuliz
eT
DE
704
Dilu
ted in
15
ml 0
.9%
sal
ine
solu
tio
n
Ery
thro
myc
inC
hic
ken
0.10
2 g/
LD
rin
kQ
DA
544
Ch
ick
do
sage
Ery
thro
myc
inF
inch
0.2
g/kg
fo
od
Fee
dQ
DE
1572
Ery
thro
myc
inF
inch
0.12
5 g
/L
Dri
nk
QD
E15
72
Ery
thro
myc
inP
igeo
n10
0P
ON
LA
1055
Ery
thro
myc
inP
igeo
n2.
2 g/
LD
rin
kQ
DE
704
Ery
thro
cin
So
lub
le®
, 5 g
per
tea
spo
on
Ery
thro
myc
inP
oult
ry0.
25 g
/L
Fee
dQ
DC
564
Ery
thro
myc
inP
oult
ry10
-20
Dri
nk
QD
C70
5
Ery
thro
myc
inP
oult
ry50
-100
NL
BID
G58
5
Ery
thro
myc
inP
sitt
acin
e44
-88
PO
BID
E74
1F
or
sin
usi
tis
Ery
thro
myc
inP
sitt
acin
e10
-20
PO
BID
E12
40F
or
myc
op
lasm
al s
inusi
tis
and a
ir s
accu
litis
Ery
thro
myc
inP
sitt
acin
e10
-20
Par
ente
ral-
PO
BID
E14
73
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 273
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ery
thro
myc
inR
atit
e5-
10P
OT
IDG
1308
Est
rad
iol
Avi
an10
-15
IMQ
WB
677
Induce
mo
ltin
g X
4 w
eeks
Eth
am
bu
tol
HC
lA
maz
on
, Yel
low
-ch
eeke
d30
NL
QD
G71
3A
dd r
ifam
pin
+ is
on
iazi
d
Eth
amb
uto
l HC
lA
vian
30P
OQ
DD
1470
Eth
amb
uto
l HC
lA
vian
15P
OB
IDE
1473
Eth
amb
uto
l HC
lA
vian
30P
OQ
DE
1650
Add e
nro
flo
xaci
n +
rif
abuti
n f
or
myc
ob
acte
rio
sis
Eth
amb
uto
l HC
lA
vian
10P
OB
IDG
55A
dd r
ifam
pin
+ s
trep
tom
ycin
fo
r
myc
ob
acte
rio
sis
Eth
amb
uto
l HC
lC
ran
e, W
ho
op
ing
30P
OQ
DG
207
Add r
ifam
pin
Eth
amb
uto
l HC
lP
sitt
acin
e15
-20
PO
BID
E12
40F
or
myc
ob
acte
rio
sis
Eth
amb
uto
l HC
lR
apto
r20
PO
BID
E12
40
Eto
rph
ine
Cas
sow
ary,
Do
ub
le-w
attl
ed0.
15IM
PR
NG
447
Add a
cep
rom
azin
e
Eto
rph
ine
Ost
rich
0.04
-0.0
7IM
PR
NB
447
Add a
cep
rom
azin
e
Eto
rph
ine
Ost
rich
0.04
IMP
RN
B44
7A
dd a
cep
rom
azin
e +
xyl
azin
e
F10
Avi
an1:
250
dilu
tio
nN
ebuliz
eQ
D-B
IDG
1197
Neb
uliz
e as
an
tifu
nga
l, an
tich
lam
ydo
ph
ilial
and a
nti
bac
teri
al
F10
Avi
an1:
200
dilu
tio
nT
op
ical
QD
G13
02D
aily
sp
ray
on
to f
eath
ers
for
yeas
t an
d
sup
ple
men
t to
fea
ther
pic
kin
g th
erap
y
F10
Avi
an1:
125
dilu
tio
nN
ebuliz
eT
IDB
1465
F10
Avi
an1:
125
Dilu
tio
nN
ebuliz
eB
IDG
1268
Add o
meg
a in
terf
ero
n, p
reve
nts
sec
on
dar
y
infe
ctio
n
F10
Rap
tor
1:25
0 D
iluti
on
Neb
uliz
eB
ID-T
IDG
742
Add it
raco
naz
ole
, 15
to 3
0 m
inute
s p
er d
ay
for
mild
asp
ergi
llosi
s
Fatt
y A
cid
s, O
meg
aP
sitt
acin
e0.
22 m
l/kg
PO
NL
E17
56A
dd a
spir
in, u
se <
6:1
rat
io o
meg
a 6:
om
ega
3, u
se u
nti
l ren
al h
isto
logy
no
rmal
izes
fo
r
ren
al d
isea
se
Fat
ty A
cids,
Om
ega
Psi
ttac
ine
0.11
ml/
kgP
OQ
DG
1263
Mix
5:1
N-6
:N-3
om
ega
fatt
y ac
ids
for
glo
mer
ulo
nep
hri
tis
or
acute
pan
crea
titi
s
Feb
an
tel
Ost
rich
20N
LN
LC
283
Feb
ante
lO
stri
ch5
PO
NL
G48
1
Feb
ante
lP
igeo
n30
PO
q3w
A88
8F
or
asca
rids
and c
apill
aria
Fen
ben
dazo
leA
nse
rifo
rmes
20P
OO
nce
D11
50C
on
tro
l nem
ato
des
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I274
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Fen
ben
daz
ole
An
seri
form
es5-
10P
OQ
DE
111,
147
3
Fen
ben
daz
ole
Avi
an25
NL
QD
D12
21R
epea
t in
2 w
eeks
fo
r ca
pill
aria
sis
Fen
ben
daz
ole
Avi
an10
0N
Lq2w
D12
21F
or
cap
illar
iasi
s
Fen
ben
daz
ole
Avi
an2
PO
QD
D14
70F
or
liver
par
asit
ic d
isea
se
Fen
ben
daz
ole
Avi
an20
-50
PO
q10
dE
111
Fo
r as
cari
ds
Fen
ben
daz
ole
Avi
an20
-50
PO
QD
E11
1F
or
fluke
s an
d c
apill
aria
Fen
ben
daz
ole
Avi
an50
PO
QD
E16
17F
or
asca
rids,
may
nee
d 5
-day
tre
atm
ent
for
cap
illar
ia, r
epea
t in
2 w
eeks
,
Fen
ben
daz
ole
Avi
an20
-100
PO
On
ceG
57A
void
duri
ng
bre
edin
g se
aso
n a
nd m
olt
ing
Fen
ben
daz
ole
Bir
d, A
quat
ic22
NL
NL
E14
78
Fen
ben
daz
ole
Bir
d, A
quat
ic50
PO
QD
E15
03R
epea
t in
2 w
eeks
fo
r as
cari
ds
Fen
ben
daz
ole
Bir
d, A
quat
ic10
0P
Oq2w
E15
03
Fen
ben
daz
ole
Bust
ard
30P
OO
nce
E12
40
Fen
ben
daz
ole
Bust
ard, H
oub
ara
25P
OO
nce
G93
2P
rop
hyl
axis
fo
r ro
un
d w
orm
s
Fen
den
daz
ole
Co
ckat
iels
N/A
GM
ay h
ave
leth
al r
eact
ion
Fen
ben
daz
ole
Cra
ne
100
PO
QD
E62
9R
epea
t q2w
as
nee
ded
Fen
ben
daz
ole
Cra
ne
50-1
00P
OQ
DE
1361
Rep
eat
in 2
wee
ks f
or
gap
ewo
rms
and
cap
illar
ids
Fen
ben
daz
ole
Fal
con
20P
OQ
DE
1240
Fo
r Ser
rato
spicul
um
Fen
ben
daz
ole
Fin
ch10
-25
PO
QD
E15
72
Fen
ben
daz
ole
Gro
use
0.5-
0.7
Fee
dQ
DC
704
Fo
r T
rich
ostr
ongy
lus
Fen
ben
daz
ole
Gull
50P
OQ
DE
1357
Fo
r ca
pill
aria
sis
Fen
ben
daz
ole
Gull
25P
Oq2w
E13
57F
or
asca
ridia
sis
Fen
ben
daz
ole
Ost
rich
15P
ON
LB
524
Wit
h o
r w
ith
out
reso
ran
tel
Fen
ben
daz
ole
Ost
rich
30P
ON
LB
526
Add r
eso
ran
tel
Fen
ben
daz
ole
Ost
rich
15P
ON
LG
481
Fen
ben
daz
ole
Par
akee
t, A
ust
ralia
n50
Gav
age
On
ceE
1186
Fo
r ro
un
dw
orm
s
Fen
ben
daz
ole
Par
trid
ge8
Fee
dQ
DC
704
Fo
r C
apill
aria
Fen
ben
daz
ole
Par
trid
ge12
Fee
dO
nce
C70
4F
or
Syn
gam
us, H
eter
akis
, asc
arid
s
Fen
ben
daz
ole
Pen
guin
50P
ON
LE
1478
Fo
r n
emat
odes
an
d f
luke
s
Fen
ben
daz
ole
Ph
easa
nt
12P
OO
nce
C70
6
Fen
ben
daz
ole
Ph
easa
nt
8P
OQ
DC
706
Fen
ben
daz
ole
Pig
eon
16P
OO
nce
C70
4
Fen
ben
daz
ole
Pig
eon
20P
OQ
DC
706
Fo
r ga
stro
inte
stin
al r
oun
dw
orm
s
Fen
ben
daz
ole
Pig
eon
20-5
0P
OQ
DE
1240
Fo
r ca
pill
aria
sis
Fen
ben
daz
ole
Pig
eon
8P
OO
nce
E12
40A
t 8
wee
ks o
f ag
e
Fen
ben
daz
ole
Pig
eon
7.5
PO
On
ceE
1432
Fen
ben
daz
ole
Pig
eon
7.5-
20P
OO
nce
G23
2
Fen
ben
daz
ole
Pig
eon
10-1
2P
OQ
DG
260
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 275
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Fen
ben
daz
ole
Pig
eon
50P
OQ
DG
590
Fen
ben
daz
ole
Pig
eon
15P
Oq10
dG
1208
Fo
r as
cari
ds
or
Cap
illar
ia,
no
t fo
r use
duri
ng
mo
ltin
g
Fen
ben
daz
ole
Psi
ttac
ine
20-5
0P
Or2
wE
763
Fen
ben
daz
ole
Psi
ttac
ine
15P
OQ
DE
1240
May
med
icat
e fe
ed f
or
7 day
s
Fen
ben
daz
ole
Psi
ttac
ine
100
PO
q2w
E16
13F
or
asca
ridia
sis
Fen
ben
daz
ole
Psi
ttac
ine
50P
OQ
DE
1613
Fo
r ca
pill
aria
sis
Fen
ben
daz
ole
Rap
tor
10-5
0N
Lq10
dE
1132
Fo
r as
cari
dia
sis
Fen
ben
daz
ole
Rap
tor
30-5
0N
LO
nce
E11
32F
or
fluke
s
Fen
ben
daz
ole
Rap
tor
25P
OQ
DE
1159
Fo
r n
emat
odes
Fen
ben
daz
ole
Rat
ite
15P
ON
LG
418
Wit
h o
r w
ith
out
reso
ran
tel
Fen
tan
yl
Cit
rate
Avi
an0.
2SC
NL
B13
41So
me
hyp
erac
tivi
ty f
or
firs
t 15
to
30
min
ute
s
Ferr
ic S
ub
sulf
ate
Avi
anN
/A
To
pic
alP
RN
E14
73F
or
hem
orr
hag
e
Fip
ron
ilA
vian
7.5-
15N
LO
nce
G17
29F
or
larg
er b
irds
Fip
ron
ilC
anar
yN
/A
To
pic
alO
nce
G17
29Sp
ray
on
glo
ved f
inge
r an
d r
ub
un
der
win
gs
and o
n d
ors
al a
nd v
entr
al s
urf
aces
of
bo
dy
for
red m
ites
Fip
ron
ilD
ove
, Duck
7.5-
15N
LO
nce
G17
29
Fip
ron
ilR
apto
rL
igh
t Sp
ray
To
pic
alO
nce
B15
68F
or
wild
inju
red r
apto
rs w
ith
ect
op
aras
ites
Fip
ron
ilR
apto
rN
/A
To
pic
alO
nce
E13
59F
or
ecto
par
asit
es
Fla
x S
eed
Oil
Am
azo
n, Y
ello
w-n
aped
0.02
2 m
l/kg
bo
dy
wt.
Fee
dQ
DG
1033
Dilu
te 1
:4 w
ith
co
rn o
il
Fla
x Se
ed O
ilA
vian
0.1-
0.2
ml/
kgP
ON
LG
1682
Mix
1:4
wit
h c
orn
oil
pri
or
to d
osi
ng
for
ren
al
dis
ease
Flo
xacil
lin
Haw
k12
5P
OB
IDG
1110
Flo
xaci
llin
Rap
tor
250
PO
NL
E14
63F
or
bac
teri
al in
fect
ion
s
Flu
ben
dazo
leA
nse
rifo
rmes
0.24
mg/
kg f
eed
Fee
dQ
DD
1150
Co
ntr
ol n
emat
odes
Flu
ben
daz
ole
Gal
lifo
rmes
30-6
0 g/
ton
fee
dF
eed
QD
C70
4, 7
06F
or
gast
roin
test
inal
ro
un
dw
orm
s, g
apew
orm
s
and t
apew
orm
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I276
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Flu
co
nazo
leA
maz
on
Par
rot
20IV
-PO
q2d
D13
30F
or
keto
con
azo
le-r
esis
tan
t C
andi
da, t
issu
e-
bas
ed y
east
s, e
ye, c
ereb
ral s
pin
al, l
on
g-te
rm
Asp
ergi
llus
Flu
con
azo
leA
vian
8N
LQ
DD
1221
Fo
r cr
ypto
cocc
osi
s
Flu
con
azo
leA
vian
20P
Oq2d
D12
21F
or
can
did
iasi
s
Flu
con
azo
leA
vian
5IV
-PO
QD
D13
30
Flu
con
azo
leA
vian
20IV
-PO
q2d
D13
30A
dult
do
ase
Flu
con
azo
leA
vian
4-6
IV-P
OB
IDD
1330
Juve
nile
do
se
Flu
con
azo
leB
ird, A
quat
ic15
PO
QD
E14
78F
or
pre
ven
tio
n o
f as
per
gillo
sis,
may
als
o
neb
uliz
e
Flu
con
azo
leB
ird, A
quat
ic8
PO
BID
E15
03
Flu
con
azo
leB
ird, A
quat
ic15
PO
BID
E15
59
Flu
con
azo
leC
hic
ken
100
Gav
age
BID
G13
48F
or
mac
rorh
abdo
sis
(fo
rmer
ly m
egab
acte
ria
or
avia
n g
astr
ic y
east
), t
oxi
c to
budge
riga
rs
Flu
con
azo
leP
engu
in, A
fric
an30
PO
BID
G12
8
Flu
con
azo
leP
igeo
n5-
10P
OB
IDG
56P
rop
hyl
axis
Flu
con
azo
leP
sitt
acin
e5-
15P
OB
IDD
1446
Flu
con
azo
leP
sitt
acin
e2-
5P
OQ
DG
697
Flu
con
azo
leR
apto
r2-
5P
OQ
DE
1240
Fo
r ge
ner
aliz
ed a
sper
gillo
sis
Flu
con
azo
leR
apto
r5
PO
QD
E13
59F
or
can
did
iasi
s
Flu
con
azo
leR
apto
r2-
5P
OQ
DE
1400
Asp
ergi
llosi
s
Flu
cyto
sin
eA
vian
250
PO
BID
D12
21F
or
can
did
iasi
s
Flu
cyto
sin
eA
vian
50-1
00P
OB
IDD
674,
133
0F
or
Asp
ergi
llus
or
Can
dida
pro
ph
ylax
is, a
dd
amp
ho
teri
cin
B o
r az
ole
s fo
r th
erap
y
Flu
cyto
sin
eA
vian
40-5
0P
OT
IDE
626
Add I
V a
nd I
T a
mp
ho
teri
cin
B f
or
asp
ergi
llosi
s th
erap
y
Flu
cyto
sin
eA
vian
50-6
0P
OB
IDE
626
Asp
ergi
llus
pro
ph
ylax
is
Flu
cyto
sin
eA
vian
20-5
0P
OB
IDE
1492
Flu
cyto
sin
eB
ird, A
quat
ic50
-60
NL
BID
E15
03A
sper
gillo
sis
pro
ph
ylax
is
Flu
cyto
sin
eB
ird, A
quat
ic10
0P
OT
IDE
1503
Fo
r as
per
gillo
sis
adju
nct
th
erap
y
Flu
cyto
sin
eH
orn
bill
, Gre
at25
0P
OB
IDG
1587
Flu
cyto
sin
eP
engu
in, A
fric
an25
0P
OB
IDG
1353
May
giv
e lo
ng-
term
Flu
cyto
sin
eP
sitt
acin
e75
-120
PO
BID
D13
30F
or
Asp
ergi
llus
or
Can
dida
pro
ph
ylax
is, a
dd
amp
ho
teri
cin
B o
r az
ole
s fo
r th
erap
y
Flu
cyto
sin
eP
sitt
acin
e10
0-25
0P
OB
IDD
1330
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 277
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Flu
cyto
sin
eR
apto
r12
0P
OB
IDB
1178
Add I
T a
nd I
V a
mp
ho
teri
cin
B +
rif
amp
in
for
asp
ergi
llosi
s
Flu
cyto
sin
eR
apto
r60
PO
BID
D13
30F
or
asp
ergi
llus
or
Can
dida
pro
ph
ylax
is b
irds
> 5
00 g
, add H
1176
amp
ho
teri
cin
B o
r az
ole
s
for
ther
apy
Flu
cyto
sin
eR
atit
e80
-100
PO
BID
G13
08
Flu
cyto
sin
eSw
an50
-75
PO
BID
G86
, 697
Flu
mazen
ilA
nse
rifo
rmes
0.05
IVP
RN
D15
03, 1
533
Add a
tip
amez
ole
to
rev
erse
ket
amin
e +
med
eto
mid
ine
+ m
idaz
ola
m
Flu
maz
enil
Avi
an0.
1N
LP
RN
E14
81R
ever
se b
enzo
dia
zep
ines
Flu
maz
enil
Avi
an0.
05IV
PR
NE
1533
Flu
maz
enil
Pig
eon
0.04
IMP
RN
G16
44R
ever
se m
idaz
ola
m
Flu
nix
in M
eg
lum
ine
An
seri
form
es1
SCQ
DE
1190
Flu
nix
in M
eglu
min
eA
nse
rifo
rmes
1-10
IMN
LE
1150
Fo
r jo
int
lam
enes
s
Flu
nix
in M
eglu
min
eA
vian
1-10
IMQ
DD
1533
May
cau
se r
enal
isch
emia
at
hig
her
do
sage
s
Flu
nix
in M
eglu
min
eB
ird, A
quat
ic1-
10IM
QD
E15
03M
ay c
ause
ren
al is
chem
ia a
t h
igh
er d
osa
ges
Flu
nix
in M
eglu
min
eB
ust
ard, H
oub
ara
2N
LN
LG
1594
Swel
ling
in f
oo
t def
orm
ity
of
neo
nat
e
Flu
nix
in M
eglu
min
eD
uck
, Mal
lard
5N
LN
LA
1339
Res
idual
ph
ysio
logi
cal e
ffec
t 12
ho
urs
Flu
nix
in M
eglu
min
eD
uck
, Mal
lard
5IM
BID
A14
90F
or
fro
stb
ite
Flu
nix
in M
eglu
min
eP
igeo
n1-
10IM
-IV
QD
E14
32
Flu
nix
in M
eglu
min
eP
sitt
acin
e1-
10IM
NL
E12
40
Flu
nix
in M
eglu
min
eR
apto
r2-
10IM
QD
D14
00
Flu
oxeti
ne H
Cl
Avi
an1
NL
NL
E11
86F
or
beh
avio
ral p
rob
lem
s su
ch a
s fe
ath
er
pic
kin
g
Flu
oxe
tin
e H
Cl
Avi
an1
NL
QD
E14
77F
or
feat
her
pic
kin
g
Flu
oxe
tin
e H
Cl
Psi
ttac
ine
0.4
PO
QD
D14
46F
or
beh
avio
ral f
eath
er p
icki
ng
Fu
ralt
ad
on
e
Avi
an
0.47
mg.
/kc
al P
O
QD
E
11
80
Fura
ltad
on
e P
igeo
n
15-2
0 P
O
QD
E
56
5
Fura
ltad
on
eP
igeo
n0.
125
g/L
Dri
nk
QD
E14
92, 1
650
Fo
r sa
lmo
nel
losi
s
Fura
ltad
on
eP
igeo
n0.
4 g/
LD
rin
kQ
DE
1240
Add t
etra
cycl
ine
for
tric
ho
mo
nia
sis
and
hex
amit
iasi
s, n
ot
for
adult
s fe
edin
g yo
un
g <
10 d
ays
old
Fu
razo
lid
on
e +
Fu
ralt
ad
on
e
Pig
eon
15-2
0P
OQ
DF
1061
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I278
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Fu
rose
mid
eA
maz
on
, Yel
low
-nap
ed0.
15P
OB
IDG
1033
Furo
sem
ide
Avi
an0.
165
IMB
IDG
1309
Diu
reti
c, lo
ries
sen
siti
ve
Furo
sem
ide
Avi
an0.
1-0.
2IM
-PO
QD
-BID
E11
52F
or
diu
resi
s, r
isk
of
toxi
cosi
s es
pec
ially
in
smal
l bir
ds
Furo
sem
ide
Avi
an0.
15-2
IMQ
D-B
IDE
1650
Fo
r as
cite
s an
d e
dem
a, n
ot
for
lori
keet
s
Furo
sem
ide
Avi
an0.
15-2
IM-S
CQ
D-B
IDE
111,
147
0
Furo
sem
ide
Avi
an0.
1-0.
2IM
BID
E14
31
Furo
sem
ide
Avi
an1-
2N
LQ
D-B
IDE
1470
Fo
r co
nge
stiv
e h
eart
fai
lure
wit
h li
ver
dis
ease
Furo
sem
ide
Pig
eon
0.5-
3P
OB
ID-T
IDG
590
Furo
sem
ide
Pig
eon
2.2
IM-I
V-P
OB
IDG
590
Furo
sem
ide
Psi
ttac
ine
0.15
-2IM
-SC
QD
-BID
E12
40
Furo
sem
ide
Rap
tor
1.5
IMQ
IDE
1240
Furo
sem
ide
Rap
tor
1IM
-IV
PR
NE
1359
Furo
sem
ide
Rap
tor
1.5
IMT
ID-Q
IDE
1400
Furo
sem
ide
Rap
tor
1.5
IMP
RN
G23
4
Furo
sem
ide
Secr
etar
y B
ird
2.2
IMB
IDG
41
Fu
sid
ate
So
diu
mA
vian
2% o
intm
ent
To
pic
alB
IDE
1240
Fo
r m
ild/ea
rly
bum
ble
foo
t an
d o
ther
ski
n
lesi
on
s, m
ay p
enet
rate
inta
ct s
kin
, eff
ecti
ve
agai
nst
Sta
ph a
ureu
s
Gad
op
en
teta
te
Dim
eg
lum
ine
Avi
an0.
25 m
mo
l/kg
IVO
nce
G17
54F
or
hea
d m
agn
etic
res
on
ance
imag
ing
studie
s
Gen
tam
icin
Su
lfate
Avi
an10
ITQ
DE
704
Gen
tam
icin
Sulf
ate
Avi
an5-
10IM
BID
-TID
E70
4
Gen
tam
icin
Sulf
ate
Avi
an5
g/L
Neb
uliz
eT
IDE
741,
924
Fo
r si
nusi
tis
or
airs
accu
litis
Gen
tam
icin
Sulf
ate
Avi
an4
IMN
LE
924
Fo
r P
seud
omon
as, n
eph
roto
xic
Gen
tam
icin
Sulf
ate
Avi
an5-
10N
LQ
DE
1170
Rel
ativ
ely
ren
al t
oxi
c p
arti
cula
rly
if
deh
ydra
ted
Gen
tam
icin
Sulf
ate
Avi
an5
g/L
Flu
shB
IDE
1183
Nas
al o
r si
nus
Gen
tam
icin
Sulf
ate
Avi
an2.
5IM
BID
E14
34
Gen
tam
icin
Sulf
ate
Avi
an3-
5IM
QD
-BID
E14
92
Gen
tam
icin
Sulf
ate
Avi
an3-
5IM
QD
-BID
E16
50F
or
resi
stan
t o
rgan
ism
s
Gen
tam
icin
Sulf
ate
Bust
ard
5IM
QD
-BID
E12
40F
or
firs
t 3
day
s o
f lif
e to
pre
ven
t yo
lk s
ac
infe
ctio
ns
afte
r as
sist
ed h
atch
Gen
tam
icin
Sulf
ate
Ch
icke
n1.
5IM
TID
A71
5
Gen
tam
icin
Sulf
ate
Ch
icke
n2
IMB
IDA
1056
Fo
r ro
ost
ers
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 279
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Gen
tam
icin
Sulf
ate
Ch
icke
n10
IMB
ID-Q
IDA
1143
Gen
tam
icin
Sulf
ate
Cra
ne
5IM
TID
A45
8
Gen
tam
icin
Sulf
ate
Duck
5IM
QID
A84
7
Gen
tam
icin
Sulf
ate
Duck
, Eag
le, M
acaw
, Ow
l10
IMB
ID-Q
IDA
1143
Gen
tam
icin
Sulf
ate
Em
u5
IMT
IDA
418
Gen
tam
icin
Sulf
ate
Em
u2.
5IM
BID
A84
7
Gen
tam
icin
Sulf
ate
Haw
k, R
ed-t
aile
d2.
5IM
TID
A71
4
Gen
tam
icin
Sulf
ate
Ow
l, G
reat
-ho
rned
2.5
IMT
IDA
714
Gen
tam
icin
Sulf
ate
Ph
easa
nt
5IM
TID
A45
8
Gen
tam
icin
Sulf
ate
Pig
eon
10IM
QID
A84
7
Gen
tam
icin
Sulf
ate
Pig
eon
20IM
BID
-QID
A11
43
Gen
tam
icin
Sulf
ate
Psi
ttac
ine
10IM
BID
-TID
E56
5
Gen
tam
icin
Sulf
ate
Psi
ttac
ine
5-10
ITQ
DE
741
Add c
arb
enic
illin
fo
r p
neu
mo
nia
Gen
tam
icin
Sulf
ate
Quai
l10
IMQ
IDA
458
Gen
tam
icin
Sulf
ate
Rap
tor
2.5
IMT
IDA
565,
714
Gen
tam
icin
Sulf
ate
Rat
ite
5IM
QD
G13
08M
ay c
ause
vis
cera
l go
ut
Gen
tam
icin
Sulf
ate
Turk
ey3
IMB
IDA
880
Gen
tian
Vio
let
Mac
aw, H
yaci
nth
N/A
To
pic
alN
LE
1240
Exc
elle
nt
for
cro
p o
r sk
in f
old
can
did
iasi
s in
chic
ks
Gli
piz
ide
Co
ckat
oo
, Ro
se-b
reas
ted
0.05
g/L
Dri
nk
QD
G17
26C
rush
tab
let
into
wat
er f
or
dia
bet
es m
ellit
us
Glu
co
sam
ine S
ulf
ate
Avi
an10
dro
ps/
kgP
OT
IDE
1205
Fo
r jo
int
dis
ease
Gly
bu
rid
eC
ock
atie
l0.
0012
5-0.
0025
g/L
Dri
nk
QD
G17
20F
or
po
lyuri
a/p
oly
dip
sia
Gly
ceri
nR
apto
r<
5 m
l/kg
PO
NL
E14
63F
or
imp
acti
on
, may
giv
e cl
oac
ally
Gly
co
pyrr
ola
teP
igeo
n0.
01IM
PR
NG
1644
Add m
idaz
ola
m f
or
anes
thes
ia p
rem
ed
Go
nad
otr
op
in,
Ch
ori
on
icA
vian
500-
1000
ug/
kgIM
QD
E14
74T
reat
ch
ron
ic e
gg la
yin
g, in
ject
day
on
e, o
n
day
3 if
egg
, on
day
7 if
sec
on
d e
gg, u
se u
p t
o
3-6
w
Go
nad
otr
op
in, C
ho
rio
nic
Go
ose
0.5
mg
TD
Par
ente
ral
q3-
4dB
894
Incr
ease
sp
erm
iati
on
an
d e
arly
pub
erty
in
gan
der
s
Gri
seo
fulv
inO
stri
ch30
-50
Dri
nk
QD
G53
1, 1
308
Gri
seo
fulv
inP
igeo
n10
PO
QD
E12
40F
or
der
mat
op
hyt
osi
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I280
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Halo
fug
ino
n H
Br
Po
ult
ryF
eed
QD
C70
5F
or
cocc
idia
l pro
ph
ylax
is
Hal
ofu
gin
on
HB
r C
hic
ken
3
g/to
n f
oo
d
Fee
d
QD
E
56
4 Se
ven
day
sla
ugh
ter
wit
hdra
wal
Halo
peri
do
lA
vian
0.1
PO
BID
D14
75
Hal
op
erid
ol
Avi
an
0.17
D
rin
k Q
D
E
704
Bo
dy
wei
ght
less
th
an 1
kg,
gra
dual
ly in
crea
se
do
sage
to
0.9
mg/
kg
Hal
op
erid
ol
Avi
an0.
2D
rin
kQ
DE
704
Hal
op
erid
ol
Avi
an0.
4D
rin
kQ
DE
704
Mai
nte
nan
ce d
ose
Hal
op
erid
ol
Avi
an0.
4N
LN
LE
1186
Fo
r b
ehav
iora
l pro
ble
ms
such
as
feat
her
pic
kin
g
Hal
op
erid
ol
Avi
an1-
2IM
q2-
3wE
1431
Hal
op
erid
ol
Avi
an0.
2-0.
4P
OQ
DE
1431
Hal
op
erid
ol
Avi
an0.
1-0.
15N
LN
LE
1477
Fo
r se
lf-m
uti
lati
on
Hal
op
erid
ol
Avi
an0.
2P
OB
IDE
1492
Fo
r b
irds
< 1
kg
for
feat
her
pic
kin
g an
d s
elf-
muti
lati
on
, mo
st e
ffec
tive
in c
ock
ato
os
Hal
op
erid
ol
Par
rot,
Quak
er0.
08P
OB
IDE
1492
Fo
r fe
ath
er p
icki
ng
and s
elf-
muti
lati
on
Hal
op
erid
ol
Psi
ttac
ine
0.15
PO
BID
E11
1C
on
tro
l fea
ther
pic
kin
g an
d m
uti
lati
on
, bir
ds
ove
r 1
kg
Hal
op
erid
ol
Psi
ttac
ine
1-2
IMq2-
3wE
111
Co
ntr
ol f
eath
er p
icki
ng
and m
uti
lati
on
Hal
op
erid
ol
Psi
ttac
ine
0.2
PO
BID
E11
1
Hal
op
erid
ol
Psi
ttac
ine
0.4
PO
QD
E12
40F
or
feat
her
pic
kin
g
Halo
than
eA
vian
N/A
IHP
RN
E16
17In
duct
ion
, mai
nta
in w
ith
1-1
.5%
Hal
oth
ane
Pig
eon
N/A
IHP
RN
E14
321.
5-3%
mai
nte
nan
ce
Hep
ari
n S
od
ium
Avi
an40
-50
U/kg
IVO
nce
E11
51A
dd a
min
op
hyl
line,
dex
amet
has
on
e N
a
ph
osp
hat
e, f
luid
s, o
xyge
n f
or
po
lyte
traf
louro
eth
ylen
e ga
s p
ois
on
Hep
arin
So
diu
mA
vian
0.1
ml o
f 10
00U
/m
lN
ebuliz
eQ
DG
1705
Add t
o 6
.5 m
l sal
ine
Hep
arin
So
diu
mA
vian
1.0
ml o
f 10
00U
/m
l T
op
ical
QD
G17
05A
dd a
loe
vera
Hep
arin
So
diu
mSw
an55
IVO
nce
G17
07E
mac
iate
d n
ear
dea
th
Hep
asa
nA
vian
1 m
l/kg
PO
QD
G10
35F
or
liver
dis
ease
Hep
asan
Psi
ttac
ine
1 m
l/kg
PO
QD
G17
22L
iver
sup
po
rt
Heta
starc
hA
vian
10-1
5 m
l/kg
IVT
IDE
1650
Fo
r em
erge
ncy
car
e, r
educe
cry
stal
loid
flu
ids
Het
asta
rch
Avi
an10
-15
ml/
kgIV
TID
E11
51F
or
hyp
op
rote
inem
ia
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 281
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Het
asta
rch
Haw
k, R
ed-t
aile
d10
ml/
kgIV
NL
G16
26Su
pp
ort
ive
ther
apy
po
st-t
raum
a
Hexyl
Pyro
ph
eo
bo
rbid
e-a
Ho
rnb
ill, G
reat
0.3
IVq2m
G15
87F
or
squam
ous
cell
carc
ino
ma
Hyalu
ron
idase
Avi
an15
0 U
/L
flu
ids
SCN
LG
1103
Mix
wit
h f
luid
s to
aid
in a
bso
rpti
on
Hya
luro
nid
ase
Avi
an1.
5 K
IU/L
Flu
shN
LG
1719
Mix
into
nas
al a
nd s
inus
flush
es
Hya
luro
nid
ase
Avi
an1.
5 K
IU/L
Neb
uliz
eN
LG
1719
Mix
into
neb
uliz
atio
n f
luid
Hya
luro
nid
ase
Avi
an1.
5 K
IU/L
IVN
LG
1719
Fo
r eg
g yo
lk s
tro
ke
Hyd
roco
rtis
on
e S
od
ium
Su
ccin
ate
Avi
an10
IVN
LE
1470
Fo
r le
ad t
oxi
city
an
d s
ever
e in
fect
ion
wit
h
liver
dis
ease
Hyd
roxych
loro
qu
ine
Su
lfate
Pig
eon
4 ta
ble
ts/L
Dri
nk
NL
G59
0C
han
ge d
aily
Hyd
roxyzin
e H
Cl
Avi
an2
PO
TID
G13
24F
or
pru
riti
s
Hyd
roxy
zin
e H
Cl
Psi
ttac
ine
2P
OT
IDD
1446
Fo
r h
yper
sen
siti
vity
-tri
gger
ed f
eath
er p
icki
ng
Hyp
eri
cu
mA
vian
10 d
rop
s/kg
PO
TID
E12
05F
or
feat
her
pic
kin
g, a
nxi
ety
Imid
aclo
pri
dR
apto
r7
IT-I
VN
LE
1359
Fo
r b
abes
iosi
s
Imid
ocarb
HC
lR
apto
r7
NL
q3w
E13
59F
or
bab
esio
sis
Imiq
uim
od
Am
azo
n, B
lue-
fro
nte
dcr
eam
Ven
tq2-
3dB
1281
Fo
r cl
oac
al p
apill
om
ato
sis,
ap
ply
to
clo
acal
surf
ace
Ind
om
eth
acin
Avi
an0.
4IM
NL
E12
32
Indo
met
hac
inC
hic
ken
2P
ON
LA
772
Eff
ecti
ve f
or
8-10
ho
urs
Indo
met
hac
in, C
op
per
Avi
an0.
4IM
QD
E14
92F
or
acute
/ch
ron
ic in
flam
mat
ion
fro
m
trau
ma,
infe
ctio
n o
r o
rgan
dys
fun
ctio
n
Insu
lin
, N
PH
Avi
an0.
01-0
.1 U
TD
Par
ente
ral
NL
E16
50F
or
dia
bet
es m
ellit
us
in b
irds
larg
er t
han
budge
riga
r
Insu
lin, N
PH
Avi
an0.
07 U
/kg
IMQ
DG
1325
Fo
r dia
bet
es, m
on
ito
r b
loo
d g
luco
se
Insu
lin, N
PH
Budge
riga
r0.
067-
3.3
U/kg
IMB
IDE
1326
Fo
r dia
bet
es
Insu
lin, N
PH
Budge
riga
r0.
002
U T
DIM
PR
NG
58
Insu
lin, N
PH
Psi
ttac
ine
0.01
-0.1
U T
DIM
PR
NG
58, 8
8
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I282
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Insu
lin, R
egula
rA
vian
0.00
13 m
g/kc
alIM
QD
E11
80
Insu
lin, Z
inc
Susp
ensi
on
To
uca
n, T
oco
0.1-
0.5
U T
DIM
PR
NG
58
Inte
rfero
n,
Alp
ha
Avi
an15
KIU
/m
²SC
q2d
E14
70G
ive
15, 0
00 U
nit
s/m
² o
f b
ody
surf
ace
for
lym
ph
osa
rco
ma
Inte
rfer
on
, Om
ega
Avi
an10
00 K
IU T
DIM
q2d
B14
65A
dd F
10®
fo
r ci
rco
viru
s p
reve
nti
on
an
d
limit
ed e
ffec
tive
nes
s th
erap
y o
f 90
day
s
Inte
rfer
on
, Om
ega
Avi
an10
00 K
IU T
DP
aren
tera
lQ
D-B
IDG
1268
Add F
10®
fo
r ci
rco
viru
s th
erap
y
Iod
ine,
Lu
go
l's
Avi
an4
dro
ps
solu
tio
n/L
Dri
nk
NL
E11
86U
sed t
o k
eep
dri
nki
ng
wat
er u
nco
nta
min
ated
Iodin
e, L
ugo
l'sR
apto
r4
dro
ps/
L 7
% s
oln
Dri
nk
QD
E16
12
Iod
op
ho
rA
vian
N/A
To
pic
alP
RN
E11
51U
se 0
.5-1
% s
olu
tio
n f
or
wo
un
d d
ebri
dem
ent
and f
lush
ing
Iodo
ph
or
Avi
anN
/A
To
pic
alN
LE
1240
Fo
r w
oun
ds,
ap
ply
an
d w
ash
off
aft
er 3
min
ute
s, v
ery
safe
Iodo
ph
or
Rap
tor
N/A
To
pic
alN
LE
1400
Fo
r w
oun
ds,
was
h o
ff w
ith
in 5
min
ute
s
Ioh
exo
lA
vian
700-
800
IVN
LE
1182
Use
70-
80%
iodin
e co
nce
ntr
atio
n f
or
uro
grap
hy
Ioh
exo
lC
ock
atie
l24
0P
ON
LG
1623
Iop
am
ido
lA
vian
0.8-
1.2
INN
LG
1270
Use
20%
co
nce
ntr
atio
n, s
inus
con
tras
t st
udy,
flush
wit
h s
alin
e w
hen
co
mp
lete
d
Ipro
nid
azo
leA
vian
0.12
5 g/
LD
rin
kQ
DE
111,
741
Ipro
nid
azo
leP
igeo
n0.
250
g/L
Dri
nk
QD
G59
0C
han
ge d
aily
Ipro
nid
azo
leP
sitt
acin
e0.
232
g/L
PO
NL
E11
1
Iro
n D
extr
an
An
seri
form
es10
IMQ
WD
1150
Fo
r h
emo
po
iesi
s
Iro
n D
extr
anA
vian
10IM
QW
G62
Iro
n D
extr
anP
sitt
acin
e10
IMQ
W-q
10d
E12
40H
emo
po
iesi
s
Iro
n D
extr
anR
apto
r10
IMO
nce
E14
00F
or
iro
n-d
efic
ien
cy a
nem
ia
Iso
flu
ran
eA
vian
N/A
IHP
RN
E14
83M
ain
tain
1.5
-3%
Iso
nia
zid
A
maz
on
, Yel
low
-ch
eeke
d
30
NL
Q
D
G
713
Add e
tham
buto
l + r
ifam
pin
, an
tib
acte
rial
Iso
nia
zid
Avi
an
30
PO
Q
D
D
1470
A
dd e
tham
buto
l +
rif
amp
in, an
tib
acte
rial
Iso
nia
zid
Avi
an
15
PO
B
ID
E
1473 A
nti
par
asit
ic
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 283
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Iso
xu
pri
ne H
Cl
Rap
tor
5-10
PO
QD
E13
59, 1
400
Fo
r w
ing
tip
edem
a
Itra
co
nazo
leA
maz
on
Par
rot
10P
OQ
DA
16D
isso
lve
in 0
.1N
HC
l, dilu
te w
ith
ora
nge
juic
e to
tub
e fe
ed
Itra
con
azo
leA
maz
on
, Blu
e-fr
on
ted
5-10
PO
BID
A17
39C
on
tin
ue
on
ce d
aily
fo
r dura
tio
n o
f th
erap
y
Itra
con
azo
leA
nse
rifo
rmes
5-10
PO
BID
E14
73
Itra
con
azo
leA
nse
rifo
rmes
10P
OQ
DG
708
Itra
con
azo
leA
vian
10P
OQ
DA
577
Itra
con
azo
leA
vian
5-10
NL
BID
E12
39
Itra
con
azo
leB
ird, A
quat
ic20
PO
QD
E15
03F
or
asp
ergi
llosi
s p
rop
hyl
axis
Itra
con
azo
leB
ird, A
quat
ic15
PO
QD
E15
59F
or
asp
ergi
llosi
s p
rop
hyl
axis
Itra
con
azo
leC
hic
ken
10P
OB
IDA
1376
Add m
ico
naz
ole
fo
r ep
ider
mal
Asp
ergi
llus
and
Alte
rnar
ia c
ysts
aft
er s
urg
ical
rem
ova
l
Itra
con
azo
leC
ock
atie
l5
PO
QD
D13
30D
isso
lve
100
mg
cap
sule
2 m
l HC
l + 1
8 m
l
ora
nge
juic
e fo
r ca
ndid
iasi
s
Itra
con
azo
leC
ran
e10
PO
BID
B11
89A
dd e
nro
flo
xaci
n +
clo
trim
azo
le f
or
asp
ergi
llosi
s
Itra
con
azo
leC
ran
e5-
10P
OB
IDE
1361
Itra
con
azo
leE
mu
5-10
PO
QD
G16
Itra
con
azo
leF
alco
n10
-20
PO
QD
G74
6F
or
asp
ergi
llosi
s
Itra
con
azo
leG
ull
5P
OQ
DE
1357
Itra
con
azo
leP
engu
in10
NL
BID
G13
53A
sper
gillo
sis
ther
apy
lon
g-te
rm
Itra
con
azo
leP
igeo
n6
PO
BID
A70
9
Itra
con
azo
leP
igeo
n26
PO
BID
A70
9F
or
resp
irat
ory
dis
ease
, th
is d
osa
ge m
ay b
e
toxi
c
Itra
con
azo
leP
sitt
acin
e10
NL
QD
A14
24F
or
asp
ergi
llosi
s
Itra
con
azo
leP
sitt
acin
e5-
10P
OB
IDD
1446
Fo
r cu
tan
eous
cryp
toco
cco
sis
or
asp
ergi
llosi
s
Itra
con
azo
leR
apto
r5-
10N
LB
IDE
1188
Co
nti
nue
QD
fo
r 4
mo
nth
s fo
r
asym
pto
mat
ic c
ases
of
asp
ergi
llosi
s
Itra
con
azo
leR
apto
r10
PO
BID
G74
2A
dd a
mp
ho
teri
cin
B o
r en
ilco
naz
ole
+ F
10®
for
mild
asp
ergi
llosi
s
Itra
con
azo
leR
atit
e6-
10P
OQ
DG
1308
Red
uce
do
sage
if n
euro
logi
c si
gns
occ
ur
Iverm
ecti
nA
nse
rifo
rmes
0.2
PO
-SC
On
ceD
1150
, 119
0, 1
240
Co
ntr
ol n
emat
odes
an
d n
asal
or
duck
leec
hes
Iver
mec
tin
Avi
an0.
2IM
r10d
E74
1, 9
24
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I284
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Iver
mec
tin
Bir
d, A
quat
ic0.
4-0.
8N
LN
LE
1559
Fo
r p
aras
ites
Iver
mec
tin
Budge
riga
r0.
2T
op
ical
NL
E12
40In
ject
able
fo
rm m
ay b
e to
xic
Iver
mec
tin
Budge
riga
r0.
4IM
-PO
q10
dG
1309
Iver
mec
tin
Bust
ard, H
oub
ara
0.3
PO
On
ceG
932
Iver
mec
tin
Can
ary
0.2
PO
QW
G86
1F
or
air
sac
mit
es a
nd s
caly
leg
mit
es
Iver
mec
tin
Cra
ne
0.2
IM-P
Oq2w
E62
9N
emat
odes
an
d m
ites
Iver
mec
tin
Em
u0.
2SC
NL
G13
08E
ffec
tive
aga
inst
ch
andle
rello
sis
Iver
mec
tin
Fal
con
2-3
IMO
nce
B14
27F
or
serr
ato
s pic
ulia
sis
Iver
mec
tin
Fal
con
1SC
On
ceB
1585
Fo
r ca
pill
aria
sis
Iver
mec
tin
Pas
seri
ne
0.2-
0.4
PO
-To
pic
alQ
WE
1438
Fo
r m
ites
Iver
mec
tin
Pen
guin
0.4-
1P
ON
LE
1478
Fo
r n
emat
odes
Iver
mec
tin
Pig
eon
0.3
SCN
LG
57
Iver
mec
tin
Pig
eon
0.2
PO
NL
G23
2
Iver
mec
tin
Pig
eon
0.5-
1P
aren
tera
l-
PO
NL
G26
0
Iver
mec
tin
Psi
ttac
ine
0.2
IM-P
O-S
Cq2-
4wD
1446
Iver
mec
tin
Rap
tor
0.4
SCN
LG
57
Iver
mec
tin
Rap
tor
0.2
SCO
nce
G23
4
Iver
mec
tin
Rap
tor
0.2
IMN
LG
1409
Fo
r ca
pill
aria
sis
Iver
mec
tin
Rat
ite
0.2
SCN
LG
1308
Iver
mec
tin
Sto
rk, S
addle
-bill
ed0.
2P
OQ
DG
1645
Fo
r m
icro
fila
ria
Kan
am
ycin
Su
lfate
An
seri
form
es20
-40
IMB
IDG
739
Fo
r la
rge
wat
erfo
wl
Kan
amyc
in S
ulf
ate
Avi
an10
-20
IMB
IDE
565
Kan
amyc
in S
ulf
ate
Rat
ite
20-4
0IM
BID
G73
9
Kao
lin
+ P
ecti
nP
sitt
acin
e2
ml/
kgP
OB
ID-Q
IDG
632
Neo
nat
e do
sage
Kao
lin +
Pec
tin
Rap
tor
67 d
rop
s/kg
PO
TID
E16
12F
or
dia
rrh
ea
Keta
min
e H
Cl
Am
azo
n P
arro
t10
-20
IMP
RN
E24
3A
dd x
ylaz
ine
Ket
amin
e H
Cl
An
seri
form
es25
NL
PR
ND
1403
Add d
iaze
pam
, sup
ple
men
t at
15
mg/
kg
PR
N
Ket
amin
e H
Cl
An
seri
form
es10
IVP
RN
D15
03A
dd m
edet
om
idin
e +
mid
azo
lam
,
atip
amez
ole
+ f
lum
azen
il re
vers
es, g
oo
d
anes
thes
ia 3
0 m
inute
s
Ket
amin
e H
Cl
Avi
an5-
25N
LP
RN
C13
92
Ket
amin
e H
Cl
Avi
an10
-30
IMP
RN
E24
3A
dd d
iaze
pam
, hig
her
do
sage
fo
r sm
alle
r b
ird
Ket
amin
e H
Cl
Avi
an20
IMP
RN
E70
4A
dd m
idaz
ola
m
Ket
amin
e H
Cl
Avi
an5-
10IM
PR
NE
704
Add m
edet
om
idin
e
Ket
amin
e H
Cl
Avi
an10
-25
IMP
RN
G53
Add m
idaz
ola
m
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 285
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ket
amin
e H
Cl
Avi
an10
-50
IMP
RN
G53
Add d
iaze
pam
Ket
amin
e H
Cl
Bir
d, A
quat
ic3-
8IM
PR
NE
1503
Add m
edet
om
idin
eK
etam
ine
HC
lB
ird, A
quat
ic2.
5-5
IVP
RN
E15
03A
dd x
ylaz
ine
Ket
amin
e H
Cl
Can
ary
100-
200
IMP
RN
G13
28
Ket
amin
e H
Cl
Cas
sow
ary
2.2
IVP
RN
E15
33A
dd x
ylaz
ine
Ket
amin
e H
Cl
Ch
icke
n20
-100
IMP
RN
G13
28
Ket
amin
e H
Cl
Ch
icke
n4-
5P
aren
tera
lP
RN
G17
18A
dd b
uto
rph
ano
l + m
edet
om
idin
e,
pre
anes
thet
ic f
or
iso
flura
ne
Ket
amin
e H
Cl
Co
ckat
iel
25IM
PR
NE
243
Add x
ylaz
ine
Ket
amin
e H
Cl
Co
ckat
oo
, Pal
m5
IM-S
CP
RN
E92
4Se
dat
ive
Ket
amin
e H
Cl
Duck
, Mal
lard
8.8
IMP
RN
B76
4A
dd m
edet
om
idin
e +
mid
azo
lam
, 33%
mo
rtal
ity
Ket
amin
e H
Cl
Duck
, Pek
in20
IVO
nce
B71
8
Ket
amin
e H
Cl
Em
u3
NL
PR
NC
1392
Tra
nquili
zati
on
Ket
amin
e H
Cl
Em
u2.
2IV
PR
NE
1533
Add x
ylaz
ine
Ket
amin
e H
Cl
Fal
con
, Per
egri
ne
30IV
PR
ND
1401
Add d
iaze
pam
, sup
ple
men
t at
5 m
g/kg
IV
PR
N
Ket
amin
e H
Cl
Fin
ch10
0-20
0IM
PR
NG
1328
Ket
amin
e H
Cl
Gal
lifo
rmes
3P
aren
tera
lP
RN
G17
18A
dd b
uto
rph
ano
l + m
edet
om
idin
e,
pre
anes
thet
ic f
or
iso
flura
ne
Ket
amin
e H
Cl
Go
ose
5-10
IM-I
VP
RN
B15
77A
dd m
edet
om
idin
e
Ket
amin
e H
Cl
Go
ose
20-5
0IM
PR
NG
1328
Ket
amin
e H
Cl
Guin
ea F
ow
l25
IMP
RN
B55
3A
dd x
ylaz
ine
Ket
amin
e H
Cl
Haw
k25
-30
IMP
RN
E24
3A
dd x
ylaz
ine
Ket
amin
e H
Cl
Haw
k4-
5P
aren
tera
lP
RN
G17
18A
dd b
uto
rph
ano
l + m
edet
om
idin
e,
pre
anes
thet
ic f
or
iso
flura
ne,
imp
rove
s qual
ity
of
anes
thes
ia
Ket
amin
e H
Cl
Haw
k, B
road
-win
ged
30-4
0IV
PR
NB
1092
Co
mb
ine
wit
h d
iaze
pam
Ket
amin
e H
Cl
Her
on
20N
LP
RN
G13
56
Ket
amin
e H
Cl
Ost
rich
5IV
PR
NB
555
Add x
ylaz
ine
+ a
lph
axal
on
e/al
ph
ado
lon
e
Ket
amin
e H
Cl
Ost
rich
2IM
PR
NB
1628
Add m
edet
om
idin
e
Ket
amin
e H
Cl
Ow
l10
IM-S
CP
RN
E92
4Se
dat
ive
Ket
amin
e H
Cl
Pel
ican
7IM
PR
NG
595
Ket
amin
e H
Cl
Pig
eon
20IM
PR
NB
779
Fo
llow
wit
h p
rop
ofo
l
Ket
amin
e H
Cl
Pig
eon
5IM
PR
NB
1588
Add m
edet
om
idin
e, u
sual
ly m
oder
ate
to
hea
vy s
edat
ion
Ket
amin
e H
Cl
Po
ult
ry50
IMP
RN
E4
Ket
amin
e H
Cl
Po
ult
ry30
IM-S
CP
RN
E92
4Se
dat
ive
Ket
amin
e H
Cl
Psi
ttac
ine
3-7
IMP
RN
B15
77A
dd m
edet
om
idin
e
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I286
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ket
amin
e H
Cl
Psi
ttac
ine
2-5
IVP
RN
B15
77A
dd m
edet
om
idin
e
Ket
amin
e H
Cl
Psi
ttac
ine
10N
LP
RN
D14
01A
dd d
iaze
pam
, sup
ple
men
t at
5 m
g/kg
PR
N
Ket
amin
e H
Cl
Psi
ttac
ine
3-7
IMP
RN
E64
9A
dd m
edet
om
idin
e
Ket
amin
e H
Cl
Psi
ttac
ine
2.5-
7IV
PR
NE
649
Add m
edet
om
idin
e
Ket
amin
e H
Cl
Psi
ttac
ine
20IM
-SC
PR
NE
924
Sedat
ive
Ket
amin
e H
Cl
Rap
tor
25-3
5IM
PR
NB
1176
Fo
r la
par
osc
op
y
Ket
amin
e H
Cl
Rap
tor
2-4
IVP
RN
B15
77A
dd m
edet
om
idin
e
Ket
amin
e H
Cl
Rap
tor
3-5
IMP
RN
B15
77A
dd m
edet
om
idin
e
Ket
amin
e H
Cl
Rat
ite
3-7
IMP
RN
E4
Add m
edet
om
idin
e
Ket
amin
e H
Cl
Rat
ite
2-4
IVP
RN
E24
3P
roce
ed w
ith
xyl
azin
e
Ket
amin
e H
Cl
Rat
ite
3-20
NL
PR
NE
1386
May
add d
iaze
pam
or
xyla
zin
e if
des
ired
Ket
amin
e H
Cl
Rh
ea6.
6IM
PR
NG
1628
Add b
uto
rph
ano
l + m
edet
om
idin
e
Ket
amin
e H
Cl
Spo
on
bill
20N
LP
RN
G13
56
Ket
amin
e H
Cl
Sto
rk20
NL
PR
NG
1356
Ket
amin
e H
Cl
Swan
4IV
PR
NG
1291
Add m
edet
om
idin
e, g
as a
nes
thes
ia p
rem
ed
Ket
amin
e H
Cl
Swan
, Mute
12.5
IVP
RN
E11
90A
dd x
ylaz
ine
Ket
amin
e H
Cl
Vult
ure
10IM
PR
NB
568
Add x
ylaz
ine
Keto
co
nazo
leA
maz
on
Par
rot
30P
OB
IDB
68
Ket
oco
naz
ole
Am
azo
n, Y
ello
w-n
aped
12.5
PO
BID
G74
0
Ket
oco
naz
ole
Avi
an10
-30
PO
BID
D13
30D
isso
lve
50 m
g ta
ble
t 0.
2 m
l HC
l + 0
.8 m
l
wat
er, m
ix w
ith
aci
d ju
ice,
lact
ulo
se,
met
hyl
cellu
lose
Ket
oco
naz
ole
Avi
an10
-30
PO
BID
D17
43F
or
syst
emic
yea
st
Ket
oco
naz
ole
Bir
d, A
quat
ic25
PO
BID
E15
03F
or
can
did
iasi
s an
d a
sper
gillo
sis
ther
apy
no
t
resp
on
din
g to
nys
tati
n
Ket
oco
naz
ole
Can
ary
0.2
g/kg
so
ft f
oo
dF
eed
QD
D13
30
Ket
oco
naz
ole
Can
ary
0.2
g/L
Dri
nk
QD
E69
5
Ket
oco
naz
ole
Ost
rich
10P
OQ
DG
401
Ket
oco
naz
ole
Pas
seri
ne,
Sm
all
1 g/
LD
rin
kN
LE
1187
Ket
oco
naz
ole
Pas
seri
ne,
Sm
all
0.2
g/kg
fo
od
Fee
dO
nce
E11
87
Ket
oco
naz
ole
Pig
eon
30P
OB
IDA
68
Ket
oco
naz
ole
Pig
eon
3P
OQ
DE
704
Tab
les
crush
ed a
nd w
ater
susp
ensi
on
Ket
oco
naz
ole
Pig
eon
3G
avag
eQ
DE
1240
Fo
r re
sist
ant
can
did
iasi
s, M
ucor
an
d
Pen
icill
ium
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 287
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ket
oco
naz
ole
Psi
ttac
ine
25P
OB
IDE
763
Fo
r ca
ndid
iasi
s o
r ad
jun
ct f
or
asp
ergi
llosi
s
ther
apy,
dis
guis
e ta
ste
in f
oo
d
Ket
oco
naz
ole
Psi
ttac
ine
10P
OB
IDE
1240
Fo
r re
sist
ant
can
did
iasi
s, M
ucor
an
d
Pen
icill
ium
Ket
oco
naz
ole
Rap
tor
15P
OB
IDE
1132
Ket
oco
naz
ole
Rap
tor
25IM
BID
E12
40F
or
resi
stan
t ca
ndid
iasi
s, M
ucor
an
d
Pen
icill
ium
Ket
oco
naz
ole
R
apto
r 60
P
O
BID
E
12
40
"
Ket
oco
naz
ole
Rap
tor
25P
OB
IDE
1359
Ket
oco
naz
ole
Rat
ite
5-10
PO
QD
G13
09
Ket
oco
naz
ole
Swan
12.5
PO
BID
D13
30D
isso
lve
50 m
g ta
ble
t 0.
2 m
l HC
l + 0
.8 m
l
wat
er, m
ix w
ith
aci
d ju
ice,
lact
ulo
se,
met
hyl
cellu
lose
Keto
pro
fen
An
seri
form
es1
IMQ
DD
1150
Fo
r p
ain
rel
ief
or
arth
riti
s
Ket
op
rofe
nA
vian
2IM
NL
D12
40, 1
533
Ket
op
rofe
nA
vian
1-4
IMN
LE
1167
Ket
op
rofe
nD
uck
5IM
NL
B13
39E
ffec
tive
30
to 7
0 m
inute
s, g
iven
duri
ng
iso
flura
ne
anes
thes
ia
Ket
op
rofe
nP
igeo
n1
mg
TD
IM-S
CQ
D-B
IDE
1240
Pai
n r
elie
f, a
rth
riti
s, a
nti
infl
amm
ato
ry
Ket
op
rofe
n
Psi
ttac
ine
2 IM
N
L
E
1240
"
Ket
op
rofe
nQ
uai
l2
PO
NL
B16
74
Lactu
lose
Am
azo
n P
arro
t0.
.07
g T
DP
OB
ID-T
IDG
1309
Fo
r h
epat
ic e
nce
ph
alo
pat
hy
Lac
tulo
seA
vian
0.3
ml/
kgP
ON
LE
1492
Fo
r liv
er d
isea
se
Lac
tulo
seP
sitt
acin
e20
0P
OB
ID-T
IDG
632
Neo
nat
e do
sage
Lasa
locid
Ch
icke
n75
Fee
dQ
DB
958
Fo
r co
ccid
ial p
rop
hyl
axis
Las
alo
cid
Gal
lifo
rmes
90-1
20 g
/to
nF
eed
QD
C70
5F
or
cocc
idia
l pro
ph
ylax
is
Leu
pro
lid
e A
ceta
teA
maz
on
, Yel
low
-nap
ed0.
75-1
Par
ente
ral
q2-
3wG
1033
Dep
ot
form
ula
tio
n
Leu
pro
lide
Ace
tate
Avi
an0.
1IM
NL
D14
75F
or
feat
her
pic
kin
g tr
igge
rin
g b
y ex
cess
ive
beh
avio
r
Leu
pro
lide
Ace
tate
Avi
an0.
5-1
IMq2w
E11
51A
fter
egg
bin
din
g
Leu
pro
lide
Ace
tate
Avi
an0.
1-0.
14P
aren
tera
lN
LE
1474
Tre
at c
hro
nic
egg
layi
ng
Leu
pro
lide
Ace
tate
Avi
an0.
052-
0.15
6IM
NL
E15
70U
se 3
0-day
dep
ot
form
ula
tio
n f
or
egg
chro
nic
egg
layi
ng
Leu
pro
lide
Ace
tate
Avi
an0.
75IM
q2w
G99
4F
or
bir
ds
300
g o
r le
ss
Leu
pro
lide
Ace
tate
Avi
an0.
5IM
q2w
G99
4F
or
bir
ds
mo
re t
han
300
g
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I288
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Leu
pro
lide
Ace
tate
Avi
an0.
75IM
q2w
G12
78In
duce
mo
lt
Leu
pro
lide
Ace
tate
Psi
ttac
ine
0.1
IMQ
DD
1446
Fo
r se
xual
ly-t
rigg
ered
fea
ther
pic
kin
g
Leu
pro
lide
Ace
tate
Rap
tor
0.25
IMq2-
3wE
1359
Fo
r cy
stic
ova
ries
Levam
iso
le H
Cl
An
seri
form
es25
-50
SCO
nce
D11
50, 1
190
Co
ntr
ol n
emat
odes
Lev
amis
ole
HC
lA
vian
2P
OQ
DD
1470
Fo
r liv
er p
aras
itic
dis
ease
Lev
amis
ole
HC
lA
vian
2IM
-SC
q2w
E11
1
Lev
amis
ole
HC
lA
vian
10-2
0P
Oq2w
E70
4
Lev
amis
ole
HC
lA
vian
8IM
-SC
r10d
E74
1N
ot
for
deb
ilita
ted b
irds
or
lori
es, u
se
13.6
5% in
ject
able
Lev
amis
ole
HC
lA
vian
10-2
0P
O-S
Cq2w
E14
34
Lev
amis
ole
HC
lA
vian
5IM
-SC
q2w
E14
73
Lev
amis
ole
HC
lA
vian
0.8
g/L
Dri
nk
QD
E14
79F
or
roun
dw
orm
s, c
ecal
wo
rms
and h
air
wo
rms
Lev
amis
ole
HC
lA
vian
40-5
0P
ON
LE
1492
Fo
r m
ost
wo
rms
Lev
amis
ole
HC
lC
ran
e25
PO
q2w
E13
61C
hic
k do
sage
fo
r in
test
inal
str
on
gyle
s, a
cari
ds
and c
apill
arid
s
Lev
amis
ole
HC
lC
ran
e40
PO
q2w
E13
61F
or
inte
stin
al s
tro
ngy
les,
asc
arid
s an
d
cap
illar
ids
Lev
amis
ole
HC
lF
inch
40-5
0P
ON
LE
1650
Fo
r m
ost
wo
rms
exce
pt
tap
ewo
rm,
par
ticu
larl
y ef
fect
ive
on
acu
aria
in A
ust
ralia
n
fin
ch
Lev
amis
ole
HC
lG
allif
orm
es40
PO
On
ceE
1503
Lev
amis
ole
HC
lG
allif
orm
es40
PO
On
ceE
1526
Lev
amis
ole
HC
lM
agp
ie30
SCN
LG
1609
Lev
amis
ole
HC
lO
stri
ch30
PO
NL
B52
6A
dd r
eso
ran
tel
Lev
amis
ole
HC
lP
arak
eet,
Aust
ralia
n15
Gav
age
q10
dG
1309
Fo
r in
test
inal
nem
ato
des
, use
inje
ctab
le
Lev
amis
ole
HC
lP
hea
san
t25
SCN
LG
678
His
tom
on
iasi
s th
erap
y
Lev
amis
ole
HC
lP
igeo
n15
IMQ
DE
704
Lev
amis
ole
HC
lP
igeo
n0.
18 g
/L
Dri
nk
QD
E70
4
Lev
amis
ole
HC
lP
igeo
n40
PO
On
ceE
1503
Lev
amis
ole
HC
lP
igeo
n40
PO
On
ceE
1526
Lev
amis
ole
HC
lP
igeo
n10
-20
PO
On
ceG
232
Rep
eat
in 2
wee
ks if
nee
ded
Lev
amis
ole
HC
lP
igeo
n40
PO
On
ceG
260
Lev
amis
ole
HC
lP
oult
ry18
-36
PO
On
ceG
1332
Lev
amis
ole
HC
lP
oult
ry1.
25-2
.5P
O-S
CN
LE
111
Lev
amis
ole
HC
lP
sitt
acin
e20
IMr2
wE
763
Em
esis
co
mm
on
Lev
amis
ole
HC
lP
sitt
acin
e20
-50
PO
QD
E12
40L
oft
tre
atm
ent
for
cap
illar
iasi
s an
d a
scar
iasi
s,
follo
w u
p w
ith
par
ente
ral t
her
apy
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 289
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Lev
amis
ole
HC
lP
sitt
acin
e2-
5IM
-SC
q10
dE
1240
Imm
un
ost
imula
nt,
low
th
erap
euti
c in
dex
Lev
amis
ole
HC
lQ
uai
l25
SCN
LG
678
His
tom
on
iasi
s th
erap
y
Lev
amis
ole
HC
lQ
uai
l20
SCN
LG
678
An
thel
min
tic
Lev
amis
ole
HC
lR
apto
r10
-20
PO
-SC
QD
E14
00N
arro
w t
her
apeu
tic
mar
gin
Lev
amis
ole
HC
lR
apto
r15
PO
-SC
NL
E14
63A
nth
elm
inti
c
Lev
amis
ole
HC
lR
apto
r2
SCq4-
6dD
1612
Imm
un
e st
imula
nt
Lev
amis
ole
HC
lR
atit
e30
IM-P
OQ
MG
1308
Beg
in a
t 1
mo
nth
of
age,
juve
nile
do
se f
or
Lib
yast
rong
ylus
dou
glas
si
Lev
amis
ole
HC
lR
atit
e30
IM-P
Oq3m
G13
08A
dult
do
se f
or
Lib
yast
rong
ylus
dou
glas
si
Levo
thyro
xin
e S
od
ium
Avi
an20
ug/
kgP
OQ
D-B
IDE
111
Lev
oth
yro
xin
e So
diu
mA
vian
1IM
-PO
NL
E92
4F
or
seve
re f
eath
er d
iso
rder
s an
d li
po
mas
Lev
oth
yro
xin
e So
diu
mA
vian
20-1
00 u
g/kg
PO
BID
E14
31M
on
ito
r le
vels
to
avo
id t
hyr
oto
xico
sis
Lev
oth
yro
xin
e So
diu
mA
vian
20 u
g/kg
PO
QD
-BID
E14
73
Lev
oth
yro
xin
e So
diu
mA
vian
0.00
08-0
.002
5 g/
LD
rin
kQ
DE
1492
Fo
r go
iter
an
d h
ypo
thyr
oid
ism
Lev
oth
yro
xin
e So
diu
mA
vian
0.02
-0.0
4P
OQ
DG
58
Lev
oth
yro
xin
e So
diu
mA
vian
0.02
PO
QD
-BID
G88
Lev
oth
yro
xin
e So
diu
mB
udge
riga
r0.
004-
0.00
8 g/
LD
rin
kQ
DD
1446
Fo
r lip
om
ato
us
gro
wth
an
d x
anth
om
as
Lev
oth
yro
xin
e So
diu
mB
udge
riga
r0.
003
g/L
Dri
nk
QD
G13
09F
or
hyp
oth
yro
idis
m, s
tir
wat
er a
nd o
ffer
fo
r
15 m
inute
s, r
epea
t dai
ly
Lev
oth
yro
xin
e So
diu
mP
sitt
acin
e0.
020-
0.1
PO
BID
E12
40F
or
hyp
oth
yro
idis
m
Lev
oth
yro
xin
e So
diu
mR
apto
r1
PO
QD
E11
60T
o in
duce
mo
ltin
g
Lid
ocain
eA
vian
2-3
SCN
LB
1346
Lo
cal i
nfi
ltra
tio
n
Lid
oca
ine
Rap
tor
2SC
NL
E14
00D
ilute
to
0.4
%, i
nfu
se lo
cally
, use
wit
h
cauti
on
in s
mal
l bir
ds
Lid
oca
ine
Rap
tor
10SC
NL
E14
63D
ilute
to
0.2
% f
or
larg
e b
ird lo
cal a
nal
gesi
a
Lin
co
mycin
HC
lA
maz
on
Par
rot
75P
OB
IDE
111,
143
1
Lin
com
ycin
HC
lA
vian
50P
OB
IDE
1234
Fo
r b
um
ble
foo
t
Lin
com
ycin
HC
lA
vian
0.2
g/L
Dri
nk
QD
E14
31F
or
infe
cted
fo
ot
lesi
on
s
Lin
com
ycin
HC
lA
vian
100
IMB
IDE
1431
Fo
r in
fect
ed f
oo
t le
sio
ns
Lin
com
ycin
HC
lH
awk
50P
OB
IDG
1110
Th
erap
y p
rio
r to
ten
do
n s
urg
ical
rep
air
Lin
com
ycin
HC
lP
igeo
n25
-50
IMN
LG
260
Lin
com
ycin
HC
lP
igeo
n35
-50
PO
QD
G59
0
Lin
com
ycin
HC
lP
oult
ry2.
2 m
g/kg
fo
od
Fee
dQ
DC
564
Lin
com
ycin
HC
lP
oult
ry0.
017
g/L
Dri
nk
QD
C56
4
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I290
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Lin
com
ycin
HC
lP
sitt
acin
e10
0IM
BID
E12
40F
or
Gra
m p
osi
tive
bum
ble
foo
t, d
erm
atit
is
and m
yco
pla
smal
res
pir
ato
ry in
fect
ion
.
Lin
com
ycin
HC
lR
apto
r11
0P
OQ
DE
741
Fo
r sk
in d
isea
se
Lin
co
mycin
HC
l +
Sp
ecti
no
mycin
HC
l
Avi
an50
PO
QD
E56
5
Lin
com
ycin
HC
l +
Spec
tin
om
ycin
HC
l
Ch
icke
n50
PO
QD
B10
65
Lin
com
ycin
HC
l +
Spec
tin
om
ycin
HC
l
Fal
con
30IM
TID
E10
27B
road
sp
ectr
um
fo
r m
yco
pla
sma
and
salm
on
ella
Lin
com
ycin
HC
l +
Spec
tin
om
ycin
HC
l
Pig
eon
50P
OQ
DF
1061
Lit
hiu
m C
arb
on
ate
Avi
an6-
25N
LB
IDE
1477
Fo
r av
ian
beh
avio
r p
rob
lem
s, m
oo
d s
tab
ilize
r
and a
nti
psy
cho
tic,
no
lon
ger
use
d in
bir
ds
LL
-E19
020
Po
ult
ry0.
01-5
0F
eed
QD
G56
4Im
pro
ves
feed
eff
icie
ncy
Mad
ura
mic
inA
vian
7.5
PO
QD
E16
50F
or
Pla
smod
ium
Mad
ura
mic
inC
hic
ken
5F
eed
QD
B95
8F
or
cocc
idia
l pro
ph
ylax
is
Mag
nesi
um
Su
lfate
An
seri
form
es50
0-10
00P
OQ
DE
1240
Incr
ease
gut
mo
tilit
y an
d a
id p
assa
ge o
f le
ad
Mag
nes
ium
Sulf
ate
Bir
d, A
quat
ic50
0-10
00P
ON
LE
1503
Pre
cip
itat
es le
ad a
nd c
ath
arti
c
Mag
nes
ium
Sulf
ate
Budge
riga
r 53
IM
P
RN
B
10
84
Add c
hlo
ral h
ydra
te +
pen
tob
arb
ital
so
diu
m,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
Mag
nes
ium
Sulf
ate
Can
ary
53
IM
PR
N
B
1084
S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Ch
icke
n
53
IM
PR
N
B
1084
S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Cro
w, E
aste
rn
53
IM
PR
N
B
1084
S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Eag
le, G
old
en
40.3
IM
P
RN
B
10
86 S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Gull
(Her
rin
g, la
ugh
ing) 5
3 IM
P
RN
B
10
84 S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Haw
k, M
arsh
32
.4
IM
PR
N
B
1086
S
ee a
bo
ve
Mag
nes
ium
Sulf
ate
Ost
rich
1.25
-30
ml T
DP
ON
LG
401
Mag
nes
ium
Sulf
ate
Pig
eon
53IM
PR
NB
1084
Add c
hlo
ral h
ydra
te +
pen
tob
arb
ital
so
diu
m,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
Mag
nes
ium
Sulf
ate
Rap
tor
250-
1000
PO
QD
E14
00F
or
ora
l hea
vy m
etal
po
iso
nin
g
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 291
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Mag
nes
ium
Sulf
ate
Rap
tor
500-
1000
PO
QD
E12
40In
crea
se g
ut
mo
tilit
y an
d a
id p
assa
ge o
f le
ad
Mala
thio
nA
vian
1 g/
LT
op
ical
NL
E14
79R
emo
ve b
irds
and t
reat
en
viro
nm
ent
for
flea
,
lice,
man
ge a
nd m
ite
trea
tmen
t an
d a
id in
tic
k
con
tro
l
Mal
ath
ion
Avi
an1
g/L
Dip
NL
E14
79F
or
flea
, lic
e, m
ange
an
d m
ite
trea
tmen
t an
d
aid in
tic
k co
ntr
ol
Mal
ath
ion
Rap
tor
5% m
ixtu
reT
op
ical
q10
dG
1411
Fo
r ch
ewin
g lic
e
Man
nit
ol
Avi
an0.
5IV
QD
E11
1G
ive
slo
wly
Marb
ofl
oxacin
Buzz
ard, C
om
mo
n2
IVB
IDA
778,
142
8
Mar
bo
flo
xaci
nB
uzz
ard, C
om
mo
n10
PO
QD
A97
9
Mar
bo
flo
xaci
nC
hic
ken
2P
OQ
DA
765
Mar
bo
flo
xaci
nR
apto
r10
IM-P
OQ
DE
1433
Mar
bo
flo
xaci
nR
apto
r15
-20
IM-P
OQ
DG
1068
Fo
r si
nusi
tis
Meb
en
dazo
leA
nse
rifo
rmes
5-15
PO
QD
D1,
150,
111
Co
ntr
ol Syn
gam
us
Meb
endaz
ole
Avi
an25
PO
QD
E14
92, 1
650
Fo
r al
l in
test
inal
wo
rms
Meb
endaz
ole
Can
ary
10P
OB
IDG
57A
void
duri
ng
bre
edin
g se
aso
n
Meb
endaz
ole
Fo
wl,
Do
mes
tic
0.06
g/kg
fo
od
Fee
dQ
DE
1051
Meb
endaz
ole
Pig
eon
5-6
PO
QD
G26
0
Meb
endaz
ole
Psi
ttac
ine
25P
OB
IDE
111,
147
3
Meb
endaz
ole
Rap
tor
25P
OB
IDE
111
Meclo
fen
am
ic A
cid
Avi
an2.
2P
OQ
DD
1533
Mec
lofe
nam
ic A
cid
Avi
an2.
2P
OQ
DG
201,
132
0
Mec
lofe
nam
ic A
cid
Avi
an2.
2P
OQ
DE
1573
Mec
lofe
nam
ic A
cid
Bir
d, A
quat
ic2.
2P
OQ
DE
1503
Med
eto
mid
ine H
Cl
Am
azo
n, Y
ello
w-c
row
ned
2IM
PR
NB
1629
Sedat
ion
pro
duce
d n
ot
relia
ble
, rev
erse
wit
h
atip
amez
ole
Med
eto
mid
ine
HC
lA
nse
rifo
rmes
0.05
IVP
RN
D15
03A
dd k
etam
ine
+ m
idaz
ola
m
Med
eto
mid
ine
HC
lA
nse
rifo
rmes
0.6-
0.85
IMP
RN
E12
31A
dd k
etam
ine
Med
eto
mid
ine
HC
lA
nse
rifo
rmes
0.06
Par
ente
ral
PR
NG
1718
Add b
uto
rph
ano
l + k
etam
ine,
pre
anes
thet
ic
for
iso
flura
ne
Med
eto
mid
ine
HC
lA
vian
0.1
IMN
LG
704,
132
0
Med
eto
mid
ine
HC
lB
ird, A
quat
ic0.
025-
0.07
5IV
PR
NE
1503
Add k
etam
ine,
rev
erse
wit
h a
tip
amez
ole
Med
eto
mid
ine
HC
lB
ird, A
quat
ic0.
05-0
.1IM
PR
NE
1503
Add k
etam
ine,
rev
erse
wit
h a
tip
amez
ole
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I292
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Med
eto
mid
ine
HC
lC
asso
war
y, D
oub
le-w
attl
ed0.
26-0
.31
IMP
RN
B12
29F
or
rest
rain
t o
f ca
pti
ve b
irds
Med
eto
mid
ine
HC
lC
hic
ken
0.1
IMP
RN
E15
73Se
dat
ion
Med
eto
mid
ine
HC
lC
hic
ken
0.06
-0.0
8P
aren
tera
lP
RN
G17
18A
dd b
uto
rph
ano
l + k
etam
ine,
pre
anes
thet
ic
for
iso
flura
ne
Med
eto
mid
ine
HC
lD
uck
, Mal
lard
0.44
IMP
RN
B76
4A
dd k
etam
ine
+ m
idaz
ola
m, 3
3% m
ort
alit
y
Med
eto
mid
ine
HC
lG
oo
se0.
1-0.
2IM
-IV
PR
NB
1577
Add k
etam
ine
Med
eto
mid
ine
HC
lH
awk
0.06
-0.0
8P
aren
tera
lP
RN
G17
18A
dd b
uto
rph
ano
l + k
etam
ine
Med
eto
mid
ine
HC
lO
stri
ch0.
08IM
PR
NB
1628
Add k
etam
ine
Med
eto
mid
ine
HC
lO
stri
ch0.
1IM
PR
NE
1573
Sedat
ion
Med
eto
mid
ine
HC
lP
igeo
n0.
.08
IMP
RN
B15
88A
dd k
etam
ine,
usu
ally
mo
der
ate
to h
eavy
sedat
ion
Med
eto
mid
ine
HC
lP
igeo
n0.
2IM
PR
NB
1588
Var
iab
le li
ght
sedat
ion
Med
eto
mid
ine
HC
lP
sitt
acin
e0.
075-
0.15
IMP
RN
B15
77A
dd k
etam
ine
Med
eto
mid
ine
HC
lP
sitt
acin
e0.
05-0
.1IV
PR
NB
1577
Add k
etam
ine
Med
eto
mid
ine
HC
lP
sitt
acin
e0.
06-0
.085
IMP
RN
E12
40A
dd k
etam
ine
Med
eto
mid
ine
HC
lR
apto
r0.
1-0.
3IM
NL
E14
00C
an b
e re
vers
ed, c
om
bin
ed w
ith
ket
amin
e fo
r
anes
thes
ia
Med
eto
mid
ine
HC
lR
apto
r0.
025-
0.07
5IV
PR
NB
1577
Add k
etam
ine
Med
eto
mid
ine
HC
lR
apto
r0.
05-0
.1IM
PR
NB
1577
Add k
etam
ine
Med
eto
mid
ine
HC
lR
apto
r0.
15-0
.35
IMP
RN
E12
40A
dd k
etam
ine
Med
eto
mid
ine
HC
lR
apto
r0.
2N
LP
RN
E14
33A
dd k
etam
ine,
rev
erse
wit
h a
tip
amez
ole
Med
eto
mid
ine
HC
lR
atit
e0.
05-0
.15
IMP
RN
E4
Add k
etam
ine
Med
eto
mid
ine
HC
lR
hea
0.73
IMP
RN
G16
28A
dd b
uto
rph
ano
l + k
etam
ine
Med
eto
mid
ine
HC
lSw
an0.
15IV
PR
NG
1291
Add k
etam
ine,
gas
an
esth
esia
pre
med
Med
roxyp
rog
est
ero
ne
Aceta
te
Lo
wer
do
se f
or
larg
er b
irds.
Si
de
effe
cts:
leth
argy
, in
app
etan
ce, p
oly
dip
sia,
fat
ty li
ver
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an25
IM-S
CQ
DE
111
Fo
r 70
0 g
bir
d
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an40
IM-S
CQ
DE
111
Fo
r 15
0 to
300
g b
ird
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an50
IM-S
CQ
DE
111
Fo
r <
150
g b
ird
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an30
IM-S
CQ
DE
111
Fo
r 30
0 to
700
g b
ird
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an5-
25IM
-SC
QD
E11
1
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 293
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an5-
10IM
-SC
NL
E70
4F
or
per
sist
ent
egg
layi
ng
Med
roxy
pro
gest
ero
ne
Ace
tate
Avi
an2-
10P
O-S
CQ
WE
924
Rep
eat
afte
r 4
mo
nth
s fo
r o
vula
tio
n
sup
pre
ssio
n
Med
roxy
pro
gest
ero
ne
Ace
tate
Psi
ttac
ine
25-5
0IM
-SC
q4-
6wE
1240
Lo
wer
do
se f
or
larg
er b
irds.
Si
de
effe
cts:
leth
argy
, in
app
etan
ce, p
oly
dip
sia,
fat
ty li
ver
Mefl
oq
uin
e H
Cl
Pas
seri
ne
30P
OP
RN
E14
38G
ive
BID
on
day
1, g
ive
dai
ly o
n d
ays
2 an
d
3 an
d o
nce
per
wee
k
Meg
est
rol
Aceta
teA
vian
2.5
NL
QD
E14
31T
hen
co
nti
nue
q3-
4d f
or
feat
her
pic
kin
g w
ith
ho
rmo
nal
eti
olo
gy
Meg
estr
ol A
ceta
teC
ock
ato
o, R
ose
-bre
aste
d0.
2 g/
LD
rin
kN
LG
1609
Fo
r se
lf-m
uti
lati
on
Meg
estr
ol A
ceta
teC
ock
ato
o, R
ose
-bre
aste
d0.
2 g/
kg f
oo
dF
eed
On
ceG
1609
Fo
r se
lf-m
uti
lati
on
Melo
xic
am
Avi
an0.
1IM
-PO
QD
E11
67, 1
431
Mel
oxi
cam
Avi
an0.
1-0.
2IM
QD
E14
31L
on
g co
urs
e w
ell t
ole
rate
d
Mel
oxi
cam
Avi
an0.
1 -
1.0
PO
QD
G13
41
Mel
oxi
cam
Avi
an0.
1N
LQ
DG
1484
Mel
oxi
cam
Avi
an0.
1P
OQ
DG
1671
, 167
5
Mel
oxi
cam
Avi
an0.
1P
OQ
DE
1431
Lo
ng
cours
e w
ell t
ole
rate
d
Mel
oxi
cam
Cra
ne
0.5
PO
BID
G13
41
Mel
oxi
cam
Rap
tor
0.1-
0.2
IM-P
OQ
DE
1400
Fo
r ar
thri
tis
and o
ther
pai
nfu
l co
ndit
ion
s
Mel
oxi
cam
Rap
tor
0.1
IM-P
OQ
DE
1359
, 143
3
Mep
eri
din
e H
Cl
Rap
tor
3-5
NL
QID
G14
81
Mep
erid
ine
HC
lR
apto
r3-
5N
LN
LG
1483
, 148
4
Metf
orm
in (
glu
co
ph
ag
e)
Avi
an
100
mg/
L w
ater
D
rin
k Q
D
G
T. L
igh
tfo
ot,
2005 H
yper
glyc
emia
Meth
ocarb
am
ol
Avi
an50
IVN
LG
201
Meth
oh
exit
al
So
diu
mC
hic
ken
5-10
IVP
RN
G49
7
Met
ho
hex
ital
So
diu
mD
ove
5 g/
L b
ait
Fee
dO
nce
G17
63C
orn
is u
sual
bai
t
Met
ho
hex
ital
So
diu
mD
uck
5-10
IVP
RN
G49
8
Met
ho
hex
ital
So
diu
mG
oo
se5-
10IV
PR
NG
498
Met
ho
hex
ital
So
diu
mP
oult
ry4-
8IV
PR
NG
496
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I294
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Meth
op
ren
eR
apto
r0.
02 g
/L
To
pic
alN
LE
1068
Add p
erm
eth
rin
+ p
iper
on
yl b
uto
xide
for
ecto
par
asit
es
Meth
ylp
red
nis
olo
ne
Aceta
te
Avi
an0.
5-1
IA-I
MN
LD
1533
Met
hyl
pre
dn
iso
lon
e A
ceta
teB
ird, A
quat
ic0.
5-1
IA-I
MN
LE
1503
Met
hyl
pre
dn
iso
lon
e A
ceta
teR
apto
r5
IMQ
WE
1463
Meth
ylp
red
nis
olo
ne
So
diu
m S
uccin
ate
Avi
an0.
5-1
IM-I
VN
LD
1554
Fo
r sh
ock
Meto
clo
pra
mid
e H
Cl
Avi
an0.
3IM
-IV
-PO
NL
E11
1
Met
ocl
op
ram
ide
HC
lA
vian
0.5
IMB
ID-T
IDE
1151
To
imp
rove
mo
tilit
y, t
his
do
sage
no
t fo
r
mac
aws
Met
ocl
op
ram
ide
HC
lA
vian
0.5
IM-I
V-P
ON
LE
1473
Met
ocl
op
ram
ide
HC
lA
vian
0.5
Par
ente
ral
NL
E16
50In
crea
se g
astr
ic m
oti
lity
Met
ocl
op
ram
ide
HC
lH
awk,
Red
-tai
led
0.5
IMN
LG
1626
Sup
po
rtiv
e th
erap
y p
ost
-tra
um
a
Met
ocl
op
ram
ide
HC
lL
ori
keet
, Rai
nb
ow
0.5
SCB
IDG
1620
Fo
r vo
mit
ing
Met
ocl
op
ram
ide
HC
lM
acaw
0.1
IM-P
ON
LE
1151
To
imp
rove
mo
tilit
y- U
se lo
w d
ose
Met
ocl
op
ram
ide
HC
lO
stri
ch0.
1IV
NL
G12
55A
dd p
sylli
um
fo
r p
rove
ntr
icula
r o
bst
ruct
ion
Met
ocl
op
ram
ide
HC
lP
sitt
acin
e0.
5IM
-IV
-PO
TID
E12
40A
nti
emet
ic a
nd f
or
gut
stas
is
Met
ocl
op
ram
ide
HC
lP
sitt
acin
e0.
5N
LB
IDG
1263
Fo
r ile
us
Met
ocl
op
ram
ide
HC
lR
apto
r0.
5-2
IM-S
Cq4-
6hE
1359
Fo
r ga
stro
inte
stin
al s
tasi
s
Meto
mid
ate
HC
lA
vian
10IM
PR
NE
1130
Met
om
idat
e H
Cl
Duck
, Mal
lard
17P
OP
RN
B10
95
Met
om
idat
e H
Cl
Eag
le, A
fric
an H
awk
15.2
IMP
RN
G16
11
Met
om
idat
e H
Cl
Eag
le, T
awn
y9.
6IM
PR
NG
1611
Met
om
idat
e H
Cl
Haw
k, A
fric
an H
arri
er14
.4-1
6IM
PR
NG
1611
Met
om
idat
e H
Cl
Ost
rich
15-2
0IM
PR
NG
481
Wit
h o
r w
ith
out
azap
ero
ne
for
cap
tive
an
imal
Met
om
idat
e H
Cl
Ow
l, B
arn
10.2
IMP
RN
G16
11
Met
om
idat
e H
Cl
Rap
tor
10IM
PR
NE
1463
Smal
ler
do
sage
s fo
r vu
lture
s
Met
om
idat
e H
Cl
Rap
tor
5IM
PR
NE
1463
Fo
r se
dat
ion
Met
om
idat
e H
Cl
Turk
ey17
g/L
wh
ole
co
rnF
eed
On
ceE
1386
Safe
r th
an c
hlo
ralo
se
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 295
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Metr
on
idazo
leA
vian
25P
OB
IDD
1221
Fo
r cl
ost
ridio
sis
Met
ron
idaz
ole
Avi
an25
-50
PO
QD
E70
4, 9
24
Met
ron
idaz
ole
Avi
an0.
2 g/
LD
rin
kN
LE
1180
Met
ron
idaz
ole
Avi
an50
PO
NL
E14
34
Met
ron
idaz
ole
Avi
an5
IMB
IDE
1434
Met
ron
idaz
ole
Avi
an10
-30
PO
BID
E16
50F
or
anae
rob
ic in
fect
ion
s
Met
ron
idaz
ole
Avi
an10
IMQ
DE
1650
Fo
r an
aero
bic
infe
ctio
ns
Met
ron
idaz
ole
Avi
an50
PO
QD
G55
Met
ron
idaz
ole
Avi
an20
PO
-SC
QD
C70
5F
or
tric
ho
mo
nia
sis
Met
ron
idaz
ole
Avi
an10
-30
PO
BID
D14
70F
or
liver
par
asit
ic d
isea
se
Met
ron
idaz
ole
Avi
an10
IMQ
DD
1470
Fo
r liv
er p
aras
itic
dis
ease
Met
ron
idaz
ole
Can
ary
0.1
g/kg
fo
od
Fee
dO
nce
E11
87
Met
ron
idaz
ole
Ch
icke
n30
PO
BID
A79
5
Met
ron
idaz
ole
Fal
con
50P
OQ
DE
1027
Fo
r tr
ich
om
on
iasi
s
Met
ron
idaz
ole
Ost
rich
1.25
g/L
Dri
nk
QD
E62
7A
nti
his
tom
on
iasi
s
Met
ron
idaz
ole
Pas
seri
ne
0.1
g/L
Dri
nk
QD
E14
37A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e
Met
ron
idaz
ole
Pas
seri
ne
0.1
g/kg
so
ft f
oo
dF
eed
QD
E14
37A
dd d
rug
to d
rin
k at
th
e sa
me
tim
e
Met
ron
idaz
ole
Pig
eon
200
PO
QD
E70
4
Met
ron
idaz
ole
Pig
eon
200-
250
PO
QD
G26
0
Met
ron
idaz
ole
Po
ult
ry20
Dri
nk
QD
C70
5
Met
ron
idaz
ole
Po
ult
ry11
0P
OB
IDG
585
Met
ron
idaz
ole
Psi
ttac
ine
10-3
0P
OB
IDE
111,
147
3
Met
ron
idaz
ole
Psi
ttac
ine
25P
OB
IDE
763
Met
ron
idaz
ole
Rap
tor
30-5
0P
OQ
DE
1359
Fo
r tr
ich
om
on
iasi
s, m
ay in
crea
se d
osa
ge t
o
100
mg/
kg
Met
ron
idaz
ole
Rap
tor
50P
OQ
DE
1400
, 143
3F
or
tric
ho
mo
nia
sis
Met
ron
idaz
ole
Rap
tor
100
PO
NL
E14
63F
or
tric
ho
mo
nia
sis
Met
ron
idaz
ole
Rap
tor
50P
OQ
DG
61, 2
34
Met
ron
idaz
ole
Rap
tor
10-4
0P
OQ
DG
94Ju
ven
ile d
osa
ge
Met
ron
idaz
ole
Rap
tor
100
PO
QD
G10
68
Met
ron
idaz
ole
Rap
tor
30-6
5P
OQ
DG
1409
Fo
r tr
ich
om
on
iasi
s
Met
ron
idaz
ole
Rat
ite
20-2
5P
OB
IDG
1308
Fo
r an
aero
bic
infe
ctio
ns
Met
ron
idaz
ole
Sto
rk, S
addle
-bill
ed42
PO
BID
G16
45A
dd a
mik
acin
+ e
nro
flo
xaci
n
Mic
on
azo
le N
itra
teA
maz
on
, Red
Lo
red
2 m
gN
ebuliz
eQ
DG
700
Add a
cety
lcys
tein
e
Mic
on
azo
le N
itra
teA
vian
20IV
TID
D13
30
Mic
on
azo
le N
itra
teA
vian
10-2
0IM
QD
E56
5
Mic
on
azo
le N
itra
teA
vian
20IM
NL
E92
4F
or
can
did
iasi
s, A
sper
gillu
s, M
ucor
an
d
Pen
icill
ium
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I296
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Mic
on
azo
le N
itra
teA
vian
40IV
NL
E92
4F
or
can
did
iasi
s, A
sper
gillu
s, M
ucor
and
Pen
icill
ium
Mic
on
azo
le N
itra
teF
alco
ncr
eam
To
pic
alB
IDG
1589
Mic
on
azo
le N
itra
teP
sitt
acin
e20
IM-I
VQ
DE
704
Mic
on
azo
le N
itra
teR
apto
r10
IM-I
VQ
DE
704
Mid
azo
lam
HC
lA
nse
rifo
rmes
2IV
PR
ND
1503
, 153
3A
dd k
etam
ine
+ m
edet
om
idin
e
Mid
azo
lam
HC
l A
nse
rifo
rmes
1-
2 IV
P
RN
E
15
03
"
Mid
azo
lam
HC
l A
vian
1-
2 IM
-IV
N
L
E
1573
"
Mid
azo
lam
HC
lA
vian
1IM
NL
G20
1
Mid
azo
lam
HC
lA
vian
1-2
IM-I
VN
LG
1320
Use
wit
h a
n a
nal
gesi
c fo
r p
ain
co
ntr
ol
Mid
azo
lam
HC
lA
vian
4IM
PR
NE
704
Add k
etam
ine
Mid
azo
lam
HC
lA
vian
0.2
IMP
RN
E11
81, 1
231
Add k
etam
ine,
sm
oo
th in
duct
ion
an
d
reco
very
Mid
azo
lam
HC
lD
uck
, Mal
lard
4IM
On
ceG
1468
Pre
-gas
an
esth
esia
Mid
azo
lam
HC
lE
mu
0.4
IVP
RN
G41
8
Mid
azo
lam
HC
lO
stri
ch0.
15IV
PR
NG
418
Mid
azo
lam
HC
lP
hea
san
t, R
ing-
nec
ked
1IM
PR
NG
1644
An
esth
esia
pre
med
Mid
azo
lam
HC
lP
igeo
n0.
5IM
PR
NB
1588
Add m
edet
om
idin
e, u
sual
ly m
oder
ate
to
hea
vy s
edat
ion
Mid
azo
lam
HC
lP
igeo
n2
IMP
RN
G16
44A
dd g
lyco
pyr
rola
te f
or
anes
thes
ia p
rem
ed,
reve
rse
wit
h f
lum
azen
il
Mid
azo
lam
HC
lP
sitt
acin
e0.
2IM
-SC
PR
NE
1240
Use
in c
om
bin
atio
n w
ith
ket
amin
e
Mid
azo
lam
HC
lR
apto
r0.
5-1
IM-I
VT
IDE
1240
, 140
0C
on
tro
l sei
zure
s
Mid
azo
lam
HC
lSw
an0.
1-1
NL
PR
NG
1291
May
add b
uto
rph
ano
l, p
rem
ed f
or
gas
anes
thes
ia, l
ow
er d
osa
ge if
add b
uto
rph
ano
l
Mid
azo
lam
HC
l T
urk
ey
0.1-
1 N
L
PR
N
G
1291
"
Mil
bem
ycin
Oxim
eG
allif
orm
es2
PO
QM
B58
8
Milb
emyc
in O
xim
eG
allif
orm
es2
PO
NL
E14
92, 1
650
Fo
r H
eter
akis
, C
apill
aria
an
d a
scar
ids
Mil
k T
his
tle
Am
azo
n P
arro
t2
dro
ps
mix
ture
TD
PO
BID
G14
88M
ixtu
re is
5 d
rop
s ex
trac
t p
er 7
.5 m
l
lact
ulo
se, u
sefu
l fo
r tr
eati
ng
bir
ds
on
all
seed
die
t
Min
era
l O
ilA
vian
5 m
l/kg
Gav
age
On
ceE
1309
, 155
4T
o f
lush
GI
- la
xati
ve
Min
ocycli
ne H
Cl
Budge
riga
r5.
5 g/
kg s
eed
Fee
dQ
DA
731
Hulle
d m
edic
ated
mill
et,
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 297
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Min
ocy
clin
e H
Cl
Haw
k, R
ed-s
ho
uld
ered
5P
OB
IDG
1179
Add le
vam
iso
le +
Sta
phyl
ococ
cus
toxo
id f
or
bum
ble
foo
t
Mip
ora
mic
inP
oult
ry0.
1 g/
kgF
eed
QD
G56
4
Mo
nen
sin
So
diu
mC
hic
ken
0.1
g/kg
Fee
dQ
DB
869
Pre
ven
tive
fo
r co
ccid
iosi
s
Mo
nen
sin
So
diu
mC
hic
ken
100
Fee
dQ
DB
958
Fo
r co
ccid
ial p
rop
hyl
axis
Mo
nen
sin
So
diu
mC
hic
ken
100-
120
g/to
nF
eed
QD
C70
5F
or
cocc
idio
sis
Mo
nen
sin
So
diu
mC
ran
e0.
099
g/kg
fo
od
Fee
dO
nce
E11
1
Mo
nen
sin
So
diu
mG
allif
orm
es0.
099
g/kg
fo
od
Fee
dQ
DE
1473
Mo
nen
sin
So
diu
mP
igeo
n1-
1.2
g/kg
fee
dF
eed
On
ceE
1492
Fo
r co
ccid
iosi
s
Mo
nen
sin
So
diu
mP
igeo
n1-
1.2
g/kg
fo
od
Fee
dQ
DE
1650
Fo
r co
ccid
ia
Mo
nen
sin
So
diu
mT
urk
ey90
-100
g/to
nF
eed
QD
C70
5F
or
cocc
idio
sis
Mo
rph
ine S
ulf
ate
Gal
lifo
rmes
2.5-
3IM
-SC
NL
E11
1, 1
473
Mo
xid
ecti
nA
vian
0.2-
0.8
NL
On
ceD
1221
Fo
r ca
pill
aria
sis
Mo
xidec
tin
Car
din
al, R
ed-c
rest
ed0.
2P
ON
LG
1585
Fo
r ca
pill
aria
sis
Mo
xidec
tin
Fal
con
1P
OQ
WG
1068
Fo
r Ser
rato
spicul
um, C
apill
aria
, Phy
slao
pter
a an
d
Aca
ntho
ceph
alae
Mo
xidec
tin
Fin
ch2
PO
NL
E14
79F
or
lice,
mit
es a
nd n
emat
odes
Mo
xidec
tin
Pen
guin
0.2
PO
NL
E14
78F
or
nem
ato
des
Mo
xidec
tin
Pig
eon
0.25
mg
TD
PO
NL
D14
79F
or
lice,
mit
es a
nd n
emat
odes
Mo
xidec
tin
Psi
ttac
ine
0.2
Gav
age
On
ceD
1479
Fo
r lic
e, m
ites
an
d n
emat
odes
Mo
xidec
tin
Rap
tor
0.2
PO
QD
E13
59F
or
cap
illar
iasi
s
Mo
xidec
tin
Spar
row
haw
k0.
2SC
NL
G15
85F
or
nem
ato
dia
sis
Mu
llein
Avi
an10
dro
ps/
kgP
OT
IDE
1205
Res
pir
ato
ry, w
oun
d s
up
po
rt
Myco
bacte
riu
m V
accae
Vaccin
e
Cra
ne,
Wh
oo
pin
g0.
05 m
l TD
IDq2m
G20
7
Nalb
up
hin
e H
Cl
Guin
ea F
ow
l1-
2IM
q3h
G25
2
Nalo
xo
ne H
Cl
Avi
an0.
05-0
.25
IM-I
VP
RN
E15
73
Nal
oxo
ne
HC
lP
sitt
acin
e0.
05-0
.25
IM-I
VN
LG
1320
Use
slo
w I
V
Nal
oxo
ne
HC
lR
atit
e0.
05-0
.067
NL
PR
NG
418
Nalt
rexo
ne H
Cl
Avi
an1.
5D
rin
kN
LE
704
Beh
avio
r m
odif
icat
ion
, fea
ther
pic
kin
g
Nal
trex
on
e H
Cl
Ost
rich
300
mg
TD
IVP
RN
B52
1R
ever
se c
arfe
nta
nil
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I298
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Nal
trex
on
e H
Cl
Psi
ttac
ine
1.5
PO
BID
E12
40P
reve
nt
self
-muti
lati
on
Nan
dro
lon
eP
sitt
acin
e0.
4IM
-SC
q3w
E12
40F
or
chro
nic
an
d d
ebili
tati
ng
dis
ease
, may
cause
live
r dis
ease
Nan
dro
lon
e R
apto
r 0.
4 IM
-SC
q3w
E
12
40
"
Nara
sin
Ch
icke
n70
Fee
dQ
DB
958
Fo
r co
ccid
ial p
rop
hyl
axis
Nar
asin
Ch
icke
n60
-80
mg/
kg f
oo
dF
eed
QD
E56
4A
dd n
icar
baz
in, 5
-day
sla
ugh
ter
wit
hdra
wal
,
pro
ph
ylac
tic
Neo
mycin
Su
lfate
Avi
an1.
25 g
/L
Dri
nk
NL
E11
1
Neo
myc
in S
ulf
ate
Avi
an10
PO
QD
E56
5
Neo
myc
in S
ulf
ate
Avi
an20
PO
NL
E92
4G
ram
neg
ativ
e, p
oo
r ab
sorp
tio
n
Neo
myc
in S
ulf
ate
Ch
icke
n11
Dri
nk
BID
C13
07F
or
bac
teri
al e
nte
riti
s
Neo
myc
in S
ulf
ate
Ch
icke
n.0
77-.
154
g/kg
fo
od
Fee
dQ
DC
1307
Fo
r b
acte
rial
en
teri
tis
Neo
myc
in S
ulf
ate
Duck
.077
-.15
4 g/
kg f
oo
dF
eed
QD
C13
07F
or
bac
teri
al e
nte
riti
s
Neo
myc
in S
ulf
ate
Duck
11D
rin
kB
IDG
1307
Fo
r b
acte
rial
en
teri
tis
Neo
myc
in S
ulf
ate
Pas
seri
ne
0.2
g/kg
so
ft f
oo
dF
eed
QD
E14
37A
dd d
rug
to d
rin
k at
th
e sa
me
tim
e
Neo
myc
in S
ulf
ate
Pas
seri
ne
0.2
g/L
Dri
nk
QD
E14
37A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e
Neo
myc
in S
ulf
ate
Po
ult
ry0.
035-
0.08
g/L
Dri
nk
QD
C56
4P
rop
hyl
acti
c
Neo
myc
in S
ulf
ate
Po
ult
ry38
.5-1
54 m
g/kg
fo
od
Fee
dQ
DC
564
Neo
myc
in S
ulf
ate
Po
ult
ry11
PO
QD
C56
4
Neo
myc
in S
ulf
ate
Rap
tor
15P
ON
LE
1463
Fo
r b
acte
rial
infe
ctio
ns
Neto
bim
inA
vian
0.03
5-0.
08 g
/L
Dri
nk
QD
E14
92F
or
tap
ewo
rms,
asc
arid
s an
d H
eter
akis
Net
ob
imin
Bir
d, A
quat
ic0.
35 g
/L
Dri
nk
QD
E15
03
Net
ob
imin
Rap
tor
20P
OQ
DB
1568
Nic
arb
azin
Ch
icke
n20
-50
mg/
kg f
oo
dF
eed
QD
E56
4A
dd n
aras
in, 5
-day
sla
ugh
ter
wit
hdra
wal
,
pro
ph
ylac
tic
Nic
losa
mid
eA
vian
50P
Oq2w
E11
1
Nic
losa
mid
eA
vian
150-
250
PO
NL
G57
Nic
losa
mid
eA
vian
5 g/
kg f
oo
dF
eed
QD
G57
Nic
losa
mid
eC
ran
e25
0N
Lq2w
G59
6
Nic
losa
mid
eF
alco
n20
0P
OO
nce
E10
27F
or
tap
ewo
rms
Nic
losa
mid
eF
inch
500
Fee
dQ
WE
111
Nic
losa
mid
eO
stri
ch10
0P
Oq6w
G40
1
Nic
losa
mid
eO
stri
ch50
PO
NL
G48
1
Nic
losa
mid
eP
elic
an, B
row
n10
3-16
0P
OO
nce
B10
89
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 299
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Nic
losa
mid
eP
igeo
n75
PO
NL
G57
Nic
losa
mid
eR
apto
r15
6P
OO
nce
D16
12F
or
cest
odia
sis
Nic
losa
mid
eR
apto
r12
5P
ON
LE
1068
Fo
r ce
sto
des
Nif
urs
ol
Po
ult
ry77
mg/
kg f
oo
dF
eed
QD
C56
4P
rop
hyl
acti
c
Nif
urs
ol
Turk
ey75
mg/
kg f
oo
dF
eed
QD
E56
4N
utr
itio
nal
use
, 5-d
ay s
laugh
ter
wit
hdra
wal
Nif
urs
ol
Turk
ey50
g/to
nF
eed
QD
C70
5F
or
his
tom
on
iasi
s
Nit
hia
mid
eR
apto
r40
PO
NL
E14
63F
or
tric
ho
mo
nia
sis
Nit
rofu
razo
ne
Avi
an1.
25 m
l/L
Dri
nk
QD
E74
1F
or
cocc
idia
l in
fect
ion
s
Nit
rofu
razo
ne
Ch
icke
n55
mg/
kg f
oo
dF
eed
QD
E56
45-
day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Nit
rofu
razo
ne
Lo
rike
et
0.62
5 cc
/L
D
rin
k N
L
E
111
Do
sage
bas
ed o
n 9
.2%
po
wder
Nit
rofu
razo
ne
Po
ult
ry
55 m
g/kg
fo
od
Fee
d
QD
C
56
4
Nit
rofu
razo
ne
Psi
ttac
ine
1.25
cc/
LD
rin
kN
LE
111
Do
sage
bas
ed o
n 9
.2%
po
wder
Nit
rom
ide
Ch
icke
n25
0 m
g/kg
fo
od
Fee
dQ
DE
564
Add s
ulf
anit
ran
+ r
oxa
rso
ne,
5-d
ay s
laugh
ter
wit
hdra
wal
Nit
roxin
ilG
allif
orm
es24
Dri
nk
QD
C70
6F
or
gap
ewo
rms
No
rdih
yd
roq
uaia
reti
cA
vian
2 dro
ps/
kgP
OB
IDE
1205
Use
wit
h c
auti
on
in e
gg la
yers
or
w/ h
epat
ic
dis
ease
No
rflo
xacin
Ch
icke
n10
PO
BID
A78
9
No
rflo
xaci
nC
hic
ken
8P
OQ
DA
830
No
rflo
xaci
nC
hic
ken
20-4
0D
rin
kN
LA
840
Fo
r H
emop
hilu
s pa
raga
llina
rum
in
fect
ion
.
No
rflo
xaci
nG
oo
se10
PO
BID
A78
9
No
rflo
xaci
nO
stri
ch30
Dri
nk
QD
G56
2
No
rflo
xaci
nP
oult
ry8
PO
QD
G56
4
No
rflo
xaci
nT
urk
ey10
PO
QID
A78
9
No
rflo
xaci
nT
urk
ey10
SCQ
DA
1020
No
rtri
pty
lin
e H
Cl
Psi
ttac
ine
0.01
6 g/
LD
rin
kN
LE
111
Co
ntr
ol f
eath
er p
icki
ng
No
sih
ep
tid
eC
hic
ken
5-10
mg/
kgF
eed
QD
G56
4Im
pro
ves
feed
eff
icie
ncy
No
vo
bio
cin
So
diu
mA
nse
rifo
rmes
385
mg/
kg f
oo
dF
eed
On
ceG
597
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I300
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
No
vob
ioci
n S
odiu
mD
uck
, Pek
in0.
3 g/
kg f
oo
dF
eed
On
ceB
984
Pro
ph
ylax
is f
or
Pas
teur
ella
mul
tocida
in
duck
lings
.
Nyst
ati
nA
nse
rifo
rmes
300
KIU
/kg
PO
BID
D11
50F
or
can
did
iasi
s
Nys
tati
n
Avi
an
200
KIU
/kg
F
eed
QD
E
70
4 So
ft f
oo
d
Nys
tati
n
Avi
an
0.05
g/kg
fo
od
PO
N
L
E
924
Fo
r ca
ndid
iasi
s
Nys
tati
n
Avi
an
300
KIU
/kg
P
O
BID
E
12
21 F
or
can
did
iasis
Nys
tati
n
Avi
an
200-
300
KIU
/kg
P
O
BID
G
13
73 F
or
can
did
iasis
Nys
tati
n
Avi
an
100
KIU
/L
D
rin
k Q
D
G
1744
F
or
can
did
iasis
Nys
tati
n
Fin
ch
333
KIU
/kg
P
O
QD
E
15
72 F
or
can
did
iasis
Nys
tati
nH
um
min
gbir
d10
0 K
IU/m
lT
op
ical
q4-
6hG
599
Fo
r m
outh
lesi
on
s
Nys
tati
nH
um
min
gbir
d25
KIU
/L
Nec
tar
Dri
nk
QD
G59
9
Nys
tati
nO
stri
ch25
00 K
IU/kg
fo
od
Fee
dO
nce
G28
3
Nys
tati
nO
stri
ch12
.5 K
IU/kg
PO
QD
G40
1
Nys
tati
nO
stri
ch0.
24 g
/kg
fee
dF
eed
QD
G12
54F
or
can
did
iasi
s
Nys
tati
nO
stri
ch20
-50
KIU
/kg
PO
QD
G12
54
Nys
tati
nP
asse
rin
e10
0 K
IU/L
Dri
nk
QD
D13
30A
dd t
o f
oo
d a
lso
, up
per
GI
Can
did
iasi
s
Nys
tati
nP
igeo
n20
-100
KIU
PO
QD
E70
4
Nys
tati
nP
igeo
n10
0-15
0 K
IU/kg
PO
BID
G59
0
Nys
tati
nP
oult
ry11
0 m
g/kg
fo
od
Fee
dQ
DC
564
Hal
f do
sage
is p
rop
hyl
acti
c
Nys
tati
nP
sitt
acin
e30
0 K
IU/kg
PO
-To
pic
alB
ID-T
IDD
1330
Up
per
GI
can
did
iasi
s
Nys
tati
nP
sitt
acin
e33
3 K
IU/kg
PO
TID
E76
3F
or
can
did
iasi
s, u
se le
sser
do
sage
to
die
t fo
r
neo
nat
es o
n a
nti
bio
tic
ther
apy
Nys
tati
nR
apto
r10
0 K
IU/kg
PO
TID
D16
12
Nys
tati
nR
apto
r1
KIU
/kg
PO
BID
E11
32
Nys
tati
nR
apto
r20
KIU
/kg
PO
BID
E11
88
Nys
tati
nR
atit
e30
0 K
IU/kg
PO
NL
G41
8
Nys
tati
nR
atit
e10
0 K
IU T
DP
OT
IDG
594
Nys
tati
n
Turk
ey
0.05
5-0.1
1 g/
kg f
ood F
eed
QD
C
13
07
Ole
an
do
mycin
Ph
osp
hate
Avi
an1.
17 m
g/kc
alP
OQ
DE
1180
Ole
ando
myc
in P
ho
sph
ate
Avi
an0.
58 m
g/kc
alIM
QD
E11
80
Ole
ando
myc
in P
ho
sph
ate
Pig
eon
25IM
QD
E56
5
Ole
ando
myc
in P
ho
sph
ate
Pig
eon
50P
OQ
DE
565
Orm
eto
pri
m +
Su
lfad
imeth
oxin
e
Ch
icke
n0.
2 g/
kg f
oo
dF
eed
QD
E56
45-
day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 301
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Cra
ne
0.41
g/kg
fo
od
Fee
dQ
DE
1361
Fo
r co
ccid
iosi
s
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Duck
0.22
g/kg
Fee
dO
nce
B82
5F
or
Pas
teur
ella
mul
tocida
in d
uck
lings
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Duck
0.2-
0.8
g/kg
fo
od
Fee
dO
nce
B86
0F
or
riem
erel
losi
s an
d c
olib
acill
osi
s
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Po
ult
ry0.
3-0.
5 g/
LD
rin
kQ
DG
585
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Turk
ey0.
44 g
/kg
Fee
dO
nce
B84
6P
rop
hyl
axis
fo
r P
aste
urel
la m
ulto
cida
Orm
eto
pri
m +
Sulf
adim
eth
oxi
ne
Turk
ey0.
1 g/
kg f
oo
dF
eed
QD
E56
45-
day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Oxacil
lin
So
diu
mP
sitt
acin
e10
0P
OT
IDD
1446
Fo
r st
aph
ylo
cocc
al d
erm
atit
is
Oxfe
nd
azo
leA
vian
10N
Lq2w
D12
21F
or
cap
illar
iasi
s
Oxf
endaz
ole
Avi
an40
PO
QD
D14
70F
or
liver
par
asit
ic d
isea
se
Oxf
endaz
ole
Avi
an4
PO
QD
D14
79F
or
mo
st in
test
inal
wo
rms
incl
udin
g
tap
ewo
rms
Oxf
endaz
ole
Avi
an0.
1-0.
2 g/
LD
rin
kQ
DD
1479
Fo
r m
ost
inte
stin
al w
orm
s in
cludin
g
tap
ewo
rms
Oxf
endaz
ole
A
vian
10
P
O
QD
E
16
50
Fo
r m
ost
inte
stin
al w
orm
s
Oxf
endaz
ole
Avi
an0.
1-0.
2 g/
LD
rin
kQ
DE
1650
Fo
r m
ost
inte
stin
al w
orm
s
Oxf
endaz
ole
Ost
rich
5P
Oq3w
G40
1B
egin
at
age
4 m
on
ths,
alt
ern
ate
ther
apeu
tic
agen
t
Oxf
endaz
ole
Pig
eon
10-4
0P
OO
nce
G59
0
Oxf
endaz
ole
Rap
tor
10P
OQ
WG
1068
Oxyte
tracycli
ne
Am
azo
n P
arro
t22
-58
IMQ
D-B
IDA
266
Oxy
tetr
acyc
line
An
seri
form
es2.
5 g/
LD
rin
kQ
DE
1240
Fo
r ch
lam
ydo
ph
ilosi
s
Oxy
tetr
acyc
line
An
seri
form
es50
mg
TD
PO
QD
E12
40
Oxy
tetr
acyc
line
Avi
an50
00 m
g/kg
Fee
dQ
DE
704
Add c
itri
c ac
id, t
her
apeu
tic
do
sage
Oxy
tetr
acyc
line
Avi
an50
-100
IMQ
DE
1431
Oxy
tetr
acyc
line
Avi
an50
IMQ
D-B
IDE
1492
Oxy
tetr
acyc
line
Avi
an10
0P
OQ
D-B
IDE
1492
Oxy
tetr
acyc
line
Bir
d, A
quat
ic10
0SC
QD
E15
03F
or
resp
irat
ory
infe
ctio
ns
Oxy
tetr
acyc
line
Budge
riga
r2
g/L
Neb
uliz
eq4-
6hA
876
Fo
r re
spir
ato
ry d
isea
se
Oxy
tetr
acyc
line
Ch
icke
n2.
5 g/
LD
rin
kN
LA
802
Add o
xyte
trac
yclin
e fe
ed a
lso
Oxy
tetr
acyc
line
Ost
rich
10IM
QD
G40
1D
oub
le d
osa
ge f
or
bir
ds
bel
ow
5 k
g
Oxy
tetr
acyc
line
Ow
l16
IMQ
DA
55
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I302
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Oxy
tetr
acyc
line
Ph
easa
nt
43IM
QD
A55
Oxy
tetr
acyc
line
Pig
eon
50IM
-SC
QD
A10
67
Oxy
tetr
acyc
line
Pig
eon
0.13
3-0.
444
g/L
Dri
nk
QD
E70
4
Oxy
tetr
acyc
line
Pig
eon
100
IMq2d
E70
4
Oxy
tetr
acyc
line
Pig
eon
20IM
q2d
E12
40A
dd t
etra
cycl
ine
for
bir
ds
ove
r 70
0 g
Oxy
tetr
acyc
line
Pig
eon
80IM
q2d
E12
40A
dd t
etra
cycl
ine
for
bir
ds
un
der
400
g
Oxy
tetr
acyc
line
Po
ult
ry0.
0265
-0.1
06 g
/L
Dri
nk
QD
C56
4
Oxy
tetr
acyc
line
Po
ult
ry6.
25-2
00 m
g T
DP
OQ
DC
564
Oxy
tetr
acyc
line
Po
ult
ry11
0-22
0 m
g/kg
fo
od
Fee
dQ
DC
564
Add n
eom
ycin
Oxy
tetr
acyc
line
Po
ult
ry0.
06-0
.25
g/L
Dri
nk
QD
C70
5
Oxy
tetr
acyc
line
Psi
ttac
ine
58IM
QD
A55
Oxy
tetr
acyc
line
Psi
ttac
ine
50IM
QD
E12
40
Oxy
tetr
acyc
line
Psi
ttac
ine
50-1
00SC
q2-
3dE
1365
Fo
r ch
lam
ydo
ph
ilosi
s
Oxy
tetr
acyc
line
Rap
tor
25-5
0IM
-PO
TD
E12
40IM
inje
ctio
n m
ay c
ause
musc
le n
ecro
sis
Oxy
tetr
acyc
line
Turk
ey2.
5 g/
LD
rin
kN
LA
802
Add o
xyte
trac
yclin
e fe
ed a
lso
Oxy
tetr
acyc
line
Turk
ey25
00 p
pm
Fee
dO
nce
A80
2A
dd o
xyte
trac
yclin
e dri
nki
ng
wat
er a
lso
Oxy
tetr
acyc
line
Turk
ey22
0 m
g/kg
fo
od
Fee
dQ
DE
564
3-day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Oxyte
tracycli
ne
Am
ph
ote
ric
Am
azo
n P
arro
t60
IMQ
DA
847
Oxy
tetr
acyc
line
Am
ph
ote
ric
Am
azo
n, B
lue-
fro
nte
d75
SCq3d
E70
3F
or
chla
myd
op
hilo
sis
Oxy
tetr
acyc
line
Am
ph
ote
ric
An
seri
form
es20
0IM
QD
D11
50F
or
pas
teure
llosi
s an
d o
ther
bac
teri
a
Oxy
tetr
acyc
line
Am
ph
ote
ric
Avi
an50
SCq3-
5dE
1648
Fo
r re
spir
ato
ry in
fect
ion
s, m
ay c
ause
musc
le
nec
rosi
s
Oxy
tetr
acyc
line
Am
ph
ote
ric
Bir
d, A
quat
ic50
SCq3-
5dE
1503
Fo
r re
spir
ato
ry in
fect
ion
s
Oxy
tetr
acyc
line
Am
ph
ote
ric
Co
ckat
oo
, Go
ffin
50-1
00IM
-SC
q3d
A38
0
Oxy
tetr
acyc
line
Am
ph
ote
ric
Mac
aw, B
lue
and G
old
50-7
5SC
q2-
3dE
1170
Cau
ses
irri
tati
on
at
inje
ctio
n s
ite
Oxy
tetr
acyc
line
Am
ph
ote
ric
Ost
rich
20IM
q3d
G40
1D
oub
le d
osa
ge f
or
bir
ds
bel
ow
5 k
g
Oxy
tetr
acyc
line
Am
ph
ote
ric
Psi
ttac
ine
50-1
00IM
-SC
q2-
3dE
565
Oxy
tetr
acyc
line
Am
ph
ote
ric
Rap
tor
50-2
00IM
q3-
5dE
1240
Fo
r p
aste
ure
llosi
s
Oxy
tetr
acyc
line
Am
ph
ote
ric
Turk
ey15
0SC
q3d
A72
7L
on
g-la
stin
g fo
rmula
tio
n
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 303
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Oxyto
cin
An
seri
form
es3-
5 IU
/kg
IMN
LD
1150
Egg
bin
din
g
Oxy
toci
nA
vian
0.5-
1 IU
TD
IMN
LE
924
Use
wit
h c
alci
um
an
d v
itam
in A
fo
r eg
g
exp
uls
ion
Oxy
toci
nA
vian
5 U
/kg
IV-S
CO
nce
E11
51T
o h
elp
wit
h e
gg e
xpuls
ion
, add c
alci
um
,
fluid
s an
d h
eat
Oxy
toci
nA
vian
2 IU
/kg
NL
NL
E14
31F
or
egg
bin
din
g, g
ive
calc
ium
bo
rogl
uco
nat
e
also
Oxy
toci
nO
stri
ch5
IU T
DIV
On
ceB
1257
Giv
e 2
to 4
min
ute
s b
efo
re s
emen
co
llect
ion
Paro
mo
mycin
Su
lfate
Avi
an10
0P
OB
IDE
1474
Fo
r n
eon
ate
wit
h c
ryp
tosp
ori
dio
sis
Pen
etr
an
Avi
anT
op
ical
NL
G14
86F
or
rash
es, u
lcer
atio
n, l
oca
l irr
itat
ion
, tra
um
a,
bit
es, b
urn
s, e
tc.
Pen
etra
nA
vian
2.5
ml/
L s
pra
yT
op
ical
NL
G11
03F
or
pic
kin
g o
r it
chin
g
Pen
icil
lam
ine
An
seri
form
es55
PO
BID
D11
50F
or
hea
vy m
etal
po
iso
nin
g
Pen
icill
amin
eA
vian
55P
OB
IDD
1221
Fo
r le
ad o
r zi
nc
toxi
cosi
s, m
ay u
se in
con
jun
ctio
n w
ith
edet
ate
calc
ium
dis
odiu
m
Pen
icill
amin
eA
vian
52P
OQ
DF
1236
Fo
r co
pp
er t
oxi
cosi
s
Pen
icill
amin
eA
vian
55P
OB
IDG
87R
epea
t af
ter
3 to
5 d
ays
Pen
icill
amin
eP
sitt
acin
e50
-55
PO
BID
E12
40C
hel
atio
n a
gen
t fo
r co
pp
er, z
inc,
mer
cury
and le
ad
Pen
icill
amin
eR
apto
r55
PO
BID
E12
40F
or
hea
vy m
etal
po
iso
nin
g
Pen
icil
lin
An
seri
form
es50
KIU
/kg
Par
ente
ral
NL
G59
7
Pen
icill
inP
oult
ry44
KIU
/kg
PO
QD
C56
4A
dd s
trep
tom
ycin
Pen
icill
inP
oult
ry55
-110
mg/
kg f
oo
dF
eed
QD
C56
4P
rop
hyl
acti
c
Pen
icill
inP
oult
ry37
5 K
IU/L
Dri
nk
QD
C56
4
Pen
icill
inP
oult
ry11
0 m
g/kg
fo
od
Fee
dQ
DC
564
Pen
icill
inP
oult
ry2.
65 m
g/kg
fo
od
Fee
dQ
DE
564
Add s
trep
tom
ycin
, nutr
itio
nal
use
, no
slau
ghte
r w
ith
dra
wal
Pen
icill
inR
apto
r<
100
KIU
/kg
IM-I
VN
LE
1463
Use
cry
stal
line
form
ula
tio
n f
or
bac
teri
al
infe
ctio
ns
Pen
icil
lin
G B
en
zath
ine
Rh
ea10
0 K
IU T
DSC
QD
G58
2A
dd t
ylo
sin
Pen
icill
in G
Ben
zath
ine
Turk
ey 100 IM
Q
D
A
385
Add p
enic
illin
G p
roca
ine
for
Pas
teur
ella
mul
tocida
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I304
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pen
icil
lin
G P
ota
ssiu
mA
vian
66-1
33 K
IU/kg
IMN
LF
1209
Pen
icill
in G
Po
tass
ium
Fal
con
, Lan
ner
20 K
IU/kg
IMQ
IDB
1175
Po
st-s
urg
ical
tre
atm
ent
of
bum
ble
foo
t
Pen
icill
in G
Pro
cain
eG
allif
orm
es10
0IM
q2d
E11
1, 1
473
Pen
icill
in G
Pro
cain
e T
urk
ey
100
IM
On
ce
A
385
Lo
adin
g do
se, a
dd p
enic
illin
G w
ith
pro
cain
e
ben
zath
ine
for
Pas
teur
ella
mul
tocida
Pen
tob
arb
ital
+ C
hlo
ral
Hyd
rate
+ M
ag
nesi
um
Su
lfat
Avi
an16
0-18
0IM
PR
NF
1209
Do
sage
bas
e o
n c
om
bin
ed m
g o
f
pen
tob
arb
ital
/ch
lora
l hyd
rate
/m
agn
esiu
m
sulf
ate
Pen
tob
arb
ital
So
diu
mA
vian
5IM
PR
NE
1130
Pen
tob
arb
ital
So
diu
mA
vian
50IM
PR
NF
1209
Pen
tob
arb
ital
So
diu
mB
udge
riga
r24
IMP
RN
B10
84A
dd c
hlo
ral h
ydra
te +
mag
nes
ium
sulf
ate,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
Pen
tob
arb
ital
So
diu
m
Can
ary
24
IM
PR
N
B
1084
S
ee a
bo
ve
Pen
tob
arb
ital
So
diu
mC
hic
ken
16.2
IMP
RN
B10
80A
dd t
hio
pen
tal s
odiu
m
Pen
tob
arb
ital
So
diu
mC
ock
ato
o, M
ajo
r M
itch
ell's
100
mg
TD
IVN
LG
1590
Pen
tob
arb
ital
So
diu
mC
ow
bir
d10
0-15
0 g/
kg f
oo
dF
eed
On
ceB
1094
Pen
tob
arb
ital
So
diu
mC
ran
e, E
uro
pea
n24
IMP
RN
B10
84A
dd c
hlo
ral h
ydra
te +
mag
nes
ium
sulf
ate,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
Pen
tob
arb
ital
So
diu
mD
uck
, Mal
lard
22P
OP
RN
B10
95
Pen
tob
arb
ital
So
diu
mD
uck
, No
rth
ern
Pin
tail
390
IVO
nce
B15
93P
rece
de
wit
h k
etam
ine
by
15 m
inute
s
Pen
tob
arb
ital
So
diu
mE
agle
, Go
lden
18.2
IMP
RN
B10
86A
dd c
hlo
ral h
ydra
te +
mag
nes
ium
sulf
ate,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds,
fled
glin
g
Pen
tob
arb
ital
So
diu
mE
mu
13.3
IVP
RN
G28
3P
rem
edic
ate
wit
h d
iaze
pam
Pen
tob
arb
ital
So
diu
mG
allif
orm
es50
-100
PO
PR
NE
1130
Use
tab
lets
Pen
tob
arb
ital
So
diu
mG
oo
se50
-100
PO
PR
NE
1130
Use
tab
lets
Pen
tob
arb
ital
So
diu
mG
ull,
Cal
ifo
rnia
24IM
PR
NB
1084
Add c
hlo
ral h
ydra
te +
mag
nes
ium
sulf
ate,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
Pen
tob
arb
ital
So
diu
mH
awk
14.7
IMP
RN
B10
86"
Pen
tob
arb
ital
So
diu
mP
engu
in33
NL
On
ceG
595
Pen
tob
arb
ital
So
diu
mP
igeo
n24
IMP
RN
B10
84A
dd c
hlo
ral h
ydra
te +
mag
nes
ium
sulf
ate,
reduce
do
se 1
5 to
20%
in d
ebili
tate
d b
irds
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
e
Chapter 9 | T H E R A P E U T I C A G E N T S 305
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pen
tob
arb
ital
So
diu
mQ
uai
l, Ja
pan
ese
25-5
0 g/
kg f
oo
dF
eed
On
ceB
1094
Pen
tob
arb
ital
So
diu
mR
apto
r<
20
PO
PR
NE
1463
Fo
r se
dat
ion
Pen
tob
arb
ital
So
diu
mR
apto
r30
IM-I
VP
RN
E14
63N
ot
usu
ally
rec
om
men
ded
Pen
tob
arb
ital
So
diu
mSk
ua,
McC
orm
ick'
s47
IM-I
VP
RN
B10
75
Pen
tob
arb
ital
So
diu
mSw
an, M
ute
25 m
g T
DIV
PR
NG
1074
Adult
Pen
tob
arb
ital
So
diu
mT
urk
ey16
.2IM
PR
NB
1080
Add t
hio
pen
tal s
odiu
m
Pen
toxif
yll
ine
Avi
an15
PO
BID
-TID
G14
89A
dd a
loe
vera
fo
r fr
ost
bit
e, v
aso
dila
tor
Perm
eth
rin
Pig
eon
dust
ing
To
pic
alN
LE
1240
Fo
r fl
eas
and li
ce
Per
met
hri
nP
sitt
acin
edust
ing
To
pic
alN
LE
1240
Ect
op
aras
ite
con
tro
l
Ph
en
ob
arb
ital
Avi
an1-
5P
OB
IDE
111,
147
3
Ph
eno
bar
bit
alA
vian
3.5-
7N
LB
IDD
1475
Co
ntr
ol o
f se
izure
s
Ph
eno
bar
bit
alA
vian
0.04
8-0.
080
g/L
Dri
nk
PR
NG
58
Ph
eno
bar
bit
alP
sitt
acin
e3
PO
BID
E12
40F
or
feat
her
pic
kin
g, m
ay c
ause
dee
p s
edat
ion
and in
abili
ty t
o p
erch
Ph
eno
bar
bit
alR
apto
r<
30
PO
PR
NE
1463
Fo
r se
dat
ion
Ph
eno
bar
bit
alR
apto
r20
PO
NL
D16
12F
or
neu
rolo
gic
sign
s w
ith
org
ano
chlo
rin
e
toxi
city
Ph
en
ylb
uta
zo
ne
Ost
rich
2.2
PO
QD
G71
0
Ph
enyl
buta
zon
eP
sitt
acin
e3.
5-7
PO
BID
-TID
E14
73
Ph
enyl
buta
zon
eR
apto
r3.
5-7
PO
BID
-TID
E11
1
Ph
yto
nad
ion
eA
vian
2.5-
5P
aren
tera
lB
ID-Q
IDE
1492
Fo
r an
tico
agula
nt
roden
tici
de
Ph
yto
nad
ion
eR
apto
r0.
2-2.
5IM
-PO
QD
E14
33F
or
anti
coag
ula
nt
po
iso
nin
g
Pip
era
cil
lin
So
diu
mA
maz
on
Par
rot
75-1
00IM
q4-
6hA
1473
Pip
erac
illin
So
diu
mA
vian
4.31
mg/
kcal
IM-I
VT
ID-Q
IDE
1180
Syn
ergi
stic
wit
h a
min
ogl
yco
sides
Pip
erac
illin
So
diu
mA
vian
2.55
mg/
kcal
IM-I
Vq4-
6hE
1180
Syn
ergi
stic
wit
h a
min
ogl
yco
sides
Pip
erac
illin
So
diu
mA
vian
10 g
/L
sal
ine
Flu
shB
ID-Q
IDE
1183
Nas
al o
r si
nus
Pip
erac
illin
So
diu
mA
vian
10 g
/L
sal
ine
Neb
uliz
eB
ID-Q
IDE
1185
10 t
o 3
0 m
inute
s
Pip
erac
illin
So
diu
mA
vian
100-
200
IMT
ID-Q
IDE
1650
Syn
ergi
stic
wit
h a
min
ogl
yco
sides
Pip
erac
illin
So
diu
mA
vian
150
IMB
IDG
55
Pip
erac
illin
So
diu
mB
ird, A
quat
ic10
0-20
0IM
BID
E14
78P
ost
-tra
um
a in
fect
ion
s
Pip
erac
illin
So
diu
mB
udge
riga
r20
0IM
TID
A41
1
Pip
erac
illin
So
diu
mC
ock
ato
o, C
itro
n-c
rest
ed90
Par
ente
ral
BID
G74
0A
dd a
mik
acin
Pip
erac
illin
So
diu
mC
ran
e10
0IM
-IV
-SC
BID
E62
9
Pip
erac
illin
So
diu
mD
uck
, Ruddy
100
IMB
IDG
1468
Beg
in p
re-o
per
ativ
ely
for
ten
do
n s
urg
ery
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I306
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pip
erac
illin
So
diu
mF
alco
n20
0IM
TID
-QID
E10
27B
road
sp
ectr
um
Pip
erac
illin
So
diu
mG
ull
100
IMB
IDE
1357
Pip
erac
illin
So
diu
mL
ori
keet
, Rai
nb
ow
100
IMB
IDG
1620
Pip
erac
illin
So
diu
mM
acaw
4 m
g T
D p
er e
ggP
aren
tera
lq4d
G82
0F
or
emb
ryo
nic
dea
th, b
egin
fir
st d
ose
at
day
14, u
se 2
6 ga
nee
dle
Pip
erac
illin
So
diu
mP
igeo
n10
0IM
BID
-TID
G26
0
Pip
erac
illin
So
diu
mP
igeo
n10
0-20
0IM
BID
G59
0
Pip
erac
illin
So
diu
mP
sitt
acin
e10
0IM
BID
A41
1
Pip
erac
illin
So
diu
mP
sitt
acin
e50
-100
SCT
IDE
632
Neo
nat
e do
sage
Pip
erac
illin
So
diu
mP
sitt
acin
e10
0-20
0IM
-IV
BID
-TID
E12
40, 1
756
Pip
erac
illin
So
diu
mR
apto
r10
0IM
-IV
BID
E14
33
Pip
era
cil
lin
So
diu
m +
Tazo
bacta
m S
od
ium
Avi
an15
0-20
0IM
-IV
QD
-BID
G12
79Su
bst
itute
fo
r p
iper
acill
in s
odiu
m, D
O N
OT
use
am
ino
glyc
osi
des
co
ncu
rren
tly
Pip
erac
illin
So
diu
m +
Taz
ob
acta
m S
odiu
m
Fal
con
, Per
egri
ne
200
IMB
IDG
1426
Pip
era
zin
eA
nse
rifo
rmes
45-2
00P
ON
LE
111
Pip
eraz
ine
Avi
an10
0-50
0P
Oq2w
E16
50F
or
roun
dw
orm
s
Pip
eraz
ine
Cra
ne
4-5.
26 g
/L
Dri
nk
QD
G59
6R
epea
t in
2 w
eeks
Pip
eraz
ine
Fin
ch0.
3 g/
LD
rin
kN
LE
1572
Pip
eraz
ine
Gal
lifo
rmes
100-
500
PO
q2w
E11
1
Pip
eraz
ine
Pig
eon
1.9
g/L
Dri
nk
QD
C70
4F
or
30 b
irds
Pip
eraz
ine
Pig
eon
500
mg
Dri
nk
TD
C70
6F
or
cap
illar
ia
Pip
eraz
ine
Pig
eon
250
mg
Dri
nk
TD
C70
6F
or
asca
ridia
sis
Pip
eraz
ine
Pig
eon
12.5
Dri
nk
QD
E12
40R
epea
t ev
ery
10 t
o 1
4 day
s
Pip
eraz
ine
Pig
eon
35P
OQ
DG
260
Pip
eraz
ine
Po
ult
ry1
g/L
Dri
nk
QD
G57
Pip
eraz
ine
Po
ult
ry10
0-50
0P
Oq10
dG
1309
Fo
r as
cari
ds
Pip
eraz
ine
Psi
ttac
ine
250
PO
NL
G57
Pip
eraz
ine
Quai
l30
-50
mg
TD
PO
NL
G67
8A
nth
elm
inti
c
Pip
eraz
ine
Rap
tor
100
PO
NL
E57
, 146
3A
nth
elm
inti
c
Pip
ero
nyl
Bu
toxid
eR
apto
r6.
25 g
/L
To
pic
alN
LE
1068
Add p
erm
eth
rin
+ m
eth
op
ren
e fo
r
ecto
par
asit
es
Pir
oxic
am
Cra
ne
0.5
PO
BID
G16
71
Po
lico
san
ol
Am
azo
n P
arro
t1
mg
TD
PO
BID
G12
73F
or
hyp
erlip
idem
ia o
r h
yper
cho
lest
ero
lem
ia
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 307
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Po
lico
san
ol
Am
azo
n, Y
ello
w-n
aped
2P
OQ
DG
1466
Mix
wit
h la
ctulo
se f
or
hyp
erlip
idem
ia o
f
trig
lyce
ride
and c
ho
lest
ero
l
Po
lym
yxin
B S
ulf
ate
Avi
an10
-15
IM-P
ON
LE
924
Po
lym
yxin
B S
ulf
ate
Avi
an10
00 m
g/kc
alP
OB
IDE
1180
Po
lym
yxin
B S
ulf
ate
Avi
an30
00 K
IU/L
Dri
nk
NL
E11
80
Po
lym
yxin
B S
ulf
ate
Avi
an50
KIU
/kg
PO
BID
E56
5
Po
lym
yxin
B S
ulf
ate
Can
ary
50 K
IU/L
Dri
nk
QD
E69
5
Po
lym
yxin
B S
ulf
ate
Can
ary
50 K
IU/kg
fo
od
Fee
dQ
DE
695
Po
lym
yxin
B S
ulf
ate
Can
ary
500
KIU
/L
Dri
nk
NL
E11
87
Po
lym
yxin
B S
ulf
ate
Can
ary
500
KIU
/kg
fo
od
Fee
dO
nce
E11
87
Po
lym
yxin
B S
ulf
ate
Pas
seri
ne
100
KIU
/kg
fo
od
Fee
dQ
DE
1437
Add d
rug
to d
rin
k at
th
e sa
me
tim
e
Po
lym
yxin
B S
ulf
ate
Pas
seri
ne
100
KIU
/L
Dri
nk
QD
E14
37A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e
Po
lym
yxin
B S
ulf
ate
Pas
seri
ne,
Sm
all
500
KIU
/L
Dri
nk
NL
E11
87
Po
lym
yxin
B S
ulf
ate
Pas
seri
ne,
Sm
all
500
KIU
/kg
fo
od
Fee
dO
nce
E11
87
Po
lysu
lfate
d
Gly
co
sam
ino
gly
can
Cra
ne,
Dem
ois
elle
50 m
g T
DIA
On
ceG
579
Musc
ulo
sket
al jo
int
ther
apy
Po
lysu
lfat
ed
Gly
cosa
min
ogl
ycan
Ph
easa
nt,
Pea
cock
12.5
mg
TD
IMO
nce
G57
9M
usc
ulo
sket
al jo
int
ther
apy
Po
lysu
lfat
ed
Gly
cosa
min
ogl
ycan
Vult
ure
, Kin
g20
mg
TD
IMQ
WG
579
Musc
ulo
sket
al jo
int
ther
apy
Po
tass
ium
Bro
mid
eC
ock
ato
o, U
mb
rella
80P
OQ
DG
1691
Fo
r co
ntr
ol o
f se
izure
s
Po
tass
ium
Bro
mid
eP
arro
t, G
rey
80P
OQ
DG
1274
Seiz
ure
co
ntr
ol
Po
tass
ium
Bro
mid
eP
igeo
n80
PO
QD
G12
74Se
izure
co
ntr
ol
Po
tass
ium
Ch
lori
de
Avi
an0.
3IV
NL
E14
73
Po
tass
ium
Ch
lori
de
Avi
an0.
1-0.
3IV
NL
E11
1
Po
tass
ium
Perm
an
gan
ate
Fal
con
14 g
/m
³N
LO
nce
G10
29A
dd f
orm
aldeh
yde
for
fum
igat
ion
TO
XIC
Pra
lid
oxim
e C
hlo
rid
eA
vian
10-3
0IM
QD
E11
1
Pra
lido
xim
e C
hlo
ride
Rap
tor
100
NL
BID
-QID
E14
00F
or
org
ano
ph
osp
hat
e p
ois
on
ing
Pra
lido
xim
e C
hlo
ride
Rap
tor
20IM
PR
NG
50C
on
tin
ue
on
ly if
fir
st d
ose
pro
duce
s re
spo
nse
Pra
lid
oxim
e I
od
ide
Avi
an10
-100
Par
ente
ral
NL
E14
92R
educe
do
sage
if u
sed w
ith
atr
op
ine
for
org
ano
ph
osp
hat
es
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I308
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pra
lido
xim
e Io
did
eA
vian
10-1
00P
aren
tera
lB
ID-T
IDE
1650
Use
low
er d
osa
ge if
use
d w
ith
atr
op
ine
for
org
ano
ph
osp
hat
e to
xici
ty
Pra
lido
xim
e Io
did
eR
apto
rs10
0IM
On
ceB
1093
Fo
r m
on
ocr
oto
ph
os
toxi
city
Pra
lid
oxim
e M
esy
late
An
seri
form
es10
0IM
QID
D11
50F
or
org
ano
ph
osp
hat
e to
xici
ty
Pra
lido
xim
e M
esyl
ate
Psi
ttac
ine
100
IMQ
IDE
1240
Pra
ziq
uan
tel
An
seri
form
es10
-20
PO
-SC
q10
dD
1150
Co
ntr
ol c
esto
des
Pra
ziquan
tel
Avi
an10
-20
PO
QD
D14
70F
or
liver
par
asit
ic d
isea
se
Pra
ziquan
tel
Avi
an9
IMQ
DD
1470
Co
nti
nue
PO
fo
r 11
day
s fo
r liv
er p
aras
itic
dis
ease
Pra
ziquan
tel
Avi
an10
PO
NL
E16
48F
or
tap
ewo
rms
Pra
ziquan
tel
Bir
d, A
quat
ic10
PO
NL
E15
03F
or
tap
ewo
rms
Pra
ziquan
tel
Bust
ard
10P
O-S
CO
nce
E12
40F
or
cest
odes
an
d t
rem
ato
des
Pra
ziquan
tel
Fin
ch10
-20
PO
q10
-14d
E15
72
Pra
ziquan
tel
Fin
ch12
mg/
kg
Fee
dO
nce
E16
17C
rush
tab
let
and m
ix w
ith
en
ough
fo
od f
or
1
day
, sca
tter
th
rough
out
avia
ry
Pra
ziquan
tel
Ost
rich
7.5
PO
NL
C28
3
Pra
ziquan
tel
Ost
rich
5P
ON
LG
481
Pra
ziquan
tel
Pas
seri
ne,
Sm
all
10N
LN
LE
1187
Fo
r tr
emat
odes
Pra
ziquan
tel
Pen
guin
10-2
0P
ON
LE
1478
Fo
r ce
sto
des
Pra
ziquan
tel
Pig
eon
11.4
SCQ
ME
704
Pra
ziquan
tel
Pig
eon
10-2
0P
Oq2w
E70
4T
able
t cr
ush
ed in
wat
er s
usp
ensi
on
Pra
ziquan
tel
Pig
eon
10P
ON
LE
1192
Fo
r ce
sto
des
Pra
ziquan
tel
Psi
ttac
ine
9IM
NL
E76
3F
or
tap
ewo
rms
Pra
ziquan
tel
Psi
ttac
ine
10-2
0P
OO
nce
E12
40F
or
tap
ewo
rms
rep
eat
afte
r 10
day
s
Pra
ziquan
tel
Rap
tor
50P
O-S
CN
LE
1068
Fo
r tr
emat
odes
an
d c
esto
des
Pra
ziquan
tel
Rap
tor
30N
Lq10
dE
1132
Fo
r ta
pew
orm
s an
d f
luke
s
Pra
ziquan
tel
Rap
tor
5-10
PO
-SC
QD
E12
40
Pra
ziquan
tel
Rap
tor
10-5
0P
Oq2w
E13
59F
or
tap
ewo
rms
Pre
dn
iso
lon
eA
vian
2P
OB
IDE
1431
May
pre
dis
po
se t
o m
yco
tic
infe
ctio
n
Pre
dn
iso
lon
eA
vian
6.7
PO
NL
E15
26U
se d
ecre
asin
g do
sage
fo
r lo
ng-
term
th
erap
y
Pre
dn
iso
lon
eP
sitt
acin
e2
PO
BID
E12
40A
lso
an
alge
sic
Pre
dn
iso
lon
eR
apto
r0.
5-1
IMO
nce
E14
00
Pre
dn
iso
lon
eR
apto
r2-
4IM
-IV
On
ceE
1400
Fo
r sh
ock
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 309
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pre
dn
iso
lon
e S
od
ium
Ph
osp
hate
Avi
an0.
5-1
IM-I
VN
LE
111
Pre
dn
iso
lon
e So
diu
m
Ph
osp
hat
e
Avi
an2-
4IM
-IV
NL
E11
1Im
mun
osu
pp
ress
ive
Pre
dn
iso
lon
e So
diu
m
Ph
osp
hat
e
Rap
tor
10-3
0IM
-IV
PR
NG
234
Pre
dn
iso
lon
e S
od
ium
Su
ccin
ate
Avi
an0.
5-1
IM-I
VO
nce
E11
51F
or
neu
rolo
gic
emer
gen
cies
Pre
dn
iso
lon
e So
diu
m
Succ
inat
e
Avi
an10
-20
IM-I
VN
LD
1554
Fo
r sh
ock
Pri
maq
uin
e P
ho
sph
ate
Avi
an0.
03P
OQ
DD
1470
Fo
r liv
er p
aras
itic
dis
ease
Pri
maq
uin
e P
ho
sph
ate
Avi
an1
PO
QW
E14
79
Pri
maq
uin
e P
ho
sph
ate
Avi
an1
PO
QW
E14
92A
dd c
hlo
roquin
e fo
r P
lasm
odiu
m
Pri
maq
uin
e P
ho
sph
ate
Avi
an0.
3-1
PO
TID
G57
Usu
ally
in c
om
bin
atio
n w
ith
ch
loro
quin
e
Pri
maq
uin
e P
ho
sph
ate
Fal
con
0.75
NL
On
ceE
1177
Add c
hlo
roquin
e
Pri
maq
uin
e P
ho
sph
ate
Pen
guin
0.03
PO
QW
D14
70F
or
liver
par
asit
ic d
isea
se p
rop
hyl
axis
Pri
maq
uin
e P
ho
sph
ate
Pen
guin
0.03
PO
QD
E11
1, 1
473
Pri
maq
uin
e P
ho
sph
ate
Pen
guin
1P
OQ
DB
262
Add c
hlo
roquin
e p
ho
sph
ate
Pri
maq
uin
e P
ho
sph
ate
Psi
ttac
ine
1P
OQ
DE
1365
Fo
r sa
rco
cyst
osi
s
Pri
maq
uin
e P
ho
sph
ate
Rap
tor
1P
OQ
DG
61A
dd c
hlo
roquin
e
Pri
maq
uin
e P
ho
sph
ate
Rap
tor
1P
OQ
WG
94A
dd c
hlo
roquin
e p
ho
sph
ate,
juve
nile
do
sage
Pri
mid
on
eA
maz
on
Par
rot
125
mg
TD
Dri
nk
QD
G17
53L
on
g-te
rm s
eizu
re c
on
tro
l
Pri
mid
on
eR
apto
r12
5P
OP
RN
E14
63F
or
sedat
ion
Pro
ben
ecid
Avi
an20
0N
Lq2d
E70
4F
or
bo
dy
wei
ght
> 2
00g,
to
dec
reas
e
excr
etio
n r
ate
of
pen
icill
in/ce
ph
alo
spo
rin
duri
ng
ther
apy
Pro
ben
ecid
Mac
aw12
5P
OQ
IDG
45U
rico
siuri
c
Pro
bio
tic
An
seri
form
es21
ml/
kg f
oo
dF
eed
On
ceE
1240
Fo
r h
and-r
eari
ng
(6 h
ours
old
) an
d
con
vale
scin
g b
irds,
Avi
pro
Ped
iatr
ic®
Pro
bio
tic
An
seri
form
es5
sco
op
s/L
Dri
nk
NL
E12
40D
oub
le d
osa
ge f
or
stre
ssed
bir
d, A
vip
ro®
Pro
bio
tic
Avi
an5
cc/L
Fee
dO
nce
E11
1A
dd t
o h
and f
eedin
g fo
rmula
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I310
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Pro
bio
tic
Avi
an1
pin
ch T
DF
eed
QD
E11
1
Pro
bio
tic
Psi
ttac
ine
21 m
l/kg
fo
od
Fee
dO
nce
E12
40F
or
han
d-r
eari
ng
(6 h
ours
old
) an
d
con
vale
scin
g b
irds,
Avi
pro
Ped
iatr
ic®
Pro
bio
tic
Psi
ttac
ine
5 sc
oo
ps/
LD
rin
kN
LE
1240
Do
ub
le d
osa
ge f
or
stre
ssed
bir
d, A
vip
ro®
Pro
bio
tic
Psi
ttac
ine
5 m
l/L
fo
od
Fee
dO
nce
E14
73H
and f
eedin
g fo
rmula
Pro
bio
tic
Psi
ttac
ine
pin
ch T
DP
OQ
DE
1473
Pro
bio
tic
Rat
ite
PO
NL
G41
8
Pro
flavin
eA
vian
30 m
g T
DT
op
ical
QD
-BID
E12
40F
or
wo
un
ds,
sti
mula
te g
ran
ula
tio
n
Pro
pen
tofy
llin
eA
vian
5P
OQ
DG
1240
Vas
odila
tor
for
win
g ti
p e
dem
a o
r dry
gan
gren
e
Pro
pen
tofy
llin
eR
apto
r5
PO
BID
E14
00Im
pro
ve c
ircu
lati
on
(w
ing
tip
edem
a)
Pro
po
fol
Am
azo
n, H
isp
anio
lan
5IV
PR
NB
1436
Mai
nta
in a
nes
thes
ia b
y co
nti
nuo
us
infu
sio
n a
t
1 m
g/kg
per
min
ute
Pro
po
fol
An
seri
form
es8
IVP
RN
E11
90In
duct
ion
age
nt
Pro
po
fol
Avi
an1.
33-1
4IV
PR
NE
1181
Sho
rt d
ura
tio
n, s
mo
oth
induct
ion
, hig
h s
afet
y
mar
gin
Pro
po
fol
Duck
, Mal
lard
10IV
PR
NB
1358
Adm
inis
ter
ove
r 1
min
ute
, fo
llow
wit
h 4
mg/
kg, r
esp
irat
ory
dep
ress
ion
Pro
po
fol
Ost
rich
3IV
PR
NB
1628
Mai
nta
in w
ith
0.2
mg/
kg/m
in c
on
stan
t ra
te
infu
sio
n
Pro
po
fol
Pig
eon
4.1-
8.6
IVP
RN
B77
9F
ollo
ws
keta
min
e
Pro
po
fol
Pig
eon
14IV
PR
NB
779
Pre
limin
ary
to in
hal
atio
n a
nes
thes
ia
Pro
po
fol
Psi
ttac
ine
1.33
IVP
RN
E12
40F
or
anes
thes
ia in
duct
ion
Pro
po
fol
Swan
6IV
On
ceG
1695
Induct
ion
fo
r is
ofl
ura
ne
Pro
po
fol
Swan
(B
lack
, Mute)
10
IV
PR
N
B
1291
G
as a
nes
thes
ia p
rem
ed
Pro
po
lis
Ch
icke
n30
mg
TD
On
ceB
1632
Imm
un
e an
d g
row
th s
tim
ula
nt
Pro
pra
no
lol
HC
lA
vian
0.2
IMN
LE
111
Pro
pra
no
lol H
Cl
Avi
an0.
04IV
NL
E11
1
Pro
stag
lan
din
E (
See
Din
op
rost
on
e)
Rap
tor
N/A
To
pic
alP
RN
E14
00F
or
egg
bin
din
g, u
se g
el f
orm
ula
tio
n
Psy
lliu
m H
yd
rop
hil
ic
Mu
cil
loid
Avi
an2.
5 m
l/kg
PO
NL
G87
Mix
wit
h s
yrin
geab
le f
oo
d, b
ulk
ing
agen
t to
rem
ove
GI
mat
eria
ls
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 311
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Psy
llium
Hyd
rop
hili
c
Muci
lloid
Bir
d, A
quat
ic40
ml/
L s
oft
fo
od
Fee
dO
nce
E14
78A
dd s
odiu
m +
mag
nes
ium
sulf
ate
+ m
iner
al
oil
for
lead
po
iso
nin
g, a
dd b
ran
Pyra
nte
l P
am
oate
An
seri
form
es7
PO
q2w
E13
58F
or
nem
ato
des
Pyr
ante
l Pam
oat
eA
vian
4.5-
25P
Oq2w
D11
1,12
21, 1
473
Fo
r n
emat
odia
sis
Pyr
ante
l Pam
oat
eC
ran
e4.
5P
Oq10
dE
1361
Fo
r in
test
inal
nem
ato
des
Pyr
ante
l Pam
oat
eF
inch
4.5
PO
q10
-14d
E15
72
Pyr
ante
l Pam
oat
eP
asse
rin
e10
0P
OO
nce
G13
35F
or
inte
stin
al n
emat
odes
Pyr
ante
l Pam
oat
eP
igeo
n20
-25
PO
QW
-q2w
E13
64
Pyr
ante
l Pam
oat
eP
sitt
acin
e4.
5P
Oq10
dE
1240
Fo
r n
emat
odes
Pyr
ante
l Pam
oat
eP
sitt
acin
e10
0P
ON
LG
57, 1
335
Pyr
ante
l Pam
oat
eR
apto
r20
PO
On
ceE
1240
, 140
0F
or
nem
ato
des
Pyr
ante
l Pam
oat
eR
apto
r4.
5P
Oq2w
G94
Juve
nile
do
sage
Pyr
ante
l Pam
oat
eR
atit
e5-
7P
ON
LG
418
Pyre
thri
nC
ran
e0.
1% p
ow
der
To
pic
alQ
W-q
2wE
1361
Fo
r ec
top
aras
ites
, ap
ply
ligh
tly
Pyr
eth
rin
Fin
chT
op
ical
QD
E15
72D
ust
fea
ther
s
Pyr
eth
rin
Rap
tor
0.5-
2% m
ixtu
reT
op
ical
q10
dG
1411
Fo
r ch
ewin
g lic
e
Pyri
meth
am
ine
An
seri
form
es0.
25-0
.5P
OB
IDD
1150
Fo
r sa
rco
cyst
osi
s an
d t
oxo
pla
smo
sis
Pyr
imet
ham
ine
Avi
an0.
5P
OB
IDD
1470
Pyr
imet
ham
ine
Avi
an0.
3P
ON
LE
1650
Fo
r L
euco
cyto
zoo,
Pla
smod
ium
Pyr
imet
ham
ine
Rap
tor
0.25
-0.5
PO
BID
E14
00F
or
sarc
ocy
sto
sis,
to
xop
lasm
osi
s an
d o
ther
pro
tozo
al in
fect
ion
s
Pyr
imet
ham
ine
Rap
tor
0.5
PO
BID
E14
33F
or
leuco
cyto
zoo
no
sis
Pyri
meth
am
ine +
Su
lfaq
uin
oxali
ne
An
seri
form
es0.
06 g
/L
Dri
nk
QD
D11
502
day
s o
ff, t
hen
rep
eat
for
cocc
idio
sis
Pyr
imet
ham
ine
+
Sulf
aquin
oxa
line
Psi
ttac
ine
0.06
g/L
Dri
nk
QD
E12
40W
ait
2 day
s th
en r
epea
t fo
r co
ccid
iosi
s
Qu
inacri
ne H
Cl
Avi
an5-
10P
OQ
DE
111
Quin
acri
ne
HC
lA
vian
240
NL
QD
E14
79F
or
Pla
smod
ium
Quin
acri
ne
HC
lA
vian
7.5
PO
QD
E16
50F
or
Pla
smod
ium
Quin
acri
ne
HC
lC
anar
y24
0P
OB
IDG
57
Quin
acri
ne
HC
lP
igeo
n10
mg
TD
PO
QD
G47
Quin
acri
ne
HC
lP
sitt
acin
e5-
10P
OQ
DE
1473
Red
Clo
ver
Avi
an10
dro
ps/
kgP
OQ
DE
1435
Use
low
alc
oh
ol f
orm
ula
tio
n f
or
soft
sh
elle
d
egg
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I312
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Red
Palm
Oil
Avi
an10
-60
dro
ps/
kgP
OQ
DG
1727
May
giv
e o
ver
foo
d
Resc
ue R
em
ed
yF
inch
2 dro
ps
TD
PO
On
ceG
1723
Fo
r st
ress
of
han
dlin
g o
r m
ino
r p
roce
dure
s
Rese
rpin
eR
apto
r2-
4P
OP
RN
E14
63F
or
pro
lon
ged s
edat
ion
Reso
ran
tel
Ost
rich
130
PO
NL
B28
3,40
1, 5
24A
dd f
enb
endaz
ole
or
leva
mis
ole
Rif
ab
uti
nA
vian
15P
OQ
DD
1470
Add e
tham
buto
l + e
nro
flo
xaci
n f
or
myc
ob
acte
rio
sis
Rif
abuti
nA
vian
1.15
mg/
kcal
PO
QD
E11
80A
dd e
tham
buto
l + a
zith
rom
ycin
or
clar
ith
rom
ycin
fo
r m
yco
bac
teri
osi
s
Rif
am
pin
Am
azo
n, Y
ello
w-c
hee
ked
45N
LQ
DG
713
Add e
tham
buto
l + is
on
iazi
d
Rif
amp
inA
vian
10-2
0P
OB
IDE
111,
147
3
Rif
amp
inA
vian
15P
OQ
DG
1154
Add c
ipro
flo
xaci
n +
eth
amb
uto
l fo
r
myc
ob
acte
rio
sis
Rif
amp
inB
ust
ard, H
oub
ara
20P
OB
IDG
932
Fo
r b
acte
rial
dia
rrh
ea
Rif
amp
inC
ran
e, W
ho
op
ing
45P
OQ
DG
207
Add e
tham
buto
l
Rif
amp
inP
sitt
acin
e15
PO
BID
E12
40F
or
avia
n t
ub
ercu
losi
s
Rif
amp
inR
apto
r30
PO
TID
B11
78A
dd I
T a
nd I
V a
mp
ho
teri
cin
B +
flu
cyto
sin
e
for
asp
ergi
llosi
s
Rim
an
tad
ine H
Cl
Po
ult
ry0.
1 g/
LD
rin
kN
LG
435
Ro
ben
idin
e H
Cl
Ch
icke
n33
mg/
kg f
oo
dF
eed
QD
E56
47-
day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Ro
ben
idin
e H
Cl
Ph
easa
nt,
Rin
g-n
ecke
d0.
033
g/kg
Fee
dQ
DB
895
Fo
r co
ccid
iosi
s
Ro
nid
azo
leA
vian
0.32
3 m
g/kc
alP
OQ
DE
1180
Fo
r fl
agel
late
s
Ro
nid
azo
leA
vian
0.65
g/L
Dri
nk
NL
E11
80
Ro
nid
azo
leA
vian
1 g/
LD
rin
kQ
DE
1479
Tre
at 4
tim
es y
earl
y fo
r T
rich
om
on
iasi
s
Ro
nid
azo
leA
vian
6-10
PO
QD
G57
Ro
nid
azo
leB
udge
riga
r1
g/L
Dri
nk
QD
E14
79T
reat
4 t
imes
yea
rly
for
Tri
cho
mo
nia
sis
Ro
nid
azo
leC
anar
y0.
4 g/
LD
rin
kQ
DE
695
Ro
nid
azo
leC
anar
y0.
4 g/
kg f
oo
dF
eed
On
ceE
1187
Ro
nid
azo
leF
inch
0.1
g/L
Dri
nk
QD
E15
72
Ro
nid
azo
leF
inch
6-10
PO
QD
E15
72
Ro
nid
azo
leF
inch
0.05
g/kg
fo
od
Fee
dQ
DG
1334
Fo
r co
chlo
som
iasi
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 313
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ro
nid
azo
leF
inch
0.05
g/L
Dri
nk
QD
G13
34F
or
coch
loso
mia
sis
Ro
nid
azo
leP
asse
rin
e0.
04 g
/L
Dri
nk
QD
D14
38F
or
tric
ho
mo
nia
sis,
gia
rdia
sis
and
coch
loso
mia
sis
Ro
nid
azo
leP
igeo
n6-
10N
LQ
DD
1221
Fo
r tr
ich
om
on
iasi
s
Ro
nid
azo
leP
igeo
n0.
1 g/
LD
rin
kQ
DE
1192
Fo
r h
exam
itia
sis,
add t
rim
eth
op
rim
or
enro
flo
xaci
n in
sev
ere
infe
ctio
ns
Ro
nid
azo
leP
igeo
n0.
1-0.
2 g/
LD
rin
kN
LE
1192
Fo
r tr
eatm
ent
of
tric
ho
mo
nia
sis,
giv
e
per
iodic
ally
fo
r 2
to 3
day
s fo
r p
rop
hyl
axis
Ro
nid
azo
leP
igeo
n12
.5D
rin
kQ
DE
1240
Fo
r tr
ich
om
on
iasi
s tr
eatm
ent
Ro
nid
azo
le
Pig
eon
10
P
O
NL
E
14
32
"
Ro
nid
azo
le
Pig
eon
0.
1 g/
L
Dri
nk
NL
E
14
32
"
Ro
xars
on
eP
oult
ry25
-50
mg/
kg f
oo
dF
eed
QD
E56
4N
utr
itio
nal
use
, no
sla
ugh
ter
wit
hdra
wal
Sali
cyli
c A
cid
Psi
ttac
ine
To
pic
alq2w
D14
46A
dd 3
g t
ann
ic a
cid +
3 g
sal
icyl
ic a
cid +
eth
yl a
lco
ho
l fo
r 10
0 m
l of
solu
tio
n f
or
der
mat
om
yco
sis
Sali
no
mycin
Ch
icke
n0.
06 g
/kg
Fee
dQ
DB
869
Pre
ven
tive
fo
r co
ccid
iosi
s
Salin
om
ycin
Ch
icke
n0.
075
g/kg
Fee
dQ
DB
869
Pre
ven
tive
fo
r co
ccid
iosi
s
Salin
om
ycin
Ch
icke
n60
Fee
dQ
DB
958
Fo
r co
ccid
ial p
rop
hyl
axis
Salin
om
ycin
Ch
icke
n44
-66
mg/
kg f
oo
dF
eed
QD
E56
4N
o s
laugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Salin
om
ycin
Ph
easa
nt,
Rin
g-n
ecke
d60
pp
mF
eed
On
ceB
783
Fo
r co
ccid
iosi
s
Salin
om
ycin
Po
ult
ry60
g/to
nF
eed
QD
C70
5F
or
cocc
idio
sis
Sara
flo
xacin
HC
lC
hic
ken
10P
OB
ID-T
IDA
787
Sara
flo
xaci
n H
Cl
Ch
icke
n8
Dri
nk
QD
B85
5C
on
tin
uo
us
or
4-h
our
puls
e do
se
Sara
flo
xaci
n H
Cl
Ch
icke
n0.
02 g
/L
Dri
nk
QD
B86
4F
or
Esc
heri
chia
col
i in
fect
ion
s
Sara
flo
xaci
n H
Cl
Turk
ey0.
05 g
/L
Dri
nk
NL
A80
5
Seco
barb
ital
So
diu
mB
lack
bir
d, R
ed-w
inge
d0.
025-
0.03
PO
PR
NG
1769
Add c
hlo
ralo
se
Seco
bar
bit
al S
odiu
mD
ove
5 g/
L b
ait
Fee
dO
nce
G17
63B
ait
is u
sual
ly c
orn
Seco
bar
bit
al S
odiu
mD
uck
, Mal
lard
25P
OP
RN
B10
95
Sele
niu
mP
sitt
acin
e0.
06N
Lq3d
-q2w
G16
13
Sem
du
ram
ycin
Ch
icke
nP
OQ
DG
564
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I314
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Sero
mycin
Avi
an10
PO
BID
G11
54A
dd la
mp
ren
e +
eth
amb
uto
l HC
l, ad
d
cip
rofl
oxa
cin
or
enro
flo
xaci
n o
r st
rep
tom
ycin
for
adva
nce
d c
ases
Sil
ver
Nit
rate
Avi
anT
op
ical
q10
dE
1650
Fo
r ca
ute
ry o
f p
apill
om
as
Sil
ver,
Co
llo
idal
Avi
an2
dro
ps/
kgP
OQ
DE
1435
Bro
ad s
pec
trum
Silv
er, C
ollo
idal
Avi
an40
dro
ps/
LD
rin
kQ
DE
1435
Bro
ad s
pec
trum
So
diu
m B
icarb
on
ate
Avi
an1
mE
q/kg
IV-S
CP
RN
G13
09F
irst
do
se I
V, r
emai
nder
SC
, max
imum
to
tal
do
se 4
mE
q/kg
fo
r m
etab
olic
aci
do
sis
Sodiu
m B
icar
bo
nat
eA
vian
1-4
mE
q/kg
IVN
LE
1473
Giv
e sl
ow
ly o
ver
15 t
o 3
0 m
inute
s, d
o n
ot
exce
ed 4
mE
q/kg
Sodiu
m B
icar
bo
nat
eA
vian
5 m
Eq/kg
IO-I
VO
nce
G13
11F
or
card
iop
ulm
on
ary
resu
scit
atio
n
So
diu
m C
hlo
rid
e
Avi
an
30 m
l/kg
P
O T
ID-Q
ID E
11
51 U
se 0
.9%
so
luti
on
Sodiu
m C
hlo
ride
Bir
d, A
quat
ic10
g/L
Gav
age
QD
D15
59T
o m
ain
tain
act
ivit
y o
f sa
lt g
lan
d o
f m
arin
e
bir
ds
kep
t o
n f
resh
wat
er
Sodiu
m C
hlo
ride
Bir
d, A
quat
ic10
0F
eed
QD
E15
01F
or
pel
agic
sea
bir
ds
kep
t in
fre
sh w
ater
Sodiu
m C
hlo
ride
Bir
d, A
quat
ic10
0P
ON
LE
1503
Fo
r p
roce
llifo
rm b
irds
kep
t in
fre
sh w
ater
Sodiu
m C
hlo
ride
Pen
guin
150-
1667
PO
QD
G13
53Su
pp
lem
ent
fish
die
t
Sodiu
m C
hlo
ride
Psi
ttac
ine
50 m
l/kg
IM-I
V-S
C
Q
D E
1240
Use
0.9
% s
olu
tio
n
Sodiu
m C
hlo
ride
Rap
tor
1-2%
so
luti
on
T
op
ical
N
L
E
1400
1-
2% s
olu
tio
n f
or
wo
un
ds,
was
h o
ff w
ith
in 5
min
ute
s
So
diu
m H
yp
och
lori
teF
inch
30 m
l/L
To
pic
alN
LE
1572
Fo
r sa
lmo
nel
losi
s en
viro
nm
enta
l cle
anup
, use
ho
use
ho
ld b
leac
h
So
diu
m I
od
ide
Avi
an60
IMP
RN
G54
Sodiu
m I
odid
eA
vian
67-2
00IM
NL
F12
09
Sodiu
m I
odid
eB
udge
riga
r2
mg
TD
IMP
RN
G85
Sodiu
m I
odid
eB
udge
riga
r13
4-20
0IM
QD
G12
12F
or
acute
th
yro
id h
yper
pla
sia
Sodiu
m I
odid
eB
udge
riga
r67
IMQ
DG
1212
Fo
r ch
ron
ic t
hyr
oid
hyp
erp
lasi
a
So
diu
m L
acta
te S
olu
tio
nA
vian
50 m
l/kg
IVN
LE
111
Mai
nte
nan
ce f
luid
s
Sodiu
m L
acta
te S
olu
tio
nA
vian
10-3
0 m
l/kg
IVN
LE
1650
Em
erge
ncy
car
e, g
ive
slo
wly
, war
m f
luid
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 315
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Sodiu
m L
acta
te S
olu
tio
nA
vian
25 m
l/kg
IO-I
V-S
CN
LG
1311
Sodiu
m L
acta
te S
olu
tio
nA
vian
50-1
00 m
l/kg
IO-I
V-S
CB
IDG
1756
Fo
r h
yper
uri
cem
ia, g
ive
un
til l
evel
dro
ps
to
no
rmal
Sodiu
m L
acta
te S
olu
tio
nH
awk,
Red
-tai
led
20 m
l/kg
IVN
LG
1626
Sup
po
rtiv
e th
erap
y p
ost
-tra
um
a
Sodiu
m L
acta
te S
olu
tio
nL
ory
, Red
50 m
l/kg
SCN
LG
1621
Intr
a-o
per
ativ
e fl
uid
s
Sodiu
m L
acta
te S
olu
tio
nP
sitt
acin
e50
-100
ml/
kgIO
-IP
-IV
-SC
NL
E16
88
So
diu
m S
ulf
ate
Avi
an20
00P
OQ
DE
111
Lar
ge b
irds,
giv
e sl
urr
y
Sodiu
m S
ulf
ate
Avi
an50
0-10
00P
ON
LE
1554
Fo
r b
otu
lism
to
flu
sh g
astr
oin
test
inal
tra
ct
Sodiu
m S
ulf
ate
Avi
an12
5-25
0P
ON
LG
1746
Fo
r re
mo
val o
f m
etal
s fr
om
GI
trac
t
So
mato
stati
nT
ouca
n, S
ulf
ur-
bre
aste
d0.
003
SCB
IDG
589
Sp
ecti
no
mycin
HC
lA
vian
30P
OQ
DE
565
Spec
tin
om
ycin
HC
lA
vian
1 g/
LD
rin
kQ
DE
704
Spec
tin
om
ycin
HC
lA
vian
10-4
5IM
NL
E70
4
Spec
tin
om
ycin
HC
lA
vian
0.58
mg/
kcal
IM-S
CT
IDE
1180
Spec
tin
om
ycin
HC
lA
vian
1 g/
LD
rin
kN
LE
1180
Spec
tin
om
ycin
HC
lC
anar
y0.
2-0.
4 g/
LD
rin
kN
LE
1187
Spec
tin
om
ycin
HC
lC
hic
ken
5 m
g T
DSC
On
ceB
848
Day
-old
neo
nat
es
Spec
tin
om
ycin
HC
lC
hic
ken
2 g/
LD
rin
kN
LC
1307
Fo
r M
ycop
lasm
a ga
llise
pticum
in b
roile
rs
Spec
tin
om
ycin
HC
lC
hic
ken
0.5
g/L
Dri
nk
NL
C13
07F
or
imp
rove
d w
eigh
t ga
in in
bro
ilers
Spec
tin
om
ycin
HC
lD
uck
5SC
On
ceB
841
Fo
r E
. col
i an
d S
alm
onel
la
Spec
tin
om
ycin
HC
lF
inch
0.2-
0.4
g/L
Dri
nk
QD
E15
72
Spec
tin
om
ycin
HC
lF
inch
0.4
g/kg
fo
od
Fee
dQ
DE
1572
Spec
tin
om
ycin
HC
lP
asse
rin
e0.
2-0.
4 g/
LD
rin
kQ
DE
1437
Add d
rug
to f
oo
d a
t th
e sa
me
tim
e
Spec
tin
om
ycin
HC
lP
asse
rin
e0.
4 g/
kg s
oft
fo
od
Fee
dQ
DE
1437
Add d
rug
to d
rin
k at
th
e sa
me
tim
e
Spec
tin
om
ycin
HC
lP
asse
rin
e, S
mal
l0.
4 g/
kg f
oo
dF
eed
On
ceE
1187
Spec
tin
om
ycin
HC
lP
asse
rin
e, S
mal
l0.
2-0.
4 g/
LD
rin
kN
LE
1187
Spec
tin
om
ycin
HC
lP
igeo
n25
IM-S
CT
IDE
565,
106
1
Spec
tin
om
ycin
HC
lP
igeo
n30
PO
QD
F10
61
Spec
tin
om
ycin
HC
lP
igeo
n0.
15-0
.25
g/L
Dri
nk
NL
G26
0
Spec
tin
om
ycin
HC
lP
oult
ry0.
264-
0.53
g/L
Dri
nk
QD
C56
4
Spec
tin
om
ycin
HC
lP
oult
ry0.
132
g/L
Dri
nk
QD
C56
4P
rop
hyl
acti
c
Spec
tin
om
ycin
HC
lP
oult
ry2.
5-20
mg
TD
SCQ
DC
564
Ch
ick
do
sage
Spec
tin
om
ycin
HC
lP
sitt
acin
e10
-30
IMB
ID-T
IDE
1240
Gra
m n
egat
ive
ente
riti
s
Spec
tin
om
ycin
HC
lP
sitt
acin
e35
INN
LE
1240
Giv
e 1/
3 ea
ch n
are,
rem
ain
der
IM
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I316
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Spec
tin
om
ycin
HC
lR
apto
r50
IMB
IDG
234
Spec
tin
om
ycin
HC
lT
urk
ey12
.5-2
5 m
g T
DSC
NL
C13
07D
ilute
1:4
no
rmal
sal
ine
for
new
ly h
atch
ed
chic
ks
Spec
tin
om
ycin
HC
lT
urk
ey10
mg
TD
SCN
LC
1307
Inje
ct in
bas
e o
f th
e n
eck
of
1 to
3-d
ay-o
ld
po
ult
s fo
r ai
rsac
culit
is
Sp
iram
ycin
Avi
an25
0P
OQ
DE
565
Spir
amyc
inA
vian
100
IM-P
ON
LE
924
Spir
amyc
inA
vian
2 g/
LD
rin
kN
LE
1180
Spir
amyc
inA
vian
0.58
mg/
kcal
IMQ
DE
1180
Spir
amyc
inA
vian
1.08
mg/
kcal
PO
QD
E11
80
Spir
amyc
inC
anar
y0.
2-0.
4 g/
LD
rin
kQ
DE
695
Spir
amyc
inC
anar
y40
0 m
g/kg
fo
od
Fee
dQ
DE
695
Spir
amyc
inP
asse
rin
e, S
mal
l0.
2-0.
4 g/
LD
rin
kN
LE
1187
Spir
amyc
inP
asse
rin
e, S
mal
l0.
4 g/
kg f
oo
dF
eed
On
ceE
1187
Spir
amyc
inP
igeo
n25
IMQ
DE
565,
106
1
Spir
amyc
inP
igeo
n50
PO
QD
F10
61
Spir
amyc
inP
oult
ry0.
4 g/
LD
rin
kQ
DC
564
Spir
amyc
inR
apto
r20
IMN
LE
1463
Fo
r b
acte
rial
infe
ctio
ns
Sta
no
zo
lol
Avi
an25
-50
IMq3d
-QW
E11
1, 1
209,
124
0
Stan
ozo
lol
Avi
an25
-50
IMq3-
4dE
1473
Stan
ozo
lol
Avi
an25
-50
IMq3d
-QW
G13
09A
nab
olic
age
nt
Stan
ozo
lol
Psi
ttac
ine
0.01
6 g/
LD
rin
kN
LE
763
Fo
r deb
ilita
tio
n, a
no
rexi
a an
d a
nem
ia
Stan
ozo
lol
Psi
ttac
ine
0.5-
1P
aren
tera
lN
LE
763
Fo
r deb
ilita
tio
n, a
no
rexi
a an
d a
nem
ia
Str
ep
tom
ycin
Su
lfate
Avi
an10
-30
IMB
ID-T
IDE
111
Stre
pto
myc
in S
ulf
ate
Avi
an33
IMB
ID-T
IDE
741
Use
d in
larg
e b
irds
and p
oult
ry
Stre
pto
myc
in S
ulf
ate
Avi
an15
IM-P
ON
LE
924
Po
or
spec
trum
Stre
pto
myc
in S
ulf
ate
Avi
an0.
65 m
g/kc
alIM
BID
-TID
E11
80
Stre
pto
myc
in S
ulf
ate
Avi
an1.
28-4
.67
mg/
kcal
PO
QD
E11
80
Stre
pto
myc
in S
ulf
ate
Avi
an10
-30
IMB
ID-T
IDE
1470
Stre
pto
myc
in S
ulf
ate
Avi
an30
IMB
IDG
55, 1
154
Add e
tham
buto
l + r
ifam
pin
fo
r
myc
ob
acte
rio
sis
Stre
pto
myc
in S
ulf
ate
Avi
an10
IMB
IDG
819
Add r
ifam
pin
+ e
tham
buto
l fo
r av
ian
tub
ercu
losi
s
Stre
pto
myc
in S
ulf
ate
Ch
icke
n25
-50
IMQ
DA
320
Stre
pto
myc
in S
ulf
ate
Ch
icke
n50
-100
PO
QD
E56
5
Stre
pto
myc
in S
ulf
ate
Ph
easa
nt
220
mg/
kg f
oo
dF
eed
QD
G67
8
Stre
pto
myc
in S
ulf
ate
Ph
easa
nt
55-1
10 m
g/kg
fo
od
Fee
dQ
DG
678
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 317
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Stre
pto
myc
in S
ulf
ate
Pig
eon
100-
200
PO
QD
E56
5, 1
061
Stre
pto
myc
in S
ulf
ate
Pig
eon
25-5
0IM
QD
F10
61
Stre
pto
myc
in S
ulf
ate
Po
ult
ry55
PO
QD
C56
4
Stre
pto
myc
in S
ulf
ate
Po
ult
ry0.
068-
0.1
g/L
Dri
nk
QD
C56
4
Stre
pto
myc
in S
ulf
ate
Po
ult
ry13
.2 m
g/kg
fo
od
Fee
dQ
DE
564
Add p
enic
illin
, nutr
itio
nal
use
, no
sla
ugh
ter
wit
hdra
wal
Stre
pto
myc
in S
ulf
ate
Quai
l55
-110
mg/
kg f
oo
dF
eed
QD
G67
8
Stre
pto
myc
in S
ulf
ate
Rap
tor
15P
ON
LE
1463
May
giv
e w
ith
kao
lin o
r su
lfo
nam
ide
for
bac
teri
al in
fect
ion
s
Su
ccim
er
Avi
an25
-35
PO
BID
D12
21, 1
470
Pre
ferr
ed o
ral d
rug
for
lead
to
xico
sis
Succ
imer
Avi
an30
PO
QD
E11
20F
or
zin
c to
xico
ses
Succ
imer
Avi
an30
PO
BID
E11
51M
etal
ch
elat
ing
agen
t
Succ
imer
Avi
an25
-35
PO
BID
E12
36G
ive
5 day
s p
er w
eek
for
lead
to
xico
sis
Succ
imer
Avi
an15
-35
PO
BID
G13
37F
or
lead
po
iso
nin
g
Succ
imer
Bir
d, A
quat
ic25
-35
PO
BID
D14
78
Succ
imer
Psi
ttac
ine
30N
LN
LG
1710
Fo
r zi
nc
toxi
city
Succ
imer
R
apto
r 25
P
O
BID
E
13
59
Aft
er 2
day
s o
ff, r
epea
t o
ver
3-5
wee
ks f
or
lead
to
xici
ty
Su
cra
lfate
Avi
an25
PO
TID
E14
92M
ix w
ith
wat
er f
or
GI
ble
edin
g
Sucr
alfa
teL
ori
keet
, Rai
nb
ow
24P
OB
IDG
1620
Fo
r in
test
inal
ulc
ers
Sucr
alfa
te
Psi
ttac
ine
25
PO
T
ID
E
111
Su
cro
seR
apto
r<
5 m
l/kg
5%
so
lnP
OP
RN
E14
00M
ild p
urg
ativ
e, m
ay s
tim
ula
te a
pp
etit
e
Su
lfach
lorp
yri
dazin
e
Avi
an
0.17
5 g/
L
Dri
nk
QD
E
12
40 A
nti
bac
teri
al,*
use
5-1
0 day
s
Sulf
ach
lorp
yrid
azin
e A
vian
0.
125
ml p
ow
der
D
rin
k Q
Dlll
llll
G
1309
A
nti
bac
teri
al*
*
Vet
isulid
Ora
l Po
wder
® is
560
mg/
ml
vo
lum
e fo
r fl
ock
tre
atm
ent
for
E. c
oli
Sulf
ach
lorp
yrid
azin
e A
vian
5
9 g/
L D
rin
k Q
D
E
1479
U
se 5
day
s p
er w
eek,
red
uce
s sh
eddin
g o
f
Ato
xop
lasm
a
Sulf
ach
lorp
yrid
azin
e A
vian
0.
4 g/
L
Dri
nk
QD
G
57
R
epea
t af
ter
2 day
s, a
nti
par
asit
ic
Sulf
ach
lorp
yrid
azin
eC
anar
y0.
15 g
/L
Dri
nk
QD
-q2d
E11
87G
ive
5 day
s p
er w
eek
un
til m
olt
ing
com
ple
te
in ju
ven
iles
wit
h a
toxo
pas
mo
sis
Sulf
ach
lorp
yrid
azin
eC
anar
y0.
3 g/
LD
rin
kQ
D-q
2dE
1187
Giv
e 5
day
s p
er w
eek
for
cocc
idio
sis
Sulf
ach
lorp
yrid
azin
eC
anar
y0.
15-.
0.3
g/L
Dri
nk
NL
E11
87
Sulf
ach
lorp
yrid
azin
eP
asse
rin
e0.
15 g
/L
Dri
nk
QD
G13
34G
ive
5 day
s o
f ea
ch w
eek,
co
nti
nue
un
til a
fter
mo
ltin
g
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I318
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Sulf
ach
lorp
yrid
azin
eP
asse
rin
e, S
mal
l0.
15-.
0.3
g/L
Dri
nk
NL
E11
87
Sulf
ach
lorp
yrid
azin
eP
igeo
n0.
3 g/
LD
rin
kQ
DG
260
Sulf
ach
lorp
yrid
azin
eP
igeo
n0.
3 g/
LD
rin
kQ
DG
260
Su
lfad
iazin
e,
Sil
ver
Psi
ttac
ine
1% c
ream
fo
rmula
To
pic
alN
LD
1448
Po
st-s
urg
ical
wo
un
d c
are
Su
lfad
iazin
e,
Su
lfam
era
zin
e,
Su
lfam
eth
azin
e
Pen
guin
, Afr
ican
300-
400
Fee
dB
IDD
1614
Pre
cede
wit
h s
ulf
amet
haz
ine
inje
ctab
le, g
ive
do
se in
fis
h f
or
mal
aria
Su
lfad
imeth
oxin
eA
vian
24IM
NL
F12
09
Sulf
adim
eth
oxi
ne
Avi
an25
IM-P
ON
LE
924
Sulf
adim
eth
oxi
ne
Ch
icke
n0.
5 g/
LD
rin
kN
LB
826
Fo
r P
aste
urel
la m
ulto
cida
an
d H
emop
hilu
s
galli
naru
m
Sulf
adim
eth
oxi
ne
Cra
ne
50P
OQ
DE
1361
Fo
r co
ccid
iosi
s
Sulf
adim
eth
oxi
ne
Fal
con
25 (
50 lo
adin
g do
se)
PO
QD
E10
27F
or
cocc
idio
sis,
do
no
t dep
rive
of
wat
er
Sulf
adim
eth
oxi
ne
Gull
25P
OB
IDE
1357
cocc
idio
sis
Sulf
adim
eth
oxi
ne
Pig
eon
25P
OB
IDG
590
Sulf
adim
eth
oxi
ne
Pig
eon
250
IMB
IDA
992
Fo
r co
ccid
iosi
s
Sulf
adim
eth
oxi
ne
Pig
eon
0.
5 g/
L
Dri
nk
QD
E
14
32
Fo
r co
ccid
iosi
s an
d a
toxo
pla
smo
sis
Sulf
adim
eth
oxi
ne
Pig
eon
0.19
-0.2
5 g/
LD
rin
kQ
DG
260
Lo
adin
g do
se 3
75 m
g/L
Sulf
adim
eth
oxi
ne
Po
ult
ry0.
25-0
.5 g
/L
Dri
nk
QD
C56
4
Sulf
adim
eth
oxi
ne
Rap
tor
25N
LQ
DE
1132
Do
ub
le d
ose
fo
r fi
rst
day
fo
r co
ccid
iosi
s
Sulf
adim
eth
oxi
ne
Rap
tor
25-5
0P
OQ
DG
94Ju
ven
ile d
osa
ge, r
epea
t af
ter
2 day
s
Su
lfad
oxin
e +
Pyri
meth
am
ine
Avi
an1
PO
QW
E14
79
Sulf
ado
xin
e +
Pyr
imet
ham
ine
Avi
an0.
3P
ON
LE
1650
Do
sage
bas
ed o
n p
yrim
eth
amin
e fo
r
Leu
cocy
tozo
on a
nd P
lasm
odiu
m
Sulf
ado
xin
e +
Pyr
imet
ham
ine
Psi
ttac
ine
0.5
PO
BID
E13
65F
or
sarc
ocy
sto
sis
Sulf
amer
azin
eA
vian
2 g/
LD
rin
kQ
DE
924
Rep
eat
afte
r 2
day
s fo
r co
ccid
iosi
s
Su
lfam
eth
azin
eA
vian
30IM
-SC
NL
E70
4
Sulf
amet
haz
ine
Avi
an0.
2 g/
LD
rin
kQ
DE
704
Rep
eat
afte
r 2
day
s
Sulf
amet
haz
ine
Avi
an50
PO
NL
E70
4
Sulf
amet
haz
ine
Avi
an1
g/L
Dri
nk
NL
E74
1F
or
cocc
idio
sis
plu
s m
ild r
esp
irat
ory
an
d
ente
ric
dis
ease
s
Sulf
amet
haz
ine
Avi
an1
g/L
Dri
nk
NL
E74
1F
or
cocc
idio
sis
plu
s m
ild r
esp
irat
ory
an
d
ente
ric
dis
ease
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 319
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Sulf
amet
haz
ine
Avi
an0.
15 g
/L
Dri
nk
NL
E11
80
Sulf
amet
haz
ine
Avi
an0.
125
g/L
Dri
nk
QD
G57
Use
liquid
fo
rmula
tio
n, w
ait
2 day
s th
en
rep
eat
Sulf
amet
haz
ine
Budge
riga
r7
PO
QD
G57
Wai
t 2
day
s th
en r
epea
t
Sulf
amet
haz
ine
Can
ary
0.15
g/L
Dri
nk
NL
E11
87
Sulf
amet
haz
ine
Can
ary
0.15
g/L
Dri
nk
QD
E69
5
Sulf
amet
haz
ine
Ch
icke
n1
g/L
Dri
nk
QD
E56
412
-day
sla
ugh
ter
wit
hdra
wal
Sulf
amet
haz
ine
Pas
seri
ne
0.15
g/L
Dri
nk
QD
E14
37
Sulf
amet
haz
ine
Pas
seri
ne,
Sm
all
0.15
g/L
Dri
nk
NL
E11
87
Sulf
amet
haz
ine
Pen
guin
, Afr
ican
83-1
25IM
BID
D16
14Sw
itch
to
sulf
adia
zin
e +
sulf
amer
azin
e +
sulf
amet
haz
ine
wh
en a
ble
to
giv
e o
rally
fo
r
mal
aria
Sulf
amet
haz
ine
Pig
eon
2
g/L
D
rin
k Q
D
E
704
Rep
eat
1 to
2 t
imes
at
2-day
inte
rval
s
Sulf
amet
haz
ine
Pig
eon
2
g/L
D
rin
k Q
D
E
704
Rep
eat
afte
r 5
day
s
Sulf
amet
haz
ine
Pig
eon
2 g/
LD
rin
kQ
DE
1240
Wai
t 2
day
s th
en r
epea
t fo
r 3
trea
tmen
t cy
cles
for
cocc
idio
sis,
per
hap
s to
xop
lasm
osi
s
Sulf
amet
haz
ine
Pig
eon
3.33
-6.6
6 g/
LD
rin
kQ
DE
1240
Fo
r co
ccid
iosi
s, p
erh
aps
To
xop
lasm
osi
s
Sulf
amet
haz
ine
Pig
eon
3.33
-6.6
6 g/
LD
rin
kQ
DE
1432
Sulf
amet
haz
ine
Pig
eon
1.1
g/L
Dri
nk
QD
G23
2
Sulf
amet
haz
ine
Pig
eon
1.1
g/L
Dri
nk
QD
G26
0L
oad
ing
do
se 3
75 m
g/L
, tre
at w
ith
B
vita
min
s fo
r 5
day
s th
en r
epea
t
Sulf
amet
haz
ine
Po
ult
ry0.
19-0
.25
g/L
PO
QD
C56
4
Sulf
amet
haz
ine
Po
ult
ry1
g/L
Dri
nk
QD
C56
4
Sulf
amet
haz
ine
Rap
tor
1 g/
LD
rin
kQ
DE
1612
Rep
eat
afte
r 2
day
s
Su
lfan
itra
nC
hic
ken
300
mg/
kg f
oo
dF
eed
QD
E56
4A
dd n
itro
mid
e +
ro
xars
on
e, 5
-day
sla
ugh
ter
wit
hdra
wal
, pro
ph
ylac
tic
Sulf
anit
ran
Po
ult
ry30
0 m
g/kg
fo
od
Fee
dQ
DE
564
Add n
itro
mid
e +
ro
xars
on
e, n
utr
itio
nal
use
,
no
sla
ugh
ter
wit
hdra
wal
Su
lfaq
uin
oxali
ne
An
seri
form
es50
0 m
g/kg
fo
od
Fee
dO
nce
G59
7
Sulf
aquin
oxa
line
Ch
icke
n0.
17 g
/L
Dri
nk
QD
E56
410
-day
sla
ugh
ter
wit
hdra
wal
Sulf
aquin
oxa
line
Duck
0.25
g/kg
Fee
dO
nce
B82
5F
or
Rie
mer
ella
ana
tipe
stife
r in
duck
lings
Sulf
aquin
oxa
line
Lo
ry10
0P
OQ
DG
57
Sulf
aquin
oxa
line
Pig
eon
100
PO
QD
G57
Sulf
aquin
oxa
line
Po
ult
ry0.
397
g/L
Dri
nk
QD
C56
4
Sulf
aquin
oxa
line
Rap
tor
0.03
4 g/
LD
rin
kQ
DE
1612
Rep
eat
afte
r 2
day
s
Sulf
aquin
oxa
line
Turk
ey0.
17 g
/L
Dri
nk
QD
E56
410
-day
sla
ugh
ter
wit
hdra
wal
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I320
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Su
lfaq
uin
oxali
ne +
Dia
veri
din
e
Avi
an0.
1 g/
kg f
eed
Fee
dQ
DE
1492
Fo
r co
ccid
iosi
s
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Avi
an0.
1 g/
LD
rin
kQ
DE
1492
Fo
r co
ccid
iosi
s
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Avi
an0.
1 g/
kg f
oo
dF
eed
QD
E16
50F
or
cocc
idio
sis
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Avi
an0.
1 g/
LD
rin
kQ
DE
1650
Fo
r co
ccid
iosi
s
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Ch
icke
n0.
5 g/
kg f
eed
Fee
dq4d
E14
79C
occ
idia
l pre
ven
tive
fo
r m
arke
t b
roile
rs
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Ch
icke
n0.
55 g
/kg
fee
dF
eed
QD
E14
79C
occ
idia
l pre
ven
tive
fo
r re
pla
cem
ent/
bre
eder
0 to
8-w
eek
old
bro
ilers
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Ch
icke
n0.
33 g
/kg
fee
dF
eed
QD
E14
79C
occ
idia
l pre
ven
tive
fo
r re
pla
cem
ent/
bre
eder
8 to
12-
wee
k o
ld b
roile
rs
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Po
ult
ry0.
56 g
/L
Dri
nk
QD
E14
79R
epea
t af
ter
3 day
s, c
occ
idio
sis
ther
apy
Sulf
aquin
oxa
line
+
Dia
veri
din
e
Po
ult
ry0.
56 g
/L
Dri
nk
q4d
E14
79C
occ
idia
l pre
ven
tive
Su
lfath
iazo
le S
od
ium
Po
ult
ry1
g/L
Dri
nk
QD
C56
4
Su
lfatr
oxazo
leP
igeo
n50
PO
BID
A56
5A
dd t
rim
eth
op
rim
Su
lfo
nam
ide
Avi
an0.
045
g/L
Dri
nk
QD
E92
4R
epea
t af
ter
2 day
s fo
r co
ccid
iosi
s
Tam
oxif
en
Cit
rate
Gal
lifo
rmes
40N
LN
LB
677
Induce
mo
ltin
g
Tan
nic
Acid
Avi
an3
gT
op
ical
PR
NE
1240
Add a
spir
in +
eth
yl a
lco
ho
l to
pre
par
e 10
0
ml f
or
fun
gal d
erm
atit
is
Tan
nic
Aci
dP
sitt
acin
eT
op
ical
q2w
D14
46A
dd 3
g t
ann
ic a
cid +
3 g
sal
icyl
ic a
cid +
eth
yl a
lco
ho
l fo
r 10
0 m
l of
solu
tio
n f
or
der
mat
om
yco
sis
Tea
Ram
ph
asti
dD
ilute
so
luti
on
Dri
nk
QD
G14
70P
reve
nt
hem
och
rom
ato
sis
by
limit
ing
iro
n
up
take
, no
cit
rus
in d
iet
Terb
inafi
ne
Avi
an10
-15
PO
QD
-BID
E16
68M
ay c
om
bin
e w
ith
itra
con
azo
le f
or
syst
emic
myc
osi
s
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 321
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Ter
bin
afin
eA
vian
10-1
5P
OQ
D-B
IDG
1338
Fo
r m
yco
sis
Ter
bin
afin
eP
arro
t, G
rey
Co
ngo
1g/L
aqueo
us
Neb
uliz
eT
IDG
1743
Fo
r re
spir
ato
ry a
sper
gillo
sis
Ter
bin
afin
eR
apto
r30
PO
QD
E13
59P
rop
hyl
acti
c
Test
ost
ero
ne
Avi
an10
IMQ
WE
924
Fo
r fe
ath
er d
iso
rder
s
Tes
tost
ero
ne
Avi
an8
IMQ
WE
1473
Tes
tost
ero
ne
Can
ary
2.5
IMQ
WD
1441
Fo
r b
aldn
ess
Tes
tost
ero
ne
Cyp
ion
ate
Psi
ttac
ine
8IM
QW
E12
40U
se w
ith
gre
at c
are
Teta
nu
s A
nti
toxin
Fal
con
, Sak
er25
0 IU
IMQ
DG
822
Lo
adin
g do
se o
f 12
5 IU
eac
h I
V a
nd I
M in
lesi
on
fo
r lo
caliz
ed t
etan
us
Tetr
acycli
ne
Avi
an0.
031-
0.12
4 g/
LD
rin
kN
LE
111
Tet
racy
clin
eA
vian
200-
250
PO
BID
E11
1
Tet
racy
clin
eA
vian
1.25
ml/
LD
rin
kN
LE
741
Tet
racy
clin
eG
allif
orm
es30
-60
Dri
nk
QD
E70
4
Tet
racy
clin
eP
hea
san
t0.
04-0
.12
g/L
Fee
dQ
DG
678
Tet
racy
clin
eP
hea
san
t55
-110
mg/
kg f
oo
dF
eed
QD
G67
8
Tet
racy
clin
eP
igeo
n22
0 m
g/kg
fo
od
Dri
nk
QD
E70
450
%, 2
.5 g
per
tea
spo
on
Tet
racy
clin
eP
igeo
n0.
549
g/L
Dri
nk
QD
E12
40F
or
chla
myd
op
hilo
sis
Tet
racy
clin
eP
igeo
n50
mg
TD
PO
QD
G47
Rem
ove
gri
t fr
om
die
t duri
ng
trea
tmen
t
Tet
racy
clin
eP
oult
ry60
Dri
nk
QD
C70
5
Tet
racy
clin
eP
sitt
acin
e50
PO
TID
E56
5
Tet
racy
clin
eP
sitt
acin
e1
g/L
so
ft f
oo
dF
eed
On
ceE
763
May
add lo
ng-
last
ing
oxy
tetr
acyc
line
Tet
racy
clin
eQ
uai
l22
0 m
g/kg
fo
od
Fee
dQ
DG
678
Tet
racy
clin
eQ
uai
l55
-110
mg/
kg f
oo
dF
eed
QD
G67
8
Th
iab
en
dazo
leA
nse
rifo
rmes
550
NL
NL
G13
25F
or
tho
rny
hea
ded
wo
rms
Th
iab
endaz
ole
Avi
an10
0P
OQ
DE
111
Fo
r Syn
gam
us
Th
iab
endaz
ole
Avi
an25
0-50
0P
Oq2w
E11
1F
or
asca
rids
Th
iab
endaz
ole
Avi
an20
0P
Oq10
dE
924
Fo
r Syn
gam
us, A
mid
osto
mum
Th
iab
endaz
ole
Avi
an10
0P
OQ
DG
1309
Fo
r Syn
gam
us tra
chei
Th
iab
endaz
ole
Avi
an25
0-50
0P
Oq10
dG
1309
Fo
r as
cari
ds
Th
iab
endaz
ole
Ch
icke
n5
g/kg
fo
od
Fee
dQ
DG
1325
Fo
r as
cari
ds,
Cap
illar
ia a
nd g
apew
orm
s
Th
iab
endaz
ole
Ch
icke
n44
PO
On
ceG
1325
Fo
r A
scar
ids,
Cap
illar
ia a
nd g
apew
orm
s
Th
iab
endaz
ole
Cra
ne
100
PO
QW
-q2w
E13
61F
or
inte
stin
al s
tro
ngy
les,
asc
arid
s
Th
iab
endaz
ole
Fal
con
100
PO
On
ceG
1325
Fo
r as
cari
ds,
Cap
illar
ia a
nd g
apew
orm
s
Th
iab
endaz
ole
Pig
eon
44P
OO
nce
G13
25F
or
Asc
arid
s, C
apill
aria
an
d g
apew
orm
s
Th
iab
endaz
ole
Rap
tor
100-
200
PO
BID
E14
00C
on
tro
l of
nem
ato
des
, may
inte
rfer
e w
ith
egg
layi
ng
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I322
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Th
iab
endaz
ole
Rat
ite
50N
LN
LG
418
Th
iab
endaz
ole
Turk
ey44
PO
On
ceG
1325
Fo
r as
cari
ds,
Cap
illar
ia a
nd g
apew
orm
s
Th
iam
ine
An
seri
form
es25
mg/
kg f
ish
Fee
dO
nce
E11
90
Th
iam
ine
An
seri
form
es25
Fee
dQ
DG
46Su
pp
lem
ent
for
fish
eat
ers
Th
iam
ine
Avi
an1-
2IM
-PO
On
ceE
1650
Fo
r h
ypo
vita
min
osi
s B1
Th
iam
ine
Bir
d, P
isci
voro
us
0.2
g/kg
fis
hF
eed
QD
E15
54F
or
fish
die
t
Th
iam
ine
Bir
d, P
isci
voro
us
1-2
PO
QD
E15
54F
or
fish
die
t
Th
iam
ine
Cra
ne
1-2
PO
QD
E11
1
Th
iam
ine
Duck
100
µg/
LD
rin
kQ
DE
1358
Fo
r st
arga
zin
g an
d w
eigh
t lo
ss in
duck
lings
Th
iam
ine
Eag
le, B
ald
1-3
NL
QW
E11
88If
eat
ing
fro
zen
fis
h
Th
iam
ine
Osp
rey
1-3
NL
QW
E11
88If
eat
ing
fro
zen
fis
h
Th
iam
ine
Rap
tor
1-2
PO
QD
E11
1
Th
iam
ine
Rap
tor
2P
OQ
WE
1068
Wh
ile f
eedin
g fr
oze
n f
ish
Th
iam
ine
Rap
tor
0.2-
0.25
g/kg
fis
hF
eed
QD
E11
32F
or
fish
die
ts
Th
iam
ine
Rap
tor
25IM
NL
E14
33
Th
iam
ine
Rap
tor
1IM
NL
E14
63
Th
iop
en
tal
So
diu
mC
hic
ken
16.2
IMP
RN
B10
80A
dd p
ento
bar
bit
al s
odiu
m
Th
iop
enta
l So
diu
mC
hic
ken
10-1
2.5
NL
PR
NB
1126
Th
iop
enta
l So
diu
mD
uck
, Mal
lard
54P
OP
RN
B10
95
Th
iop
enta
l So
diu
m
Turk
ey
16.2
IM
P
RN
B
10
80
Add p
ento
bar
bit
al s
odiu
m
Th
yro
id S
tim
ula
tin
g
Ho
rmo
ne
Am
azo
n P
arro
t1
IU T
DIM
On
ceB
88
Th
yro
id S
tim
ula
tin
g
Ho
rmo
ne
Co
ckat
iel
0.1
U T
DIM
On
ceB
88
Th
yro
id S
tim
ula
tin
g
Ho
rmo
ne
Par
rot,
Gre
y1
U T
DIM
NL
B53
3
Th
yro
id S
tim
ula
tin
g
Ho
rmo
ne
Pig
eon
1 U
TD
IMO
nce
B88
Th
yro
id S
tim
ula
tin
g
Ho
rmo
ne
Psi
ttac
ine
1-2
IU/kg
IMN
LE
1473
Tia
mu
lin
Avi
an25
-50
PO
QD
E56
5
Tia
mulin
Avi
an1.
08 m
g/kc
alP
OQ
DE
1180
Tia
mulin
Avi
an25
PO
QD
E14
92F
or
myc
op
lasm
osi
s
Tia
mulin
Ch
icke
n0.
25 g
/L
Dri
nk
NL
B85
7F
or
Myc
opla
sma
Tia
mulin
Gal
lifo
rmes
25-3
0D
rin
kQ
DE
704
Use
1/2
stre
ngt
h f
or
pro
ph
ylax
is
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 323
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Tia
mulin
Pig
eon
0.22
5 g/
LD
rin
kQ
DE
704
Tic
arc
illi
nA
vian
150-
200
IM-I
VT
ID-Q
IDE
111
Tic
arci
llin
Avi
an5.
1 m
g/kc
alIM
-IV
q2-
4hE
1180
Syn
ergi
stic
wit
h a
min
ogl
yco
sides
Tic
arci
llin
Rap
tors
200
IMT
IDE
1027
Tic
arci
llin
Pig
eon
200
IM-I
VB
ID-T
IDG
590
Tic
arci
llin
Psi
ttac
ine
200
IMB
ID-Q
IDE
565
Til
eta
min
e +
Zo
lazep
am
Alb
atro
ss2
IVP
RN
E16
17In
duct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amA
vian
5-10
IMP
RN
E11
81, 1
231
Go
od im
mo
bili
zati
on
Tile
tam
ine
+ Z
ola
zep
amA
vian
2IV
PR
NE
1617
Induct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amB
udge
riga
r15
-20
IMP
RN
E24
3
Tile
tam
ine
+ Z
ola
zep
amB
udge
riga
r20
-22
IMP
RN
G51
8
Tile
tam
ine
+ Z
ola
zep
amC
asso
war
y2-
3IV
PR
NE
1533
Tile
tam
ine
+ Z
ola
zep
amC
hic
ken
30IM
On
ceB
1737
Tile
tam
ine
+ Z
ola
zep
amC
ock
ato
o, G
Sulf
ur-
cres
ted
2.64
-25.
2IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amD
ove
, Rin
g-n
ecke
d50
-75
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amD
uck
5-10
IMP
RN
E24
3
Tile
tam
ine
+ Z
ola
zep
amE
agle
, Bal
d15
NL
PR
ND
1401
Sup
ple
men
t w
ith
15
mg/
kg k
etam
ine
Tile
tam
ine
+ Z
ola
zep
amE
gret
, Cat
tle
2IV
PR
NE
1617
Induct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amE
mu
2-3
IVP
RN
E15
33
Tile
tam
ine
+ Z
ola
zep
amE
mu
5-10
IMP
RN
E16
17In
duct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amF
lam
ingo
22IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amF
lam
ingo
, Ch
ilean
6.6
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amG
ann
et2
IVP
RN
E16
17In
duct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amG
oo
se, L
esse
r M
agel
lan
6.6-
8.8
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amG
oo
se, W
hit
e-fr
on
ted
2.7
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amH
awk
15N
LP
RN
D14
01M
ay c
ause
sal
ivat
ion
an
d p
oo
r
imm
ob
iliza
tio
n
Tile
tam
ine
+ Z
ola
zep
amH
orn
bill
, Rh
ino
cero
s28
.7IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amIb
is, W
oo
d11
IMP
RN
G51
8
Tile
tam
ine
+ Z
ola
zep
amJa
bir
us
2IV
PR
NE
1617
Induct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amM
acaw
, Sca
rlet
4.4-
11IM
PR
NB
1393
Tile
tam
ine
+ Z
ola
zep
amO
spre
y9.
26-1
7.6
IMP
RN
G51
8
Tile
tam
ine
+ Z
ola
zep
amO
stri
ch5-
20IM
PR
NB
522
Ch
ick
do
sage
Tile
tam
ine
+ Z
ola
zep
amO
stri
ch4-
5IM
PR
NB
1393
Tile
tam
ine
+ Z
ola
zep
amO
stri
ch5-
10IM
PR
NG
481
Add d
iaze
pam
just
pri
or
to r
eco
very
fo
r
cap
tive
an
imal
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I324
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Tile
tam
ine
+ Z
ola
zep
amO
wl
10N
LP
RN
D14
01Su
pp
lem
ent
wit
h 1
0 m
g/kg
ket
amin
e P
RN
Tile
tam
ine
+ Z
ola
zep
amP
arak
eet,
Rin
g-n
ecke
d26
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amP
arro
t, P
atag
on
ian
11IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amP
artr
idge
, Cre
sted
Wo
od
10IM
PR
NB
1393
Tile
tam
ine
+ Z
ola
zep
amP
ea F
ow
l11
.3IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amP
elic
an2
IVP
RN
E16
17In
duct
ion
fo
r ga
s an
esth
esia
Tile
tam
ine
+ Z
ola
zep
amP
hea
san
t, G
old
en16
.6IM
PR
NB
1393
Tile
tam
ine
+ Z
ola
zep
amP
igeo
n40
-60
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amP
igeo
n30
-60
IMO
nce
B17
37
Tile
tam
ine
+ Z
ola
zep
amP
love
r17
.6IM
PR
NG
518
Tile
tam
ine
+ Z
ola
zep
amP
sitt
acin
e10
NL
PR
ND
1401
Tile
tam
ine
+ Z
ola
zep
amP
sitt
acin
e5-
10IM
PR
NE
1240
Pro
vides
go
od im
mo
bili
zati
on
Tile
tam
ine
+ Z
ola
zep
amR
apto
r10
-20
IMN
LD
1400
Tile
tam
ine
+ Z
ola
zep
amR
atit
e2-
5IM
PR
NG
418
Sup
ple
men
t w
ith
ket
amin
e P
RN
Tile
tam
ine
+ Z
ola
zep
amSt
ork
2-5
IMN
LE
243
Sedat
ion
Tile
tam
ine
+ Z
ola
zep
amSw
an, B
lack
6.6
NL
PR
ND
1401
Sup
ple
men
t w
ith
6.6
mg/
kg k
etam
ine
PR
N
Tile
tam
ine
+ Z
ola
zep
amT
eal,
Blu
e-w
inge
d22
-35
IMP
RN
B13
93
Tile
tam
ine
+ Z
ola
zep
amW
oo
dco
ck44
IMP
RN
G51
8
Til
mic
osi
nC
hic
ken
0.07
5 g/
LD
rin
kN
LA
804
Fo
r M
ycop
lasm
a
Tilm
ico
sin
Ch
icke
n0.
25-0
.5 g
/L
Dri
nk
NL
B76
8F
or
Myc
opla
sma
Tilm
ico
sin
Ch
icke
n0.
1-0.
3 g/
LD
rin
kN
LB
798
Tin
idaz
ole
Avi
an50
PO
NL
G57
To
bra
mycin
Avi
an10
IMB
ID-T
IDE
565
To
bra
myc
inA
vian
5IM
BID
-TID
E70
4
To
bra
myc
inA
vian
5 g/
LN
ebuliz
eT
IDE
741
Fo
r si
nusi
tis
or
airs
accu
litis
To
bra
myc
inC
ran
e2.
5-5
IMB
IDE
1473
To
bra
myc
inP
arro
t, G
rey
10IM
TID
E74
1P
oss
ible
po
lyuri
a
To
bra
myc
inP
hea
san
t2.
5-5
IMB
IDE
1473
To
bra
myc
inP
sitt
acin
e2.
5-5
IMB
IDE
111
To
bra
myc
inP
sitt
acin
e5-
10IT
QD
E74
1A
dd c
arb
enic
illin
fo
r p
neu
mo
nia
To
bra
myc
inR
apto
r2.
5-5
IMB
IDE
1240
Fo
r re
sist
ant
Pse
udom
onas
To
bra
myc
inR
apto
r5-
10IM
-IV
BID
E14
00L
ess
nep
hro
toxi
c th
an o
ther
am
ino
glyc
osi
des
To
bra
myc
inR
apto
r10
IMB
IDG
234
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 325
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
To
lazo
lin
e H
Cl
Avi
an15
IVP
RN
E13
20R
ever
se x
ylaz
ine
+det
om
idin
e +
med
eto
mid
ine
To
lazo
line
HC
lO
stri
ch1
IVP
RN
G48
1R
ever
se x
ylaz
ine
To
lazo
line
HC
lR
apto
r15
IVP
RN
G20
1
To
ltra
zu
ril
An
seri
form
es0.
0125
g/L
Dri
nk
QD
D11
50F
or
cocc
idio
sis
To
ltra
zuri
lA
vian
7P
OQ
DD
1221
An
tip
roto
zoal
To
ltra
zuri
lA
vian
0.15
g/L
Dri
nk
NL
E11
80
To
ltra
zuri
lA
vian
0.09
0 m
g/kc
alP
OQ
DE
1180
Co
ccid
iost
atic
To
ltra
zuri
lA
vian
7-10
PO
QD
E15
54F
or
cocc
idio
sis
To
ltra
zuri
lC
hic
ken
6P
OQ
DE
1479
May
rep
eat
afte
r 5
day
s fo
r tr
eatm
ent
and
con
tro
l of
Eim
eria
co
ccid
iosi
s
To
ltra
zuri
lC
hic
ken
25P
OQ
DG
564
To
ltra
zuri
lF
alco
n25
PO
QW
B11
34F
or
Car
yosp
ora
infe
stat
ion
To
ltra
zuri
lK
estr
el, E
uro
pea
n25
PO
QD
B11
31F
or
Car
yosp
ora
infe
ctio
n
To
ltra
zuri
lK
iwi
25P
OO
nce
G12
23F
or
cocc
idio
sis
To
ltra
zuri
lM
ynah
, Bal
i12
.5P
OQ
DD
1438
Fo
r co
ccid
iosi
s
To
ltra
zuri
lT
urk
ey0.
025
g/L
Dri
nk
QD
B10
25
Tri
bro
mo
eth
an
ol
Bir
d, S
eed-e
ater
2 g/
kg g
rain
Fee
dO
nce
E4
Add c
hlo
ralo
se
Tri
bro
mo
eth
ano
lB
ird, S
eed-e
ater
0.02
5 g/
LF
eed
On
ceE
4
Tri
bro
mo
eth
ano
lB
oo
by
125
PO
PR
NB
1081
Add a
myl
ene
hyd
rate
Tri
bro
mo
eth
ano
lC
orm
ora
nt
125
PO
PR
NB
1081
Add a
myl
ene
hyd
rate
Tri
bro
mo
eth
ano
lD
uck
, Mal
lard
100-
158
PO
PR
NB
1095
Tri
bro
mo
eth
ano
lF
riga
teb
ird, M
agn
ific
ent
125
PO
PR
NB
1081
Add a
myl
ene
hyd
rate
Tri
bro
mo
eth
ano
lT
urk
ey40
-44
g/L
bai
tF
eed
On
ceG
1767
Co
rn is
usu
al b
ait
Tri
ch
lorf
on
Rap
tors
1.5
g/L
(0.
15%
)T
op
ical
NL
G14
08Sp
ray
for
mit
es
Tri
cid
eA
vian
5 g/
LT
op
ical
NL
G12
78Sp
ray
on
wo
un
ds
and d
erm
atit
is
Tri
cide
Avi
an5
g/L
Flu
shN
LG
1278
Sin
us
flush
, add a
nti
bio
tic
to s
olu
tio
n,
po
ten
tiat
es a
nti
bio
tics
am
ikac
in, n
eom
ycin
,
enro
flo
xaci
n
Tri
meth
op
rim
+ S
ulf
aA
nse
rifo
rmes
0.04
8 g/
LD
rin
kQ
DE
1240
Fo
r n
eph
riti
s, s
epti
cem
ia, h
epat
itis
. Fo
r E
.
coli,
Pas
teur
ella
, Pro
teus
, Sal
mon
ella
, L
iste
ria
Tri
met
ho
pri
m +
Sulf
aA
vian
25IM
BID
E14
34
Tri
met
ho
pri
m +
Sulf
aA
vian
50IM
QD
E14
34
Tri
met
ho
pri
m +
Sulf
aA
vian
30-6
0P
O-S
CB
IDE
1483
Em
erge
ncy
th
erap
y
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I326
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Tri
met
ho
pri
m +
Sulf
aA
vian
50-1
00P
OB
IDG
1319
Tri
met
ho
pri
m +
Sulf
aA
vian
0.15
-0.4
g/L
Dri
nk
NL
E11
80D
osa
ge b
ased
on
tri
met
ho
pri
m
Tri
met
ho
pri
m +
Sulf
aA
vian
20-5
0P
OB
IDE
1431
Fo
r co
ccid
iosi
s
Tri
met
ho
pri
m +
Sulf
aA
vian
1 g/
LD
rin
kQ
DE
1431
Fo
r co
ccid
iosi
s
Tri
met
ho
pri
m +
Sulf
aA
vian
10IM
BID
E14
31F
or
cocc
idio
sis
Tri
met
ho
pri
m +
Sulf
aB
ust
ard
8-30
IMB
IDE
1240
Fo
r n
eph
riti
s, s
epti
cem
ia, h
epat
itis
. Fo
r E
.
coli,
Pas
teur
ella
, Pro
teus
, Sal
mon
ella
, Lis
teri
a
Tri
met
ho
pri
m +
Sulf
aC
anar
y0.
05-0
.1 g
/L
Dri
nk
QD
E69
5D
osa
ge b
ased
on
tri
met
ho
pri
m
Tri
met
ho
pri
m +
Sulf
aC
anar
y0.
1 g/
kg f
oo
dF
eed
QD
E69
5D
osa
ge b
ased
on
tri
met
ho
pri
m
Tri
met
ho
pri
m +
Sulf
aC
anar
y0.
2 g/
kg f
oo
dF
eed
On
ceE
1187
Do
sage
bas
ed o
n t
rim
eth
op
rim
on
ly
Tri
met
ho
pri
m +
Sulf
aC
anar
y0.
15-0
.4 g
/L
Dri
nk
NL
E11
87D
osa
ge b
ased
on
tri
met
ho
pri
m o
nly
Tri
met
ho
pri
m +
Sulf
adia
zin
e
Ch
icke
n46
-62
Dri
nk
QD
A10
23
Tri
met
ho
pri
m +
Sulf
ach
lorp
yrid
azin
e
Go
ose
0.3-
0.7
g/kg
Fee
dO
nce
A77
6F
or
Pas
teur
ella
mul
tocida
,tr
imet
ho
pri
m t
o s
ulf
a
rati
o 1
:5
Tri
met
ho
pri
m +
Sulf
aO
stri
ch15
IMQ
DG
401
Tri
met
ho
pri
m +
Sulf
aP
asse
rin
e0.
2 g/
LD
rin
kQ
DE
1437
Do
sage
bas
ed o
n t
rim
eth
op
rim
, add d
rug
to
foo
d a
t th
e sa
me
tim
e
Tri
met
ho
pri
m +
Sulf
aP
asse
rin
e0.
2 g/
kgF
eed
QD
E14
37D
osa
ge b
ased
on
tri
met
ho
pri
m, a
dd d
rug
to
dri
nk
at t
he
sam
e ti
me
Tri
met
ho
pri
m +
Sulf
aP
engu
in, A
fric
an11
0P
OB
IDG
128
Tri
met
ho
pri
m +
Sulf
aP
igeo
n12
0P
OQ
DE
704
Tri
met
ho
pri
m +
Sulf
aP
oult
ry55
PO
BID
G58
5
Tri
met
ho
pri
m +
Sulf
aP
oult
ry0.
3-0.
5 g/
LD
rin
kQ
DG
585
Tri
met
ho
pri
m +
Sulf
aP
sitt
acin
e20
PO
BID
-TID
E12
40F
or
nep
hri
tis,
sep
tice
mia
, hep
atit
is. F
or
E.
coli,
Pas
teur
ella
, Pro
teus
, Sal
mon
ella
, Lis
teri
a
Tri
met
ho
pri
m +
Sulf
aP
sitt
acin
e8
IMB
IDE
1240
Fo
r n
eph
riti
s, s
epti
cem
ia, h
epat
itis
. Fo
r E
.
coli,
Pas
teur
ella
, Pro
teus
, Sal
mon
ella
, Lis
teri
a
Tri
met
ho
pri
m +
Sulf
aP
sitt
acin
e16
-100
PO
BID
-TID
E17
56U
se lo
wer
do
sage
fo
r b
irds
un
der
300
g f
or
bac
teri
al n
eph
riti
s
Tri
met
ho
pri
m +
Sulf
aP
sitt
acin
e52
.8IM
QD
-BID
G13
09F
or
resp
irat
ory
an
d e
nte
ric
infe
ctio
ns
Tri
met
ho
pri
m +
Sulf
aR
apto
r30
SCB
IDE
1240
Fo
r n
eph
riti
s, s
epti
cem
ia, h
epat
itis
. F
or E
.
coli,
Pas
teur
ella
, Pro
teus
, Sal
mon
ella
, Lis
teri
a
Tri
met
ho
pri
m +
Sulf
aR
apto
r20
-50
PO
BID
E14
33D
o n
ot
use
on
deh
ydra
ted b
irds
Tri
met
ho
pri
m +
Sulf
aR
apto
r60
PO
BID
E14
00F
or
cocc
idio
sis,
rep
eat
afte
r 2
day
s
Tri
met
ho
pri
m +
Sulf
aR
apto
r17
.5P
OQ
DG
94Ju
ven
ile d
osa
ge
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 327
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Tri
met
ho
pri
m +
Sulf
aR
apto
r50
IMB
IDG
234
Tri
met
ho
pri
m +
Sulf
aR
atit
e30
-50
IMB
IDG
1308
Fo
r to
xop
lasm
osi
s
Tri
met
ho
pri
m +
Sulf
amet
ho
xazo
le
Pig
eon
60P
OQ
DA
968
Tri
met
ho
pri
m +
Sulf
amet
ho
xazo
le
Psi
ttac
ine
16-2
4P
OB
ID-T
IDA
1473
Tri
met
ho
pri
m +
Sulf
amet
ho
xazo
le
Psi
ttac
ine
8IM
BID
A14
73
Tri
met
ho
pri
m +
Sulf
atro
xazo
le
Pig
eon
60P
OB
IDA
968
Tu
bo
cu
rari
ne C
lR
apto
r3
g/L
Op
hth
alm
icN
LE
111
Eve
ry 5
min
ute
s
Tylo
sin
An
seri
form
es20
-30
IMT
IDD
1150
Fo
r m
yco
pla
smo
sis
Tyl
osi
nA
nse
rifo
rmes
20P
OT
IDD
1150
Fo
r m
yco
pla
smo
sis
Tyl
osi
nA
nse
rifo
rmes
10 g
/L
Flu
shQ
DD
1150
Fo
r m
yco
pla
smo
sis,
use
10
ml p
er b
ird
Tyl
osi
nA
vian
0.75
g/L
Dri
nk
NL
E11
80
Tyl
osi
nA
vian
0.86
mg/
kcal
IMT
ID-Q
IDE
1180
Tyl
osi
nA
vian
1.08
mg/
kcal
PO
QD
E11
80
Tyl
osi
nA
vian
10 g
/L
sal
ine
Flu
shB
IDE
1183
Nas
al o
r si
nus
Tyl
osi
nA
vian
10 g
/L
sal
ine
Neb
uliz
eB
IDE
1185
10 t
o 6
0 m
inute
s
Tyl
osi
nA
vian
15IM
TID
E12
40F
or
bir
ds
> 1
kg
for
up
per
res
pir
ato
ry
infe
ctio
n f
or
Myc
opla
sma,
Pas
teur
ella
,
Chl
amyd
ophi
la
Tyl
osi
nA
vian
10IM
BID
E16
17F
or
Myc
op
lasm
a
Tyl
osi
nA
vian
10 g
/L
Neb
uliz
eT
ID-Q
IDE
1650
Add d
imet
hyl
sulf
oxi
de,
adju
nct
to
par
ente
ral
ther
apy
for
air
sacc
ulit
is
Tyl
osi
nA
vian
10-4
0IM
BID
E16
50M
ay u
se w
ith
lin
com
ycin
+ s
pec
tin
om
ycin
for
myc
op
lasm
osi
s
Tyl
osi
nB
ird, A
quat
ic10
IMB
IDE
1503
Fo
r M
ycop
lasm
a
Tyl
osi
nB
ust
ard, H
oub
ara
20IM
TID
G93
2F
or
Myc
opla
sma
Tyl
osi
nC
anar
y0.
25-0
.4 g
/L
Dri
nk
QD
E69
5
Tyl
osi
nC
anar
y0.
4 g/
kg f
oo
dF
eed
On
ceE
1187
Tyl
osi
nC
hic
ken
0.5
g/L
Dri
nk
NL
A83
8F
or
Myc
opla
sma
galli
sept
icum
, les
s ef
fect
ive
than
dan
ofl
oxa
cin
Tyl
osi
nC
hic
ken
0.25
g/L
Dri
nk
QD
B10
16A
dd c
olis
tin
fo
r ch
ron
ic r
esp
irat
ory
dis
ease
wit
h E
. co
li
Tyl
osi
nC
ock
atie
lM
ix p
ow
der
1:1
0O
ph
thal
mic
BID
-TID
E11
1M
ix p
ow
der
wit
h s
teri
le w
ater
1 t
o 1
0
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I328
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Tyl
osi
nC
ock
atie
l1:
10 d
iluti
on
wat
erT
op
ical
QD
-TID
E74
1E
ye s
pra
y, p
ow
der
250
g/8.
8 o
z,
con
jun
ctiv
itis
, may
use
wit
h t
ylo
sin
in w
ater
Tyl
osi
nC
ran
e15
SCT
IDA
596
Tyl
osi
nE
mu
15-2
5IM
TID
-QID
E14
73
Tyl
osi
nF
alco
n30
IMT
IDE
1027
Fo
r M
ycop
lasm
a
Tyl
osi
nF
inch
0.4
g/kg
fo
od
Fee
dQ
DE
1572
Tyl
osi
nF
inch
0.25
-0.4
g/L
Dri
nk
QD
E15
72
Tyl
osi
nF
inch
, Ho
use
1 g/
LD
rin
kQ
DD
1439
Add c
ipro
flo
xaci
n f
or
myc
op
lasm
osi
s
Tyl
osi
nF
inch
, Ho
use
0.3
g/L
Dri
nk
QD
D14
39P
reve
nti
ve f
or
myc
op
lasm
osi
s
Tyl
osi
nO
stri
ch11
.4P
OT
IDG
467
Tyl
osi
nP
asse
rin
e0.
25-0
.4 g
/L
Dri
nk
QD
E14
37A
dd d
rug
to f
oo
d a
t th
e sa
me
tim
e
Tyl
osi
nP
asse
rin
e, S
mal
l0.
25-0
.4 g
/L
Dri
nk
NL
E11
87
Tyl
osi
nP
igeo
n25
IMQ
IDA
847
Tyl
osi
nP
igeo
n15
-25
IMT
ID-Q
IDE
111
Tyl
osi
nP
igeo
n50
PO
QD
E70
4
Tyl
osi
nP
igeo
n0.
5 g/
LD
rin
kQ
DE
704
Tyl
osi
nP
igeo
n15
-25
IMT
ID-Q
IDE
1473
Tyl
osi
nP
sitt
acin
eM
ix p
ow
der
1:1
0O
ph
thal
mic
BID
-TID
E11
1M
ix p
ow
der
wit
h s
teri
le w
ater
1 t
o 1
0
Tyl
osi
nP
sitt
acin
e40
IMN
LE
763
Init
ial M
ycop
lasm
a th
erap
y, u
sed in
com
bin
atio
n w
ith
am
ino
glyc
osi
des
Tyl
osi
nP
sitt
acin
e20
-40
IMT
IDE
1240
Tyl
osi
nQ
uai
l15
-25
IMT
ID-Q
IDE
1473
Tyl
osi
nR
apto
r15
IMQ
DD
1612
Fo
r ch
ron
ic a
ir s
accu
litis
Tyl
osi
nR
apto
r20
IMB
IDG
234
Tyl
osi
nR
hea
12.5
mg
TD
Par
ente
ral
On
ceG
582
Into
dis
ten
ded
sin
us
Tyl
osi
nR
hea
50 m
g T
DSC
QD
G58
2A
dd p
enic
illin
G b
enza
thin
e
Ura
te O
xid
ase
Haw
k, R
ed-t
aile
d10
0-20
0 K
IU/kg
NL
NL
A17
61U
rico
lyti
c
Ura
te O
xidas
eP
igeo
n20
-600
KIU
/kg
NL
NL
A17
61U
rico
lyti
c
Valn
em
uli
nC
hic
ken
0.5
g/L
Dri
nk
QD
B87
3F
or
Myc
opla
sma
Vaso
tocin
, A
rgin
ine
Spar
row
, Ho
use
0.00
04-0
.001
6IV
PR
NB
1759
Do
sage
is d
osa
ge p
er m
inute
, use
d f
or
anti
diu
resi
s
Vecu
ron
ium
Bro
mid
eA
vian
1 dro
p 4
mg/
ml s
oln
Op
hth
alm
icq15
min
E12
33
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 329
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Vec
uro
niu
m B
rom
ide
Co
ckat
oo
0.8
g/L
Op
hth
alm
icN
LG
218
Vin
cri
stin
e S
ulf
ate
Avi
an0.
75 m
g/m
2 surf
ace
IO
QW
E
14
70
Fo
r ly
mp
ho
sarc
om
a -
Ch
eck
cure
nt
liter
ature
Vin
eg
ar,
Ap
ple
Cid
er
Avi
an15
ml/
LD
rin
kQ
DD
1330
Fo
r lo
w-g
rade
can
did
iasi
s
Vin
egar
, Ap
ple
Cid
erA
vian
60-1
20 m
l/L
Dri
nk
QD
E12
05F
or
dys
bio
sis,
Clo
stri
dium
, GI
trac
t b
acte
rio
sis
Vin
egar
, Ap
ple
Cid
erA
vian
60-1
20 m
l/L
Dri
nk
QD
E14
87F
or
dys
bio
sis,
can
did
iasi
s, c
hro
nic
bac
teri
al
dia
rrh
ea, G
ram
neg
ativ
e in
fect
ion
s, f
oul s
mel
l
fece
s
Vir
gin
iam
ycin
Po
ult
ry22
mg/
kg f
oo
dF
eed
QD
C56
4
Vit
am
in A
Am
azo
n, R
ed L
ore
d20
KIU
/kg
IMO
nce
G70
0
Vit
amin
AA
vian
< 5
0 K
IU/kg
NL
On
ceE
1481
Fo
r cl
inic
al d
efic
ien
cy
Vit
amin
AR
apto
r<
20
KIU
/kg
IMQ
WE
1400
Fo
r h
ypo
vita
min
osi
s A
an
d e
pit
hel
ial
rege
ner
atio
n (
bum
ble
foo
t)
Vit
am
in B
Co
mp
lex
Am
azo
n, Y
ello
w-n
aped
1P
aren
tera
lN
LG
1697
Do
sage
bas
ed o
n t
hia
min
e
Vit
amin
B C
om
ple
xA
vian
1-3
IMQ
WE
1470
Aft
er h
emo
rrh
age
wit
h li
ver
dis
ease
Vit
amin
B C
om
ple
xA
vian
10IM
NL
E16
50D
osa
ge b
ased
on
th
iam
ine
for
emer
gen
cy
care
Vit
amin
B C
om
ple
xB
ird, A
quat
ic10
-30
IM-S
CQ
WE
1503
Fo
r deb
ilita
tio
n, a
nem
ia, a
pp
etit
e st
imula
nt,
neu
rolo
gica
l dis
ord
ers
Vit
amin
B C
om
ple
xH
awk,
Red
-tai
led
10P
OO
nce
G16
44D
osa
ge b
ased
on
th
iam
ine
for
deb
ilita
tio
n
Vit
amin
B C
om
ple
xP
sitt
acin
e10
-30
(th
iam
ine
do
se)
IMq2d
E12
40D
osa
ge b
ased
on
th
iam
ine,
neu
rom
usc
ula
r
dis
ease
, hep
atic
dis
ord
ers,
th
iam
ine-
resp
on
sive
sei
zure
s
Vit
amin
B C
om
ple
xR
apto
r10
-30
IMQ
WE
1240
Do
sage
bas
ed o
n t
hia
min
e, s
tim
ula
te a
pp
etit
e
Vit
am
in D
Avi
an6.
6 K
IU/kg
IMO
nce
G58
Add c
alci
um
glu
con
ate
+ o
xyto
cin
Vit
am
in E
Avi
an40
IM-P
ON
LE
924
An
tio
xidan
t, m
etal
to
xici
ty
Vit
amin
EA
vian
0.05
-0.1
Par
ente
ral
QW
E16
50F
or
hyp
ovi
tam
ino
sis
E
Vit
amin
EB
ird, A
quat
ic0.
1 K
IU/kg
oil
fish
Fee
dO
nce
E14
78
Vit
amin
EO
stri
ch0.
2-0.
3 K
IU/kg
IMN
LG
93Ju
ven
ile d
ose
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I330
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Vit
am
in E
+ S
ele
niu
m
Am
azo
n, R
ed L
ore
d
1 m
g Se
, 25
mg
E
IM
On
ce
G
700
Vit
amin
E +
Sel
eniu
mA
vian
0.05
-0.1
IMq2w
E11
1
Vit
amin
E +
Sel
eniu
mO
stri
ch4-
100
KIU
TD
IMQ
MG
401
Vit
amin
E +
Sel
eniu
mR
apto
rSC
q3d
E12
400.
05 m
g se
len
ium
+ 3
.4 I
U v
itam
in E
to
tal
do
se f
or
musc
ula
r w
eakn
ess,
cap
ture
myo
pat
hy,
def
icie
ncy
Vit
am
in K
Am
azo
n, Y
ello
w-n
aped
0.2
Par
ente
ral
NL
G16
97
Vit
amin
KA
vian
0.2-
2.2
IMq4-
8hG
87F
ollo
w w
ith
dai
ly d
ose
fo
r 1
to 4
wee
ks
Vit
amin
KA
vian
0.2-
2.5
IMP
RN
E11
51F
or
hem
ato
chez
ia
Vit
amin
KA
vian
0.02
5-2.
5N
LB
IDF
58G
ive
ever
y 2
to 3
wee
ks
Vit
amin
KA
vian
0.2-
2.5
Par
ente
ral
NL
G24
6
Vit
amin
KL
ory
, Ch
atte
rin
g0.
2IM
BID
G42
Vit
amin
KP
sitt
acin
e0.
25-0
.5IM
q2d
-QW
E63
2N
eon
ate
do
sage
Vit
am
ins
A,
D,
EA
vian
36.3
KIU
/kg
IMQ
WE
111
Giv
e 33
KIU
vit
amin
A +
3.3
KIU
vit
amin
D p
er k
g
Vit
amin
s A
, D, E
Pig
eon
33 K
IU V
it A
/kg
IMQ
WG
590
Do
sage
bas
ed o
n V
itam
in A
Vit
amin
s A
, D, E
Psi
ttac
ine
33-6
6 K
IU/kg
IMQ
WE
1240
Fo
r def
icie
nci
es, r
epro
duct
ive
dis
ord
ers
and
bo
ne
hea
ling
Xyla
zin
e H
Cl
Am
azo
n P
arro
t1-
2IM
PR
NE
243
Add k
etam
ine
Xyl
azin
e H
Cl
Am
azo
n P
arro
t1-
2 m
g T
DIV
PR
NG
1609
Add k
etam
ine,
mix
to
geth
er in
syr
inge
, may
star
t w
ith
hal
f do
se
Xyl
azin
e H
Cl
Avi
an4
IMP
RN
E70
4A
dd k
etam
ine
Xyl
azin
e H
Cl
Avi
an2.
2IM
PR
NE
1181
Add k
etam
ine,
rev
erse
wit
h a
tip
amez
ole
,
pro
lon
ged r
eco
very
if n
ot
reve
rsed
Xyl
azin
e H
Cl
Avi
an2.
2IV
PR
NE
1431
Add k
etam
ine,
go
od f
or
sho
rt s
urg
ical
pro
cedure
s, m
ust
rev
erse
Xyl
azin
e H
Cl
Budge
riga
r6.
5IM
PR
NE
243
Add k
etam
ine
Xyl
azin
e H
Cl
Cas
sow
ary
0.25
IVP
RN
E16
17A
dd k
etam
ine,
use
yo
him
bin
e to
sh
ort
en
reco
very
Xyl
azin
e H
Cl
Cas
sow
ary
1IM
PR
NE
1617
Add k
etam
ine,
use
yo
him
bin
e to
sh
ort
en
reco
very
Xyl
azin
e H
Cl
Co
ckat
iel
2.5
IMP
RN
E24
3A
dd k
etam
ine
Xyl
azin
e H
Cl
Cra
ne
1N
LP
RN
E11
89A
dd k
etam
ine
for
anes
thes
ia
Xyl
azin
e H
Cl
Em
u0.
25IV
PR
NE
1617
Add k
etam
ine,
use
yo
him
bin
e to
sh
ort
en
reco
very
Xyl
azin
e H
Cl
Fal
con
2IM
PR
NE
243
Add k
etam
ine
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 331
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Xyl
azin
e H
Cl
Haw
k2.
2N
LP
RN
G13
88A
dd k
etam
ine
Xyl
azin
e H
Cl
Ost
rich
0.66
IMP
RN
B44
7A
dd a
cep
rom
azin
e +
eto
rph
ine
Xyl
azin
e H
Cl
Ost
rich
150
mg
TD
IMP
RN
G28
3A
dd c
arfe
nta
nil
Xyl
azin
e H
Cl
Par
rot,
Gre
y1.
5IM
PR
NE
243
Add k
etam
ine
Xyl
azin
e H
Cl
Pig
eon
10IM
PR
NG
1481
Add b
uto
rph
ano
l + k
etam
ine
for
surg
ery
Xyl
azin
e H
Cl
Psi
ttac
ine
1-2.
2IM
-IV
PR
NE
1240
Use
in c
om
bin
atio
n w
ith
ket
amin
e 1:
3 o
r 1:
5,
reve
rse
wit
h y
oh
imb
ine
Xyl
azin
e H
Cl
Psi
ttac
ine
1-10
IMP
RN
E15
73Se
dat
ion
fo
r sm
all b
irds
at h
igh
do
sage
s
Xyl
azin
e H
Cl
Psi
ttac
ine
1-10
IMP
RN
G20
1Se
dat
ion
, sm
all p
sitt
acin
e
Xyl
azin
e H
Cl
Rap
tor
0.5
IVP
RN
D14
01A
dd k
etam
ine
Xyl
azin
e H
Cl
Rap
tor
3IM
PR
NE
4A
dd k
etam
ine
Xyl
azin
e H
Cl
Rap
tor
1-2.
2IM
-IV
PR
NE
1240
Use
in c
om
bin
atio
n w
ith
ket
amin
e 1:
3 o
r 1:
5,
reve
rse
wit
h y
oh
imb
ine
Xyl
azin
e H
Cl
Rap
tor
2IV
PR
NG
1174
Add k
etam
ine
for
diu
rnal
rap
tors
, las
ts 1
ho
ur
Xyl
azin
e H
Cl
Rap
tor
0.25
-0.5
IVP
RN
G11
74A
dd k
etam
ine,
low
er d
osa
ge r
egim
en
pro
duce
s le
ss r
esp
irat
ory
dis
turb
ance
Xyl
azin
e H
Cl
Rat
ite
2.2
IMP
RN
E4
Add k
etam
ine
Xyl
azin
e H
Cl
Rat
ite
1-2.
2IM
PR
NE
4Im
mo
bili
zati
on
Xyl
azin
e H
Cl
Rat
ite
0.5-
1IM
PR
NE
243
Add k
etam
ine
afte
r 15
min
ute
s
Xyl
azin
e H
Cl
Rat
ite
1-2.
2P
aren
tera
lP
RN
G41
8H
eavy
sed
atio
n
Xyl
azin
e H
Cl
Sto
rk0.
2-0.
4IM
PR
NE
243
Sedat
ion
Xyl
azin
e H
Cl
Swan
(B
lack
, Mute
) 2
mg
TD
IV
P
RN
G
12
91
Add k
etam
ine,
giv
e 3/
4 do
se in
itia
lly,
rem
ain
der
if n
eeded
, gas
an
esth
esia
pre
med
Xyl
azin
e H
Cl
Swan
, Mute
0.28
IVP
RN
E11
90A
dd k
etam
ine
Yeast
Cell
Deri
vati
ves
Avi
anN
/A
To
pic
alP
RN
E11
1P
rom
ote
ski
n h
ealin
g, P
rep
arat
ion
H®
Yo
him
bin
e H
Cl
Avi
an1
IO-I
VP
RN
E24
3
Yo
him
bin
e H
Cl
Avi
an0.
1-0.
2IV
PR
NE
1181
Rev
erse
xyl
azin
e
Yo
him
bin
e H
Cl
Avi
an0.
1N
LP
RN
E12
31R
ever
sal o
f xy
lazi
ne
Yo
him
bin
e H
Cl
Avi
an0.
125-
1N
LP
RN
E14
81R
ever
se x
ylaz
ine
Yo
him
bin
e H
Cl
Budge
riga
r0.
11-0
.27
IMO
nce
G83
Yo
him
bin
e H
Cl
Cas
sow
ary
0.2
IVP
RN
E15
33Sh
ort
en k
etam
ine
+ x
ylaz
ine
anes
thes
ia
Yo
him
bin
e H
Cl
Em
u0.
2IV
PR
NE
1617
To
sh
ort
en x
ylaz
ine
reco
very
Yo
him
bin
e H
Cl
Guin
ea F
ow
l1
IVP
RN
B55
3
Yo
him
bin
e H
Cl
Guin
ea F
ow
l0.
15N
LP
RN
D14
01A
nta
gon
ize
keta
min
e/xy
lazi
ne
anes
thes
ia
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Cl inica l Avian Medic ine - Volume I332
DR
UG
NA
ME
SP
EC
IES
DO
SA
GE
(m
g/
kg
un
less
oth
erw
ise
state
d)
RO
UT
ED
OS
AG
E
INT
ER
VA
L
C.I
.**
RE
FE
RE
NC
EC
OM
ME
NT
S (
see r
efe
ren
ces
for
du
rati
on
, p
recau
tio
ns
an
d
co
ntr
ain
dic
ati
on
s)
Yo
him
bin
e H
Cl
Haw
k, R
ed-t
aile
d0.
1N
LP
RN
D14
01A
nta
gon
ize
keta
min
e/xy
lazi
ne
anes
thes
ia
Yo
him
bin
e H
Cl
Ost
rich
0.12
5N
LP
RN
D14
01A
nta
gon
ist
for
xyla
zin
e
Yo
him
bin
e H
Cl
Ost
rich
12.5
mg
TD
IVP
RN
G28
3
Yo
him
bin
e H
Cl
Ost
rich
0.12
5IV
PR
NG
481
Rev
erse
xyl
azin
e
Yo
him
bin
e H
Cl
Psi
ttac
ine
0.1-
0.2
IVP
RN
E12
40R
ever
se x
ylaz
ine
Yo
him
bin
e H
Cl
Rap
tor
0.1-
0.2
IVP
RN
E12
40R
ever
se x
ylaz
ine
Yo
him
bin
e H
Cl
Rap
tor
0.1
IVP
RN
G20
1
Yo
him
bin
e H
Cl
Rat
ite
0.12
5IV
PR
NG
418
Yu
nn
an
Paiy
ao
Avi
an1
ml/
kgP
OQ
DE
1435
Sto
ck s
olu
tio
n 2
cap
sule
s p
er 1
5 m
l lac
tulo
se
Yun
nan
Pai
yao
Avi
an1.
25-2
.5 m
l TD
PO
BID
G11
12M
ix w
ith
3 (
cock
atie
l) t
o 1
0 (m
acaw
) m
l
wat
er, u
se 1
day
pre
-op
erat
ive,
als
o u
se a
s
top
ical
flu
sh
Zera
no
lO
stri
ch12
mg
TD
SCN
LC
283
Imp
lan
t gr
ow
th p
rom
oti
on
Zin
c M
eth
ion
ine
Rap
tor
25P
OQ
DE
1359
An
tio
xidan
t th
erap
y, a
dm
inis
ter
duri
ng
lead
chel
atio
n t
her
apy
**A
= P
harm
acok
inet
ic r
esea
rch;
B=
Clin
ical
eff
icac
y tr
ial;
C=
Man
ufac
ture
r’s
reco
mm
enda
tion;
D=
Pub
lishe
d w
ith r
efer
ence
; E
= P
ublis
hed
with
out
refe
renc
e; F
= E
xtra
pola
tion
from
oth
er s
peci
es;
G=
Ane
cdot
al
Chapter 9 | T H E R A P E U T I C A G E N T S 333
AAbbbbrreevviiaattiioonnssAbbreviation Translation
< less than
> greater than
>= greater than or equal
Bath 1 day or more in therapeutic liquid
BID two times daily
BID-q2d two times daily to every two days
BID-QID two to four times daily
BID-TID two to three times daily
cm² square centimeter
cm³ cubic centimeter
d day
d>w days to weeks
Dip less than 1 day in therapeutic liquid
doses number of doses to give
Drink drinking water
Epidural epidural injection
Feed include in feed
Flow constant flow
Flush flush
Fog fog the environment
g gram
ga gauge
GI gastrointestinal
gr grain
h hour
IA intraarticular
IA-IM intraarticular or intramuscular
ICa intracardiac
ICa-IP-IV intracardiac or intraperitoneal or intravenous
ICr intracranial
ID intradermal
IH inhalation
IM intramuscular
IM-IN-IO-IV intramuscular or intranasal or intraosseous or intravenous
IM-IN-IV intramuscular or intranasal or intravenous
IM-IO-IT-IV intramuscular or intraosseous or intratracheal or intravenous
IM-IO-IV intramuscular or intraosseous or intravenous
IM-IP intramuscular or intraperitoneal
IM-IP-IV intramuscular or intraperitoneal or intravenous
IM-IP-IV-SC intramuscular or intravenous or intraperitoneal or subcutaneous
IM-IP-PO intramuscular or intraperitoneal or by mouth
IM-IP-PO-SC intramuscular or intraperitoneal or by mouth or subcutaneous
IM-IP-SC intramuscular or intraperitoneal or subcutaneous
IM-IV intramuscular or intravenous
IM-IV-PO intramuscular or intravenous or by mouth
IM-IV-PO-SC intramuscular or intravenous or by mouth or subcutaneous
IM-IV-SC intramuscular or intravenous or subcutaneous
IM-PO intramuscular or by mouth
IM-PO-SC intramuscular or by mouth or subcutaneous
IM-SC intramuscular or subcutaneous
IM-Topical intramuscular or topical
Abbreviation Translation
IN intranasal
indef indefinite
IO intraosseous
IO-IP-IT-IV intraosseous or intraperitoneal or intratracheal or intravenous
IO-IP-IV-SC intraosseous or intraperitoneal or intravenous or subcutaneous
IO-IT-IV intraosseous or intratracheal or intravenous
IO-IV intraosseous or intravenous
IO-IV-SC intraosseous or intravenous or subcutaneous
IP intraperitoneal or intracoelomic or intrapleuroperitoneal
IP-IM intraperitoneal or intramuscular
IP-IV intraperitoneal or intravenous
IP-IV-PO intraperitoneal or intravenous or by mouth
IP-IV-SC intraperitoneal or intravenous or subcutaneous
IP-PO intraperitoneal or by mouth
IP-SC intraperitoneal or subcutaneous
IT intratracheal
IT-IV intratracheal or intravenous
IT-IV-PO intratracheal, intravenous and orally
IU International Units
IUt intrauterine
IV intravenous
IV-PO intravenous or by mouth
IV-PO-SC intravenous or by mouth or subcutaneous
IV-SC intravenous or subcutaneous
kcal kilocalories
kg kilogram
KHz kilohertz
KIU thousand International Units
L liter
life lifelong therapy
long long therapy regimen
m month
m² square meter
m³ cubic meter
MD maximum dose
mEq milliequivalent
mg milligram
min minute
MIU million International Units
ml milliliter
mm² square millimeter
mmol millimoles
mol molar solution
months for several months
N normal solution
nebulize nebulization
NL not listed
once give single dose
ophthalmic in the eye
oz ounce
Parenteral-PO parenteral or by mouth
PO by mouth
PO-SC by mouth or subcutaneous
PO-SC-Topical by mouth or subcutaneous or topical
Cl inica l Avian Medic ine - Volume I334
Abbreviation Translation
PO-Topical by mouth or apply topically
ppm parts per million
ppt parts per thousand
PRN as needed
q10-14d every ten to fourteen days
q10d every ten days
q1-2h every one to two hours
q1-4h every one to four hours
q15min every fifteen minutes
q2-3d every two days to three days
q2-3h every two to three hours
q2-3w every two to three weeks
q2-4d every two days to four days
q2-4h every two to four hours
q2-4w every two weeks to four weeks
q2-5d every two days to five days
q2-6h every two to six hours
q2d every two days
q2d-QW every two days to every week
q2h every two hours
q2m every two months
q2w every two weeks
q30min every thirty minutes
q33h every thirty three hours
q3-4d every three to four days
q3-4h every three to four hours
q3-4w every three to four weeks
q3-5d every three to five days
q36h every thirty six hours
q3-6h every three to six hours
q3-6w every three to six weeks
q3-7d every three to seven days
q3-8h every three to eight hours
q3d every three days
q3d-q2w every 3 days to two weeks
q3d-QW every three days to every week
q3h every three hours
q3m every three months
q3w every three weeks
q4-5d every four to five days
q4-5h every four to five hours
q4-6d every four to six days
q4-6h every four to six hours
q4-6m every four to six months
q4-6w every four to six weeks
q4-8h every four to eight hours
q4d every four days
q4d-QW every four days to weekly
q4h every four hours
q4m every four months
q5d every five days
q5d-QW every five days to every week
Abbreviation Translation
q5h every five hours
q5min every five minutes
q60h every sixty hours
q6d every six days
q6m every six months
q6m-QA every six months to every year
q6w every six weeks
q7w every seven weeks
QA every year
QD every day
QD-BID every day to two times daily
QD-q2d every day or every two days
QD-q3d every day to every three days
QD-QID every day to four times daily
QD-QW every day to every week
QD-TID every day to three times daily
QH every hour
QID four times daily
QM every month
QM-q2m every month to every two months
qow every other week
QS add sufficient quantity
QW every week
QW-q10d every week to ten days
QW-q2w ever week to every two weeks
QW-q3w every week to every three weeks
r10d repeat in ten days
r2m repeat in two months
r2w repeat in two weeks
r6m repeat in six months
r7-10d repeat in seven to ten days
ra repeat annually
rm repeat in one month
rw repeat in one week
SC subcutaneous
SCJ subconjunctival
SC-Topical subcutaneous or topical
sec second
short short therapy regimen
slowly administer slowly
soln solution
TD total dose
TID three times daily
TID-q2d three times daily to every two days
TID-QID three to four times daily
topical apply topically
vapor vapor in enclosure
vent anus, rectum or cloaca
w week
weeks for several weeks
y year
µg microgram
Chapter 9 | T H E R A P E U T I C A G E N T S 335
References4. Fowler M: Restraint And Handling
of Wild And Domestic Animals.Iowa State University Press Ames2 1995.
6. Kollias G: Diets feeding practicesand nutritional problems inpsittacine birds. Vet Med 90 29-391995.
16. Orosz S: Fungal and mycobacter-ial diseases. Proc N Am Vet ConfEastern States Vet AssocGainesville FL 569-70 1995.
30. Miller P, Langenberg J, et al:Pseudomonas aeruginosa associ-ated corneal ulcers in captivecranes. J Am Assoc Zoo Vet 25449-54 1995.
31. Law J, Tully T, et al: Verminousencephalitis apparently caused bythe Filaroid nematode in emus.Avian Dis 37 597-601 1993.
32. Ramsay E, Vulliet R: Pharma-cokinetic properties of gentam-icin and amikacin in the cockatiel.Avian Dis 37 628-634 1993.
40. Coleman C and Oliver RLymphosarcoma in a blue andgold macaw and a mature canaryJ Assoc Avian Vet 8 64-8 1994.
41. Wack R, Kramer L, et al:Cardiomegaly and endocardialfibrosis in a secretary bird. J AssocAvian Vet 8 76-80 1994.
42. Orcutt C, Bartick T: Mucormy-cotic meningoencephalitis andpneumonia in a chattering lory. JAssoc Avian Vet 8 85-9 1994.
43. Ramsay E, Grindlinger H: Treat-ment of obsessive behavior withclomipramine J Assoc Avian Vet. 89-15 1994.
44. Oglesbee B, Oglesbee M: Featherdystrophy in a cockatiel. J AssocAvian Vet 8 16-20 1994.
45. Clyde V, Kollias G: Diet associatedgout in juvenile macaws. Proc AmAssoc Zoo Vet 90 1989.
46. Pokras M: Captive management ofaquatic birds. AAV Today 2 24-331988.
47. Marx D: Preventive medicine forpigeons AAV Today 2 41-43 1988.
48. Dustin L: Clinical conditions inpet canary practice. J Assoc AvianVet 4 80-2 1990.
49. Haneveld M, Dorrestein G:Sudden high mortality incanaries. J Assoc Avian Vet 4 821990.
50. Porter S and Snead S Pesticidepoisoning in birds of prey J AssocAvian Vet 4 84-5 1990.
51. Degernes L, Talbot B, et.al.Raptor foot care J Assoc Avian Vet4 93-5 1990.
52. Rode J, Bartholow S, et al:Ventilation through an air saccanula during tracheal obstruc-tion in ducks. J Assoc Avian Vet 498-102 1990.
53. Wheeler C: Avian anesthetics anal-gesics and tranquilizers. Bauck, L:Semin Avian Exotic Pet Med, WBSaunders, Philadelphia 2 7-121993.
54. Huff D: Fluid therapy and nutri-tional therapeutics. Bauck, L:Semin Avian Exotic Pet Med, WBSaunders, Philadelphia 2 13-161993.
55. Bauck L, Hoefer H: Avian antimi-crobial therapy. Bauck, L: SeminAvian Exotic Pet Med, WBSaunders, Philadelphia 2 17-221993.
56. Prus S: Avian antifungal therapy.
Bauck, L: Semin Avian Exotic PetMed WB Saunders, Philadelphia 230-32 1993.
57. Marshal R: Avian anthelminticsand antiprotozoals. Bauck, L:Semin Avian Exotic Pet Med, WBSaunders, Philadelphia 2 33-411993.
58. Worrell A: Therapy of noninfec-tious avian disorders. Bauck, L:Semin Avian Exotic Pet Med, WBSaunders, Philadelphia 2 42-71993.
61. Porter S: Veterinary care of nativewildlife. Proc N Am Vet ConfEastern States Vet Assoc,Gainesville, FL 693-6 1995.
62. Tseng F: Medical management ofoiled wildlife. Proc N Am Vet ConfEastern States Vet AssocGainesville, FL 697-8 1995.
68. Kollias G, Palgut J, et al: The useof ketoconazole in birds: prelimi-nary pharmacokinetic and clinicalapplications. Proc Assoc Avian VetAAV, Miami 103 1986.
80. Harris D: Care of the critically illpatient. Jenkins, J: Semin AvianExotic Pet Med, WB Saunders,Philadelphia 3 175-9 1994.
83. Jenkins J: Postoperative care.Murray, M: Semin Avian Exotic PetMed, WB Saunders, Philadelphia2 97-102 1993.
85. Bauck L: Nutritional problems inpet birds. Rosenthal, K: SeminAvian Exotic Pet Med, WBSaunders, Philadelphia 4 3-81995.
86. Degernes L: Toxicities in water-fowl. Rosenthal, K: Semin AvianExotic Pet Med, WB Saunders,Philadelphia 4 15-22 1995.
87. LaBonde J: Toxicity in pet avianpatients. Rosenthal, K: SeminAvian Exotic Pet Med, WBSaunders, Philadelphia 4 23-311995.
88. Rae M Endocrine disease in petbirds. Rosenthal, K: Semin AvianExotic Pet Med, WB Saunders,Philadelphia 4 32-8 1995.
94. Joseph V: Raptor pediatrics. SpeerB: Semin Avian Exotic Pet Med,WB Saunders, Philadelphia 2 142-51 1993.
96. Clipsham R: Rhamphortotics andsurgical corrections of maxillofa-cial defects. Redig, P: Semin AvianExotic Pet Med, WB Saunders,Philadelphia 3 92-99 1994.
109. van Reeth K, Vercruysse J:Efficacy of toltrazuril againstexperimental eimeria in racingpigeons. Avian Dis 37 218-211993.
110. Greth A, Gerlach H, et.al:Pharmacokinetics of doxycyclineafter parenteral administrationin the housra bustard, Avian Dis37 31-6 1993.
111. Ritchie B, Harrison G:Formulary. Ritchie B, HarrisonG, et al: Avian Medicine:Principles and Application,Wingers Publishing, Lake WorthFL 457-78 1994
112. Gronwell R, Brown M, et al:Pharmacokinetics of amikacin inAfrican grey parrots, Am J VetRes 50 250-2 1989.
123. Page C, Schmidt R, et al:Antemortem diagnosis and treat-ment of sarcocystosis in twospecies of psittacines, J ZooWildl Med AAZV 23 77-85 1992.
124. Frank T, Carpenter J:Coronaviral enteritis in an
ostrich, J Zoo Wildl Med AAZV23 103-7 1992.
125. Sacre B, Oppenheim Y, et.al.Presumptive histiocytic sarcomain a great horned owl, J ZooWildl Med AAZV 23 113-21 1992.
127. Garner M: Suspected lead toxi-cosis in captive goshawk, J AmVet Med Assoc 199 1069-701991.
128. Cook R: Clinical challenge caseone, J Zoo Wildl Med AAZV 23135-6 1992.
134. Balanger L, Romano J, et al:Nodular typhlitis of pheasantscaused by heterakis J Zoo WildlMed AAZV 23 249-53 1992.
145. Mainka S, Dierenfeld E, et al:Circulating tocopherol followingintramuscular or oral vitamin Eadministration, J Zoo Wildl MedAAZV 25 229-32 1994.
153. Aguilar R, Stiles J, et al: Surgicalsynechiotomy in an adult baldeagle, J Zoo Wildl Med AAZV 2463-7 1993.
168. Isaza R, Budsberg S, et al:Disposition of oral ciprofloxacinin red tailed hawks on singleoral dose, J Zoo Wildl Med AAZV24 508-14 1993.
173. Hannon D, Swaim S, et al: Fullthickness mesh skin grafts intwo great horned owls, J ZooWildl Med AAZV 24 539-52 1993.
179. Dorrestein G, Verburg E:Pharmacokinetics of Baytril inhoming pigeons after differentadministration routes, Proc ConfAvian Dis Munich 207-9 1988.
201. Clyde V: Avian analgesia. JungeR: Proc Am Assoc Zoo Vet 125-71994.
203. Gamble K, Falzone C, et al:Proventricular ascaridiasis in lap-pet-faced and African vultures.Junge R: Proc Am Assoc Zoo Vet149-50 1994.
207. Snyder S, Richard M: Treatmentof avian tuberculosis in awhooping crane. Junge, R: ProcAm Assoc Zoo Vet 167-9 1994.
230. Jakoby JR, Gylstorff I: Compara-tive investigations on chemo-therapeutic psittacosis control,Berl Munch Tieraerztl Wschr 96261-4 1983.
232. Keymer I: Pigeons. Beynon P,Cooper J: Manual of Exotic Pets,Iowa State Univ. Press, Ames180-202 1991.
233. Scullion F: Wild birds. Beynon P,Cooper J: Manual of Exotic PetsIowa State Univ Press, Ames 203-11 1991.
234. Forbes N: Birds of prey BeynonP, Cooper J: Manual of ExoticPets Iowa State Univ. Press Ames212-20 1991.
252. Heard D: Principles and tech-niques of anesthesia and analge-sia for exotic practice.Quesenberry K, Hillyer E: VetClinic NA Sm Anim Prac WBSaunders, Philadelphia 23:61301-27 1993.
260. Harlin R: Pigeons. Roston M,Marx K: Proc Mid-Atlantic StatesAssoc Avian Vet MASAAVBlacksburg, VA 16 69-82 1995.
262. Graczyk T, Shaw M, et al:Hematological characteristics ofavian malaria cases in Africanblack foot penguins, J Parasitol80 302-8 1994.
266. Teare J, Schwark W, et al:Pharmacokinetics of a long act-ing oxytetracycline preparation
on pheasants, owls and parrots,Am J Vet Res 46 2639-43 1985.
283. Huchzermeyer F: OstrichDiseases Agricultural ResearchCouncil Onderstepoort 1994.
320. Smith H: Serum levels of peni-cillin dihydrostreptomycin chlo-ramphenicol aureomycin andterramycin in chickens, J CompPathol Therap 64 225 1954.
340. Loomis M, Wright J: Treatmentof iron storage disease in Balimynah. Junge R: Proc Am AssocZoo Vet AAZV, St. Louis 28 1993.
341. Norton T, Greiner E, et al:Medical aspects of Bali mynah.Junge, R: Proc Am Assoc Zoo VetAAZV, St. Louis 29-44 1993.
354. Flammer K, Aucoin D, et al:Intramuscular and oral disposi-tion of enrofloxacin in Africangrey parrots, J Vet PharmacolTherap 14 359-66 1991.
379. Dorrestein GM: Bioavailability ofdoxycycline injectables inpigeons. Ffriis C, et al: Proc IntlCong Eur Assoc Vet PharmToxicol Acta Vet, Scand,Copenhagen 5th 291-2 1991.
380. Flammer K, Aucoin D, et al:Potential use of long actinginjectable oxytetracyclines fortreatment of chlamydiosis, AvianDis 34 228-34 1990.
385. Hirsh D, Knox S, et al: Pharma-cokinetics of penicillin G in theturkey Am J Vet Res 39 1219-211978.
394. Clark C, Thomas J, et al: Plasmaconcentrations of chlorampheni-col in birds, Am J Vet Res 431249-53 1982.
399. Locke D, Bush M, et al: Pharma-cokinetics and tissue concentra-tions of tylosin in selected avianspecies, Am J Vet Res 43 1807-101982.
401. Foggin C: Veterinary problemsof ostriches. Hallam M, Topaz:Introduction to Practical OstrichFarming, MG Hallam Harare 61-96 1992.
411. Hochleithner M, GeorgopoAulos: Experiences withpiperacillin in Psittaciformes,Proc Conf Avian Dis, Munich 1571988.
418. Jensen J, Johnson J, et al:Husbandry & MedicalManagement of Ostriches, Emus,& Rheas, Wildl & Exotic AnimTelconsult, College Station 1992.
435. Cross G Antiviral therapy. FudgeA: Semin Avian Exotic Pet MedWB Saunders, Philadelphia 4 96-101 1995.
457. Bush M, Locke D, et al: Pharma-cokinetics of cephalothin andcephalexin in selected avianspecies, Am J Vet Res 42 1014-71981.
458. Custer R, Bush M, et al: Pharma-cokinetics of gentamicin inblood plasma of quail, pheasantsand cranes, Am J Vet Res 40 892-5 1979.
467. Hoover J, Lochner F, et al: Quillmites in an ostrich with rhinitissinusitis and air sacculitis, CompAnim Practice 3:2 23-6 1988.
493. Dorrestein G, VanGogh H, et al:Bioavailability and pharmacoki-netics of ampicillin and amoxi-cillin from tablets, capsules...pigeons, J Vet Pharmacol Therap9 394-401 1986.
508. Dein F, Monard D, et al:Pharmacokinetics of chloram-
Cl inica l Avian Medic ine - Volume I336
phenicol in Chinese spot billedducks, J Vet Pharmacol Therap 3161-8 1980.
531. Onderka D, Doornenbal E:Mycotic dermatitis in ostrichesCan Vet J 33 72-6 1992.
544. Devriese L, Dutta G: Effects oferythromycin inactivating lacto-bacillus crop flora on blood lev-els, J Vet Pharmacol Therap 749-53 1984.
562. Perelman B, Kuttin E: Zygo-mycosis in ostriches, AvianPathol 21 675-80 1992.
564. Tanner A: Antimicrobial druguse in poultry Prescott J, BaggotJ: Antimicrobial Therapy inVeterinary Medicine Iowa StateUniv Press, Ames 2 507-23 1993.
565. Dorrestein GM: Antimicrobialdrug use in pet birds. Prescott J,Baggot J: Antimicrobial Therapyin Veterinary Medicine, IowaState Univ. Press, Ames 2 490-507 1993.
567. Ensley P, Janssen D: A prelimi-nary study comparing the phar-macokinetics of ampicillin givenorally and intramuscularly, J ZooAnim Med 12 42-7 1981.
577. Orosz S: Personal communica-tion extending findings of theprevious reference, Proc AssocAvian Vet AAV Reno 13 1994.
578. Tully T and Morris M A treat-ment protocol for non-respon-sive arthritis in companionbirds, Proc Assoc Avian Vet AAVReno 45-9 1994.
579. Suedmeyer W Use of Adequan inarticular diseases of avianspecies, J Assoc Avian Vet 7 1051993.
580. van der Heyden N Update onavian mycobacteriosis Proc AssocAvian Vet AAV Reno 53-61 1994.
582. Phalen D, Wigle W: Sinusitis infive rheas: response to treatment,Proc Assoc Avian Vet AAV, Reno147-50 1994.
583. Doolen M: Antimicrobial therapyincluding a focus on psittacosis.Roston M, Marx K: Proc Mid-Atlantic States Assoc Avian VetMASAAV, Blacksburg, VA 16 34-41 1995.
585. Harlin R: Backyard Poultry.Roston M, Marx K: Proc Mid-Atlantic States Assoc Avian VetMASAAV Blacksburg VA 16 65-81995.
588. Hedberg G, Bennett R: Prelimi-nary studies on the use of milbe-mycin oxime in Galliformes,Proc Assoc Avian Vet AAV, Reno261-4 1994.
589. Kahler J: Somatostatin treatmentfor diabetes mellitus in a sulfurbreasted toucan, Proc AssocAvian Vet AAV, Reno 269-731994.
590. Rupiper D, Ehrenberg M: Intro-duction to pigeon practice ProcAssoc Avian Vet AAV, Reno 203-111994.
594. Bruning D, Hyde E: Ratites.Fowler M: Zoo and Wild AnimalMedicine, WB Saunders,Philadelphia 2 277-91 1986.
595. Stoskopf M, Stoskopf S: Aquaticbirds. Fowler M: Zoo and WildAnimal Medicine, WB Saunders,Philadelphia 2 293-313 1986.
596. Carpenter J: Cranes. Fowler M:Zoo and Wild Animal Medicine,WB Saunders, Philadelphia 2315-26 1986.
599. Ingram K: Hummingbirds and
miscellaneous orders. Fowler M:Zoo and Wild Animal Medicine,WB Saunders, Philadelphia 2448-56 1986.
625. Page C: Current reptilian anes-thesia procedures. Fowler M:Zoo and Wild Animal Medicine,Current Therapy, WB Saunders,Philadelphia 3 140-3 1993.
626. Redig P: Avian aspergillosis.Fowler M: Zoo and Wild AnimalMedicine, Current Therapy, WBSaunders, Philadelphia 3 178-811993.
627. Jensen J: Diseases of birdgroups. Fowler M: Zoo and WildAnimal Medicine, CurrentTherapy, WB Saunders,Philadelphia 3 200-3 1993.
628. Hicks K: Ostrich reproduction.Fowler M: Zoo and Wild AnimalMedicine, Current Therapy, WBSaunders, Philadelphia 3 203-61993.
629. Carpenter J: Infectious and para-sitic diseases of cranes. FowlerM: Zoo and Wild AnimalMedicine, Current Therapy, WBSaunders, Philadelphia 3 229-371993.
632. Joyner K: Psittacine incubationand pediatrics. Fowler M: Zooand Wild Animal Medicine,Current Therapy, WB Saunders,Philadelphia 3 247-60 1993.
674. Flammer K: An overview of anti-fungal therapy in birds, ProcAnnu Conf Assoc Avian Vet AAV,Nashville 1-4 1993.
675. Millam J, Finney H: Leuprolideacetate can reversibly preventegg laying in cockatiels, ProcAnnu Conf Assoc Avian Vet AAV,Nashville 46 1993.
676. Turner R: Trexan use in featherpicking in avian species ProcAnnu Conf Assoc Avian Vet AAV,Nashville 116-8 1993.
677. Hines R, Kolattukuty P, et al:Pharmacological induction ofmolt and gonadal involution inbirds, Proc Annu Conf AssocAvian Vet AAV, Nashville 127-341993.
678. Olsen G: Common infectiousand parasitic diseases of quailand pheasants, Proc Annu ConfAssoc Avian Vet AAV, Nashville146-50 1993.
692. Gronwall R, Brown MP, et al:Pharmacokinetics of amikacin inAfrican grey parrots, Am J VetRes 52:2 250-2 1989.
693. Lumeij JT: Psittacine antimicro-bial therapy, AntimicrobialTherapy in Caged Birds andExotic Pets, Veterinary LearningSystems, Trenton, NJ 38-481995.
695. Dorrestein GM: Infectious dis-eases and their therapy inPasseriformes, AntimicrobialTherapy in Caged Birds andExotic Pets, Veterinary LearningSystems, Trenton, NJ 11-271995.
697. Flammer K: Antimicrobial ther-apy. Ritchie B, Harrison G, et al:Avian Medicine: Principles andApplication, Wingers Publishing,Lake Worth 434-56 1994.
700. Baumgartner R, Hoop RK, et al:Atypical nocardiosis in a red-lored Amazon parrot (Amazonaautumnalis autumnalis), JAssoc Avian Vet 8:3 125-7 1994.
701. Millam JR, Finney HL:Leuprolide acetate can reversibly
prevent egg laying in cockatiels(Nymphicus hollandicus), ZooBiol 13:2 149-55 1994.
702. Goldsmith T: The use ofazithromycin in psittacines, JAssoc Avian Vet 8:3 135 1994.
703. Smith K, et al: Compendium ofmeasures to control Chlamy-dophila psittaci infection amonghuman and pet birds,www.avma.org /pubhlth/psittacosis.asp 12/16 2003.
704. Bishop YM: Guidance on pre-scribing, Veterinary FormularyRPSGB and BVA, London 3 3-801996.
705. Bishop YM: Drugs used in thetreatment of bacterial, fungal,viral and protozoal infections,Veterinary Formulary RPSGB andBVA, London 3 83-128 1996.
706. Bishop YM: Drugs used in thetreatment and control of para-sitic infections, VeterinaryFormulary BPSGB and BVA,London 3 129-179 1996.
707. Orosz SE, Frazier DL: Antifungalagents: A review of their phar-macology and therapeutic indi-cations, J Assoc Avian Vet 9:1 8-18 1995.
708. Forbes NA: Diagnosis of avianaspergillosis and treatment withitraconazole, Vet Rec 128 2631991.
709. Lumeij JT, et al: Plasma and tis-sue concentrations of itracona-zole in racing pigeons, J AssocAvian Vet 9 32-5 1995.
710. Tully TN, et al: A subchondralcyst in the distal tibiotarsal boneof an ostrich, J Assoc Avian Vet 941-4 1995.
711. Westerhoff I: Treatment of tra-cheal obstruction in psittacinebirds using a suction technique:…study, J Assoc Avian Vet 9 45-91995.
713. Tully TN, et al: What is yourdiagnosis? J Assoc Avian Vet 957-8 1995.
714. Bird JE, Miller KW, et al:Pharmacokinetics of gentamicinin birds of prey, Am J Vet Res44:7 1245-7 83
715. Pedersoli WM, Ravis WR, et al:Pharmacokinetics of single-doseintravenous or intramuscularadministration of gentamicin inrooster, Am J Vet Res 51:2 286-91990.
716. Flammer K, Clark CH, et al:Adverse affects of gentamicin inscarlet macaws and galahs, Am JVet Res 51:3 404-7 1990.
718. Ludders JW, Rode J, et al: Effectsof ketamine, xylazine and a com-bination of ketamine andxylazine in Pekin ducks, Am J VetRes 50:2 245-9 1989.
727. Skeeles JK, Swafford WS, et al:Studies on the use of long-actingoxytetracycline in turkeys:Serum levels and tissueresidues, Avian Dis 29:1 145-91985.
728. Flammer K, Aucoin DP, et al:Plasma concentrations ofenrofloxacin in African grey par-rots treated with medicatedwater, Avian Dis 34 1017-221990.
730. Prus SE, Clubb SL, et al:Doxycycline plasma concentra-tions in macaws fed a medicatedcorn diet, Avian Dis 36 480-31992.
731. Schacter J, Bankowski RA, et al:
Measurement of tetracycline lev-els in parakeets Avian Dis 28:1295-302 1984.
732. Panigrahy B, Harmon BC, et al:Hemorrhagic disease in canaries(Serinius canarius), Avian Dis28 536-41 1984.
733. Dorrestein GM, Van Gogh H, etal: Comparative study of ampi-cillin and amoxicillin after intra-venous, intramuscular and oral,Res Vet Sci 42 343-8 1987.
734. Brisbin Jr IL, Wagner CK: Somehealth problems associated withthe maintenance of Americankestrels in captivity, Intl ZooYearbook 10 29-30 70.
736. Flammer K: Use of amikacin inbirds, Proc Int Conf Zoo AvianMed AAZV and AAV, Oahu 195-71987.
738. Luthgen W, Bretschneider J, etal: Prophylaxis and therapy ofpsittacosis in lovebirds, cock-atiels and other problematicbirds, Dtsch TierarztlWochenschr 86 426-9 1979.
739. Fudge AM: Avian antimicrobialtherapy Proc Annu Conf AssocAvian Vet AAV 162-83 1983.
740. Rosskopf WJ, Woerpel RW, et al:Successful treatment ofaspergillosis in two psittacinebirds: Esophageal and respira-tory tract, Proc Assoc Avian VetAAV, Miami 119-28 1986.
741. Clubb SL: Therapeutics in avianmedicine. Harrison GJ: VetClinic NA Sm Anim Prac, WBSaunders, Philadelphia 14:2 345-61 1984.
742. Bailey T: Aspergillosis: Therapyand Prevention in Zoo Animalswith Emphasis on Raptors, FalcoNewsletter Middle East FalconResearch Group 20 18-22 2002.
743. Biasia I, Giovanardi AA: FungalInfections. Fowler ME, CubasZS: Biology, Medicine andSurgery of South American WildAnimals, Iowa State UniversityPress, Ames, IA 163-5 2001.
745. Oglesbee B: Mycotic Diseases,Internationalen SymposiumErkrankungen Zoo undWildtiere Institut ZooWildtierforschung, Berlin 37323-31 1995.
746. Verwoerd D: Aerosol use of anovel disinfectant, … preventingand treating aspergillosis in fal-cons, Falco Newsletter MiddleEast Falcon Research Group 1715-7 2001.
747. Jensen J, Westerman E: Amikacinpharmacokinetics in ostrich(Struthio camelus). Cambre RCProc Am Assoc Zoo Vet 238-421990.
748. Flammer K: An update onpsittacine antimicrobial pharma-cokinetics, Proc Assoc Avian VetAAV, Phoenix 218-20 1990.
749. Flammer K: New advances inavian therapeutics Proc AssocAvian Vet, New Orleans 14-8 92
750. Krautwald ME, Pieper K, et al:Further experiences with the useof Baytril pet birds, Proc AssocAvian Vet, Phoenix 226-36 1990.
751. Dorrestein GM, Van Gogh H,Rinzema JD: Pharmacokineticaspects of penicillins, aminogly-cosides and chloramphenicol inbirds …mammals, Vet Q 6:4216-24 1984.
758. Locke D, Bush M: Tylosinaerosol therapy in quail and
Chapter 9 | T H E R A P E U T I C A G E N T S 337
pigeons, J Zoo Anim Med 15 67-72 1984.
759. Bush M, Locke D, et al:Gentamicin tissue concentrationin various avian species follow-ing recommended dosage ther-apy, Am J Vet Res 42:12 2114-61981.
762. Anadon A, Martinez-LarrangaMR, et al: Pharmacokinetics ofdoxycycline in broiler chickens,Avian Pathol 23 79-90 1994.
763. McDonald SE: Summary of med-ications for use in psittacinebirds, J Assoc Avian Vet 3 120-61989.
765. Anadon A, Martinez-LarrangaMR, et al: Pharmacokinetic char-acteristics and tissue residuesfor marbofloxacin…in broilerchickens, Am J Vet Res 63 927-332002.
778. Garcia-Montijano M, Waxman S,et al: The disposition of mar-bofloxacin in Eurasian buzzardsafter intravenous administration,J Vet Pharmacol Therap 24 155-72001.
779. Fitzgzgerald G, Cooper JEPreliminary studies of the use ofpropofol in the domesticpigeon, Res Vet Sci 49 334-81990.
787. Ding HZ, Zeng ZL, et al:Pharmacokinetics of sarafloxacinin pigs and broilers following IV,IM and oral single doses, J VetPharmacol Therap 24 303-82001.
788. Tell L, Harrenstein L, et al:Pharmacokinetics of ceftiofursodium in exotic and domesticavian species, J Vet PharmacolTherap 21 85-91 1998.
789. Laczay P, Semjen G, et al:Comparative studies on thepharmacokinetics of norfloxacinin chickens, turkeys and geese, JVet Pharmacol Therap 21 161-41998.
790. Bailey TA, Sheen RS, et al:Pharmacokinetics of enro-floxacin after IV, IM and oraladministration in a houbara bus-tard, J Vet Pharmacol Therap 21288-97 1998.
795. Cybulski W, Larrson P, et al:Disposition of metronidazole inhens and quails: pharmacokinet-ics and autoradiography, J VetPharmacol Therap 19 352-81996.
815. Bailey TA, Sheen RS, et al:Pharmacokinetics of enro-floxacin after IV, IM and oraladministration to houbara bus-tards, J Vet Pharmacol Therap 20Suppl 204-5 1997.
818. Clipsham R: New treatment fortapeworms, J Assoc Avian Vet 3132 1989.
819. Rosskopf WJ: Clinical use ofselected therapeutics, J AssocAvian Vet 3 127-8 1989.
820. McDonald SE: Injecting eggswith antibiotics, J Assoc AvianVet 3:1 9 1989.
821. Bond M: Intradermal injectionsfor pox eye lesions, J AssocAvian Vet 3 132 1989.
822. Oaks JL Treatment of a falconfor localized tetanus J AssocAvian Vet 3 140-2 1989.
823. McCluggage DM Self AssessmentTest J Assoc Avian Vet 3 168, 1731989.
830. Anadon A, Martinez-LarrangaMR, et al: Pharmacokinetics of
norfloxacin and metabolites inbroiler chickens, Am J Vet Res53:11 2084-9 1992.
835. Vaden SL, Cullen JM, Riviere JE:Pharmacokinetics ofcyclosporine in woodchucks andPekin ducks, J Vet PharmacolTherap 18 30-3 1995.
841. Freed M, Clarke JP, et al: Effectof spectinomycin on Escherichiacoli infection in 1-day-old duck-lings, Avian Dis 37 763-6 1993.
842. Kempf I, Gesbert F et al: Dosetitration study of enrofloxacinagainst respiratory colibacillosisin Muscovy ducks, Avian Dis 39480-8 1995.
843. Bradley FA, Bickford AA, WalkerRL: Efficacy of miconazolenitrate against favus in orientalbreed chickens, Avian Dis 39900-1 1995.
847. Bush M Pharmacokinetics ofselected antibiotics in avianspecies (a review), Proc SympAvian Dis Fifth 53-9 1983.
848. Vernimb GD, Bachman H, PanitzE: Effect of gentamicin on earlymortality and later performanceof chickens, Avian Dis 20:4 706-13 1976.
849. Turbahn A, de Jackel SC, et al:Dose response study of enro-floxacin against Riemerellaanatipestifer in ducklings, AvianPathol 26 791-802 1997.
851. Hamdy AH, Kratzer DD, et al:Effect of a single injection of lin-comycin and spectinomycin onearly chick mortality, Avian Dis23:1 164-73 1979.
853. Intorre L, Mengozzi G, et al: Theplasma kinetics and tissue distri-bution of enrofloxacin andciprofloxacin in the Muscovyduck, Vet Res Comm 21 127-361997.
854. Froyman R, Sheer M, De Jong A:Serum kinetics of enrofloxacinin Pekin ducks during drinkingwater medication and Baytril10%. Lees, P: Proc Intl Cong EurAssoc Vet Pharm ToxicolBlackwell Scientific Publ,Edinburgh 6th 236-7 1994.
855. Charleston B, Gate JJ, et al:Comparison of the efficacies ofthree fluoroquinolone antimi-crobial agents…chickens, Anti-microbial Agents Chemother 4283-7 1998.
856. Jordan FTW, Gilbert S, et al:Effects of Baytril, tylosin and tia-mulin on avian mycoplasmas,Avian Pathol 18 659-73 1989.
861. Rosskopf WJ, Woerpel RW:Practical avian therapeutics anddosages of commonly used med-ications. Rosskopf WJ, WoerpelRW: Vet Clinic NA Sm Anim PracWB Saunders, Philadelphia 21:61265-71 1991.
862. Barbour EK, Hamadeh S, et al:Evaluation of an enrofloxacin-treatment program againstMycoplasma gallisepticum inbroilers, Preventive VeterinaryMedicine 35 91-9 1998.
863. Sumano LH, Ocampo CL, et al:Effectiveness of two fluoro-quinolones for the treatment ofchronic respiratory disease out-break, British Poultry Sciences39 42-6 1998.
864. McCabe MW, Rippel RH, MillerRE: Efficacy of sarafloxacin forthe control of mortality associ-ated with E. coli infections, Proc
Western Poultry Disease Conf,Sacramento 42nd 75 1993.
865. Glisson JR The efficacy ofenrofloxacin for the treatment ofcolibacillosis…and fowl cholerain turkeys, Proc Western PoultryDisease Conf, Cancun 45th 222-4 1996.
866. Dorrestein GM and Verburg EPharmacokinetics of enro-floxacin in homingpigeons, ProcIntl Cong Eur Assoc Vet PharmToxicol Univ of VeterinaryScience, Budapest 4th 27-301988.
869. Migaki TT, Chappel LR, BabcockWE: Anticoccidial efficacyof…salinomycin, in comparisonto monensin and lasalocid inbattery trials, Proc WesternPoultry Disease Conf, Davis, CA27th 40-2 1978.
870. Galvan G, Huerta A, del Oro M:Efficacy of tiamulin in the treat-ment of mycoplasmosis in chick-ens in Mexico, Proc WesternPoultry Disease Conf, Davis, CA27th 80-2 1978.
872. Hamdy AH, Saif YM: Efficacy ofvarious concentrations of lin-comycinspectinomycin againstmycoplasma in turkey poults,Proc Western Poultry DiseaseConf, Davis, CA 26th 115-81977.
873. Jordan FTW, Forrrester CA, et al:In vitro and in vivo…valnemu-lin, tiamulin, tylosin, enro-floxacin, lincomycin/spectino-mycin, Avian Dis 42 738-451998.
874. Droual R, Bickford AA, et al:Favus in a backyard flock ofgame chickens Avian Dis 35 625-30 1991.
876. Dyer DC, van Alstine WG:Antibiotic aerosolization: tissueand plasma oxytetracycline con-centration in parakeets, AvianDis 31 677-9 1987.
877. Jordan FTW, Knight D: The mini-mum inhibitory concentration ofkitasamycin, tylosin and tiamulinfor Mycoplasma, Avian Pathol 13151-62 1984.
878. Law JM, Tully TN, Stewart TB:Verminous encephalitis appar-ently caused by the filaroid nem-atode Chandlerella quicali inemus, Avian and Exotic AnimalMedicine Symposium 37 597-601 1993.
879. Ramsey EC, Vulliet R: Pharma-cokinetic properties of gentam-icin and amikacin in the cock-atiel, Avian Dis 37 628-34 1993.
880. Pedersoli WM, Ravis WR, et al:Pharmacokinetics of single dosesof gentamicin given intra-venously and intramuscularly toturkeys, J Vet Pharmacol Therap12 124-32 1989.
881. Cracknell VC, Andreotis J, et al:An evaluation of apramycin solu-ble powder for the treatment ofnaturally acquired E. coli infec-tions, J Vet Pharmacol Therap 9273-9 1986.
882. Hamlin RL, Stalnaker PS: Basisfor use of digoxin in small birds,J Vet Pharmacol Therap 10 354-61987.
883. Maldonado A: ReportePreeliminar: Digitalizacion enpollos de engorda com metodopreventivo el sindrome ascitico,Proc Western Poultry DiseaseConf 35th 1986.
888. Baert L, van Poucke S, et al:Pharmacokinetics andanthelmintic efficacy of febantelin the racing pigeon, J VetPharmacol Therap 16 223-311993.
890. Schriemer TR, Paulissen JB,Dame KJ: Evaluation of ceftiofursodium for control of terminalbacterial infections in broilerchickens, Proc World’s PoultryCong, Amsterdam 19th:1 4271992.
891. Vanparijs O, Hermans L, van deFlaes L: Anticoccidial efficacy ofdiclazuril in game birds ProcWorld’s Poultry Cong,Amsterdam 19th:1 394-7 1992.
893. Tanner AC, Davidson JN: Efficacyof danofloxacin against inducedcolisepticemia in broiler chick-ens, Proc World’s Poultry Cong,Amsterdam 19th:3 84-5 1992.
894. Schneider KH, Scheller W: Effectof exogenous testosterone andgonadotropic hormones on ejac-ulate production by ganders,Proc World’s Poultry Cong,Amsterdam 19th:3 307 1992.
895. Ruff MD, Chute MB, Wilkins GC:Control of coccidiosis in ring-necked pheasants, Proc World’sPoultry Cong, Amsterdam 19th:3337-41 1992.
899. Flinchum G: Infraorbital SinusFlushes in Birds, Exotic DVM 1.118-22 1999.
905. Lierz M: Phallus Amputation inPet Ducks, Exotic DVM 1.3 51-41999.
912. Harrison GJ: Rescue remedy forbirds, Exotic DVM 1.4 40 1999.
914. Schoemaker NJ: SelectedDermatologic Conditions inExotic Pets, Exotic DVM 1.5 5-111999.
916. Dorrestein GM: Enrofloxacin inpet avian and exotic animal ther-apy, Proc Int Baytril Symp Bonn1st 63-70 1992.
918. Redmann T, Glunder G, et al:Attempted therapy withenrofloxacin of a flock of layinghens with pullorum-salmonel-losis, Dtsch TierarztlWochenschr 96 137-8 1989.
919. Dorrestein GM, Verburg E:Pharmacokinetics of Baytril inhoming pigeons after differentadministration routes, ProcSymp Avian Dis, Munich 6th132-43 1988.
921. Linderstruth H: Feldversuch zurwirksamkeits- und ver-traglichkeitsprufung von Baytrilbei importierten Psittaciden..VetMed Diss, Giessen 1992.
922. Uyttenbroek E, Gevaert D,Devriese LA: Effect of differentchemotherapeutics on experi-mental salmonellosis in pigeons,Vlaams Diergeneesk Tijdschr 5851-4 1989.
923. Schmahl C: Therapieversuchebei der spontanen infektion vonBrief- und Rasstauben mitSalmonella typhimurium, ProcTagung Vogelkrankheiten.Munich 7th 148-53 1990.
924. Krautwald-Junghans ME: Aviantherapeutics. Proc Eur ChapAssoc Avian Vet. Vienna 1st 30-91991.
925. Bougerol C: Antibiotherapiechez les oiseaux, Rec Med Vet166 361-6 1990.
932. Ostrowski S, Greth A, MikaelianI: Pathology and Veterinary Care.
Cl inica l Avian Medic ine - Volume I338
Saint Jalme M, van Heezik Y:Propagation of the Houbara bus-tard Kegan Paul International,London 70-96 1995.
936. Scheer M: Concentrations ofactive ingredient in the serumand in tissues after oral and par-enteral…Baytril, Vet Med Rev 2104-18 1987.
939. Zantop D: Medetomidine inbirds, Exotic DVM 1.5 34 1999.
943. Harcourt-Brown NH: Treatmentof bumblefoot in an eagle,Exotic DVM 1.6 5-11 2000.
951. Lindenstruth H: Feldversuch zurwirksamkeits- und ver-traglichkeitsprufung von Baytrilbei importierten psittaciden. VetMed Diss, Giessen 1992.
956. Bauditz R: Enrofloxacin - clinicalevaluation in several animalspecies. Simon F, et al: Proc IntlCong Eur Assoc Vet PharmToxicol Univ of Veterinary Scien,Budapest 4th 21-6 1988.
957. Vlaminck K, Vanparijs O, et al:Clazuril, anticoccidial agent forpigeons. Simon F, et al: Proc IntlCong Eur Assoc Vet PharmToxicol Univ. of Veterinary Scien,Budapest 4th 177-9 1988.
958. Varga I, Laczay P, Voros G:Anticoccidial efficacy of madu-ramicin in batter, floor pen andfield trials. Simon F, et al: ProcIntl Cong Eur Assoc Vet PharmToxicol Univ of Veterinary Scien,Budapest 4th 181-6 1988.
962. Meyer KF, Eddie B: Chemo-therapy of natural psittacosisand ornithosis field trials oftetracyclines, AntibiotChemother 5 289-9 1955.
966. Dorrestein GM, Van Gogh H, etal: Clinical pharmacology andpharmacokinetics of flumequineIV, IM and oral administration inpigeons, J Vet Pharmacol Therap6 281-92 1983.
968. Dorrestein, GM, Rinzema JD, etal: Clinical pharmacology andpharmacokinetics of trimetho-prim and selected sulfonamidesin the pigeon, DissertationProefschrift Utrecht 139-691987.
978. Herrenstien LA: Disposition ofenrofloxacin in red-tailed hawksand great horned owls. SobackS, McKellar QA: Proc Intl CongEur Assoc Vet Pharm ToxicolBlackwell Science Ltd, Jerusalem8th B49 2000.
979. Waxman S, Garcia-Montijano M,et al: Pharmacokinetic behaviorof marbofloxacin after oraladministration in Buteo buteo.Soback S, McKellar QA: Proc IntlCong Eur Assoc Vet PharmToxicol Blackwell Science Ltd,Jerusalem 8th B51 2000.
983. Webb AI, French RA, Gaskin JM:The efficacy and safety of fen-bendazole in gamebirds. SobackS, McKellar QA: Proc Intl CongEur Assoc Vet Pharm ToxicolBlackwell Science Ltd. Jerusalem8th H27 2000.
987. Bauditz R: Results of clinicalstudies with Baytril in poultry,Vet Med Rev 2 130-6 1987.
990. TerHune TN, Wages DP, et al:Clinical evaluation of efficacy ofdanofloxacin treatment of E. coliairsacculitis, Proc WesternPoultry Disease Conference,Acapulco 40th 270 1991.
991. Krieg J, Kosters J: Pharma-cokinetics of amoxycillin inhealthy and specifically com-promised adult pigeons, ProcConf Avian Dis, Munich 5th 90-6 1986.
992. Bruch JV, Aufinger P, Jakoby JR:Studies of pharmacokineticsand efficacy of sulphadimeth-oxine to…adult pigeons, ProcConf Avian Dis, Munich 5th 97-106 1986.
994. Zantop D: Using LeuprolideAcetate to Manage CommonAvian Reproductive Problems,Exotic DVM 2.3 70 2000.
1006. Aerts R, Verheijen F, et al:Efficacy of dosage schemes ofParacillin SP in E. coli chal-lenged broilers. Lees P: ProcIntl Cong Eur Assoc Vet PharmToxicol Blackwell ScientificPubl, Edinburgh 6th 94-5 1994.
1009. Semjen G, Magyar T, Laczay P:Efficacy of doxycycline in thetreatment of experimentallyinduced fowl cholera in broilerchickens. Lees P: Proc IntlCong Eur Assoc Vet PharmToxicol Blackwell ScientificPubl, Edinburgh 6th 200-11994.
1015. Pashov D, Deyanov M, et al:Efficacy of some formulationscontaining tylosin against avianborreliosis. Lees P: Proc IntlCong Eur Assoc Vet PharmToxicol Blackwell ScientificPubl, Edinburgh 6th 223-41994.
1016. Rolinski Z, Furmaga R, et al:Laboratory, pharmacologicaland clinical studies on a combi-nation of colistin and tylosin.Lees P: Proc Intl Cong EurAssoc Vet Pharm ToxicolBlackwell Scientific Publ,Edinburgh 6th 224-5 1994.
1020. Gulkarov A, Ziv G: Some phar-macokinetic features of nor-floxacin nicotinate in turkeys.Lees P: Proc Intl Cong EurAssoc Vet Pharm ToxicolBlackwell Scientific Publ,Edinburgh 6th 235 1994.
1021. Delaporte J, Froyman R, et al:Distribution of enrofloxacinwithin hatching eggs during…treatment with Baytril 10% inturkeys. Lees P: Proc Intl CongEur Assoc Vet Pharm ToxicolBlackwell Scientific Publ,Edinburgh 6th 235-6 1994.
1023. Bousquet E, Barrowman P, etal: pharmacokinetics of atrimethoprim/sulfadiazine com-bination administered drinkingwater to broilers. Lees P: ProcIntl Cong Eur Assoc Vet PharmToxicol Blackwell ScientificPubl, Edinburgh 6th 241 1994.
1024. de Backer P, Vermeersch H, etal: Pharmacokinetics andanthelmintic efficacy of feban-tel in racing pigeons. Lees P:Proc Intl Cong Eur Assoc VetPharm Toxicol BlackwellScientific Publ, Edinburgh 6th248-9 1994.
1025. Pashov D, Koinarski V:Comparative studies of anticoc-cidial efficacy sulfadimidine,trimethoprim and toltrazuril inturkey. Lees P: Proc Intl CongEur Assoc Vet Pharm ToxicolBlackwell Scientific Publ,Edinburgh 6th 264 1994.
1027. Remple JD, Riddle SK:
Pharmacological Considera-tions. Weaver JD, Cade TJ:Falcon Propagation ThePeregrine Fund, Boise, Idaho,2nd Ed 77-85 1991.
1028. Sandfort C, Dierenfeld E, Lee J:Nutrition. Weaver JD, Cade TJ:Falcon Propagation ThePeregrine Fund. Boise, Idaho,2nd Ed 81-2 1991.
1029. Heck WR, Konkel D: Incuba-tion and rearing Weaver JD,Cade TJ: Falcon PropagationThe Peregrine Fund, Boise,Idaho, 2nd Ed 34-76 1991.
1033. Zantop DW: Treatment of BileDuct Carcinoma in Birds withCarboplatin, Exotic DVM 2.376-8 2000.
1034. Lierz M: Use of inhalationchamber for aspergillosis ther-apy, Exotic DVM 2.3 79-802000.
1035. Hochleithner D, HochleithnerM: Innovative approach to liverand kidney diseases inpsittacine birds, Exotic DVM2.3 84-7 2000.
1051. McKellar QA, Scott EW: Thebenzimidazole anthelminticagents, J Vet Pharmacol Therap13 223-47 1990.
1056. Pedersoli WM, Askins D, et al:Pharmacokinetics of gentam-icin in chickens after single andrepeated administration,Pharmacologist 28 204 1986.
1058. El-Gammal AA, Ravis WR, et al:Pharmacokinetics and intra-muscular bioavailability ofamikacin in chickens followingdosing, J Vet Pharmacol Therap15 133-42 1992.
1060. Norton TM, Kollias GV, et al:Acyclovir (Zovirax) pharmaco-kinetics in Quaker parakeets, JVet Pharmacol Therap 15 252-81992.
1061. Zwijnenberg RJG, Vulto AG, etal: Evaluation of antibiotics forracing pigeons available in theNetherlands, J Vet PharmacolTherap 15 364-78 1992.
1062. Gylstorff I, Jakoby JR,Gerbermann H: Investigationsof the efficacy different med-icated feed to parrots infectedwith Chlamydia psittaci, BerlMunch Tieraerztl Wschr 97 91-9 1984.
1065. Oostindjer AJ, Frankenhuis MT,et al: Compendium Behandel-ingsadviezen VogelziektenGezondheidsdienst voorPlumvee Doorn 5th 1987.
1066. Dorrestein GM, van der HageMH, Zwart P: Examination,diagnosis and therapy of dis-eases of aviary birds, Proc EurSymp Bird Dis, Beerse 123-541987.
1067. McDonald SE Practical aviantherapeutics Proc Assoc AvianVet Houston 7-19 1988.
1068. Samour J: Management of rap-tors. Harrison G, Lightfoot T(eds): Clinical Avian Medicine,914-956 2005.
1070. Arnstein P, Cohen DH, et al:Medication of pigeons withchlortetracycline in feed, J AmVet Med Assoc 9 921-4 1964.
1072. Reid BL, Hulett BJ: Aspirinstimulates egg production,Feedstuffs 36 32 1964.
1077. Arnstein P, Buchanan WG, et al:Chlortetracycline chemother-apy for nectar-feeding
psittacine birds, J Am Vet MedAssoc 154 190-1 1969.
1079. Arnstein P, Eddie B, et al:Control of psittacosis by groupchemotherapy of infected par-rots, Am J Vet Res 29 2213-271968.
1087. Bush M: External fixation ofavian fractures, J Am Vet MedAssoc 171 943-6 1977.
1088. Kennedy S, Crisler JP, et al:Lead poisoning in sand hillcranes, J Am Vet Med Assoc 171955-8 1977.
1089. Courtney CH, Forrester DJ,White FH: Anthelmintic treat-ment of brown pelicans, J AmVet Med Assoc 171 991-2 1977.
1090. Stoskopf MD, Beier J: Avianmalaria in African black-footedpenguins, J Am Vet Med Assoc175 944-7 1979.
1091. Ensley PK, Davis CE, et al:Cryptococcosis in a maleBeccari’s crowned pigeon, JAm Vet Med Assoc 175 992-41979.
1093. Shlosberg A: Treatment ofmonocrotophos-poisoned birdsof prey with pralidoximeiodide, J Am Vet Med Assoc 169989-90 1976.
1096. Ward FP: Thiamine deficiencyin a peregrine falcon, J Am VetMed Assoc 159 599-601 1971.
1110 Harcourt-Brown NH: TendonRepair in the Avian Pelvic Limb,Exotic DVM 2.5 28-33 2000.
1112. Flinchum G, Harrison G:Yunnan Paiyan for surgical sup-port, Exotic DVM 2.6 10 2001.
1114. Samour JH, Naldo JL: Medicalmanagement of avian poxlesions on the cere of captivefalcon, Exotic DVM 2.6 14-52001.
1119. Rodriguez-Quiros J: Bone graft-ing in birds, Exotic DVM 3.117-23 2001.
1120. Richardson JA, Murphy LA, etal: Managing pet bird toxi-coses, Exotic DVM 3.1 23-72001.
1124. Samour J, Naldo J: Tricho-moniasis infections in captivefalcons, Exotic DVM 3.2 10-12001.
1127. Bailey TA, Samour JH, et al:Analysis of amoxycillin in bus-tard plasma by highperfor-mance liquid chromatography,J Vet Pharmacol Therap 19 313-5 1996.
1128. Bailey T: On long-acting amoxi-cillin in birds Personal notes orcommunications, BirdMed 3-182003.
1131. Klueh PN: Investigations ontherapy and prophylaxis ofCaryospora-infections in fal-cons with toltrazuril…Dissertation TierarzlichenHochschule, Hanover 1994.
1132. Arent L, Martell M: Care andManagement of CaptiveRaptors, Raptor Center Univ,Minnesota, St Paul 1996.
1133. Forbes NA: Falcon herpesvirusin the UK, Falco, NewsletterMiddle East Falcon ResearchGroup 17 2001.
1134. Forbes NA: Control of endemicCaryospora species infestationof captive raptors, Falco,Newsletter Middle East FalconResearch Group 16 2000.
1135. McKinney P: Amyloidosis in fal-cons in the United Arab
Chapter 9 | T H E R A P E U T I C A G E N T S 339
Emirates Falco, NewsletterMiddle East Falcon ResearchGroup 16 2000.
1139. Dorrestein GM, Buitelaar MN,Wiggelinkhuizen JM: Pharma-kokinetishce aspectin vonantibiotika bei volierevogelnund tauben, Proc Symp AvianDis, Munich 2nd 1981.
1140. Lawrence K: Therapeutics.Price CJ: Manual of Parrots,Budgerigars & Other PsittacineBirds, BSAVA West Sussex 171-87 1988.
1142. Lawrence K: Facts and data tohelp the treatment of smallerdomestic pets. Evans J:Henston Veterinary VadeMecum Henston, London1986.
1143. Clark CH: Pharmacology ofantibiotics. Harrison GJ,Harrison LR: Clinical AvianMedicine and Surgery, WBSaunders, Philadelphia 319-261986.
1150. Flinchum GB: Management ofwaterfowl. Harrison G,Lightfoot T (eds): Clinical AvianMedicine, 830-848 2005.
1151. Harrison GJ, Flinchum GB:Emergency and critical care.Harrison G, Lightfoot T (eds):Clinical Avian Medicine, 213-232 2005.
1152. Pees M, Straub J, Krautwald-Junghanns ME: Evaluating andtreating the cardiovascular sys-tem. Harrison G, Lightfoot T(eds): Clinical Avian Medicine,379-410 2005.
1154. Pollock CG: Implications ofmycobacteria in clinical disor-ders. Harrison G, Lightfoot T(eds): Clinical Avian Medicine,681-690 2005.
1156. Forbes NA: Epidemic andendemic chlamydiosis in a col-lection of raptors. Samour JH:Proc Specialist Group MiddleEast Falcon Research GroupMEFRG, Abu Dhabi 3-8 1995.
1157. Verwoerd D: Observations onthe use of azithromycin in fal-cons Falco, Newsletter MiddleEast Falcon Research Group 16Letters 2000.
1158. Samour J: Serratospiculiasis inbirds of prey, Falco, NewsletterMiddle East Falcon ResearchGroup 16 Letters 2000.
1159. Lierz M, Remple D: Endopara-sitenbefall bei grossfalken inDubai Kleintier, Praxis 42 757-68 1997.
1160. Baronetzky-Mercier A, Seidel B,Goltenberg R & HG: KlosKrankheiten der Zoo undWildtiere Blackwell Berlin 443-65 1995.
1167. Bradley T: Recognizing pain inexotic animals Exotic DVM 3.321-6 2001.
1169. Papich MG: Drug therapy andselection in exotic medicineCompend Contin Educ Prac Vet25, Suppl 15-20 2003.
1170. Flammer K: Common bacterialinfections and antibiotic use incompanion birds, CompendContin Educ Prac Vet 20, Supp3A 34-48 1998.
1175. Riddle KE: Surgical treatmentof bumblefoot in raptors.Cooper JE, Greenwood AG:Proc Intl Symp of Diseases ofBirds of Prey, ChironPublications, West Yorkshire
1980 67-73 1981.
1177. Remple JD: Avian malaria withcomments on Haemosporidiain large falcons. Cooper JE,Greenwood AG: Proc Intl Sympof Diseases of Birds of Prey,Chiron Publications, WestYorkshire 1980 107-10 1981.
1178. Redig PT: Aspergillosis in rap-tors. Cooper JE, GreenwoodAG, Proc Intl Symp of Diseasesof Birds of Prey, ChironPublications, West Yorkshire1980 117-22 1981.
1179. Satterfield WC, O’Rourke KI:Immunological considerationsin the management of bumble-foot. Cooper JE, GreenwoodAG: Proc Intl Symp of Diseasesof Birds of Prey, ChironPublications, West Yorkshire1980 123-9 1981.
1180. Dorrestein GM: Quick refer-ence for drug dosing. Tully TN,Lawton MPC, et al: AvianMedicine, ButterworthHeinemann, Oxford 386-902000.
1183. Dorrestein GM: Nursing thesick bird. Tully TN, LawtonMPC, et al: Avian Medicine,Butterworth Heinemann,Oxford 74-111 2000.
1184. Gaggemeier B, Henke J, et al:Lihtersachunjen en schmerzlin-derung unit buprenorphine beihanstauben, Proc Conf AvianDis, Munich 12th 21 2000.
1185. Rupley AE: Manual of AvianPractice, WB Saunders,Philadelphia 1997.
1186. Harcourt-Brown NH: Psittacinebirds. Tully TN, Lawton MPC,et al: Avian Medicine,Butterworth Heinemann,Oxford 112-43 2000.
1187. Dorrestein GM: Passerines andexotic softbills. Tully TN,Lawton MPC, et al: AvianMedicine, ButterworthHeinemann, Oxford 144-792000.
1188. Redig PT, Ackermann J:Raptors. Tully TN, LawtonMPC, et al: Avian Medicine,Butterworth HeinemannOxford, 180-214 2000.
1189. Olsen G: Cranes. Tully TN,Lawton MPC, et al: AvianMedicine, ButterworthHeinemann Oxford, 215-272000.
1190. Routh A , Sanderson S:Waterfowl. Tully TN, LawtonMPC, et al: Avian Medicine,Butterworth HeinemannOxford, 234-65 2000.
1191. Worell A: Rhamphistids. TullyTN, Lawton MPC, et al: AvianMedicine, ButterworthHeinemann Oxford, 296-3112000.
1192. de Herdt P, Devriese L: Pigeons.Tully TN, Lawton MPC, et al:Avian Medicine, ButterworthHeinemann Oxford, 313-382000.
1197. Bailey T: Aerosol therapy inbirds using a novel disinfec-tant, Exotic DVM 3.4 17 2001.
1198. Stanford M: Use of F10 inpsittacines, Exotic DVM 3.4 182001.
1199. Kelleher S: Nebulization recipeExotic DVM 3.4 6 2001.
1204. Flinchum G: Corticosteroidsmay have some use in birdsExotic DVM 3.5 43 2001.
1205. McCluggage D: Overview ofnutriceutical and herbal thera-pies for birds, Exotic DVM 3.68-11 2002.
1208. Devriese LA: Ziekten vanSiervogels en DuivenRijksuniversiteit Gent 3rd 1986.
1212. Lafeber TJ: Other diseases ofbudgerigars. Kirk RW: CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia III 376-9 1968.
1217. Vickers JH: Respiratory diseasesin primates. Kirk RW: CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia III 398-400 1968.
1221. Gelis S: Evaluating and treatingthe gastrointestinal system.Harrison G, Lightfoot T (eds):Clinical Avian Medicine, 411-440 2005.
1223. Jakob-Hoff R, Bucham B,Boyland M: Kiwi coccidia -North Island survey Kokako 63-5 1999.
1224. Doneley B: Management ofcaptive ratites. Harrison G,Lightfoot T (eds): Clinical AvianMedicine, 957-990 2005.
1226. Black DG: Common medicaland surgical conditions ofostriches, Proceedings 2789Basics of Avian Medicine, Univof Sydney, Sydney 243-58 1996.
1233. Kellner SJ: Eye and eyelidinjuries. Samour J: AvianMedicine, Mosby, London 120-3 2000.
1234. Harcourt-Brown NH: Bumble-foot. Samour J: Avian Medicine,Mosby, London 126-31 2000.
1236. Samour J: Toxicology. SamourJ: Avian Medicine, Mosby,London 180-93 2000.
1238. Zwart P Bacterial diseasesSamour, J Avian MedicineMosby London 254-64 2000.
1239. Redig P: Fungal diseases -Aspergillosis. Samour J: AvianMedicine, Mosby, London 275-87 2000.
1240. Samour J: Pharmaceutics com-monly used in avian medicine.Samour J: Avian Medicine,Mosby, London 388-418 2000.
1254. Perelman B, Kuttin ES: Mycoticinfections in ostriches.Deeming DC: Improving OurUnderstanding of Ratites,Farming Environment, RatiteConf, Oxon, UK 47-9 1996.
1257. Irons PC, Bertschinger HJ, etal: Semen collection and evalu-ation in the ostrich. DeemingDC: Improving Our Under-standing of Ratites, FarmingEnvironment, Ratite Conf,Oxon, UK 157-9 1996.
1259. Macwhirter P, Pyke D, Wayne J:Use of carboplatin in the treat-ment of renal adenocarcinomain a budgerigar, Exotic DVM4.2 10-2 2002.
1263. Doneley B: Acute pancreatitisin parrots, Exotic DVM 4.3 13-62002.
1268. Stanford M: ICE presentationand discussion, InternationalConference on Exotics,Zoological Education Network,Palm Beach, FL 2003.
1269. Johnson-Delaney C: ICE pres-entation and discussion,International Conference onExotics, Zoological EducationNetwork, Palm Beach, FL 2003.
1273. Flinchum G: ICE presentation
and discussion, InternationalConference on Exotics,Zoological Education Network,Palm Beach, FL 2003.
1274. Bowles H: ICE presentationand discussion, InternationalConference on Exotics,Zoological Education Network,Palm Beach, FL Supp 16 2003.
1278. Zantop D: ICE presentationand discussion, InternationalConference on Exotics,Zoological Education Network,Palm Beach, FL 2003.
1279. Lennox A: ICE presentationand discussion, InternationalConference on Exotics,Zoological Education Network,Palm Beach, FL 2003.
1280. Cubas ZS, Godoy SN: Hemo-chromatosis in toucans, ExoticDVM 4.3 27-8 2002.
1281. Lennox AM: The use of Aldara(imiquimod) for the treatmentof cloacal papillomatosis inpsittacines, Exotic DVM 4.3 34-5 2002.
1296. Finkelstein AD, DiGesualdo CL:Wound management in apheasant, Exotic DVM 4.5 102002.
1297. Stanford M: Use of DoxirobeGel®, Exotic DVM 4.5 11 2002.
1302. Stanford M: Further uses ofF10 in exotic practice, ExoticDVM 4.5 19 2002.
1306. Oglesbee B, Bishop C: Avianinfectious disease. Birchard S,Sherding R: Manual of SmallAnimal Practice, WB Saunders,Philadelphia 1257-70 1994.
1307. Plumb DC: Veterinary DrugHandbook, Iowa State PressAmes, IA 4th 2002.
1308. Jenson J: Current ratite ther-apy, Vet Clinic NA Food AnimPrac, WB Saunders, Philadel-phia 16 1998.
1309. Clubb SL: Therapeutics:Individual and flock treatmentregimens. Harrison GJ,Harrison LR: Clinical AvianMedicine and Surgery, WBSaunders, Philadelphia 327-561986.
1311. Rupiper DJ, Carpenter JW,Mashimo TY: Formulary. OlsenGH, Orosz SE: Manual of AvianMedicine, Mosby, St. Louis, MO553-89 2000.
1313. Tully TN: Formulary. AltmanRB, Clubb SL, et al: AvianMedicine and Surgery, WBSaunders, Philadelphia 671-881997.
1314. Joseph V: Preventive healthprograms for falconry birds,Proc Annu Conf Assoc Avian Vet171-8 1995.
1316. Kasper A: Rehabilitation ofCalifornia towhees Proc AnnuConf Assoc Avian Vet 83-901997.
1317. Moore DM, Rice RL: Exotic ani-mal formulary. Holt KK, et al:Veterinary Values, VeterinaryMedicine Publishing, Lenexa,KS 5 159-245 1998.
1318. Clubb SL, Johnston DE: BristolVeterinary Handbook ofAntimicrobial Therapy,Veterinary Learning Systems,Trenton, NJ 2 188-99 1987.
1319. Hoeffer H: Antimicrobials inpet birds Bonagura, J CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia XII 1278-83 1995.
Cl inica l Avian Medic ine - Volume I340
1320. Clyde V, Paul-Murphy J: Aviananalgesia. Bonagura J: CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia XIII 1126-8 2000.
1323. McConnell VC, Hughey T:Formulary. Univ of Georgia VetHospital, Athens, GA 1987.
1324. Hillyer E: Avian dermatology.Birchard S, Sherding,R: Manualof Small Animal Practice ,WBSaunders, Philadelphia 1271-811994.
1325. Stunkard JM: Diagnosis,Treatment and Husbandry ofPet Birds, Stunkard PublishingEdgewater, MD 1984.
1326. Lothrop CD, Harrison GJ, et al:Miscellaneous diseasesHarrison GJ, Harrison LR:Clinical Avian Medicine andSurgery, WB Saunders,Philadelphia 535-6 1986.
1329. Tully T: Psittacine therapeutics,Vet Clinic NA Exotic Anim Prac,WB Saunders, Philadelphia 359-90 2000.
1330. Velasco MC: Candidiasis andcryptococcosis in Birds, SeminAvian Exotic Pet Med, WBSaunders, Philadelphia 9 75-812000.
1332. Flammer K: Oropharyngeal dis-eases in caged birds. Kirk RW:Current Veterinary TherapySmall Animal, WB Saunders,Philadelphia IX 699-702 1986.
1334. Sandmeier P, Coutteel P:Management of canaries,finches and mynahs. HarrisonG, Lightfoot T (eds): ClinicalAvian Medicine, 878-914 2005.
1335. Roberson EL: Antinematodalagents. Booth NH, McDonaldLE: Veterinary Pharmacologyand Therapeutics, Iowa StateUniversity Press, Ames, IA 6882-927 1988.
1336. Marshall R: Avian anthelminticsand antiprotozoals, SeminAvian Exotic Pet Med, WBSaunders, Philadelphia 2 33-411993.
1337. Calvert C, Mieurs K: CVTupdate. Bonagura J: CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia XIII 756-60 2000.
1338. Dalhausen B, Lindstrom J, etal: The use of terbinafine in thetreatment of avian fungal dis-ease, Proc Assoc Avian Vet,Portland 35-9 2000.
1341. Paul-Murphy J, Ludders J: Aviananalgesia. Heard DJ: Vet ClinicNA Exotic Anim Prac, WBSaunders Philadelphia 4 35-452001.
1347. Machin KL, Livingston A:Assessment of the analgesiceffects of ketoprofen in duckanesthetized with isoflurane,Am J Vet Res 63 821-6 2002.
1348. Phalen DN Implications ofmacrorhabdosis in clinical dis-orders. Harrison G, Lightfoot T(eds): Clinical Avian Medicine,705-710 2005.
1349. Filippich JL, Herdrikz JK:Prevalence of megabacteria inbudgerigar colonies, Aust Vet J76 92-5 1998.
1350. Phalen DN, Tomaszewski D,Davis A: Investigation into thedetection, treatment and path-ogenicity of avian gastric yeast,Proc Assoc Avian Vet 49-512002.
1352. Phalen DN: Implications ofviruses in clinical disorders.Harrison G, Lightfoot T (eds):Clinical Avian Medicine, 721-746 2005.
1353. Cranfield MR: Sphenisciformes(Penguins). Fowler ME, MillerER: Zoo and Wild AnimalMedicine, Saunders, St. Louis,MO 5 103-10 2003.
1354. Stoskopf MD, Beall FB: Thehusbandry and medicine ofcaptive penguins, Proc AmAssoc Zoo Vet Washington DC81-91 1982.
1355. Cranfield MR, Shaw M, et al: Areview and update of avianmalaria in the African penguin,Proc Am Assoc Zoo Vet, S PadreIs, TX 1990.
1357. Carpenter JW, Mashima TY,Rupier DJ: Raptor Biomedicine,Greystone Publications,Manhattan, KS 1996.
1358. Kearns KS: Anseriformes(Waterfowl, Screamers) Zooand Wild Animal Medicine 141-9 2003.
1359. Redig PT: Falconiformes(Vultures, Hawks, Falcons,Secretary Bird), Zoo and WildAnimal Medicine 150-61 2003.
1361. Carpenter JW: Gruiformes(Cranes, Limpkins, Rails,Gallinules, Coots, Bustards),Zoo and Wild Animal Medicine171-80 2003.
1363. Olsen GH, Carpenter JW et al:Cranes. Altman RB, Clubb SL,et al: Avian Medicine andSurgery, WB SaundersPhiladelphia 973-91 1997.
1364. Schultz DJ: Columbiformes(Pigeons, Doves), Zoo and WildAnimal Medicine 180-7 2003.
1365. Lamberski N: Psittaciformes(Parrots, Macaws, Lories), Zooand Wild Animal Medicine 187-210 2003.
1366. Flammer K, Whitt-Smith D:Plasma concentrations ofenrofloxacin in psittacine birdsoffered water medicated with200 mg/l, J Avian Med Surg16(4) 287-90 2002.
1367. Crosta L: Alloplastic and het-eroplastic bill prostheses in 2Ramphistidae birds, J AvianMed Surg 16(3) 218-22 2002.
1368. Ryan TP: Grit impaction in 2neonatal African grey parrots, JAvian Med Surg 16(3) 230-32002.
1369. Lamberski N, Theon AP:Concurrent irradiation andintratumoral chemotherapywith cisplatin for treatment of afibrosarcoma, J Avian Med Surg16(3) 234-8 2002.
1370. Heinz K, Tully TN: What is yourdiagnosis? J Avian Med Surg16(3) 245-6 2002.
1372. Samour JH, Naldo JL:Diagnosis and therapeuticmanagement of candidiasis infalcons in Saudi Arabia, J AvianMed Surg 16(2) 129-32 2002.
1373. Bauck L: Mycoses. Ritchie B,Harrison G, et al: AvianMedicine: Principles andApplication: WingersPublishing, Lake Worth, FL 997-1006 1994.
1374. Oglesbee BL: Mycotic diseases.Altman RB, Clubb SL, et al:Avian Medicine and Surgery,WB Saunders, Philadelphia323-31 1997.
1375. Boydell IP, Forbes NA: Diseasesof the head (including theeyes). Beynon PH, Forbes NA:Manual of Raptors, Pigeons andWaterfowl, BSAVA, Cheltenham140-6 1996.
1376. Suedmeyer WK, Bermudez AJ,Fales WH: Treatment of epider-mal cysts associated withAspergillus and Alternariaspecies in a chicken, J AvianMed Surg 16(2) 133-7 2002.
1377. Hernandez-Divers SJ: Endo-surgical debridement anddiode laser ablation of lungand air sac granulomas inpsittacine birds, J Avian MedSurg 16(2) 138-45 2002.
1378. Mazet JAK, Newman SH, et al:Advances in oiled bird emer-gency medicine and manage-ment, J Avian Med Surg 16(2)146-9 2002.
1379. Navarez J, Tully TN, et al: Whatis your diagnosis? J Avian MedSurg 16(2) 154-8 2002.
1380. Tellier LA, Lair S, Livingston A:Pharmacodynamics of flunixinand ketoprofen in mallardducks, J Zoo Wildl Med 32 222-9 2001.
1381. Samour JH, Naldo J: Diagnosisand therapeutic managementof lead toxicosis in falcons inSaudi Arabia, J Avian Med Surg16(1) 16-20 2002.
1382. Bowles HL, Zantop DW: Anovel surgical technique forluxation repair of thefemorotibial joint in a monkparakeet, J Avian Med Surg16(1) 34-8 2002.
1390. Africa-Avian Clark, RK, Jessup,DA: Wildlife Restraint SeriesIWVS Inc. Salinas, CA, Rev 1992A7:1-2 1991.
1400. Cooper JE: Medicine and otheragents used in treatment,including emergency anesthe-sia kit, Birds of Prey, Healthand Disease, Blackwell Science,Oxford 3 271-7 2002
1409. Smith SA: Parasites of birds ofprey: their diagnosis and treat-ment, Semin Avian Exotic PetMed, WB Saunders, Phila-delphia 5 35-7 1996.
1410. Krone O, Cooper JE: Parasiticdiseases Birds of Prey, Healthand Disease, Blackwell Science,Oxford 3 107-20 2002.
1411. Smith SA and Smith BJ Lice inbirds of prey Comp AnimPractice 2 35-7 1988.
1412. Heidenreich M: Birds of Prey,Medicine and Management,Wissenschafts-Verlag, Oxford,UK 1997.
1413. Cawthorn RJ: Cyst forming coc-cidia in raptors: significantpathogens or not. Redig PT,Cooper JE, et al: RaptorBiomedicine, Univ MinnesotaPress, Minneapolis 1993
1415. Bogue G: Treating endopara-sites and ectoparasites in birdsof prey, Methods, J AnimHealth Tech 3 10-3 1980.
1416. Stehle S: Behandlung vonhelminthosen bei Greifvogelnmit fenbendazol Kleintier,Praxis 22 261-8 1977.
1417. Lawrence K: Efficacy of fenben-dazole against nematodes incaptive birds, Vet Rec 122 433-4 1983.
1418. Santiago C, Mills PA,Kirkpatrick CE: Oral capillaria-
sis in a red-tailed hawk: treat-ment with fenbendazole, J AmVet Med Assoc 187 1205-61985.
1420. Di Somma A, Garlinzoni M:Trichomoniasis in high per-formance falcons, Proc AustAssoc Avian Vet 251-4 2002.
1421. Ostrowski S, Shobrak M:Poisoning by acetylcholin-esterase inhibiting pesticides infree-ranging raptors: a casereport, Falco, NewsletterMiddle East Falcon ResearchGroup 20 8-9 2002.
1422. Papich MG, Adams, RA, et al:Veterinary Pharmacology andTherapeutics, Iowa State UnivPress, Ames, IA 918-32 1997.
1423. Jones MP, Orosz SE, et al:Pharmacokinetic disposition ofitraconazole in redtailedhawks, J Avian Med Surg 14(1)15-22 2000.
1424. Orosz SE, Schroeder EC, et al:The effects of formulation onthe systemic availability of itra-conazole in pigeons, J AvianMed Surg 10 255-62 1996.
1426. Verwoerd D: Case study:episodic epileptiform seizuresin peregrine falcons in Dubai,UAE, Falco, Newsletter, MiddleEast Falcon Research Group 1810-13 2001.
1427. Lierz M: Evaluation of thedosage of ivermectin in falcons,Vet Rec 148 596-600 2001.
1428. Garcia-Montijano M, WaxmanS, et al: Pharmacokinetics ofmarbofloxacin in Eurasian buz-zards, Falco, Newsletter,Middle East Falcon ResearchGroup 19 20 2002.
1429. Barton N, Bailey T: Editorialcomment, Falco, NewsletterMiddle East Falcon ResearchGroup 20 2002.
1431. Stanford M: Cage and aviarybirds. Meredith A, Redrobe S:BSAVA Manual of Exotic Pets,BSAVA, Gloucester, UK 4 157-67 2002.
1432. Redrobe S: Pigeons. MeredithA, Redrobe S: BSAVA Manual ofExotic Pets, BSAVA, Gloucester,UK 4 168-78 2002.
1433. Chitty J: Birds of prey. MeredithA, Redrobe S: BSAVA Manual ofExotic Pets, BSAVA, Gloucester,UK 4 179-92 2002.
1434. Redrobe S: Avian medicine andsurgery, www.vetnet.co.uk,VetNet 10/20/2003.
1435. McCluggage D and Higdon PLHolistic Care for Birds HowellBook House New York 1999.
1437. Dorrestein GM: Diagnosticapproaches and managementof diseases in captive passer-ines, Semin Avian Exotic PetMed, Elsevier Science,Philadelphia 12 11-20 2003.
1438. Joseph V: Infectious and para-sitic diseases of captive passer-ines, Semin Avian Exotic PetMed, Elsevier Science,Philadelphia 12 21-8 2003.
1439. Massey JG: Diseases and med-ical management of wildPasseriformes, Semin AvianExotic Pet Med, ElsevierScience, Philadelphia 12 29-362003.
1441. Rosskopf WJ: Common condi-tions and syndromes ofcanaries, finches, lories andlorikeets, lovebirds and
Chapter 9 | T H E R A P E U T I C A G E N T S 341
macaws, Semin Avian Exotic PetMed, Elsevier Science,Philadelphia 12 131-43 2003.
1444. Szelinyi Z, Peczely P: Thyroxininduced moult in domestichens, Acta Physiol, Hung 72143-9 1988.
1445. Johnston MS, Ivey ES:Parathyroid and ultimo-branchial glands: calciummetabolism in birds, SeminAvian Exotic Pet Med, ElsevierScience, Philadelphia 11 84-932002.
1446. Koski MA: Dermatologic dis-ease in psittacine birds: aninvestigational approach,Semin Avian Exotic Pet Med,Elsevier Science, Philadelphia11 105-24 2002.
1447. Oglesbee BL: Hypothyroidismin a scarlet macaw, J Am VetMed Assoc 201 1599-16011992.
1457. Gerlach H: Megabacteriosis,Semin Avian Exotic Pet Med,WB Saunders, Philadelphia 1012-9 2001.
1462. Tell L, Silverman S, Wisner E:Imaging techniques for evaluat-ing the head of birds, reptilesand small exotic mammals,Exotic DVM 5.2 31-7 2003.
1463. Taylor M: A wound packingtechnique for rabbit dentalabscesses, Exotic DVM 5.3 28-31 2003.
1465. Stanford M: Recombinantomega interferon in combina-tion with F10 nebulization forthe treatment…circovirus,Exotic DVM 5.3 43-6 2003.
1466. Flinchum GB: Potential use ofpolicosanol in the treatment ofhyperlipidemia in pet birds,Exotic DVM 5.3 51-5 2003.
1468. Bowles HL: Repair of displacedflexor tendon in two ducksExotic DVM 5.3 91-4 2003.
1469. Joseph V Aspergillosis in rap-tors Semin Avian Exotic PetMed WB Saunders Philadelphia9 66-74 2000.
1470. Redrobe S: Treatment of avianliver disease, Semin AvianExotic Pet Med, WB Saunders,Philadelphia 9 136-45 2000.
1472. Bichnese EJ: Review of aviansarcystosis Proc Assoc Avian Vet52-8 1992.
1473. Black, D: Medicating birds,Birds 2000: the KVF JubbRefresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 23-39 2000.
1474. Gelis S: Avian reproductionand reproductive disorders,Birds 2000: the KVF JubbRefresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 187-208 2000.
1475. Gill J: Feather picking, Birds2000: the KVF Jubb RefresherCourse for Veterinarians, PostGraduate Fdn Vet Science,Sydney NSW 334 247-53 2000.
1476. Cannon M: Exotic avian dis-eases - their diagnosis andtreatment, Birds 2000: the KVFJubb Refresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 263-80 2000.
1477. Cannon M: Avian behavior,Birds 2000: the KVF JubbRefresher Course for
Veterinarians, Post GraduateFdn Vet Science, Sydney NSW334 281-312 2000.
1478. Cannon M: Medicine and sur-gery of aquatic birds, Birds2000: the KVF Jubb RefresherCourse for Veterinarians, PostGraduate Fdn Vet Science,Sydney NSW 334 313-50 2000.
1479. Madill DN: Parasitology, Birds2000: the KVF Jubb RefresherCourse for Veterinarians, PostGraduate Fdn Vet Science,Sydney NSW 334 351-81 2000.
1480. Taylor M: Diagnostics 2:Hematology and biochemistry,Birds 2000: the KVF JubbRefresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 385-95 2000.
1481. Taylor M: Avian anesthesia andanalgesia, Birds 2000: the KVFJubb Refresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 397-405 2000.
1483. Taylor M: Emergency and criti-cal care, Birds 2000: the KVFJubb Refresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 429-36 2000.
1484. Taylor M: Avian surgical princi-ples, Birds 2000: the KVF JubbRefresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 434-35 2000.
1485. Taylor M: Chlamydiosis: dis-ease, diagnosis and treatment,Birds 2000: the KVF JubbRefresher Course forVeterinarians, Post GraduateFdn Vet Science, Sydney NSW334 447-53 2000.
1487. McCluggage D: Apple cidervinegar. O’Donaghue D: ExoticDVM Online Group, ZoologicalEducation Network, LakeWorth, FL 10/14 2003.
1488. Flinchum G: Milk thistle seedvs. dandelion root for treat-ment of liver disease.O’Donaghue D: Exotic DVMOnline Group, ZoologicalEducation Network, LakeWorth, FL 10/14 2003.
1489. Wellehan JFX: Frostbite inbirds: pathophysiology andtreatment, Compend ContinEduc Prac Vet 25 776-81 2003.
1490. Machin KL, Tellier LA, et al:Pharmacodynamics of flunixinand ketoprofen in mallardducks, J Zoo Wildl Med 32 821-6 2001.
1491. Orosz SE, Jones MP, et al:Pharmacokinetics of amoxicillinplus clavulanic acid in blue-fronted Amazon parrots, JAvian Med Surg 14 107-122000.
1492. Doneley B: Control andTherapy of Diseases of Birds,Post Graduate Fdn Vet Science,Sydney NSW A-21 1996.
1501. Vogelnest L: Triage and treat-ment of oiled seabirds, MarineWildlife: The Fabian Fay Coursefor Veterinarians, Post GraduateFdn Vet Science, Sydney NSW335 167-78 2000.
1503. Vogelnest L: Veterinary manage-ment of seabirds, MarineWildlife: The Fabian Fay Coursefor Veterinarians, Post GraduateFdn Vet Science, Sydney NSW
335 199-236 2000.
1516. Byme RF, Davis C, et al:Prescribing for birds, Bishop YVeterinary FormularyPharmaceutical Press, London5 43-56 2001.
1519. Cannon M: Orthopedic surgeryin small exotic pets avian,Internal Medicine: SmallCompanion Animals, PostGraduate Fdn Vet Science,Sydney NSW 306 285-3051998.
1526. Vogelnest L: Veterinary manage-ment of oiled fauna, Wildlife inAustralia - Healthcare &Mangement, Post Graduate FdnVet Science, Sydney NSW 32755-80 1999.
1533. Vogelnest L: Chemical restraintof Australian native fauna,Wildlife in Australia -Healthcare & Mangement, PostGraduate Fdn Vet Science,Sydney NSW 327 149-88 1999.
1549. Bellamy T: First aid for nativefauna, Wildlife in Australia -Healthcare & Mangement, PostGraduate Fdn Vet Science,Sydney NSW 327 267-71 1999.
1554. Rose K: Common diseases ofurban wildlife, Wildlife inAustralia - Healthcare &Mangement, Post Graduate FdnVet Science, Sydney NSW 327365-430 1999.
1559. Cannon M: Medicine and sur-gery of aquatic birds, Wildlifein Australia - Healthcare &Mangement, Post Graduate FdnVet Science, Sydney NSW 327527-68 1999.
1560. Cannon M: Emerging avian dis-eases - their diagnosis andtreatment, Wildlife in Australia -Healthcare & Mangement, PostGraduate Fdn Vet Science,Sydney NSW 327 569-86 1999.
1568. Punch P: A retrospective studyof the success of medical andsurgical treatment of wildAustralian raptors, Aust Vet J 79747-52 2001.
1571. Phalen DN: Avian mycobacte-riosis. Bonagura JD: CurrentVeterinary Therapy SmallAnimal, WB Saunders,Philadelphia XIII 1116-8 2000.
1572. Steinohrt LA: Diagnosis andtreatment of common diseasesof finches. Bonagura JD:Current Veterinary TherapySmall Animal, WB Saunders,Philadelphia XIII 1119-23 2000.
1573. Clyde VL, Paul-Murphy J: Aviananalgesia. Bonagura JD:Current Veterinary TherapySmall Animal, WB Saunders,Philadelphia XIII 1126-8 2000.
1575. David S: Ibuprofen, Privatecommunication 3/26 2002.
1585. Samour JH, Naldo J: Serrato-spiculiasis in captive falcons inthe Middle East: A review, JAvian Med Surg 15(1) 2-9 2001.
1587. Suedmeyer WK, McCaw D,Turnquist, S: Attempted photo-dynamic therapy of squamouscell carcinoma in the casque ofa great hornbill, J Avian MedSurg 15(1) 44-49 2001.
1589. Abrams GA, Paul-Murphy J, etal: Aspergillus blepharitis anddermatitis in peregrine falcon-gyrfalcon hybrid, J Avian MedSurg 15(2) 114-120 2001.
1591. Doneley B: Cutaneous crypto-coccosis in an African grey par-
rot, Proc Aust Assoc Avian Vet247 1994.
1592. Tully TN, Oliver JL: What isyour diagnosis? J Avian MedSurg 15(2) 147-8 2001.
1593. Sherrill J, Ware LH, et al:Contrast radiography with posi-tive-pressure insufflation innorthern pintails, J Avian MedSurg 15(3) 178-86 2001.
1609. Perry RA: Rehabilitation ofbirds, Australian Wildlife: JohnKeep Refresher Course, PostGraduate Comm Vet Science,Sydney NSW 104 115-2101988.
1612. Jakob-Hoff RM: The husbandryand diseases of raptors,Australian Wildlife: John KeepRefresher Course, PostGraduate Comm Vet Science,Sydney NSW 104 403-51 1988.
1613. Gill J: Parrot diseases andnutrition, Australian Wildlife:John Keep Refresher Course,Post Graduate Comm VetScience, Sydney NSW 104 585-610 1988.
1614. Harrigan KE: Causes of mortal-ity in Little penguins,Australian Wildlife: John KeepRefresher Course, PostGraduate Comm Vet Science,Sydney NSW 104 705-16 1988.
1617. Vogelnest L: Veterinary care ofwild Australian native birds II -medicine, Wildlife: TGHungerford Refresher Coursefor Veterinarians, Post GraduateComm Vet Science, SydneyNSW 233 141-89 1994.
1618. Cannon M: Avian orthopaedics,Wildlife: TG HungerfordRefresher Course forVeterinarians, Post GraduateComm Vet Science, SydneyNSW 233 373-93 1994.
1620. Ferrell ST, Tell L: Clostridiumtertium infection in a rainbowlorikeet with enteritis, J AvianMed Surg 15(3) 204-8 2001.
1621. Langlois I, Jones MP: Ventralabdominal hernia associatedwith hepatic lipidosis in a redlory, J Avian Med Surg 15(3)216-22 2001.
1622. Tully TN, Porthouse K, TaylorW: What is your diagnosis? JAvian Med Surg 15(3) 223-52001.
1624. Wellehan JFX, Zens MS, et al:Diagnosis and treatment ofconjunctivitis in house finchesassociated mycoplasmosis inMinnesota, J Wildl Dis 37 245-51 2001.
1625. Flammer K, Whit-Smith D,Papich M: Plasma concentra-tions of doxycycline in selectedpsittacine birds when adminis-tered in water, J Avian MedSurg 15(4) 276-82 2001.
1626. Jones R, Redig PT: Autogenouscallus for repair of a humeralcortical defect in a red-tailedhawk, J Avian Med Surg 15(4)302-9 2001.
1631. Itoh N, Kikuchi N, Hiramune T:Antimicrobial effects ofamikacin therapy on experi-mentally induce Salmonellatyphimurium infection, ProcWorld Veterinary CongressWorld Veterinary Association,Yokohama, Japan XXV 1491995.
1632. Hegazi AG, Abd El Haey FK,Turker S: Evidence of chicken
Cl inica l Avian Medic ine - Volume I342
immune status after propolisadministration, Proc WorldVeterinary Congress WorldVeterinary Association,Yokohama, Japan XXV 1591995.
1633. Fukomoto Y, Daimaru H, et al:Acceleration of wound healingof chitosan in zoo and wild ani-mals, Proc World VeterinaryCongress World VeterinaryAssociation, Yokohama, JapanXXV 111 1995.
1638. Powers LV, Flammer K, PapichM: Preliminary investigation ofdoxycycline plasma concentra-tion in cockatiels after adminis-tration, J Avian Med Surg 14(1)23-30 2000.
1639. Flammer K, Aucoin DP, WhittD: Preliminary report on theuse of doxycyclinemedicatedfeed in psittacine birds, ProcAssoc Avian Vet AAV, Chicago 1-4 1991.
1640. Dorrestein GM: Doxycyclineformulations for avian use,Proc Assoc Avian Vet AAV,Chicago 5-7 1991.
1644. Gentz EJ, Linn KA: Use of adorsal cervical single pedicleadvancement flap in 3 birdswith cranial skin defects, JAvian Med Surg 14(1) 31-62000.
1645. Echols MS, Craig TM, Speer BL:Heartworm infection in 2 saddle-billed storks, J AvianMed Surg 14(1) 42-7 2000.
1646. Miller S, Fleetwood J, WilliamsJ: What is your diagnosis? JAvian Med Surg 14(1) 54-82000.
1647. Gibbons P, Horton S: What isyour diagnosis? J Avian MedSurg 14(1) 60-4 2000.
1648. Vogelnest L: Birds and ReptilesUrban Wildlife, Post GraduateComm Vet Science, SydneyNSW 204 1-48 1992.
1650. Doneley B: Control & Therapyof Diseases of Birds, TGHungerford Course, Post GradFoundation Vet Sci, SydneyNSW A 21 1996.
1653. Meyer KF, Eddie B, et al:Chemotherapy in the controlof psittacosis in parakeets.Richardson JH: Progress in psit-tacosis research and control,Rudgers Univ Press, NewBrunswick 163 1958.
1656. Gaggermeier B, Henke J, et al:Investigation on analgesia indomestic pigeons usingbuprenorphine and butor-phanol, Proc Eur Chap AssocAvian Vet, Munich 6 70-742001.
1668. Dahlhausen RB: Implications of
mycoses in clinical disorders.Harrison G, Lightfoot T (eds):Clinical Avian Medicine, 691-704 2005.
1669. Doneley B: Semen collection inthe ostrich, Ostrich Odyssey,Australian Ostrich Assoc 1996.
1671. Mansour A, Khachaturian H, etal: Anatomy of CNS opioidreceptors, TINS 11 308-14 88
1675. Woolf CJ, Chong MS:Preemptive analgesia - treatingpostoperative pain by prevent-ing the establishment…sensiti-zation, Anesth Analg 77 362-791993.
1682. Ness RD: Integrative therapies.Harrison G, Lightfoot T (eds):Clinical Avian Medicine, 343-364 2005.
1683. Filippich LJ: First aid in birds.Hand SJ: Care and Handling ofAustralian Native Animals,Surrey Beatty and SonsChipping Norton Revised 53-621997.
1691. Bowles HL: Management withpotassium bromide of seizuresof an undetermined origin inan umbrella cockatoo, ExoticDVM 5.4 7-8 2003.
1694. Levine BS: Review of antibiotic-impregnated polymethylmetha-crylate beads in avian an exoticpets, Exotic DVM 5.4 11-42003.
1695. Gardner G, Brown C, et al:Selected topics in captive swanmedicine and surgery, ExoticDVM 5.4 33-8 2003.
1697. Harrison GJ: Amazon upperrespiratory case report, AvianExaminer 1-12 3-4 1998.
1698. Hudelson S: Use of Spartrix,Avian Examiner 1-12 4 1998.
1699. Hudelson S: Comment onprostaglandins, Avian Examiner1-12 6 1998.
1700. Cornelissen H: Treatment ofhemochromatosis, AvianExaminer 1-12 11 1998.
1702. Lightfoot T: HCG for featherpicking, Avian Examiner 1-1216 1998.
1703. Harrison GJ: Suspected poly-omavirus in finches, AvianExaminer 1-12 16 1998.
1704. McCluggage D: Nutritionaltherapy for African greys, AvianExaminer 1-12 23 1998.
1705. Harrison GJ: Home remedies,Avian Examiner 1-12 25 1998.
1707. Harrison GJ: More on heparin,Avian Examiner 1-12 27 1998.
1708. Harrison GJ: Results withHetastarch, Avian Examiner 1-12 27 1998.
1714. Flinchum G: Convulsing cock-atiels, canary, Avian Examiner1-12 35 1998.
1715. Zantop D: Cisapride use inbirds, Avian Examiner 1-12 351998.
1716. Gerlach H: Immune stimulatorsin birds, Avian Examiner 1-1236 1998.
1720. Flinchum G: More on glyburidefor cockatiel PU/PD, AvianExaminer 17 2 1999.
1721. Zantop D: Using leuprolideacetate to manage commonavian reproductive problems,Avian Examiner 18 2 1999.
1722. Hochleithner C, HochleithnerM: Treatment of liver disease inpsittacine birds, AvianExaminer 18 2-3 1999.
1723. Graham H, Vlamis G: Bachflower remedies for birds,Avian Examiner 18 4 1999.
1724. Flinchum G: Corticosteroid usein birds, Avian Examiner 20 22001.
1725. Harrison G: Uses of Avizyme,Avian Examiner 21 2 2002.
1726 Doneley B: Treatment of dia-betes mellitus in a galah, AvianExaminer 21 7 2002.
1727. What’s new, Avian Examiner 235 2003.
1728. Kramer MH: Diagnosing aviancryptosporidium, AvianExaminer 24 4 2003.
1729. Sandmeier P: Use of fipronil incanaries, Avian Examiner 25 32003.
1731. Morelli C, Finkelstein A:Common parasitic diseases ofpasserines, Exotic DVM 5.6 11-12 2004.
1732. Dorrestein GM: Passerines andsoftbill therapeutics, Vet ClinicNA Exotic Anim Prac, WBSaunders, Philadelphia 3 35-572000.
1736. Dorrestein GM, Zwart P, vander Hage MH: Pet Bird Nutri-tion. Rubel A, Baumgartner R:Proc Eur Chap Assoc Avian Vet,Vienna 1 10-19 1991.
1737. Trah M: Tilest - ein neuesnarkotikum auch für dir vogel-praxis? Kleintier Praxis 35 413-6 1990.
1738. McDonald SE: A selection ofdisease syndromes in psittacinebirds. Rubel A, Baumgartner R:Proc Eur Chap Assoc Avian Vet,Vienna 1 46-73 1991.
1739. Orosz SE, et al: Pharma-cokinetic properties of itra-conazole in Blue-frontedAmazon Parrots (Amazona aes-tiva aestiva), J Avian Med Surg10 168-73 1996.
1740. Phalen D: Respiratory medicineof cage and aviary birds, VetClinic NA Exotic Anim Prac 3423-52 2000.
1741. Orosz SE, et al: The effects of
formulation on the systemic
availability of itraconazole in
pigeons, J Avian Med Surg 9
255-62 1995.
1742. Joseph V, Pappagianis D, Reavill
DR: Clotrimazole nebulization
for the treatment of respiratory
aspergillosis, Proc Annu Conf
Assoc Avian Vet 301-6 1994.
1743. Dahlhausen RD, Lindstrom JG,
Radabaugh CS: The use of
terbinafine hydrochloride in
the treatment of avian fungal
disease, Proc Annu Conf Assoc
Avian Vet 35-9 2000.
1744. Rupiper DJ: Diseases that affect
race performance of homing
pigeons. Part II: bacterial, fun-
gal, parasitic, J Avian Med Surg
12 138-48 1998.
1747. Hoogesteijn AL, et al: Oral
treatment of avian lead intoxi-
cation with meso-2,3-dimercap-
tosuccinic acid, J Zoo Anim
Med 34 82-7 2003.
1748. Cannon M: Avian cryptococco-
sis, a case report. Proc Aust
Assoc Avian Vet, Noosa QLD 1-5
1999.
1750. Dahlhausen B, Aldred MD,
Colaizzi E: Resolution of clini-
cal proventricular dilatation
disease by cyclooxygenase 2
inhibition, Proc Assoc Avian Vet
9-12 2002.
1752. Clippinger TL, Platt SR:
Seizures. Olsen GH, Orosz SE:
Manual of Avian Medicine
Mosby, St. Louis, MO 170-82
2000.
1753. Harrison GJ: Long term primi-
done use in an Amazon, AAV
Newsletter, AAV 4 89 1982.
1756. Echols MS: Evaluating and
treating the kidneys. Harrison
G, Lightfoot T (eds): Clinical
Avian Medicine, 451-492 2005.
1757. Dennis PM, Bennett RA:
Ureterotomy for removal of
two ureteroliths in a parrot, J
Am Vet Med Assoc 217 865-8
2000.
1758. Lumeij JT: Pathophysiology,
diagnosis and treatment of
renal disease in birds of prey.
Lumeij JT, et al: Raptor
Biomedicine, Zoological
Education Network, Lake
Worth, FL III 169-78 2000.
1759. Goecke CS, Goldstein DL:
Renal glomerular and tubular
effects of antidiuretic hormone
and two antidiuretic analogues
…sparrow, Physiol Zool 70
283-91 1997.
